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Abstract 
Protein S-palmitoylation is a dynamic, hydrophobic, post-translational 
modification of cysteine residues that is required for the spatiotemporal organization of 
hundreds of proteins. In turn, protein palmitoylation contributes to the composition of 
cellular membrane environments and plays fundamental roles in cancer, neurological 
disorders and many other human diseases.  Despite its central function in human 
pathology, still, little is known about the enzymes that catalyze the addition (protein S-
acyl transferases) and removal (S-acyl protein thioesterases) of this modification. The 
two enzyme families, DHHCs and LYPLAs, are thought to make up the so-called 
dynamic palmitoylation machinery in which dual action of acyltransferases and 
thioesterases promote proper membrane targeting for an expanding list of dynamically 
palmitoylated proteins. Indeed, a steady growth in studies of these enzymes is 
beginning to shed light on their biological functions, revealing that the interplay between 
these opposing catalysts may be more complex than previously thought. More specific 
tools for these enzymes can therefore provide a more complete molecular description of 
dynamic palmitoylation events and its regulation in various biological settings.  
The work presented in this thesis explores the chemical mechanisms and 
physiological roles of DHHCs and LYPLAs by developing, characterizing and employing 
novel tools for their study in the context of cancer biology. In the second chapter, the 
cellular targets of a widely-used, mechanism-based protein acyltransferase inhibitor are 
profiled and analyzed. In the third chapter, a mechanistic description of divergent 
thioesterase active-site ligand specificities is presented using both a structural and a 
kinetic approach. In the third chapter, novel acyl-protein thioesterase inhibitors are 
applied to define their roles in organizing cell junctions and suppressing metastatic 
transformation. One of the fundamental goals in this thesis is to address the limitations 
of current chemical tools of protein palmitoylation and provide a framework for the 
development of selective pharmacological agents to accelerate the study of this 
xvii 
 
modification. From a physiological standpoint, this work offers novel insights into the in 
vivo functions of palmitoyl transferases and de-palmitoylases, highlighting the intricacies 
of the regulatory system governing the palmitoylation state of a given protein.
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Chapter 1:  
Review of Protein S-Palmitoylation, Associated Enzymes, Substrates 
and Physiological Roles 
1.1 General introduction 
 Many soluble proteins must temporarily associate with the membrane phase to 
perform various biological tasks, such as signaling1 and trafficking2. To engage the lipid 
bilayer, these peripheral membrane proteins make use of a number of targeting 
mechanisms including: non-covalent interactions with membrane-resident proteins3,4, 
membrane-binding domains that rely on electrostatic5,6 and polar7,8 lipid head-group 
interactions, and specialized auxiliary groups deriving from posttranslational 
modifications (PTMs) of particular protein side chains. The last process, termed protein 
lipidation, involves the installment of lipid moieties that mediate direct interactions with 
hydrophobic membrane constituents9–12 (Table 1). A diverse range of lipid molecules 
are coupled to proteins and these may be classified into two main categories based on 
the "destination" to which the protein is targeted. Lipid anchors such as O-cholesteroyl, 
O- and N- acyl groups, and glycosylphosphatidylinositol (GPI) linkers are used to orient 
secreted polypeptides destined to the extracellular face of cells9,13–17. These secretory-
related modifications are beyond the scope of the research and discussion presented in 
this work; therefore, their details will not be discussed further and the reader is referred 
to reviews on these topics elsewhere 18–25. As for intracellular dwelling proteins, there 
are three types of lipidation events utilized for tethering proteins toward the cytoplasmic 
face of cells, namely prenylation, N-myristoylation and S-palmitoylation26–35. While 
palmitoylation is the focal point of the studies herein, it frequently occurs in proximity to 
N-myristoylated and prenylated sites36–39. For this reason, these modifications will be 
discussed in short within the context of protein palmitoylation. 
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Table 1 Known lipid-based protein modifications that occur in cells. The top three entries in this 
table are lipid modifications that occur in the cytoplasm, while the bottom four entries detail modifications 
that take place in the lumen of the secretory pathway. In the 'Substituent' column, protein-derived 
chemical moieties are colored in red. In the 'Site of Modification' column, uppercase single letter 
abbreviations are used in the conventional way to denote the corresponding amino acid residues, except 
for lowercase letters where 'a' stands for a hydrophobic residue and 's' for a small side chain residue. The 
lipid attachment site is highlighted by the bold underlined letter, centered three dots stands for the rest of 
the amino acid sequence, and vertical bars signify a sequence that is removed prior or after installment of 
the lipid group. 
‡
 Studies have shown that, in addition to palmitate (C16:0), other fatty acids are found to be thioacylated onto proteins.
40,41
 These 
include acyl chain lengths between 14 and 22 carbons which may have varying degrees of unsaturation (e.g. C20:4).
42–45
 
% 
Although N-Myristoyltransferases (NMTs) acylate N-terminal glycine residues cotranslationally
13
, a few proteins are known to be 
modified by fatty acyl groups on the ε-amino of lysine, although the mechanism and function of this modification are unclear
46,47
. 
* Prenylation sites of farnesyltransferase (FTase) and geranylgeranyltransferase-I (GGTase-I) are typified by the CaaX motif, 
whereas GGTase-II features a broader scope of substrate sequences.
48,49
 
∞Hedgehog (Hh) proteins are the only known targets of this intein-mediated autocatalytic modification.
23,50
 
†
 Ghrelin is the only protein known to be S-octanoylated by Ghrelin O-acyltransferase (GOAT).
51
 Wnt proteins are the only examples 
of Porcupine (Porcn)-catalyzed O-acylation with the long-chain, unsaturated fatty acid palmitoleate.
52
 The sequence displayed in the 
'Site of Modification' column is putative based on the high sequence homology in vicinity of Wnt-3a acylation site.
5317
 
#
 N-palmitoylation is featured in Hh proteins and it occurs when an N-terminal cysteine is thioacylated and subsequently undergoes 
intramolecular rearranges into a stable amide bond.
37
The process by which certain Gα subunits are N-palmitoylated at their glycine 
residue is unknown.
54
 
§
 Once fully synthesized, the GPI moiety is typically attached towards a pro-protein's C-terminus via an internal proteolytic cleavage 
followed by a transamidation reaction.
22,55
 The R groups represent variable acyl chains that have been reported.
56
 For simplicity, 
various reported modification of the oligosaccharide have been omitted.
  
∞ 
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1.2 The Physicochemical Nature and Biological Implications of Protein S- 
Palmitoylation 
 Protein S-palmitoylation broadly refers to the modification of the cysteine thiol 
side chain by activated fatty acids which results in a protein with a thioester-linked fatty 
acyl group (Figure 1-1). The particular chemical transformation taking place is a 
thioacylation reaction although it is typically dubbed as S-palmitoylation to reflect that 
most proteins display the saturated, sixteen carbon (C16:0) fatty acid, palmitate[3]. 
Nevertheless, a variety of long-chain fatty acids (LCFAs), with different chain lengths 
and degrees of unsaturation, have been reported to thioacylate proteins in vivo, these 
include arachidonate (C20:4), palmitoleate (C16:1), stearate (C18:0) and oleate 
(C18:1)40,42,45,57–59. This is in stark contrast to most other lipid modification events which 
primarily result in the installment of only one or two different types of lipid molecules as 
documented so far (Table 1). Many efforts have been made to explain the observed 
diversity of linked fatty acids, with some maintaining that it could be indicative of the 
spontaneous reaction occurring in cells as it could parallel the cellular distributions of 
activated LCFAs60,61. Others suggest that putative installing enzymes may exhibit broad 
acyl substrate specificities.62 However, to date, no satisfactory explanation has been 
offered. 
  
Figure 1-1 The dynamic nature of protein S-palmitoylation. In this reaction, protein cysteine residues 
are acylated by activated fatty acids in the form of acyl-CoAs resulting in the release of a proton and free 
CoA molecule. Unlike other lipid-based PTMs, palmitoylation is reversible on the time-scale of the protein 
and this is due to the labile nature of the scissile bond. This feature allows for both spontaneous and 
enzyme-catalyzed modes of thioester hydrolysis, that latter of which lends itself to a number of regulatory 
mechanisms. Nevertheless, some proteins remain stably palmitoylated while others cycle rapidly. 
 Akin to other forms of protein lipidation, palmitoylation promotes stable 
membrane association of otherwise soluble proteins31,63. As shall be discussed in 
greater detail, cytosolic proteins typically achieve transient membrane associations 
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before they can be thioacylated by the palmitoylation machinery.36,64 Once palmitoylated 
though, the protein exhibits increased membrane affinity and may result, in certain 
circumstances, in virtually permanent membrane attachment known as kinetic 
membrane trapping.65 This occurs because the protein, which is already weakly 
attracted to the membrane via some other mechanism, is now further equipped with a 
hydrophobic 'handle' that directly partitions into the lipid bilayer of the membrane, thus 
preventing the 'doubly-anchored' protein from fully dissociating66. In addition, a single 
protein may contain a number of palmitoylation sites67,68, which tend to cluster near 
each other, making the protein even more lipophilic65,69. Interestingly, both the 
occurrence of multiple palmitoylation sites and the identities of the attached fatty acids 
have shown to impact a protein's membrane localization by targeting it to specific 
intracellular compartments64,70–75 or segregating it into ordered lipid-microdomains such 
as lipid rafts66,76–78. 
 Although the anchoring functionality is commonly provided by all protein lipid 
modification, it is unique in S-Acylation because the lipid attachment is intrinsically 
unstable and therefore reversible37,79 which may obviate the need for devoted PTM 
'erasers'. Other lipid-based PTMs are characterized by chemically-resistant linkages 
such as the amide bond of an N-myristoylated glycine and the thioether bond of a 
prenylated cysteine (Table 1). In contrast, a typical unactivated thioester bond stores 
enough chemical potential such that its free energy of hydrolysis (∆G ~ 30 kJ/mol) is on 
par with that of the energetic phosphoric acid anhydride containing metabolite 
adenosine triphosphate (ATP).80,81 Indeed, the energy stored in thioester hydrolysis is 
ordinarily harnessed in a variety of anabolic and catabolic reactions82–84. Although highly 
reactive towards nucleophiles, thioesters are kinetically stable in neutral pH-buffered 
solutions85 suggesting that cellular S-deacylation would require specific enzymatic 
action. Though some S-acyl linkages have shown to be exceptionally stable86–88, the 
labile nature of the thioester bond guarantees a 'deadline' for the many fatty  thioacyl 
linkages31,32,89–92; in turn, S-palmitoylation gives rise to the dynamic membrane 
engagement that is necessary for subcellular trafficking, protein stability and activity of 
numerous proteins.37,93,94 
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Protein S-acylation was first observed over 35 years ago in viral envelope 
glycoproteins43,95–97 and since then, has shown to be far-reaching having been ascribed 
to a growing list of diverse integral and peripherally associated membrane proteins 
including cytoskeletal elements, soluble enzymes, signal transducers, scaffolds, 
receptors, ion channels and cell adhesion molecules.32,36,98–104 In light of this staggering 
diversity, no consensus amino acid sequence has been found to target proteins to S-
acylation, although some general commonalities exist. Palmitoylation sites are 
frequently observed at either the terminal ends of proteins, within cysteine-rich domains 
or at juxtamembrane segments such as polybasic regions and transmembrane 
domains.9,35,64,105 In addition, terminal protein palmitoylation sites often neighbor other 
stably linked lipid modifications such as N-terminal myristoyl and C-terminal prenyl 
groups94. Thus, the lack of an apparent consensus site would suggest that either non-
specific thioacylating enzymes exist or that protein palmitoylation proceeds via 
nonenzymatic mechanisms. 
Considerable efforts have been directed at delineating the in vivo mechanism by 
which fatty acyl groups install onto proteins. For a long time, S-acylation was thought to 
occur strictly via nonenzymatic means. Small molecule thiols are known to exchange 
with existing thioesters in a trans-esterification reaction called autoacylation80, however, 
the physiological extent of this reactivity was unknown. To this end, short peptides from 
the lipidated termini of several palmitoylated proteins were shown to thioacylate in vitro 
when presented with lipid vesicles and metabolic acyl donors such as acyl-coenzyme A 
(acyl-CoA) species79,106–108. Autoacylation strongly depended on the presence of a lipid 
bilayer as well as the lipophilicity of the peptide which, in this experiment, was conferred 
by prior lipid installment. This was reasonable because acyl-CoAs are amphiphilic 
compounds109 and like other detergents, would preferentially partition into the lipid 
vesicle therefore necessitating the peptide to engage the membrane before it can react 
with it. Later it was shown that the rate of in vitro autoacylation also correlated with 
sequence context surrounding the cysteine residue, with hydrophobic and basic 
residues accelerating the reaction. Again, this reactivity was justified since autoacylation 
is highly dependent on the deprotonated state of the thiol (i.e. thiolate), which basic 
residues are expected to promote by lowering the thiol's pKa value
110,111. Finally, a 
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number of full-length proteins, were reported to autoacylate in vitro when presented with 
palmitoyl-CoA (palm-CoA)59,62, in particular myristoylated Giα subunits which undergo 
near-stoichiometric conversion112. Overall, these studies contended that the impact of a 
particular sequence context on its degree of autoacylation implied that for some 
cysteines, the S-acylation site is intrinsically encoded and hence did not require 
enzymatic activity. 
A number of seminal findings have since challenged the notion of physiologically-
relevant autocatalytic palmitoylation events113,114. Namely, acyl-CoA binding proteins 
(ACBPs) were shown to inhibit the autoacylation reaction in a dose-dependent fashion. 
(ref) This was conceivable as cellular ACBPs bind tightly to and sequester activated 
fatty acids to prevent unwanted hydrolysis. Importantly, estimated cellular 
concentrations of all reactants suggested that the rate of in vivo autoacylation was 
negligible and could not account for the exceptionally fast palmitoylation rates observed 
for a number of signaling protein in cells86,115. Furthermore, the catalytic activities of 
later described thioacylating enzymes, which will be expounded upon in following 
subchapters, were shown to be largely unaffected by physiological concentrations of 
ACBPs.113 Taken together, these experiments argued that poor availability of acyl-CoA 
donors would limit the extent of spontaneous S-acylation in vivo and suggested that 
instead, most palmitoylation events were likely to be driven by specific enzymes. 
Clearly, more precise and accurate tools for measuring the endogenous distribution and 
cellular levels of ACBPs, acyl-CoAs, acylated proteins and their non-acylated 
counterparts will be indispensible in aiding our understanding of spontaneous and 
enzymatic acylation events. 
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1.3 Tools and Techniques for Studying Protein S-Palmitoylation 
 This subchapter describe some of the most prevailing approaches that 
investigators currently use for the study of protein palmitoylation. The basic principles 
and specific details of each method are discussed succinctly. The primary objective of 
this portion is to highlight the benefits and limitations associated with each technique 
and offer potential improvements which may increase the reproducibility and reliability of 
a particular method. 
 Metabolic labeling by radiolabeled palmitate isotopes. Metabolic labeling with the 
radioactive tritiated fatty acid analog, [3H]-palmitate, represents the most traditional 
method for detecting S-palmitoylation events and accurately quantifying the 
palmitoylated levels of a given protein.116,117 In this experiment, cell cultures expressing 
the desired protein are treated with [3H]-palmitate for a duration that depends on the 
turnover rate of the protein or its attached fatty acid. During this pulse period, the tracer, 
which is near identical to the naturally-occurring palmitate, is metabolically incorporated 
into endogenous sites of palmitoylation, resulting in radioactive proteins which can be 
detected by standard autoradiography techniques118. Alternatively, a chase period can 
be invoked to observe dynamic palmitoylation turnover. During this time, proteins 
overwhelmed with saturating concentrations of palmitate to facilitate the exchange of 
their tracer which results in 
decreased of metabolic 
labeling over time (Figure 1-2). 
Figure 1-2 Monitoring dynamic 
palmitoylation turnover via the 
pulse-chase method. 
 Although regarded as 
the least invasive of all 
approaches, metabolic 
radiolabeling suffers from a 
number of drawbacks, some of 
which are shared with other metabolic incorporation techniques simply due to the nature 
of the experiment. First, metabolic methods in general, relay heavily on the 
incorporation efficiency of a given protein, which may be very low for both stably 
8 
 
palmitoylated proteins and long-lived palmitoylated proteins. Furthermore, metabolic 
methods require that the cells be 'flooded' with non-physiological concentrations of a 
single fatty acid variant which has shown to exert pleiotropic effects throughout 
metabolism119–122. Most importantly, due to its weak radioactive signal, this tritiated 
palmitate labeling requires extended X-ray film exposures lasting weeks to months, 
which historically impeded the study of this important posttranslational modification. 
Some have circumvented this issue by employing the radioactive iodinated fatty acid 
analog ω-[125I]-palmitate to yield brighter signals resulting in reduced exposure times 
compared to fluorography with 3H.123 However, many have refrained from conducting 
experiments with this potent γ-particle emitting isotopologue due to serious health 
concerns. 
Metabolic labeling by alkynylated palmitate analogs. A new approach to study 
protein palmitoylation uses a commercially available fatty acid analog, 17-octadecynoic 
acid (17ODYA)10,124. After brief metabolic labeling, cell lysates are reacted with azide-
modified reporter tags, such as biotin-azide or rhodamine-azide, using the 
biocompatible click chemistry reaction (Figure 1-3). This simple approach forms a 
covalent linkage by the formation of a triazole, linking both reporter and metabolically 
labeled protein92,125. This method allows for reproducible labeling and identification of 
hundreds of palmitoylated proteins by in-gel fluorescence, as well as the capacity to 
measure their stability and turnover using traditional pulse-chase methods86. As oppose 
to radiolabel experiments, shorter experiment times may be exercised, and biotin 
attachment enables the selective enrichment of modified proteins for both detection 
(immunoblot) and enrichment (pulldown). The major disadvantage of this technique is 
the alkyne functionality of 17ODYA which makes this 
fatty acid distinct from all others, possibly restricting 
the range of incorporated proteins. 
 
Figure 1-3 Protein palmitoylation detection via 17ODYA 
labeling. (a) Metabolic bioorthogonal strategy for detecting 
endogenously palmitoylated proteins with click chemistry. (b) 
Fluorescence gel-based analysis of palmitoylated proteins 
before and after thioester hydrolysis with hydroxylamine. 
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This metabolic labeling approach has been used in chemo-proteomic platforms 
for studying the global dynamics of protein palmitoylation86,126. Stable isotope labeling 
with amino acids in cell culture (SILAC) methods were employed to generate 
isotopically‎distinct‎(i.e.‎“light”‎vs.‎“heavy”)‎peptides‎for‎comparative‎quantitative‎mass‎
spectrometry-based proteomic analysis. Dynamically palmitoylated proteins were then 
tracked by combining a pulse of 17-ODYA with a chase of excess palmitic acid (Figure 
1-4). 
Figure 1-4 Monitoring palmitoylation turnover via 17ODYA-enriched SILAC proteomics. 
In a separate pulse-chase 
experiment, the isotopic pairs were treated 
after the initial 17ODYA pulse with the 
broad-spectrum lipase inhibitor 
hexadecylfluoro-phosphate (HDFP) or 
vehicle for 4 hours. After lysis and click 
chemistry-mediated ligation to biotin-azide, 
samples were enriched by streptavidin pull-
down, combined, and digested with trypsin. 
Quantitative analysis was then performed 
using a high-resolution mass spectrometer. 
These experiments identified palmitoylation 
events which were stabilized by lipase 
inhibition, and those events for which rapid 
turnover is independent of inhibitor treatment (Figure 1-5). 
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Figure 1-5 17ODYA pulse-chase experiments in the presence of HDFP identify enzyme-mediated 
depalmitoylation events. 
Functional group exchange techniques. The labile nature of S-acylation remains 
one of the major obstacles that hamper the study of this modification. Acyl group 
exchange methods such as the well know acyl-biotin exchange (ABE) protocol127,128 are 
novel enrichment strategies that have been used to selectively exchange native S-acyl 
groups with other stably attached functionalities such as the biotin affinity group in 
ABE91. In general, free cysteine thiols are first alkylated with a capping agent such the 
α,ß-unsaturated imide N-ethylmaleimide (NEM), and then half of the sample is treated 
briefly with the nucleophilic hydroxylamine (NH2OH) reagent which, under the right 
conditions, selectively hydrolyzes thioester linked groups. The newly liberated thiols are 
then reacted with another alkylating agent coupled to an affinity tag like biotin. Stable 
biotinylated protein are then enriched with an appropriate affinity resin (e.g. streptavidin 
agarose) and can be detected by immunoblot or mass spectrometric platforms (Figure 
1-6). Aside from the protocol being lengthy and often requiring larger amounts of 
protein, ABE, if not performed right, may suffer from both false positive and false 
negative results. False positives may occur either due to incomplete preliminary 
alkylation, enrichments of other short chain thioesterified modifications, and other non-
specific reactivities which alkylating agents may exhibit, such NEM;'s reaction with 
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lysine side chains129. False negatives on the other hand, are mainly caused by the loss 
of thioester linkage before it can be selectively cleaved with NH2OH. 
 
Figure 1-6 Acyl biotin exchange protocol resulting in enriched thioacylated proteins. Free thiols are 
typically reduced with a non-sulfur reducing agent such as tris-(2-carboxyethyl)phosphine to liberate 
disulfide which may interfere with subsquent steps. See main text for procedural details. 
The major improvement offered by acyl exchange techniques is its ability to 
convert an otherwise fleeting linkage into a stable one, and in turn yield more 
reproducible experimental results. Given that any number of functional groups could, in 
theory, be exchanged with a thioester, an approach which exchanges thioesters with a 
molecule of a few kilodalton (kDa) mass may be used to measure the stoichiometry 
about the palmitoylation site. In principle, the typical ABE protocol would be followed 
until the final biotinylation step, which could be replaced with an alkylation reaction to a 
small protein (~10 kDa). This way, when the proteins are separated by SDS-PAGE and 
probed by western blots, the observed mobility shift can be used to calculated the 
fractions of the proteins that are acylated. Indeed, this type of methodology has been 
applied successfully to other challenging PTMs130 and therefore should be feasible for 
S-acylation as well. 
In conclusion all current detection techniques for thioacylation suffer from a 
common handicap: inability to reveal or decipher the chemical identity of the attached S-
acyl group. Metabolic labeling methods only allow for the examination of proteins that 
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are willing to incorporate the tracer, some of which may not normally do so, thus 
acylated proteins featuring other acyl groups other than palmitate are excluded from 
further studies. Acyl exchange methods feature a different problem which technically 
speaking, does not exclude diverse thioacylated species from the analysis per se; 
instead, the chemical exchange of the acyl group, which is central to the success of this 
method, destroys the native acylation site essentially preventing one from investigating 
the endogenous acyl species. Thus, there are currently no S-acylation detection 
techniques that can be utilize for the study of variable-chain thioacylation events other 
than palmitoylation. Indeed better techniques will be necessary for characterizing the 
physiological roles and biophysical behavior of different S-acyl forms of a given protein.   
 In vivo localization techniques. Fluorescence microscopy experiments are the 
most routinely used means for assaying the subcellular localization and trafficking of 
palmitoylated proteins.131–134 There are two general types of fluorescent experiments 
which differ by the genetic origin of the protein to be studied. Endogenous palmitoylated 
proteins can be typically monitored by end-point immunofluorescent experiments, in 
which cells must be fixed prior to probing the desired proteins with immunologically-
based stains such as antibodies raised against the palmitoylated proteins.135 The major 
obstacle associated with immunology-based methods is that the antibody cannot 
typically distinguish between the unmodified protein and its acylated counterpart, and 
therefore supplementary confirmation of the protein's palmitoylation state must be 
employed. A recent chemical biology strategy has circumvented this issue by coupling 
antibodies which detect either the target protein or the latent O-palmitoylation reporter 
fatty ω-alkynyl analog.136 A signal is thus detected only when the target protein has its 
acyl group reporter installed. Indeed, these and other innovative approaches will 
accelerate cell biology studies of protein fatty S-acylation.  
  Exogenously expressed palmitoylated proteins are frequently used when the 
localization of mutant variants are to be assayed. A variety of fluorescence microscopy 
techniques are available for probing the dynamic localization behavior of a target 
protein, many of which rely on fusing the target protein to a genetically-encoded epitope 
tag. The green fluorescent protein (GFP), or its engineered variants, is by far the most 
featured tags, as it is amenable to diverse experimental conditions.137 GFP tagging has 
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been used for obtaining both steady-state and transient localization information for 
many palmitoylated protein.138–143 Whereas steady-state subcellular localization can be 
viewed with standard epifluorescent or confocal microscopes , a protein's three-
dimensional diffusion characteristics have be monitored by fluorescence recovery after 
photobleaching experiments144–147. In these experiments, a certain region of interest 
such as a segment of the plasma membrane, is illuminated with a high-intensity laser 
and the fluorescence of the residing GFP-tagged protein is quenched. The dynamics of 
the surrounding fluorescing probes can now be monitored as they diffuse throughout the 
sample and 'fill in' the non-fluorescent patch. A recent study has used this technique to 
assay the contribution of protein palmitoylation to the membrane attachment of the 
axonal survivor factor NMNAT2.148 In conclusion, like in most other fluorescence 
microscopy techniques, one should employ both positive and negative palmitoylation 
controls as these tools cannot differentiate between the palmitoylation states of the 
target protein. 
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1.4 Functions of Protein S-Acyltransferases 
 The current prevailing view in the palmitoylation field is that protein acylation 
events are principally mediated by a family of protein acyltransferases (PATs) in a 
context-specific manner.36,37,79 These membrane bound enzymes, termed DHHCs, have 
been shown to specifically palmitoylate proteins using acyl-CoAs as lipid donors140. 
Despite their importance in a range of cellular processes and implication in human 
diseases50,75,149–151, the mechanism, regulation, substrate specificities and physiological 
roles of many PATs remain undefined. 
PATs were first discovered via elegant genetic and biochemical studies in 
yeast152–154. This fundamental finding led to the discovery of orthologous 
acyltransferases across all eukaryotic kingdoms implying that protein palmitoylation was 
catalyzed by devoted enzymes. As mentioned in an earlier chapter, some have 
speculated that the natural diversity of fatty acids incorporated into thioacylated proteins 
could be attributed to the broad acylCoA specificities of the corresponding PATs155. 
Indeed, the heterodimeric yeast PAT, Erf2/Erf4 and the human PAT DHHC2 both 
displays wide lipid substrate specificity seeing that they catalyzed comparable 
thioacylation reactions employing  a variety of acylCoA chain lengths with different 
unsaturation degrees.41,156 Furthermore, it was later confirmed that PATs showed 
exclusive preference to using metabolic acylCoAs as their acyl donors. Most 
importantly, PAT-mediated reactions were largely resistant to ACBPs  which sharply 
contrasted  with autoacylation's reported ACBP sensitivity113; Altogether, these results 
suggested that in cells, PATs had high affinity toward acylCoAs, and along with the 
discovery of endogenous PAT substrates157, it was clear that enzymes mediated a 
majority of protein S-acylation events in vivo. 
Soon after, It was realized, again in yeast, that PATs shared a central domain 
which genomic databases indicated was conserved in all eukaryotic genomes.158,159 
These PATs constitute a phylogenetic family of polytopic transmembrane proteins, all of 
which share a highly conserved cysteine rich domain (CRD) with a consensus 
aspartate-histidine-histidine-cysteine (DHHC) signature motif in its center (Figure 1-
7).160 At least twenty-three members of PAT DHHC enzymes are present in mammals, 
with most containing additional protein interaction motifs including SRC homology 3 
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(SH3) domains, PSD95-DLG1-ZO1 (PDZ) binding motifs, and ankyrin repeats. These 
auxiliary domains are thought to serve as key protein-protein interaction modules that 
direct PAT protein substrate selectivity (Figure 1-7), however, they could potentially 
serve other functions independent of acyltransferase activity62,159,161–163. To this end, 
human DHHC5 has shown to interact with the neuronal scaffolding protein, post 
synaptic density 95 (PSD95) but did not catalyze its acylation163, whereas DHHC5 
palmitoylation activity on Grip1b depended on PDZ domain interactions with the 
enzyme162. These conflicting results demonstrate that PATs can employ their interaction 
domains for additional functions outside of protein acylation. 
 
Figure 1-7 The modular architecture of human DHHC protein S-acyl transferases. Although there 
are no available crystal structures for PATs, they have been mainly characterized by their respective 
primary sequences which feature a the DHHC-CRD pictured at the bottom left and a variety of known 
protein-protein interaction motifs that are thought to guide substrate specificity and cellular functions. 
Current attempts at annotating DHHC protein substrates typically rely on over-
expression studies to ascertain which DHHCs lead to an increase in acylation levels of 
a given palmitoylated protein164,165. Thus, it generally appears that DHHC enzymes may 
share a large collection of protein substrates. In spite of being a thorough analysis of 
PAT activities, these types of experiments do not provide an answer as to which DHHC 
is the physiologically responsible acyltransferase. Instead, these heterologous studies 
may be skewed towards the activity of highly expressible enzymes and exclude PATs 
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which necessitate additional cofactors for activity, like the yeast Erf2/Erf4 enzyme166. 
Therefore, over-expression studies ought to be validated by subsequent genetic 
knockdown of DHHCs in question. In this regard, individual members have been 
suggested to differ in substrate specificity which may be a function of the distinct 
intracellular localizations found for different PATs further suggesting non-redundant 
roles in cells.157,159,167,168 Some have speculated that the size and varied substrate 
specificities of the DHHC family may explain why unrelated S-acylation sequences exist 
in nature169. Certainly DHHC's conserved interaction motifs may obviate the necessity 
for such a consensus palmitoylation sequence. 
Ever since their discovery in humans, DHHC PATs have been implicated in 
prominent diseases151 in which they were found to be either silenced, mutated or even 
highly expressed in some cases. Some of these human illnesses include schizophrenia 
(DHHC8)170, learning and cognitive disorders (DHHC5)126, alopecia and amyloidosis 
(DHHC13)171, Huntington's disease (DHHC17)172, X-linked mental retardation (DHHCs 
9,15)173,174 and cancer (DHHCs 2, 9, 11, 17, 20)151,175 Accordingly, assigning the 
functions and identifying the substrates of DHHC proteins is likely to lead to a better 
understanding of these complex diseases. 
 With regards to their enzymology, the mechanistic aspects of PAT activity have 
long been tackled from a qualitative angle given the physical nature of their acyl 
substrates and the current challenges in isolating and assaying DHHCs93,176,177. 
However, well-planned fluorescent and radiolabeling experiments have now been 
successful at addressing the transient kinetic behavior of DHHC-mediated 
thioacylation41,113,132,156,178. To this end, many DHHC PATs have been reported to 
autoacylate when reacted with acylCoAs. However, it was unclear whether this 
represented a transitory acyl-enzyme intermediate or reflected a stably acylated site on 
the enzyme. Thus, active site residues had to be determined to properly address this 
question. To this end, the high sequence conservation of the DHHC-CRD and its 
predicted cytoplasmic orientation (Figure 1-7) suggested this domain to be responsible 
for PAT activity160. Further support to this hypothesis was provided by a number of 
mutagenesis studies in which substitutions within the DHHC motif abolished the 
enzyme's auto- and trans-catalytic activities. Notably, these studies proposed the Asp-
17 
 
His-Cys residues that were within the conserved motif to be potentially catalytic as each 
of these point mutants produced a catalytically-incompetent enzyme179. Based on these 
results, some suggested these D-H-C residues to form a catalytic triad by which Asp 
and His facilitate the formation of  a Cys nucleophile that later becomes the thioacyl-
enzyme intermediate (Figure 1-8, bottom). However, it was still unclear whether these 
residues were truly catalytic as the exact site of autoacylation could never be observed. 
 
 
Figure 1-8 The currently accepted kinetic and chemical mechanisms of PAT-catalyzed protein S-
palmitoylation. Radiolabeling experiments with palmitoyl-CoA have demonstrated that DHHC PAT 
catalysis follows a bi-bi ping pong kinetic mechanism. The PAT is first esterified by the incoming acyl-CoA 
substrate and then transfers the acyl group onto the cysteine of an appropriate protein substrate. Many 
questions still remain regarding how PATs achieve substrate specificity and the molecular basis for this 
ping pong mechanism. 
 Further studies have addressed the significance of PAT autoacylation in the 
context of the overall catalytic reaction. Instead of locating the exact site of the putative 
intermediate, experiments were designed to test whether such an intermediate existed 
at all41,156; namely, the transient enzyme intermediate would conceivably transfer its acyl 
chain onto an incoming substrate when presented with one. Investigations from two 
different DHHC studies confirmed that the PATs indeed transferred their acyl groups via 
a two step process kinetically referred to as a bi-bi-ping-pong mechanism (Figure 1-8, 
top). In summary, all of these studies contented that the Cys of the DHHC motif was the 
site of autoacylation which performed the subsequent thioacyl transfer onto protein 
substrates. Unfortunately, there still remains a large gap in our understanding of the 
exact nature of the catalytic residues, substrate specificity and regulation of PATs.  
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1.5 Pharmacological Agents for the Study of PATs 
Considering that both PATs and their palmitoylated proteins are involved in 
surprisingly diverse cellular activities, it is absolutely imperative to have appropriate 
means for assessing the functional significance of the thioacyl modification. 
Unfortunately, a limited number of poorly-defined, protein S-acylation inhibitors exist, 
many of which have shown to exert pleiotropic cellular effects117,180–183 (Figure 1-9). 
These compounds include the lipid-based inhibitors cerulenin, tunicamycin, and 2-
bromopalmitate, as well as the high-throughput screen lead compound 2-(2-hydroxy-5-
nitro-benzylidene)-benzo[b]thiophen-3-one which is commonly referred to as compound 
V. It is worth noting that not all palmitoylation inhibitors have been shown to be 
pharmacologically active towards DHHC PATs with some inhibiting protein 
palmitoylation events in an unknown fashion. Thus, DHHC-targeting inhibitors have 
been experimented as mechanistic tools to gain further insight into the enzymology of 
protein S-acyl transfer.181,184,185 In this section, the details regarding palmitoylation 
inhibitors that have shown to possess PAT inhibitory activities are described. Thus, the 
unconfirmed PAT inhibitor, 
tunicamycin will not be discussed 
further and the reader is referred 
elsewhere for more details on this 
topic117,180,186,187. 
Figure 1-9 The chemical structures of 
current palmitoylation inhibitors. (A) 
depicts CV, (B) depicts 2BP, (C) depicts 
cerulenin and (D) tunicamycin. 
 2-Bromopalmitate. Among all available S-acylation inhibitors, 2-bromopalmitate 
(2BP) remains the most routinely used agent for the study of S-acylation in cells75,184,188–
193. This brominated palmitate analog has shown to inhibit the catalytic activities of 
several DHHC enzymes in a time dependent irreversible fashion185, although, at the 
time, it was unclear whether it specifically targeted the enzyme's catalytic residues. Akin 
to‎other‎α-halo carbonyl compounds, 2BP is predicted to possess electrophilic reactivity 
at‎the‎α-carbon of the fatty acid; specifically, 2BP is expected to undergo nucleophilic 
displacement reactions with a variety of physiological nucleophiles including histidine's 
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imidazole‎side‎chain,‎lysine's‎ε-amino group and cysteine's thiol functionality (Figure 1-
10). 
 
Figure 1-10 2BP structure and reactivity. The alpha-brominated fatty acid retains the activity of 
common alkylating agents, such as iodoacetamide, but gains access to membrane associated targets 
due largely to its lipophilic character and similarity to endogenous fatty acids. Thus, under physiological 
conditions, 2BP possibly partitions into cell membranes where it engages membrane bound enzymes and 
alkylates their active-sites.  
This is quite reasonable since 2BP reactivity should parallel that of iodoacetamide, 
which is well known for alkylating cysteine residues110,194–196 but can cross reacting with 
aforementioned residues197–199. Considering its chemical resemblance to ordinary fatty 
acids, 2BP has been notorious for inhibiting diverse integral and some peripheral 
membrane proteins183,200–204; some of these targets include fat metabolism enzymes 
such as fatty acid CoA ligase, carnitine palmitoyl transferase-1 and glycerol-3-
phosphate acyltransferase as well as other cellular enzymes unrelated to fatty acid 
processing pathways which include NADPH cytochrome c reductase and glucose-6-
phosphatase. Despite the reported non-specific effects, 2BP remained and still is the 
best known, most utilized inhibitor in a large number of studies probing the roles of both 
DHHC PATs and palmitoylated proteins in general117. For this reason, there are obvious 
uncertainties when interpreting palmitoylation data based on 2BP studies alone. 
Therefore, revealing the scope of 2BP targets and understanding the mechanism(s) by 
which it exerts its inhibitory palmitoylation effects will prove useful and impact all current 
investigations utilizing this inhibitor in probing the physiological role of acylation. 
 The diverse lipophilic targets of 2BP suggest two main attributes to its mode of 
inhibition: (1) 2BP primarily targets intrinsic membrane proteins that are intimately 
associated with hydrophobic components of the lipid bilayer or soluble proteins that bind 
tightly to fatty acids and molecules alike, and (2) it may react with either functionally 
conserved, mechanistic or reactive residues of  proteins and enzymes (Figure 1-11). 
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Figure 1-11 2BP inhibits PAT activity and other unrelated cellular enzymes with nucleophilic 
active-site residues. 2PB has been shown to block protein palmitoylation by inhibiting autoacylation of 
PATs which strongly suggest that it alkylates catalytic residues necessary for acylation activity. However, 
given that 2BP reacts with numerous, unrelated biomolecules, there is a possibility that it may inhibit 
palmitoylation by directly alkylating the incoming cysteines of PAT substrates as well. Catalytic steps 
colored in red have been shown to be sensitive to 2BP treatment. 
With regards to PATs, 2BP has been suggested to covalently modify the catalytic 
cysteine thiolate of DHHC motif.188 Although the exact chemical mechanism by which 
this occurs is incompletely understood, it is evident for a number of DHHCs, that 2BP 
inhibits PAT-mediated palmitoylation of their protein substrates in vitro.185 These later 
kinetic studies showed that 2BP inhibits PAT autoacylation reaction, or specifically, the 
process in which the transient enzyme-acyl intermediate forms. This finding suggested 
that 2BP may target functional active site residues which normally perform the acyl 
transfer reaction onto the incoming protein substrate. These studies did not establish 
however, which of the presumed catalytic side chains were in fact modified by 2BP, 
although‎its‎α-carbonyl electrophilic reactivity suggest it could directly alkylate either the 
cysteine and or histidine side chains present in the DHHC-CRD. Clearly, there is a need 
to uncover the molecular basis for 2BP-mediated DHHC inactivation as it may prove 
useful in the development of PAT-specific, mechanism-based inhibitors, given its broad 
reactivity towards a number of DHHC members.188 Altogether, the numerous studies in 
which 2BP has been employed as a protein acylation inhibitor suggest that the long 
chain‎α-halofatty acid may serve as a suitable reactive group in the design of an active 
site-directed probe for studying both the DHHC family of protein acyltransferases and 
their palmitoylated protein substrates (Figure 1-12). 
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Figure 1-12 A strategy of using 2BP reactivity to enrich membrane associated enzymes such as 
DHHC PATs. By using a derivative functionalized with a latent affinity tag, such as an azide, 2BP could 
be used as an enrichment platform for membrane bound enzymes given its broad target specificity. 
 Cerulenin. Cerulenin, chemically known as [2R,3S]-2,3-epoxy-4-oxo-7,10-
trans,trans-dodecadienoylamide, is a lipid-based natural product derived from the 
fungus C. caerulens205. This compound was first described as an antibiotic agent that 
potently inhibited virtually all known types of biosynthetic fatty acid synthase (FAS) 
complexes206, and therefore was expected to impact the levels of fatty acids and 
metabolically related compounds207. Detailed studies of these biosynthetic systems 
revealed that cerulenin inhibited FAS by modifying the condensing enzyme subunit ß-
ketoacyl ACP synthase. Later on, cerulenin was found to inhibit the palmitoylation of 
various proteins such lipophilin, CD36 and p21Ras117,180. In an attempt to improve its 
selectivity towards inhibiting protein palmitoylation, a series of cerulenin derivatives 
were synthesized and their effects on protein palmitoylation and FAS activity were 
examined208,209. Interestingly, analogs substituted with longer aliphatic acyl chains 
demonstrated increased potency with regards to inhibiting Ras isoform palmitoylation 
and abolished its activity towards FAS. 
 While this structure-activity relationship (SAR) study was promising to offer a 
more-targeted palmitoylation inhibitor, the mechanism by which cerulenin blocked 
palmitoylation remained elusive. The natural cerulenin molecule is composed of a core 
epoxy-carboxamide‎group‎which‎is‎α-substituted with an octadienoyl side chain (Figure 
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1-9). It was noted, that in aqueous solutions, the molecule exists in an equilibrium 
between two forms, one being the open chain epoxy-carboxamide and the other being 
the fused bicyclic hydroxylactam. Importantly, the SAR studies and the well-established 
reactivity of thiols towards activated epoxides suggested the electrophilic epoxy-
carboxamide moiety enabled cerulenin to alkylate active site cysteine residues of both 
FAS and presumably DHHC PATs208. Recent studies with clickable cerulenin analogues 
has demonstrated that similar to 2BP, this inhibitor formed a hydroxylamine-resistant 
adduct with PATs, but was more potent towards DHHCs than 2BP.182 This boost in 
activity was attributed to the nucleophilic preference of thiols for the electrophilic 
epoxide when compared to the a structurally analogous α-halo carbonyl. Interestingly, 
mutagenesis studies showed that although cerulenin alkylated PATs it did not modify 
the putative catalytic cysteine of the enzyme.182 This result was puzzling as cerulenin 
has been shown to compete with 2BP alkylation which was confirmed to be dependent 
on the active state of the enzyme.188 Thus, the investigators proposed that given its 
resemblance to coA, cerulenin covalently attached to active site-proximal cysteines 
which blocked the entry or docking of 2BP and resembling acylCoA substrates. Despite 
not being a true mechanism-based inhibitor of PATs, the clickable cerulenin reporter 
was demonstrated to label all human DHHC members whereas 2BP, as will be shown 
in chapter two, could only label a fraction of tested PATs. 
 It is worth noting that like 2BP, cerulenin likely exerts pleiotropic effects on 
cellular fatty acid metabolism as it was shown to inhibit HMG-CoA synthetase activity  
and result in reduced biosynthesis of cholesterol and related molecules180. In addition, 
cells treated with cerulenin typically demonstrate reduced palmitate incorporation into 
certain phospholipids.117 Most importantly, proteomic studies have identified greater 
than 200 membrane associated cellular targets of cerulenin which include diverse lipid 
processing enzymes such as LPC acyltransferase and MBOAT7.182 Lastly, it remains a 
mystery as to why the combined hydrophobicity and enhanced electrophilicity of 
cerulenin does not permit its engagement to the catalytic thiol of DHHC active sites. 
 Compound V. Compound V (CV) is a non-lipid compound that was among five 
candidate PAT inhibitors discovered via a high-throughput screen of nearly 17,000 small 
molecules.210 Lead compounds were selected based on their ability to block 
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palmitoylation of model substrates in a cell-based assay180. Later studies with purified 
DHHC enzymes revealed that from all the lead inhibitors, only CV had significant 
pharmacological activity towards PATs though it was shown to be less potent than 2BP 
(IC50 > 10 µM).
185 CV exerted inhibitory effects on both PAT autoacylation and enzyme-
mediated protein acylation activities. Initial cell-based screening efforts suggested CV 
had selective pharmacological action towards N-myristoylated but not prenylated 
palmitoylated proteins, suggesting that this compound may inhibit a subset of DHHCs 
that exhibit the corresponding substrate specificity. However, this hypothesis was not 
corroborated in purified PAT studies revealing that CV equally inhibited two DHHC 
enzymes with apparent differential specificities towards peptides mimicking the 
aforementioned  palmitoylation sites. 
 As opposed to all other validated PAT drugs, CV is the only compound that does 
not resemble fatty acids or related biomolecules (Figure 1-9), and appears to exhibit 
reversible inhibition behavior with PATs given that enzyme activity could be recovered 
by diluting out the inhibitor. This reversible property was perplexing seeing that CV 
features‎an‎α,ß-unsaturated ketone moiety (i.e. Michael acceptor) which are known to 
be exceptionally reactive towards and form stable bonds to thiols211–216 such as those 
contained in the active sites of DHHCs. It is possible that CV could form a covalent 
thioether adduct with PATs and that inhibitor reversibility could be conferred through a 
retro-Michael addition reaction which have been shown to take place in a number of 
glutathione S-transferase-inhibitor Michael-adducts217,218. However, this mode of novel 
PAT inhibition remains to be investigated.  
Taken together, the current suit of PAT drugs highlights the need for high affinity, 
relatively selective PAT inhibitors that could be used to accurately assign the biological 
roles of enzyme and substrates of this widespread modification. Ideal pharmacological 
agents would be expected to target DHHC members in a mechanistically related 
fashion, such as competing with DHHC's specific acylCoA-dependent autoacylation and 
react at or around the catalytic center of the enzyme. Indeed, efforts towards PAT 
inhibitor developments have been impeded by the lack of efficient, in vitro, high 
throughput assays which can directly probe acyltransferase activity or active site 
occupancy. In addition to providing invaluable pharmacological tools, the search for 
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compounds that exhibit tuned DHHC specificity may yield potential therapeutic agents 
as the importance of palmitoylation in pathophysiology suggest  PAT-specific inhibitors 
could benefit the treatment of various human diseases.  
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1.6 Functions of S-Acyl-Protein Thioesterases 
 Due to the unstable thioester linkage, 
protein palmitoylation undergoes steady 
hydrolysis in cells, generally with a half-life of 
less than a few hours. As discussed earlier, 
this hydrophobic modification is critical for the 
function, trafficking, and localization of 
diverse proteins with central roles in 
adhesion, signaling, and organelle structure. 
Recent proteomics studies have annotated 
hundreds of palmitoylated 
proteins86,91,124,126,150,219,220, uncovering a 
widespread role for such a hydrophobic 
modification. Unlike static modifications like 
protein prenylation or myristoylation, protein 
palmitoylation provides a unique mechanism 
to reversibly regulate the membrane 
association of modified proteins. Indeed, 
dynamic palmitoylation of oncogenic HRas is 
required to mediate cell transformation.221 
Furthermore, activation of Ras or the G-
protein‎Gαs stimulates palmitoylation 
turnover,222,223 suggesting palmitoylation 
dynamics may be an essential trigger in the 
activation or deactivation of distinct signaling 
pathways. In this model, protein palmitoyl thioesterases catalyze the de-palmitoylation 
and release of certain proteins from the plasma membrane, potentially attenuating 
membrane-coupled signaling pathways (Figure 1-13). The released proteins can then 
undergo re-palmitoylation by endomembrane-bound DHHC palmitoyl-transferases, 
restoring palmitoylation and resetting the cycle. 
Figure 1-13 A dynamic S-palmitoylation 
cycle regulates the membrane association 
and activity of certain palmitoylated 
proteins. Specific stimuli cause an acyl protein 
thioesterase to catalyze thioester hydrolysis of 
palmitoylated cysteine residues. De-
palmitoylation liberates the protein from the 
plasma membrane, allowing it to segregate to 
the cytosol disrupting interactions with 
membrane-associated signaling complexes. 
The protein can then undergo re-palmitoylation 
by Golgi resident DHHC palmitoyl 
transferases, transport back to the plasma 
membrane, and re-associate with signaling 
partners. 
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 Given the evidence that HRas participates in an acylation/deacylation cycle,12 a 
putative HRas thioesterase termed acyl protein thioesterase (APT1) was identified from 
soluble rat liver fractions.224 This enzyme was previously characterized as 
lysophospholipase I (LYPLA1),225 but has several hundred-fold higher activity as a 
protein thioesterase. 224 APT1 removes palmitate from diverse palmitoyl protein 
substrates in vitro.224,226 Genetic deletion of the yeast homologue of APT1 shows a 
minor‎decrease‎in‎the‎turnover‎of‎palmitate‎on‎Gαs, yet has no defects in growth, 
mating, or deacylation of other palmitoylated proteins.227 Despite these results, lysates 
from APT1-knockout‎yeast‎lack‎in‎vitro‎Gαs palmitoyl thioesterase activity. 
227 
Importantly, deletion of APT1 has no effect on lysophosphatidylcholine (LPC) hydrolysis 
activity, suggesting it is not a functional lysophospholipase. 227 
 A second lysophospholipase II (APT2), is 68% homologous toAPT1,228 but 
surprisingly is slightly more efficient than APT1 at depalmitoylating semi-synthetic 
NRas.229 The axonal protein GAP-43 or HRas are more rapidly de-palmitoylated after 
APT2 overexpression.230 Phylogenic 
analysis shows that invertebrates 
evolved only one APT enzyme, while 
vertebrates evolved two (APT1 and 
APT2) (Figure 1-14). 
Figure 1-14 Shared homology between 
vertebrate and invertebrate acyl protein 
thioesterases. Vertebrates evolved two distinct 
APT enzymes, whereas invertebrates evolved a 
single APT enzyme. Phylogeny alignments were 
generated using DIALIGN, anchored at the 
catalytic serine residue. 
 
Both APT1 and APT2 have themselves been identified as palmitoylated proteins,89,219 
although the predicted palmitoylation site is not conserved in canine APT1 or in 
vertebrate APTs. In mammalian neurons, APT1–mRNA is translationally repressed by a 
synaptic microRNA complex.231,232 Upon glutamate stimulation, the repressive complex 
is degraded to allow local translation of APT1 in synaptic spines.232 APT1expression 
induces‎a‎reduction‎in‎spine‎volume‎potentially‎by‎depalmitoylating‎Gα13 and reducing 
synaptic RhoA activation.231 In addition, a recent in vivo RNAi screen identified APT2 as 
a candidate regulator of oncogenic HRas-dependent malignancy.233 A third more distant 
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homologue lysophospholipase-like 1(LYPLAL1) contains a narrow substrate-binding 
pocket unable to accommodate long-chain fatty acids,234 and genetic studies support a 
role in obesity.235 Overall, APT enzymes represent candidate protein palmitoyl 
thioesterases, but little is known about their substrates or dependence on upstream 
signals.   
 To address the proteome-wide dynamics and the contribution of enzymatic de-
palmitoylation, we recently applied non-radioactive bioorthogonal labeling approaches 
to selectively enrich palmitoylated proteins with enhanced turnover dynamics. This 
approach uses the commercially available fatty acid analogue 17-octadecynoic acid, 
which upon exogenous addition, is efficiently incorporated into endogenous sites of 
protein palmitoylation.124,236 After sufficient labeling, harvested cell lysates are 
conjugated to biotin–azide by copper-catalyzed click chemistry for subsequent 
streptavidin‎enrichment‎and‎mass‎spectrometry‎annotation.‎Using‎“pulse-chase”‎
labeling methods, we profiled de-palmitoylation dynamics in mouse T-cells. Cells were 
first labeled with 17-ODYA, then after‎some‎time‎“chased”‎with‎excess‎palmitic‎acid‎with‎
or without the non-selective lipid-like serine hydrolase inhibitor 
hexadecylfluorophosphonate (HDFP).86 This hydrophobic mechanism-based covalent 
inhibitor targets approximately 20 serine hydrolases characterized by their common 
preference for lipid-like substrates, including APT1 and APT2, but not LYPLAL1. We 
hypothesized that any candidate thioesterase is likely a serine hydrolase inhibited by 
HDFP. Quantitative proteomic analysis identified a subpopulation (<10%) of 
palmitoylated proteins that undergo rapid cycling mediated by one or more serine 
hydrolases targeted by HDFP.86 This subset includes Ras family GTPases, G-proteins, 
and scaffolding proteins implicated in malignancy. This data confirms that enzymes 
functionally contribute to palmitoylation hydrolysis in cells, and HDFP inhibition is 
sufficient to block any enzyme mediated palmitoylation turnover. Furthermore, given the 
relatively small subset of oncogenic signaling and scaffolding proteins, inhibiting de-
palmitoylation may perturb key signaling pathways involved in malignancy.  
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1.7 Pharmacological Agents for the Study of APTs 
 As‎discussed‎in‎the‎previous‎subchapter,‎APT‎enzymes‎are‎members‎of‎the‎α/ß-
hydrolase family of serine hydrolases.237 The catalytic serine nucleophile forms a 
covalent acyl-intermediate with substrates, enabling the development of covalent 
mechanism-based inhibitors. Over the last decade several small molecule inhibitors of 
APTs have been described.92 These include both reversible and irreversible inhibitors, 
which have been useful tools in several studies supporting a functional role for APTs in 
enzymatic depalmitoylation. APT inhibition is reported to suppress MAPK signaling and 
attenuate growth of certain Ras-transduced hematopoietic cells,238,239 as well as 
modulating the membrane association of the estrogen receptor in hippocampal slices.240 
APT inhibition also enhances invasion of the parasitic protozoan T. gondii into human 
cells,241,242 suggesting unique regulation across evolution. In the following paragraphs, 
each reported APT inhibitor to date is described with regards to its chemotype, details 
regarding potency, selectivity, and biological evaluation. This includes a discussion on 
the application of competitive activity-based protein profiling (ABPP) methods to profile 
inhibitor selectivity and target occupancy in biological systems.243 
 Benzodiazepinediones. Early efforts towards the development of APT1 inhibitors 
were rationally designed based on substrate mimicry of a dually palmitoylated and 
farnesylated peptide (Figure 1-15). A peptide-imitating benzodiazepinedione core was 
fused to S-farnesyl cysteine methyl ester and an acyl-sulfonamide to mimic the serine 
hydrolase tetrahedral intermediate,244 yielding a low-nanomolar APT1 inhibitor 
(compound 10, IC50 = 27 nM). Intermediates lacking the farnesyl moiety were 5-times 
less potent (compound 6, IC50 = 148 nM), but presumably more soluble, and were 
tested in cells. Cells microinjected with the inhibitor showed complete mis-localization of 
NRas away from the plasma membrane, disrupting NRas-dependent PC12 cell 
neuronal differentiation. Adding 30 µM inhibitor to the cell growth media caused a 
similar block of neurite outgrowth, suggesting efficient cellular uptake. These impressive 
initial compounds confirmed the importance of APT enzymes in modulating Ras 
dynamics in cells, and inspired further efforts to develop more drug-like APT inhibitors. 
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Figure 1-15 Lipidated N-Ras and peptido-
mimetic benzodiazepinediones. Lipopeptide 
mimics for targeting APT1 are based on the C-
terminal portion of lipidated N-Ras (Top, PDB 
5P21). A peptide-resembling 
benzodiazepinedione core serves as a central 
scaffold equipped with both a primary amine to 
mirror the lysine side-chain and an essential 
hydrolysis-resistant hexadecylsulfonamide 
moiety imitating a palmitoyl thioester 
tetrahedral intermediate. (Middle, 6) was further 
functionalized with a farnesylated cysteine 
methyl ester to yield a mimic of the C terminus 
of a fully processed N-Ras (bottom, 10) which 
exhibited potent inhibitory activity. 
 ß-Lactones. ß-Lactone serine 
hydrolase inhibitors are best characterized by the over-the-counter weight loss drug 
tetrahydrolipstatin (THL or Orlistat).245 Originally identified as a natural product from 
Streptomyces toxytricini,246 THL is representative of diverse bacterial ß -lactones with 
functional roles as bacterial effectors. Upon oral delivery, THL is a mechanism-based 
inhibitor of several digestive lipases that acts by preventing fatty acid intestinal 
absorption. After nucleophilic attack of the lactone ester and ring opening, the 
subsequent acyl-enzyme hydrolysis is slow, rendering the enzyme predominantly in an 
inactive state247 (Figure 1-16A). 
 
Figure 1-16 Mechanism-based ß-lactones inhibit APT enzymes. (A) APT enzyme inhibition by 
Palmostatin B. Attack on the electrophilic lactone by the catalytic serine hydroxyl leads to a transient acyl-
enzyme adduct, which slowly hydrolyzes to regenerate the active enzyme. (B) Structure of Palmostatin B. 
This inhibitor was discovered through the synthesis and screening of a small library of compounds on the 
basis of active-site similarity between APT1 and gastric lipase, and the fact that b-lactones are known 
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lipase acylating reagents. (C) Structure of Palmostatin M. This inhibitor was developed based on the 
structural similarity of lysophosphatidylcholine. A common recognition motif was identified, consisting of 
an electropositive dimethylamino tail imitating choline, an electronegative sulfoxide to mirror the 
phosphate, a central electrophilic trans-ß-lactone and a lipophilic tail resembling the palmitate moiety to 
increase affinity to the lipid-binding pocket of the enzyme. 
 
In order to discover novel APT1 inhibitors, a series of ß -lactone derivatives were 
synthesized and profiled against APT1, leading to the discovery of the chiral n-decane 
substituted ß-lactone Palmostatin B (IC50 = 5.4 nM)
248,249 (Figure 1-16B). Palmostatin B 
is readily membrane-permeable, and directly reacts with APT1 and APT2 as both a 
substrate and an inhibitor in live cells.248 
 To study the effects of APT inhibition, Palmostatin B treated cells were imaged 
after microinjection of fluorescently labeled NRas, or following transfection of YFP-NRas 
in MDCK cells.248 Palmostatin B addition led to YFP-NRas mis-localization and 
decreased compartmentalized NRas activation. These experiments likely required high 
nanomolar concentrations of labeled NRas for fluorescence imaging, which may have 
encroached on the Km of APT1 towards palmitoylated NRas (~1 µM)
229 and potentially 
enhance any observed phenotypes. Further experiments showed that Palmostatin B (50 
µM) altered the morphology of oncogenic HRas transformed cells, restoring them to a 
less spindly appearance with increased E-Cadherin membrane localization. Palmostatin 
B displays poor stability in cell culture, and was added to cells at effectively 104 times 
the IC50, which may diminish selectivity. Interestingly, siRNA knockdown of APT1 did 
not statistically alter the ratio of golgi to plasma membrane NRas. This suggests either 
insufficient APT1 knockdown, or that Palmostatin B inhibits other protein thioesterases, 
such asAPT2 (Ki = 34 nM)229 that may contribute to NRas processing. Further 
experiments showed that addition of 30–100 µM of Palmostatin B dose-dependently 
impedes the growth of HRas or NRas transduced hematopoietic cells, but does not 
affect cells transduced with a non-palmitoylated isoform of KRas.239 Such high inhibitor 
concentrations may inhibit other intracellular hydrolases, but clearly define a role for de-
palmitoylation in Ras regulation. Overall, Palmostatin B has provided important 
pharmacological evidence of protein palmitoylation dynamics in live cells. 
 In efforts to selectively target APT isoforms, a polar sulfone moiety was added to 
the ß-lactone scaffold to mimic the polarity of lysophosphatidylcholine (Figure 1-16C), 
yielding the improved analogue Palmostatin M (APT1 IC50 = 2.5 nM).249 Despite 
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synthesis of a diverse library of greater than 50 compounds, no APT1 or APT2 isoform 
selective inhibitors were identified, which may signal a structural limitation of the ß-
lactone scaffold. Palmostatin M similarly induces NRas mis-localization from the plasma 
membrane and partially restores E-Cadherin localization at cell–cell junctions in HRas-
transformed MDCK cells.249 Because ß-lactones form a semi-stable covalent complex 
with their targets, an alkynyl Palmostatin M analogue was synthesized to annotate 
potential cellular targets.229 Lysates were labeled with the alkynyl probes, conjugated to 
a tri-functional rhodamine/biotin–azide by copper-catalyzed click chemistry, enriched 
with streptavidin, and analyzed by in-gel fluorescence or mass spectrometry to identify 
candidate target proteins. These experiments confirmed APT1 and APT2 as major 
Palmostatin M targets, but also identified other serine hydrolases including the 
lysosomal thioesterase PPT1 and retinoid- inducible serine carboxypeptidase (RISC). 
While these compounds are exceptionally potent, non-specific inhibition and poor drug-
like properties limit the application of these probes for in vivo studies. 
 Boronic acids. In order to discover new chemotypes that inhibit APT enzymes, an 
immobilized library of <15 000 natural products and inhibitors was assayed for APT 
binding.250 In this approach, inhibitors were covalently attached to glass using a tri-
fluoromethylaryldiazirine photo-crosslinking system, and then incubated with 
recombinant GST-fusions of APT1 or APT2. Binding was detected after incubation with 
anti-GST antibodies and visualization with fluorescent secondary antibodies. Four 
similar bis-borinic acid and bisborinate ester structures were identified (Figure 1-17), 
which were further validated by surface plasmon 
resonance. Boron-based inhibitors of serine 
hydrolases act by boronate coordination of the 
side chain hydroxyl nucleophile of the catalytic 
serine residue, mimicking the tetrahedral 
intermediate.251 
Figure 1-17 Bis-boronic acid inhibitor of APT enzymes. Representative bisboronic acid-based inhibitor 
(compound 4) and reported inhibitory values for both APT1 and APT2. 
 
Several boron-containing drugs are in clinical use, including the proteasome inhibitor 
Bortezomib (Velcade), the DPP4 inhibitor Januvia, ß-lactamase inhibitors, and many 
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more under development.251 Kinetic analysis of the diphenylboronic acids showed 
potent inhibition of APT1 (Ki = 0.99 ± 0.13 µM) and APT2 (Ki = 0.73 ± 0.20 µM).250 
Other analogues were slightly less potent, but showed a slight preference towards 
APT2. Similar to Palmostatin B, the diphenylboronate ester inhibitors demonstrated a 
dose-dependent inhibition of Erk1/2 phosphorylation and induced a less spindly 
phenotype in HRas transduced MDCK cells. While this study does not provide any data 
on the selectivity of these analogues, it does validate boron-containing inhibitors as a 
new APT inhibitor chemotype, and provides further phenotypic support that APT 
enzymes functionally regulate Ras-dependent signaling pathways. 
 Triazole ureas. Significant progress has been made in the development of 
selective serine hydrolase inhibitors through optimization of carbamates, leading to 
analogues with exquisite selectivity and potency as covalent probes.252 Despite 
considerable effort, carbamates fail to reach a broad subset of serine hydrolases, 
including APT enzymes.253 During efforts to explore novel covalent inhibitor scaffold of 
serine hydrolases, N-heterocyclic ureas were identified as a new chemotype for serine 
hydrolase inhibitor development.254 Both carbamates and N-heterocyclic ureas undergo 
nucleophilic attack by the active-site nucleophilic serine, leading to formation of a non-
hydrolysable carbamylated acyl-intermediate (Figure 1-18A). These inhibitors are 
bioavailable, selective within the serine hydrolase enzyme family, and maintain activity 
both in vitro and in vivo.254,255 Furthermore, a facile, convergent synthesis of triazole 
ureas accelerated the development of selective sub-nanomolar, in vivo active, selective 
inhibitors for acyl peptide hydrolase (APEH), as well as low nanomolar inhibitors of 
PAFAH2 and ABHD11254 with limited medicinal chemistry efforts. 
 The development of triazole urea inhibitors was reinforced by guided medicinal 
chemistry using competitive fluorophosphonate (FP) ABPP probes.243,256 In this assay, a 
complex proteome is mixed with a triazole urea analogue to achieve enzyme inhibition. 
Next, a reporter-tagged FP-probe is added that irreversibly reacts with all active serine 
hydrolases. Accordingly, any reduction in probe labeling corresponds to inhibition. 
Typically, the FP-tetramethylrhodamine (FP-TAMRA) is used for rapid gel-based 
analysis of both the potency and selectivity of a candidate inhibitor across all active 
serine hydrolases in a specific cell line or tissue isolate. For less abundant enzymes, 
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quantitative analysis is performed using FP-biotin, followed by streptavidin enrichment 
and mass spectrometry annotation.254 This approach guides medicinal chemistry efforts 
primarily based on both selectivity and potency towards a specific target. 
 Triazole urea libraries were synthesized by click chemistry of alkynyl variants 
with azide, followed by conjugation to diverse carbamoyl chlorides.254 This two-step 
approach leads to regioisomers at the N2 (major) and N1 (minor) positions, which may 
potentially have differential inhibitory properties.255 After identification of a candidate 
triazole urea lead for APT1, 19 
additional analogs were synthesized 
with variable substitutions at the three 
positions: the substituent at 4-position 
of the triazole (R1), the substituent of 
the piperidine ring (R2), and the 
identity of the atom at the 4-position of 
the piperidine ring (X)257(Figure 1-
18A). 
Figure 1-18 Triazole urea covalent APT 
inhibitors. (A) Mechanism of triazole urea 
inactivation of APT enzymes. The APT 
nucleophilic serine hydroxyl attacks the urea, 
releasing the triazole and leaving a stable 
carbamate adduct, inactivating the enzyme. 
(B) Selectivity and potency of optimized 
triazole urea inhibitors determined by gel-
based competitive ABPP. AA64-2 is highly 
potent and selective for APT enzymes, with 
the exception of the uncharacterized 
hydrolase ABHD11. AA44-1 is highly selective 
for ABHD11, and can be used as a control 
probe. 
Each round of medicinal chemistry was guided by gel-based competitive ABPP profiling. 
Optimization led to the identification of a highly potent tertbutylpiperidine (R2, X), and 
improved selectivity by addition of a bulky diphenyl methanol (R1).
257 These inhibitors 
retain potency and selectivity in live cells with no observed toxicity. Despite significant 
effort, little selectivity was achieved against the unannotated hydrolase ABHD11. This is 
less of a concern, since highly selective analogues targeting ABHD11 could be used as 
control probes.254 
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 The parasitic protozoan T. gondii is a close relative to the malaria parasite P. 
falciparum, which expresses hundreds of palmitoylated proteins, many which are 
required for infectivity. In order to explore the potential of APT inhibition in the parasitic 
life cycle, Palmostatin M was compared side by side with a piperidine (X), diphenyl 
methanol (R1), triazole urea (AA401).
241 This analogue inhibits human APT1 (IC50 < 30 
nM) and APT2 (IC50 = 200 nM), as well as ABHD11, Esterase D, and APEH (Figure 
Figure 1-18B).257 These compounds were assayed for inhibition of T. gondii invasion, 
egress, and intracellular growth. By competitive ABPP methods, the T. gondii APT 
homologue TgASH1 was completely inhibited by 10 µM Palmostatin M or as little as 100 
nM of AA401. The parasite's lytic cycle is severely inhibited by incubation with 10 µM of 
either Palmostatin M or AA401, but this result is eliminated when the inhibitor 
concentration is lowered to 1 µM. Additional analysis showed neither of the compounds 
had any effect on parasitic egress. Interestingly, Palmostatin M reduces parasitic 
invasion, while AA401 inhibition may slightly enhance invasion. Furthermore, deletion of 
TgASH1 had no quantifiable effect on the membrane localization of known T. gondii 
palmitoylated proteins by immunofluorescence and no effect on the growth or life cycle. 
Since P. falciparum does not encode a TgASH1 homologue, it is unclear if TgASH1 
accounts for all protein thioesterase activity in apicomplexans.241 Overall, the potent 
triazole urea inhibitor AA401 appears to have increased selectivity and less off-target 
effects, providing a promising alterative to Palmostatin B for in vivo studies. 
 Chloroisocoumarins. In a parallel T. gondii study, a forward chemical genetic 
screen was assayed to discover modulators of parasitic invasion. This study led to the 
discovery of compounds that attenuate invasion, including compounds targeting the 
redox chaperoneTgDJ-1.258 In addition, the chloroisocoumarin JCP174 and similar 
derivatives were identified as enhancers of parasitic invasion,242 and removing the 
aromatic amine substituent in the position-7 abolished activity, providing an inactive 
analogue (Figure 1-19B). Enhanced invasion was dose-dependent, and correlated with 
improved gliding motility, an established indicator of enhanced invasion. Invasion was 
enhanced within 5 minutes of inhibitor treatment with no observable effects on viability 
or intracellular replication. 
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Figure 1-19 Mechanism-based chloroisocoumarin JCP174 inhibits T. gondii APT. (A) Putative 
mechanism of APT irreversible enzyme inactivation by JCP174. Attack on the electrophilic carbonyl by 
the catalytic serine hydroxyl leads to the formation of an acyl-enzyme‎derivative,‎unmasking‎a‎reactive‎α-
chloro carbonyl group. Elimination of chlorine yields a quinone-imine-methide intermediate that is 
susceptible to nucleophilic attack by either the solvent or the enzyme's catalytic histidine side-chain 
producing a labile acyl-enzyme derivative or a stable alkylated acyl-enzyme adduct, respectively. (B) 
Structures of the active chloroisocoumarin inhibitor JCP174 (left), the inactive control lacking 7-amino 
substitution JCP174-IA (middle) and the click-compatible analog derivatized with an alkyne functional 
group JCP174-alk (right). 
 
 Chloroisocoumarins were first identified as mechanism-based covalent inhibitors 
of serine proteases.259 Chloroisocoumarins have limited stability and are susceptible to 
both serine and cysteine nucleophiles, leading to enhanced reactivity and significant 
potential off-targets. Indeed, JCP174 originated as a human elastase inhibitor (kobs/[I] = 
54,000 M-1 s-1),260 but may also be reactive towards other proteases and hydrolases. 
This class of double-hit irreversible inhibitors first reacts with the enzyme's serine 
nucleophile to generate an acyl-enzyme intermediate. Elimination of the α-chloro group 
produces a highly electrophilic quinone-imine methide, which is susceptible to attack by 
accessible nucleophiles including the activated histidine of the catalytic triad (Figure 1-
19A). While this mechanism was not explicitly demonstrated for TgASH1, the analogous 
chlorine elimination is predicted to produce a reactive electrophile. 
 In order to determine the functional target(s) of JCP174, parasite proteomes 
were treated with FP activity-based probes to profile potential serine hydrolase 
targets.242 In-gel competitive ABPP analysis reported a single serine hydrolase target of 
JCP174. Additionally, an alkynyl analogue, JCP174-alk, was used to directly enrich 
36 
 
targets after copper-catalyzed click chemistry to a biotin–azide and streptavidin 
enrichment. Mass spectrometry proteomics identified several proteins where JCP174-
alk enrichment was reduced by competition with JCP174, including the APT homologue 
TgASH1 (IC50 = 1.32 µM). This finding corroborates the enhanced invasion trend 
reported after treatment with AA401,241 although JCP174 induces a stronger and more 
significant enhancer phenotype. Furthermore, incomplete conditional knockdown of 
TgASH1 enhanced invasion, while a genetic knockout showed no effect and was 
unresponsive to JCP174 treatment. Recombinant TgASH1 was able to catalyze the in 
vitro depalmitoylation of established palmitoylated proteins with roles in invasion, and 
JCP174 treatment similarly enhanced their co-fractionation with membranes, suggestive 
of altered palmitoylation dynamics. In summary, chloroisocoumarins represent an 
additional chemotype targeting APT enzymes, and highlight how forward 
chemoproteomic screens can identify new regulatory pathways in parasitic invasion. 
 Piperazine amides. While several covalent chemotypes have emerged for APT 
enzymes, none are selective for either isoform. In the absence of an APT2 crystal 
structure, rational design of isoform selective inhibitors has been challenging. In 
collaboration with the NIH Molecular Libraries Production Center Network (MLPCN), 
both human APT1 and APT2 were assayed against a library of 315 004 compounds261 
to identify new inhibitor chemotypes and explore the potential to identify isoform-
selective leads. This high-throughput screening (HTS) effort used a fluorescence 
polarization-based competitive ABPP assay, termed FluoPol-ABPP262 (Figure 1-20). In 
this approach, recombinant APT enzyme is incubated with fixed amount of a candidate 
inhibitor (10 µM), followed by a short, time-dependent addition of fluorophosphonate–
rhodamine (FP-TAMRA). Upon covalent alkylation of the nucleophilic serine, the 
fluorescence polarization increases relative to enhanced anisotropy of the enzyme–
fluorophore complex. Based on these parameters, any loss of polarization identifies 
potent inhibitors able to effectively compete with the irreversible covalent reaction. This 
assay routinely yields Z-factors >0.8, providing a robust approach to identify novel 
isoform selective APT inhibitors. Importantly, the FluoPol-ABPP assay is performed 
under time-dependent non-equilibrium conditions, providing a primary selection for 
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inhibitors with potent koff constants, which correlate with enhanced residency time and 
improved in vivo pharmacokinetics.263 
 
Figure 1-20 FluoPol-ABPP high-throughput competitive assay to discover new APT inhibitor 
chemotypes. Inhibitor discovery by active site occupancy profiling with the activity-based probe FP-
TAMRA. APT enzyme is pre-incubated with inhibitor, and then under non-equilibrium conditions, treated 
with FP-TAMRA, which irreversibly competes with candidate inhibitors. Activity is reported by a change in 
fluorescence polarization induced by the increased anisotropy of the enzyme–probe complex. 
 Separate HTS screens were performed for APT1 and APT2, yielding hit rates of 
0.156% and 0.380%, respectively.257,261 Each hit compound was re-tested in a 
confirmatory screen, which validated 69% APT1 inhibitors, and 66% APT2 inhibitors. 
This list was then manually filtered to exclude non-selective compounds identified in 
similar HTS assays for the serine hydrolases RBBP9 and PME1, and the cysteine-
dependent enzyme GSTO.264 In total, 91 APT1, 61 APT2, and 95 dual APT1/APT2 
inhibitors were selected for in-gel ABPP confirmatory analysis. This filtered group of 
inhibitors included one triazole urea, but largely converged to a common (>1/3) 
piperazine amide chemotype. This motif bears striking similarity to triazole ureas, since 
each contain a five-membered ring (furan,thiophene, or triazole) linked across an 
amide/urea with a N-heterocycle. Furthermore, due to the large diversity of the library, a 
structure–activity relationship emerged, identifying APT1 inhibitors with extensions from 
the piperazine arm, and APT2 inhibitors with hydrophobic extensions off the thiophene 
arm. Surprisingly, many of the inhibitors were selective for a specific APT isoform, an 
elusive property not found with other chemotypes. Overall, the most potent inhibitors 
were characterized in a fluorogenic substrate assay, providing Ki values in the 200–300 
nM range, a surprising success for leads taken directly from the screening library 
(Figure 1-21). Interestingly, gel-based competitive ABPP shows stark differences in 
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potency between the APT1 and APT2 compounds, yet steady-state kinetic analyses 
yielded effectively similar Ki values. These findings suggest the APT inhibitor's potency 
is derived primarily from its small koff value, and highlight how such non-equilibrium 
assays can improve selection for compounds with improved residency times. 
 
Figure 1-21 Lead isoform-selective inhibitors for APT1 and APT2 identified by FluoPol-ABPP. 
 Competitive assays with aliphatic FP-TAMRA proceeded to completion quickly 
under standard conditions, making it difficult to capture the optimal kinetic window in 
competitive experiments involving reversible inhibitors.261 To circumvent this problem, 
competitive ABPP assays were performed using a less reactive hydrophilic probe, FP-
PEG-TAMRA. This probe is a poor substrate for APT enzymes, slowing the reaction 
kinetics enough to assay active site competition. Such findings have significant 
implications for competitive ABPP selectivity assays with reversible inhibitors, since 
different enzymes may react with ABPP probe variants with distinct kinetic windows. 
 For both APT1 and APT2, a small library of <10 analogues were assayed to 
establish a preliminary structure–activity relationship.261 For the APT2 lead inhibitor, the 
(p-methoxyphenyl)-piperazine arm was intolerant to substitutions in the ortho and meta 
positions. Further modifications on the thiophene arm were more tolerant, suggesting 
opportunities for further optimization. Importantly, the (o-methoxyphenyl)-piperazine 
analogue completely lost activity, providing a non-reactive control analogue. For the 
APT1 inhibitor, a similar negative control compound was identified‎with‎an‎α-methyl 
group substituted at the amide linkage. Inhibitor selectivity was confirmed by gel-based 
competitive ABPP, but also by SILAC-ABPP, a quantitative mass spectrometry method 
to quantify inhibitor occupancy with increased sensitivity.254 This approach confirmed 
isoform selective inhibition across the serine hydrolase enzyme family for each lead 
inhibitor. These experiments demonstrate how competitive ABPP methods can be used 
to profile reversible inhibitors in complex proteomes, although the relative reactivity of 
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each enzyme towards the probe may vary. Therefore, when using competitive ABPP 
methods to assay reversible inhibitors, it is important to recognize that variable ABPP 
probe reaction rates can skew observed selectively profiles. 
 In order to validate target occupancy in vivo, each lead inhibitor was injected into 
mice.261 After some time, an alkynyl triazole-urea probe was injected to profile residual 
active enzymes. This probe is poorly reactive with APT enzymes, providing an 
appropriate kinetic window to profile target occupancy in vivo. Since the rate of the 
triazole urea probe reaction with APT enzymes is slow, it was then possible to harvest 
tissues and analyze the results from the in vivo competition. The alkynyl triazole urea 
probe demonstrated isoform selective APT inhibition in the brain, kidney, lung, and 
heart. No inhibition was observed in the liver, which accumulates the triazole urea probe 
and likely distorts the reaction stoichiometry to out-compete the reversible inhibitors. 
Reduced inhibition was observed in the brain, suggesting these compounds are less 
efficient at crossing the blood–brain barrier. Overall, piperazine amide APT inhibitors 
are isoform selective, potent, and in vivo active inhibitors of APT1 and APT2 with no 
identified off-targets, making them the most promising, drug-like inhibitors to date. 
 In conclusion, the recent development of APT inhibitors has accelerated our 
understanding of the cellular regulation of palmitoylation, but has also provided a 
platform to advance new methodologies in inhibitor identification, selectivity profiling, 
and cellular validation. APT enzymes are conserved in eukaryotic organisms, 
suggesting a common biological function, which in mammals includes protein de-
palmitoylation of certain target proteins. Surprisingly, there are no reported phenotypes 
for APTs in standard invertebrate model organism, including yeast, drosophila, and C. 
elegans. This raises the possibility that for these invertebrates (1) enzymatic 
depalmitoylation may not be essential, (2) functionally redundant hydrolases 
compensate for APT deficiency, or (3) APT enzymes are not primarily de-palmitoylases. 
Future studies demand the generation of vertebrate knockout systems to profile APT 
mutant phenotypes in higher organisms. Current data suggest APT enzymes are 
responsible for regulating dynamic palmitoylation, but many of the reported experiments 
rely on over-expression studies and report subtle changes, leaving room for additional 
interpretations. With the development of new potent and selective inhibitors and bio-
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orthogonal labeling methods, it is now possible to directly answer these questions on 
endogenous palmitoylated proteins. Ongoing efforts to optimize APT1 and APT2 
inhibitors will require a structural understanding of inhibitor binding, which promises to 
add structure-guided design principles to focus new medicinal chemistry. Improved 
competitive inhibitors are the next logical path towards developing selective 
pharmacological tools for in vivo functional analysis of protein de-palmitoylation. 
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1.8 Signaling Functions of Dynamic Palmitoylation 
Unlike any other lipid-based PTM, S-palmitoylation can be subjected to a variety 
of regulatory mechanisms. This happens because both enzymes that attach and 
remove this modification are frequently co-employed to tightly control the palmitoylation 
state and hence activity of a given protein32,89,103,148,174,265. This unique mode of protein 
lipidation, which is now described for numerous palmitoylated proteins, has been 
suggested to modulate a protein's activity in much of the same way as the highly 
exploitable protein phosphorylation events.31,36,63 Signaling proteins in particular, have 
shown to possess switch-like palmitoylation behaviors that could only be possible if 
specific palmitoylation and depalmitoylation catalysts were intimately involved in their 
transduction.98,178,266,267 Certainly, it is logical for palmitoylation to play such a central 
role in protein signaling seeing that all extracellular-induced signaling cascades must 
begin at the plasma membrane and propagate into the aqueous environments of the 
cell3. Thus, it is common for highly dynamic palmitoylated proteins to serve the role of 
the so-called second messenger as they possess transitory membrane association 
which allows for shuttling between membrane and cytosolic compartments to transmit 
the necessary transduction signal36,268–271 (Figure 1-22). 
The number of reports featuring signaling proteins that undergo dynamic 
palmitoylation cycles has increased dramatically.89,90,272–275 Throughout these studies, 
dynamic palmitoylation was shown to be indispensible for transient membrane 
association, trafficking, and segregation of signaling proteins into lipid microdomains. 
For example, lipid anchoring of the small GTPase HRas has been shown to be essential 
for its ability to transduce cellular growth and proliferation.26,64,276 The palmitoylation 
behaviors of Ras family members have been well documented since they are all 
frequently mutated  in cancers and potentiate oncogenic growth pathways.50,277–282 
Interestingly, the palmitate turnover of inactive, GDP-bound ,HRas was found to be 
accelerated by 15-fold upon growth factor stimulation, going from a turnover half-life of 
almost three hours  to just fifteen minutes.223 Growth factors, which presumably 
stimulate candidate protein thioesterases, leads rapid de-palmitoylation of HRas, forcing 
a redistribute from the plasma membrane to the Golgi apparatus, where it is gradually 
re-palmitoylated and trafficked back to the plasma membrane where the cycle is 
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restarted283–285. Similarly, G-protein alpha subunits are also rapidly de-palmitoylated 
after activation, as well as multi-domain scaffolding proteins such as the neuronal 
membrane associated guanylate kinase (MAGUK) PSD-95286,287. Despite the growing 
popularity of dynamic palmitoylation, the exact pairs of opposing enzymes responsible 
for these events are often unaddressed. A deeper understanding of both the static and 
dynamic roles of protein palmitoylation is critical for defining the spatial and temporal 
regulation of cellular growth pathways. 
 
Figure 1-22 The palmitoylation of many, but not all, proteins is dynamic and can be modulated in 
response to cell stimulation. A specific example is the palmitoylation turnover cycle of NRas, an 
important growth signaling protein that is mutated in a large number of human cancers. Farnesylated 
NRas exhibits a weak membrane affinity that mediates its interaction with Golgi membranes. 
Palmitoylation at this compartment promotes a stable membrane association. The dual-lipid modified Ras 
can then be trafficked to the plasma membrane by the vesicular transport system to meet up with its 
signaling partners. In response to a stimulus, such as growth factor binding at its receptor, a putative 
protein palmitoyl thioesterase‎hydrolyzes‎the‎acyl‎group,‎thus‎decreasing‎Ras’s‎membrane‎affinity‎
resulting in membrane release and cytosolic diffusion before re-palmitoylation at the Golgi. Thus, dynamic 
palmitoylation plays an important role in regulating membrane association, cellular trafficking and activity 
of many proteins. Other examples of dynamically palmitoylated proteins include GNAS, PSD95 and 
eNOS, all of which are signal transducers. Please note the neither proteins or lipids depicted are drawn to 
their relative sizes. 
Until recently, direct in vivo evidence for a depalmitoylating enzyme has been 
lacking, although APT proteins have been attributed with multiple in vitro 
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depalmitoylating activities.224,227,288 Several exciting findings have emerged from pulse-
chase proteomic studies of 17ODYA-enriched proteins. First, palmitoylation sites on 
most proteins were found to be relatively static.86 These stable modifications could 
represent sites from various transmembrane proteins, many of which are known to 
retain their acyl groups throughout the protein's lifetime63,88,289. Therefore, only a small 
subset of palmitoylated proteins demonstrated accelerated turnover. This dynamically 
palmitoylated group of proteins comprise of scaffolds, Ras-family GTPases, G-protein 
alpha subunits, and PDZ-domain containing polarity proteins – all of which are signaling 
components critical for cellular transformation and tumor initiation290,291. Second, the 
broad-acting serine lipase inhibitor hexadecylfluorophosphonate (Figure 1-5) 
demonstrated that de-palmitoylation of this subset of signaling/scaffolding proteins was 
enzymatically-controlled and was likely mediated by member(s) of the serine hydrolase 
family, specifically those 20 hydrolases inhibited by HDFP. This is the first evidence in 
over three decades to show that palmitoylation is indeed dynamically regulated by 
protein thioesterases in mammalian cells. Additionally, based on the unique subset of 
cancer-related thioesterase substrates, these results motivate the development of 
thioesterase inhibitors to evaluate their potential as anti-cancer agents.  
 The proteomic experiments described above identified the tumor suppressor and 
cell polarity regulator Scribble (Scrib) as 
the most enzymatically regulated, most 
rapidly cycling palmitoylated protein 
(Figure 1-23). 
Figure 1-23 Quantitative SILAC palmitoylation 
proteomics of Scrib demonstrates rapid 
enzymatic turnover by 17-ODYA pulse-chase 
analysis. Peptide data has been adapted from 
Martin et. al.
86
 
Scrib is a tumor-suppressor, which unlike Ras proteins, is frequently 'turned off' in 
cancer, leading to hyperproliferation and thus cooperating with oncogenic Ras 
signaling.292,293 Scrib is normally localized to the basolateral cortex membrane of 
epithelial cells where it controls polarity, junctional integrity, proliferation, and 
metastasis.294–296 Interestingly, Scrib and Ras superfamily proteins frequently 'cross 
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roads' when it comes to cell fate decisions such as migration, cell division, cancer 
transformation, apoptosis and proliferation (Error! Reference source not found.).297–301. 
 
Figure 1-24 The loss of Scrib's membrane anchoring and tumor-suppressor ability correlate with 
hyperactivated proliferation cascades potentiated by Ras effectors. Scrib normally localizes to 
adherens junctions at the basolateral cortex where it regulates epithelial polarity, junctional integrity and 
cell proliferation (left). As cells undergo fibroblastic transformation, dysfunctional, cytosolic Scrib appears 
to potentiate Ras effectors in an elusive mechanism allowing cells to form hyperplasia (right). It has been 
suggested that Scrib suppresses the well-known mitogen activated growth cascade through interactions 
with Raf kinases downstream of Ras GTPases
302
, however the spatiotemporal coordination between 
Scrib and Ras is unknown. 
 
Thus, cells must develop strategies to tightly coordinate the localization of  these two, 
seemingly opposing proteins so that productive signaling of the aforementioned 
pathways is guaranteed. In human epithelial cells, Scrib mislocalization appears to 
induce metastatic transformation through a disruption of cell polarity and adhesion 
junctions, while also enhancing Ras growth signaling to promote cell survival and 
proliferation (Figure 1-24).301,303 Furthermore, since malignant cells appear to accelerate 
the turnover of Scrib palmitoylation86, Scrib localization, spatial interactions, and tumor 
suppression may in fact be under this post-translational control (Figure 1-25). 
45 
 
 
Figure 1-25 Scrib mis-localization and TAZ elevation in increasingly malignant cells. (a) Depicts 
cell-based models of breast cancer, in which Scrib localization becomes increasingly cytosolic as cells 
undergo an oncogenic transformation termed epithelial-mesenchymal-transition (EMT) and acquire 
aggressive fibroblastic traits. (b) Depicts the same benign cells engineered to over-express the EMT-
promoting transcription factor Snail, which significantly elevates the protein levels of the anti-apoptotic 
factor TAZ and redistributes Scrib from the membrane to the cytosol.
304
 Interestingly, when Scrib was 
constitutively anchored to the plasma membrane by over-expression of Scrib containing the prenylation 
CAAX motif, TAZ accumulation was abolished which abrogates a number of metastatic phenotypes. 
In conclusion, dynamic palmitoylation proteomic studies place opposing signaling 
proteins, e.g. Scrib and Ras, among most dynamically palmitoylated proteins in cells. 
Not surprising, proteins such as Scrib and Ras share many signaling effectors in 
common which raises questions like which signaling protein exerts more control over 
the other and under what cellular circumstances? It appears that within the context of 
cancer, as shall be discussed later in chapter four, the oncogenic potential of Ras 
proteins is strengthen all while the tumor-suppressor capacity of Scrib is diminished. In 
this dissertation work, we suggest that dynamic palmitoylation enzymes may contribute 
to this and other imbalances seeing that a number of these enzyme have been reported 
to exhibit  expression changes in cancer.233,305 In this regard, different fractions of 
palmitoylation and depalmitoylation enzymes may exist in particular cancer cells, and 
perhaps the concerted action by these enzymes could specifically promote dynamics for 
Ras but suppress those of Scrib. To complicate the matter, the acylation enzymes 
themselves ought to be spatially and temporally coordinated to promote effective 
intracellular trafficking and localization of their substrate proteins283. Clearly, the need 
for better tools to characterize the extent of dynamic palmitoylation regulation and 
understand how it functions in the context of other regulatory mechanisms cannot be 
over emphasized enough. This thesis addresses this gap by providing pharmacological 
agents and characterizing the roles of palmitoylation enzymes in cancer.  
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Chapter 2:  
Analysis of 2-Bromopalmitate Proteome Reactivity and Utility as a 
Probe for Protein S-Acyltransferases 
2.1 Abstract 
 2-Bromohexadecanoic acid, or 2-bromopalmitate,was introduced nearly 50 years 
ago as a nonselective inhibitor of lipid metabolism. More recently, 2-bromopalmitate re-
emerged as a general inhibitor of protein S-palmitoylation. Here, we investigate the 
cellular targets of 2-bromopalmitate through the synthesis and application of click-
enabled analogues. In cells, 2-bromopalmitate is converted to 2-bromopalmitoyl-CoA, 
although less efficiently than free palmitate. Once conjugated to CoA, probe reactivity is 
dramatically enhanced. Importantly, both 2-bromopalmitate and 2-bromopalmitoyl-CoA 
label DHHC palmitoyl acyltransferases (PATs), the enzymes that catalyze protein S-
palmitoylation. Mass spectrometry analysis of enriched 2-bromopalmitate targets 
identified PAT enzymes, transporters, and many palmitoylated proteins, with no 
observed preference for CoA-dependent enzymes. These data question whether 2-
bromopalmitate (or 2-bromopalmitoyl-CoA) blocks S-palmitoylation by inhibiting protein 
acyl transferases, or by blocking palmitate incorporation by direct covalent competition. 
Overall, these findings highlight the promiscuous reactivity of 2BP and validate clickable 
2BP analogues as activity-based probes of diverse membrane associated enzymes. 
 
 Individual contributions. Most of the work in this chapter was produced by me 
with the following exceptions. As for principle investigators, Dr. Brent R. Martin provided 
the major funding, conceived the project and directed all experimental designs. Dr. 
Robert T. Kennedy provided funding for and directed the metabolomic experiments. As 
for postdoctoral fellows, Dr. Mahmoud A. El Azzouny performed the metabolomic 
experiments with 2BP. Dr. Jeannie L. Hernandez generated DHHC2 active site point-
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mutants and assayed the activities of DHHC members towards 2BP. Dr. Jaimeen 
Majmudar helped with the proteomic analysis of 2BP targets and Cristopher T. M. B. 
Tom synthesized the 2BP-CoA derivative.  
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2.2 Introduction 
 2-bromopalmitate (2BP) is an irreversible inhibitor of many membrane-associated 
enzymes.1 It was initially reported as an inhibitor of‎β-oxidation2,3 but later shown to 
inhibit mono-, di-,and triacylglycerol transferases, fatty acyl CoA ligase, glycerol-3-
phosphate acyltransferase, as well as nonlipid processing enzymes such as NADPH 
cytochrome-C reductase and glucose-6-phosphatase at submillimolar concentrations.1 
Importantly, each of these enzymes has cysteine residues in or near the enzyme active 
site,‎suggesting‎α-halo-carbonyl electrophilic alkylation mediates the observed 
irreversible inhibition. This reactivity was later confirmed by labeling rat liver fractions 
with millimolar concentrations of 1-[14C],2-bromopalmitate.1 After separation by SDS-
PAGE and autoradiography, radioactivity was detected across many unique proteins, 
highlighting the promiscuous reactivity and potential issues associated with this 
nonspecific covalent inhibitor. 
 Despite these issues, 2BP was later shown to block the S-palmitoylation and 
microdomain recruitment of the Src-family kinases Lck and Fyn.4 Inhibition‎with‎100‎μM‎
2BP attenuated Jurkat T-cell calcium activation and blocked tyrosine phosphorylation of 
LAT, PLC-γ,‎ZAP-70, and Vav.4 This finding established 2BP as the only 
pharmacological tool to block protein S-palmitoylation. Over the past decade, 2BP has 
become deeply rooted in the palmitoylation field, often referenced as a selective 
inhibitor of protein S-palmitoylation. Indeed, many studies have used 2BP-induced 
phenotypes as evidence of the importance of palmitoylation in parasitic infection,5 
differentiation,6 and various other cellular phenotypes.7 
 2BP inhibition is thought to block protein palmitoylation by inhibiting a family of 
conserved protein acyl transferases (PATs).8 Mammals express 23 distinct PAT 
enzymes that are presumed to regulate the profile of palmitoylated proteins, either by 
PAT localization, protein interactions, or active site selectivity.7,8 Knockdown of specific 
PAT enzymes reduces palmitoylation of select substrates. For example, a hypomorphic 
gene-trap mouse model of DHHC5 demonstrates reduced flotilliin-2 palmitoylation, 
disrupted stem cell differentiation, and defective hippocampal-dependent learning.9 
Other genetic models of PAT enzymes reveal a wide array of phenotypes in cancer, 
neurodegeneration, hair loss, and amyloidosis.7 Similarly, overexpression of certain 
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PATs are implicated in cancer progression, malignancy, and metastasis.7 Given the 
array of novel biology regulated by PAT enzymes, selective pharmacological reagents 
are critical for advancing our basic understanding of protein palmitoylation in disease. 
 Each PAT enzyme contains a highly conserved cysteine-rich domain anchored 
by the four amino acid Asp-His-His-Cys (DHHC) motif. Mutation of the DHHC-cysteine 
residue to serine abolishes enzyme activity, suggesting this cysteine is the catalytic 
nucleophile and site of acyl-transfer.10,11 Addition of palmitoyl-CoA to purified, detergent 
solubilized PAT enzymes induces autopalmitoylation and formation of the enzyme-acyl 
intermediate,12 which then transfers the palmitoyl group to a cysteine residue on the 
substrate. In vitro, 2BP covalently blocks the formation of the PAT acyl-intermediate 
(IC50‎of‎10μM).12‎Similarly,‎GAP43-YFP plasma membrane localization is inhibited in 
live‎cells‎by‎2BP‎at‎nearly‎the‎same‎potency‎(IC50‎=14.9‎μM).13 These experiments 
strongly suggest DHHC proteins are unlikely to require a CoA conjugate for inhibition. 
 Bioorthogonal alkyne and azide palmitate analogues have been introduced for 
metabolic labeling and detection of native sites of protein palmitoylation.14,15 This 
approach uses the endogenous palmitoylation machinery to covalently tag palmitoylated 
proteins, which are then labeled using Cu(I) catalyzed click chemistry to azide or 
alkyne-linked reporters. The successful metabolic incorporation of these analogues 
demonstrates the broad tolerance of minor terminal acyl modifications in palmitoylation, 
and‎suggests‎α-brominated analogues may be useful mechanistic probes to profile the 
cellular targets of 2BP alkylation. 
 Historically, 2BP was recognized as a nonselective inhibitor of lipid metabolism.1 
Over the past decade, the promiscuity of 2BP has been overshadowed by significant 
need for pharmacological tools to study protein palmitoylation. Here, we present the 
synthesis and evaluation of a click-enabled 2BPanalogue and the corresponding CoA 
conjugate to explore the targets and mechanism of 2BP inhibition in cells, and annotate 
the consequences of promiscuous 2BP inhibition in palmitoylation analysis. 
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2.3 Materials and Methods 
 General synthetic methods. All reagents were used as received unless otherwise 
noted. All reactions were conducted in flame-dried glassware under nitrogen 
atmosphere. Flash column chromatography was performed with silica gel (Grade 923, 
100–200 mesh). Thin-layer chromatography (TLC) was performed on silica gel GHLF 
plates (250 microns) purchased from Analtech. Developed TLC plates were visualized 
with a UV lamp at 254 nm or by an appropriate chemical stain. Extraction solutions were 
dried over MgSO4 prior to concentration. 
1H and 13C spectra were obtained in CDCl3 at 
RT (25 oC), unless otherwise noted, on a Varian Mercury 400 or Varian Unity 500 MHz 
instrument. Chemical shifts of 1H NMR spectra were recorded in parts per million (ppm) 
on‎the‎δ‎scale‎from‎an‎internal‎standard‎of‎residual‎chloroform‎(7.27‎ppm).‎Chemical‎
shifts of 13C NMR spectra were recorded in ppm from the central peak of CDCl3 (77.0 
ppm)‎on‎the‎δ‎scale.‎Low‎resolution‎electrospray‎mass‎spectra‎were‎obtained‎on‎a‎
Micromass LCT spectrometer,  and high resolution electrospray mass spectra were 
obtained on a Micromass AutoSpec Ultima spectrometer at the University of Michigan 
Mass Spectrometry Laboratory. 
 Synthesis of 16-azidohexadecanoic acid (1). To a solution of 16-
bromohexadecanoic acid (250 mg, 0.75 mmol) in DMF (2 mL) was added sodium azide 
(100 mg, 1.5 mmol) and the reaction was heated to 85 °C and stirred for 12 h. It was 
then cooled to room temperature, diluted with CH2Cl2 and quenched with 0.1 N HCl. 
The organic layer was dried over MgSO4, filtered and concentrated to afford 1 as a 
white solid (183 mg, 82%) and was used without further purification. Rf 0.51 (30% 
EtOAc : hexanes). IR (thin film on NaCl): cm-1 = 2098 (-N3). 1H NMR (400 MHz, 
CDCl3):‎δ‎(ppm) = 3.18 (t, J = 7.0 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 1.58 – 1.49 (m, 4H), 
1.30 – 1.19 (m, 22H). HRMS: m/z calculated for C16H30N3O2: 296.2338, found 
296.2340 [M - H]-. 
 Synthesis of 16-azido-2-bromohexadecanoic acid, 2BPN3 (2). 1 (2.0 g, 6.7 
mmol) was dissolved in thionyl chloride (40 mL) and stirred at reflux for 1 h. Then, 
bromine (450 FL, 8.7 mmol) was added dropwise over 3 h and the reaction was further 
refluxed for 3 h. The mixture was then cooled to room temperature, concentrated, 
dissolved in H2O and stirred at room temperature for 12 h. The aqueous solution was 
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extracted with diethyl ether (3x), and the organic layers were combined, washed with 
0.1 N HCl, dried over MgSO4, filtered and concentrated to afford an orange solid. 
Purification of this solid by flash chromatography (30% EtOAc : hexanes) yielded 2 (1.0 
g, 40%) as a white solid. Rf 0.13 (30% EtOAc : hexanes). 1H NMR (400 MHz, CDCl3): 
δ‎(ppm)‎=‎4.20‎(t,‎J = 7.4 Hz, 1H), 3.21 (t, J = 7.0 Hz, 2H), 2.05 – 1.92 (m, 2H), 1.59 – 
1.52 (m, 2H), 1.47 – 1.17 (m, 22H). HRMS: m/z calculated for C16H29BrN3O2: 
374.1443, found 374.1439 [M - H]-. 
 Synthesis of N-(2-bromohexadecanoyl)succinimide (3). The succinimidyl ester 
was prepared as previously described25. 2-bromopalmitic acid (500 mg, 1.49 mmol, 
Sigma) was added to a solution of N-hydroxysuccinimide (172 mg, 1.49 mol) in dry ethyl 
acetate (5 mL). N,N'-diisopropylcarbodiimide (257 µL, 1.64 mol) was added at room 
temperature, and the mixture was allowed to react overnight. Precipitated 
diisopropylurea was removed by filtration through a glass wool plug. The solvent was 
evaporated yielding a white powder, which was then recrystallized from absolute 
ethanol, to afford 3 (457 mg, 70.8%) as white crystals. 1H NMR (400 MHz,‎CDCl3):‎δ‎
(ppm) = 4.43 (dd, J = 7.8, 6.9 Hz, 1H), 2.84 (s, 4H), 2.22 – 2.05 (m, 2H), 1.58 - 1.38 (m, 
2H) 1.39 – 1.14 (m, 22H), 0.86 (t, J = 7 Hz, 3H). 13C NMR (100 MHz,‎CDCl3):‎δ‎(ppm)‎= 
168.44, 165.64, 40.90, 34.79, 31.90, 29.66, 29.65, 29.63, 29.61, 29.54, 29.42, 29.34, 
29.21, 28.70, 26.93, 25.58, 22.67, 14.11. 
 Synthesis of 2-bromohexadecanoyl coenzyme A, 2BP-CoA (4). The acyl CoA 
was synthesized using a modified literature procedure26. 3 (26 mg, 61 µmol) was 
dissolved in freshly distilled THF (0.6 mL) and mixed with a solution of coenzyme A 
trilithiate dihydrate (5 mg, 6.1 µmol, Fisher) dissolved in deionized water (0.3 mL). 
Triethylamine (8.5 uL, 61 µmol) was added to the reaction and the homogeneous 
mixture was stirred on a rotisserie rotator for 3 hours at room temperature. The crude 
product was precipitated by adding 5% perchloric acid (1.2 mL) and excess THF was 
removed by rotary evaporation. The precipitate was collected by centrifugation (5 min, 
3220x‎g,‎4‎˚C)‎and‎the‎supernatant‎was‎discarded.‎The‎precipitate‎was‎washed, 
sonicated and centrifuged sequentially with 0.8% perchloric acid (2.5 mL), acetone (4 X 
1.5 mL) and diethyl ether (3 X 1 mL) to remove excess starting materials. The white 
residue was extracted with 2-(N-morpholino)ethanesulfonic acid buffer (0.4 mL, 50 mM, 
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pH 5) and insoluble side-products were removed by centrifuging the mixture. The 
product was precipitated again with 5% perchloric acid (0.6 mL). The precipitate was 
washed, sonicated and centrifuged sequentially with 0.8% perchloric acid (1 mL), 
acetone (3 x 0.5 mL), and dried under vacuum to afford 4 (1.3 mg, 19%) as a white 
powder. HRMS: m/z calculated for C37H63BrN7O17P3S2
-: 540.6204, found 540.6194 [M - 
2H]-. 
 Synthesis of N-(16-azido-2-bromohexadecanoyl)succinimide (5). Following the 
procedure used to prepare N-(2-bromohexadecanoyl)succinimide, 2 (23 mg, 0.061 
mmol), N-hydroxysuccinimide (7 mg, 0.061 mol), N,N'-diisopropylcarbodiimide (11 µL, 
0.067 mol) in ethyl acetate (1 mL) were used to yield 5 (7.2 mg, 25%) as white crystals. 
 Synthesis of 16-azido-2-bromohexadecanoyl coenzyme A, 2BPN3-CoA (6). 
Following the procedure used to synthesize 2-bromohexadecanoyl coenzyme A, 5 (7.2 
mg, 15.7µmol), coenzyme A trilithiate dihydrate (1.3 mg, 1.57 µmol), and triethylamine 
(2.2uL, 15.7 µmol) in THF (200 µL) and deionized water (100 µL) were employed to 
afford 6 (1.6 mg, 24%) as a white powder HRMS: m/z calculated for 
C37H62BrN10O17P3S
2-: 561.1211 [M – 2H]-, found 561.1240 [M - 2H]-. 
 Qualitative characterization of acyl-CoA conjugates. The purity of 2BP-CoA and 
2BPN3-CoA were assessed by TLC3 and the thioester content of the preparations were 
determined spectroscopically27,28. The products were eluted on C18-bonded silica 
reverse phase TLC plates using n-butanol/water/acetic acid (5:3:2) as the solvent 
system. 2BP-CoA and 2BPN3-CoA were visualized under UV light, each revealing a 
single spot with Rf-value of 0.55 and 0.57 respectively (palmitoyl-CoA authentic 
standard Rf = 0.53). In addition, these spots gave a positive nitroprusside test for free 
thiol groups only after treatment with methanolic NaOH. 2BPCoA and 2BPN3-CoA were 
dissolved in 75% isopropanol, 1 mM acetic acid to make 1 g / L stocks for spectroscopic 
analyses. The UV spectrum of each product was measured against an authentic 
palmitoyl-CoA (Sigma), with each acyl-CoA featuring a peak at 232 and at 260 nm. 
Furthermore, the 232 nm absorbance disappeared after methanolic NaOH treatment, 
indicating hydrolysis of the thioester bond. The relative concentrations of thioester to 
adenine in each acyl-CoA preparation was determined by measuring the ratio of the 232 
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nm over 260 nm absorptions and using experimentally calculated extinction coefficients 
at 232 and 260 nm for the authentic palmitoyl-CoA standard. 
 Cell culture. HEK293T cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM, Invitrogen) supplemented with 10% (vol/vol) fetal bovine serum (FBS, JR 
Scientific) and 1% (vol/vol) 10,000 units penicillin, 10,000 µg streptomycin, 29.2 mg L-
glutamate solution (PSQ, Invitrogen). Cells grown to ~60% confluency were transfected 
with pcDNA3 vectors expressing FLAG-epitope tagged proteins using Fugene HD 
transfection reagent (Promega). Cells were cultured for 48 hours to allow for sufficient 
protein expression. 
 Mass spectrometry-based metabolomic analysis of CoA conjugates. 2-
bromopalmitate and palmitate were both dissolved in BSA free fatty acid (0.05%) to 
achieve 1:6 molar ratio of BSA : fatty acid. INS-1(832/3) cells were incubated with 50 
µM 2BP or 50 µM‎palmitic‎acid‎for‎30‎minutes‎in‎Kreb’s Ringer Buffer with 0 mM 
glucose at 37°C. Cells were quenched and extracted as previously described5, and 
normalized to protein concentrations using the BCA protein assay kit (Pierce). Detection 
was performed on an Agilent Technologies LC/MSD TOF using a dual electrospray 
ionization (ESI) source in negative-ion mode and analyzed as previously described29. 
The concentration of 2BP was determined by standard addition method, where a known 
concentration of standard was added to the unknown sample (pooled extract of 2BP 
treated cell, n = 4). Data was acquired from 2 biological replicates of 4 technical 
replicates processed on separate days. INS-1(832/3) cells were kindly provided by Dr. 
Christopher Newgard (Sarah W. Stedman Nutrition and Metabolism Center, Duke 
University, Durham, NC). 
 Metabolic labeling. Labeling media was prepared with DMEM, 10% dialyzed FBS 
(Gemini Bio-Products), and 1% PSQ. 16-Azido-2-bromopalmitic acid (2BPN3) or 2 
bromopalmitic acid (2BP, Sigma) was dissolved in DMSO to make a 50 mM (1000X) 
stock, then diluted in labeling media and briefly sonicated, and then added to cells at 
~100% confluency. Cells were labeled with 2BP or 2BPN3 at the concentrations 
described for the indicated time period. Cells were collected by centrifugation at 800x g, 
washed twice with PBS, and then stored at -80ºC as cell pellets. 
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 Lysate preparation. Pellets were re-suspended in phosphate buffered saline 
(without magnesium and calcium, PBS, Invitrogen), and sonicated briefly at 4oC. Cell 
debris was removed by low-speed centrifugation at 800x g for 2 minutes, and 
supernatant was placed into a new conical tube. Lysates were separated into soluble 
and membrane particulate fractions by ultracentrifugation at 100,000x g for 45 minutes. 
The insoluble pellet was sonicated in PBS to homogenize the lysate. The protein 
concentration was determined using the BCA assay (Biorad) using a Tecan F500 plate 
reader. Membrane particulate fractions were diluted in PBS to 1 mg / mL of proteome, 
then reacted with the indicated probe at the concentrations described 
for one hour at room temperature. 
 Copper-catalyzed azide-alkyne cycloaddition. 1 mg / mL of proteome was 
combined with 20 µM Carboxytetramethylrhodamine-alkyne (TAMRA-Alkyne, Click 
Chemistry Tools), 1 mM Tris(2-carboxyethyl)phosphine (TCEP, Sigma-Aldrich), 100 µM 
Tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine (TBTA, Sigma-Aldrich), and 1 mM 
CuSO4 in PBS (25 µl) at room temperature (~22°C). After 1 hour, samples were mixed 
with SDS loading buffer and denatured at 90°C for 10 minutes. 8 µg of protein was 
loaded into each lane of a 10% SDS-PAGE, separated over 180 V-hours and 
fluorescence scanned on an Amersham Bioscience Typhoon scanner. 
 Mass spectrometry-based proteomic analysis. Samples were prepared as 
previously described6, but biotin alkyne (Click Chemistry Tools) was substituted at 20 
µM. Furthermore, samples were chloroform/methanol precipitated following the click 
reaction to remove unreacted biotin-alkyne. Higher concentrations of biotin-alkyne led to 
increased non-specific background. Mass spectrometry analysis was performed as 
previously described30, using an Agilent 1100 HPLC coupled to a Thermo LTQ mass 
spectrometer using a 5-step MuDPIT protocol. Data analysis was performed using 
previously reported algorithms. 
 Immunoblotting. Proteins were transferred to 0.45 um polyvinylidine difluoride 
membrane (Immobilon-P, Millipore) and blocked with 5% bovine serum albumin (BSA, 
Fisher) in Tris buffered saline-Tween 20 buffer (TBS-T, pH 7.4) for 1 hour at room 
temperature. After washing, the membrane was incubated with a primary mouse-anti-
FLAG antibody (M2 monoclonal, Sigma, 1 µg / mL antibody, 5% BSA, 0.02% NaN3, 
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TBS-T) for 1 hour at room temperature, washed, and probed with a secondary Alexa 
Fluor 647 nm donkey-anti-mouse antibody conjugate (IgG H +L, Invitrogen, 2 µg / mL 
antibody, 0.06% w/v NaN3, TBS-T) for 1 hour at room temperature. For streptavidin-
based detection, the membrane was probed with a Cy5-streptavidin conjugate (50 ng / 
mL conjugate, 2.5% BSA, 0.06% NaN3, TBS-T) for 1 hour at room temperature, and the 
washed as before. Blots were fluorescence scanned on an Amersham bioscience 
typhoon scanner.  
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2.4 Results 
Figure 2-1 Metabolic 
labeling with 2BPN3 
allows click-enabled 
detection of cellular 
targets. (A) Schematic of 
2BPN3  alkylation of 
cysteine thiolates on 
proteins‎by‎attack‎of‎the‎α-
halo-carbonyl group, 
followed by click chemistry 
detection of labeled 
proteins. (B) Concentration-
dependent metabolic 
labeling with 2BPN3 in 293T 
cells. (C) Time-dependent 
metabolic labeling with 
2BPN3 in 293T cells. (D) 
Preincubation with 2BP 
attenuated 2BPN3 labeling 
at higher concentrations. Each inhibitor was added for 1 h at the described concentrations. For each gel, 
lysates were reacted with rhodamine-alkyne and separated by SDS-PAGE gel followed by fluorescence 
analysis. 
 Given the broad use of 2BP as a palmitoylation inhibitor, we sought to test the 
utility of this scaffold as an activity-based probe for DHHC PAT enzymes. Such probes 
would covalently label endogenous targets for click chemistry conjugation to alkyne-
linked reporters, including fluorescent dyes for gel-based detection, or biotin for mass 
spectrometry annotation (Figure 2-
1A).  
Figure 2-2 2BPN3 labeling is significantly 
increased at higher concentrations in 293T 
cells. Cells were labeled for 1 hour. (A) 
2BPN3 labeling adjusted to maximize contrast 
at 10-fold higher than the standard labeling 
concentration. (B) 2BPN3 labeling adjusted to 
maximize contrast at 50 µM. 
Because of the generic scaffold and 
electrophilic reactive group, we anticipated this approach would likely label a profile of 
proteins‎involved‎in‎lipid‎metabolism.‎The‎ω-azido analogue of 2BP (2BPN3) was 
synthesized and added directly to the growth media of human 293T cells at varying 
concentrations. After 1 h, the cells were harvested and lysed for copper catalyzed 
azide−alkyne cycloaddition to rhodamine-alkyne for gel-based detection. Membrane 
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fractions demonstrated significant contrast and dose-dependent labeling of 2BPN3 
(Figure 2-1B). 
Figure 2-3 Soluble cell fractions show significant 
labeling with rhodamine alkyne in the absence of 
2BPN3. 293T cells were labeled with 2BPN3 for 1 hour, 
then lysed by sonication and centrifuged at 100,000x g 
for 45 minutes. The soluble fraction was quantified 
using‎the‎BCA‎assay‎and‎mixed‎with‎20‎μM‎rhodamine-
alkyne and remaining click chemistry reagents for 1 
hour. Samples were separated using a 4-20% gradient 
SDS-PAGE gel. 
Higher concentrations led to enhanced 
labeling (Figure 2-2) but also pronounced cytotoxicity. In contrast, analysis of soluble 
fractions was complicated by nonspecific, alkyne-dependent background (Figure 2-3). 
Copper-free strain promoted cycloaddition with rhodamine-linked aza-
dibenzocyclooctyne (DIBAC)16 showed dramatically enhanced labeling but did little to 
improve the overall contrast (Figure 2-4). These findings corroborate recent reports 
quantifying thiol cross-reactivity of strain-promoted 
cycloadditions.1 
Figure 2-4 Comparison of copper and copper-free click 
chemistry labeling of 2BPN3. Cells were labeled for 1 hour with 
2BPN3, followed by incubation with either rhodamine-alkyne or 
rhodamine-aza-dibenzocyclooctyne (DIBAC). Samples were 
separated using a 4-20% gradient gel. DIBAC labeling is significantly 
more efficient, but has no clear increase in contrast over no-probe 
controls. 
 Surprisingly, 2BPN3 labeling occurs within 5 min 
and gradually increases until ~60 min (Figure 2-1C). This 
rapid labeling suggests direct action of the native probe but also may involve metabolic 
activation to the CoA conjugate. Based on these‎results,‎we‎selected‎50‎μM‎2BPN3‎for‎
1 h as an effective protocol for labeling live cells. These conditions are consistent with 
cell-based experiments of palmitoylation inhibition and the reported IC50 for PAT 
inhibition of 10−15‎μM.13 In cells, preincubation‎with‎50‎μM‎2BP‎reduced‎but‎did‎not‎
eliminate 2BPN3 metabolic labeling (Figure 2-1D). In vitro, higher 2BP concentrations 
could effectively compete with 2BPN3 (Figure 2-5), suggesting poor cellular uptake and 
distribution in live cells. Moreover, 2BPN3 addition reduced but did not eliminate 
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metabolic incorporation of 17-octadecynoic acid (17-
ODYA), suggesting a significant fraction of protein 
palmitoylation is highly stable or nonenzymatic (Figure 2-
6). 
Figure 2-5 Efficient in vitro competition of 2BPN3 labeling with 
2BP. 293T cell lysates were labeled with increasing concentrations 
of 2BP for 1 hour, followed by labeling with 2BPN3 for 1 hour. 
Competition in vitro is by far more effective than live cell 
competition, as shown in Error! Reference source not found.D. 
 2BP is believed to undergo activation to the CoA intermediate in live cells, which 
then directs reactivity toward CoA-dependent enzymes. Metabolic labeling with 2BPN3 
is ~10-fold less efficient than in vitro labeling (Figure 2-7A), but the profile of labeled 
proteins appears largely similar. This discrepancy may be due to insufficient probe 
solubility and uptake in culture. In order to establish metabolic activation of 2BP to the 
CoA conjugate, cells were incubated with 2BP or palmitic acid for 30 min, followed by 
extraction, chromatographic separation, and high-resolution mass spectrometry analysis 
(Figure 2-7B). 
 
Figure 2-6 2BP reduces metabolic 
incorporation of the palmitate analogue 17-
octadecynoic acid (17-ODYA) in cells. 293T 
cells were labeled for 1 hour with varying 
concentrations of 2BP, followed by addition of 17-
ODYA for 4 additional hours. Palmitoylation levels 
are reduced most effectively at the highest 
concentrations of 2BP. Samples were separated 
using a 4-20% gradient SDS-PAGE gel. 
 
Synthetic 2BP-CoA was shown to ionize similarly (99.8 ± 0.3%, standard error) to 
palmitoyl-CoA across a series of dilutions (Figure 2-8). Basal palmitoyl-CoA levels were 
measured as 250 ± 31 pmol/mg of protein, yet were elevated 3.2-fold (805 ± 101 
pmol/mg) after a 30 min incubation with 50‎μM‎palmitic‎acid.‎Addition‎of 50‎μM‎2BP‎led‎
to the formation of 36 ± 4 pmol/mg of 2BPCoA but had no major effect on palmitoyl-CoA 
levels (205 ± 17pmol/mg). 2BP-CoA was nearly 6-fold lower than endogenous levels of 
palmitoyl-CoA, which likely competes with 2BP-CoA for access to CoA processing 
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enzymes. These data confirm 2BP metabolic conversion in live cells to the CoA 
conjugate within 30 min, although at reduced efficiency as compared to palmitoyl-CoA. 
 Next, a 2BPN3−CoA conjugate was synthesized for analysis in cell lysates. 
2BPN3−CoA (cLogP = 4.4) is predicted to be much more water-soluble than 2BPN3 
(cLogP = 7.7). Furthermore, 2BP is negatively charged at physiological pH, which 
increases the electron density and delocalization at the carboxylate and reduces the 
electrophilic‎character‎of‎the‎α-carbon. Thioesterification is predicted to reduce the 
delocalization and‎enhance‎the‎carbonyl‎dipole‎to‎promote‎α-substitution, resulting in 
improved probe reactivity. Experimentally, the CoA conjugate achieved equivalent 
labeling with10-fold less probe (Figure 2-7C), and unexpectedly labeled a similar profile 
of targets as the free acid. Furthermore, 2BPN3 and 2BPN3−CoA react with different 
targets than 2-iodacetamide-rhodamine (Figure 2-7D). Whether the enhanced reactivity 
of 2BPN3−CoA is a function of the CoA motif, or a manifestation of the thioester linkage 
remains to be investigated. Overall, we observe that 2BP is coupled to CoA in cells at a 
reduced efficiency, yet the conjugate is exceptionally reactive. 
 
Figure 2-7 2BPN3 is conjugated to CoA in cells, resulting in an increase in probe reactivity. (A) 
Comparison of 2BPN3 metabolic labeling and in vitro labeling. Cells or lysates were labeled for 1 h with 
2BPN3. Lower probe concentrations were required for equivalent labeling in vitro compared to metabolic 
labeling. (B) 2BP is marginally converted to 2BP-CoA in cells. Control samples were collected 
immediately‎after‎transfer‎from‎RPMI‎to‎ringer’s‎solution.‎The‎remaining‎cells‎were‎left‎for‎30‎min‎in‎the‎
presence‎of‎fatty‎acid‎free‎BSA,‎BSA‎bound‎to‎50‎μM‎palmitic‎acid,‎or‎BSA‎bound‎to‎50‎μM‎2BP.‎Cells‎
were quenched and metabolites were extracted and analyzed in quadruplicate by high-resolution LC-MS. 
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Samples were run as biological quadruplicates and standard errors are shown. Synthetic palmitoyl-CoA 
and 2BP-CoA were used to generate a standard curve to calculate endogenous metabolite 
concentrations. (C) Labeling of cell lysates with increasing concentrations of 2BPN3−CoA in vitro. The 
control lane is lysate incubated‎with‎50‎μM‎2BP-CoA, which did not show significant labeling following the 
click chemistry reaction. (D) Comparison of 2BPN3, 2BPN3−CoA, and 2-iodoacetamide-rhodamine (2IA-
Rh) shows probe-specific labeling in vitro. The control lanes are lysates incubated‎with‎either‎50‎μM‎2BP‎
(left)‎or‎2.5‎μM‎2BPCoA‎(center).‎2BPN3−CoA labeling is more reactive but labels a similar pattern of 
proteins. 2IA-Rh labels a distinct pattern of proteins. 
 
Figure 2-8 Equal ionization efficiency of palmitoyl-CoA and 2BP-CoA in negative mode 
electrospray ionization mass spectrometry. (A) Synthetic standards of palmitoyl-CoA and 2BP-CoA 
([M - 2H] shown) were doped into cell extracts and analyzed by LC-MS. The observed isotopic distribution 
correlates with the bromine adduct. (B) Equivalent intensities were measured across a 4-point dilution 
series. This data demonstrates equivalent ionization efficiency and allows direct comparison of ion 
intensities in profiling experiments. 
 The DHHC PAT family contains a cysteine-rich domain with seven highly 
conserved cysteines, including the cysteine present in the Asp-His-His-Cys (DHHC) 
catalytic motif.8 Mutation of the conserved DHHC cysteine to serine (DHHS) abolishes 
acyl-transferase activity, and prevents palmitoyl-CoA dependent formation of the 
enzyme-acyl intermediate.10,11 Other residues may also be involved in catalysis, 
potentially by acyl-transfer between other active site catalytic cysteines. To explore the 
mechanism of DHHC catalysis, 2BPN3 was added to cells overexpressing epitope-
tagged DHHC2 or DHHS2(C157S), and conjugated to rhodamine-alkyne for gel-based 
analysis. DHHC2 was efficiently labeled in transfected cells (Figure 2-9A), but labeling 
of the catalytic dead DHHS2 mutant was nearly abolished. 
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Figure 2-9 2BPN3 and 2BPN3-CoA are activity-based probes for DHHC2. (A) 2BPN3 labels FLAG 
epitope-tagged DHHC2 but not DHHS2 (C157S) by metabolic labeling in live cells. Labeling is resistant to 
hydroxylamine, demonstrating the absence of a stable acyl-intermediate. (B) 2BPN3 and 2BPN3−CoA 
both label DHHC2, but not DHHS2 (C157S) in vitro. Anti-FLAG Western blots show recombinant protein 
expression levels. 
 
DHHC2 labeling was not affected by hydroxylamine addition, demonstrating the 
absence of the acyl intermediate and formation of the covalent alkylation product. 
Further detailed analysis of selected proximal cysteines (C146S,C149S, and C163S) 
showed reduced 2BPN3 labeling (Figure 2-10). 
Figure 2-10 Mutational analysis of select cysteines in the 
DHHC2 active site. 293T cells were transfected with FLAG 
epitope-tagged‎DHHC2‎mutants‎and‎labeled‎with‎50‎μM‎
2BPN3‎for‎1‎hour.‎Control‎lanes‎were‎labeled‎with‎50‎μM‎2BP.‎
Mutants showed reduced labeling, especially C163S. Labeling 
was not sensitive to hydroxylamine treatment, demonstrating 
stable alkylation of the enzyme. 
These results confirm that other cysteine residues 
are functionally important in the maturation and/or 
mechanism of DHHC PAT-catalyzed protein 
palmitoylation.18 Importantly, these results reinforce 
existing evidence for more complex catalysis in the 
DHHC PAT active site,18 potentially through multiple reactive thiolates. Finally, these 
experiments validate 2BPN3 as an activity-based probe for select DHHC PAT enzymes, 
which may be useful for competitive assays to profile active site occupancy. Indeed, 
transfection studies show robust 2BPN3 alkylation of six of nine tested epitope-tagged 
DHHC PATs (Figure 2-11). 
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Figure 2-11 Over-expressed DHHC PAT 
enzymes metabolically labeled with 2BPN3. 
Nine epitope-tagged DHHC PAT cDNAs were 
transfected into 293T cells for 48 hours, and 
labeled with 2BPN3 for 1 hour. Over-expressed 
DHHC PAT enzymes are clearly visible in 
transfected lysates as dominant bands, and 
confirmed by anti-FLAG western blotting. 
 Metabolic conversion of 2BP to 
2BP-CoA is thought to guide inhibition to 
CoA-dependent enzymes. To examine 
the role of CoA in DHHC PAT inhibition, 
membrane lysates were prepared from cells overexpressing DHHC2 and DHHS2 and 
labeled in vitro with 2BPN3 or 2BPN3−CoA (Figure 2-9B). Similar to metabolic labeling, 
in vitro labeling showed DHHC2 reactivity but not DHHS2. Importantly, both 2BPN3 and 
2BPN3−CoA demonstrate activity-dependent labeling of DHHC2, although at different 
optimal probe concentrations. These results corroborate previous reports that DHHC2 is 
directly inhibited by 2BP,12,19 and suggest CoA conjugation accelerates inhibition 
without altering the profile of labeled targets. Furthermore, these findings confirm the 
predominant reactivity of the catalytic DHHC cysteine over other proximal cysteine 
residues. 
 
Figure 2-12 Enhanced background at higher concentrations of 
biotin-alkyne in 2BPN3-labeled lysates. Biotin-alkyne click 
chemistry‎was‎more‎selective‎at‎20‎μM‎than‎at‎100‎μM‎
concentrations.‎20‎μM‎Biotin-alkyne was selected for further 
enrichment for mass spectrometry. 
 In order to annotate the targets of 2BPN3, cells 
were metabolically labeled with 2BP or 2BPN3 for 1 h. 
After lysis, membrane proteomes were conjugated to 
biotin-alkyne for streptavidin enrichment, trypsin digestion, and mass spectrometry 
analysis. Biotin−alkyne conjugation required careful optimization of labeling 
concentrations to reduce alkyne-dependent nonspecific reactions (Figure 2-12). 
Mass spectrometry results were filtered to include proteins with ≥2 average spectral 
counts, identified in 2 of 3 replicates, and ≥5-fold enrichment as compared to the 
2BPcontrols. Approximately 450 protein targets of 2BPN3 were annotated (Appendix A), 
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including carriers, transporters, and channels. The most frequently identified targets in 
293T cells of 2BPN3 were the voltage-dependent anion channel, SERCA Ca2+ 
ATPase, heme oxygenase 2, and CKAP4; all validated palmitoylated proteins (Table 
2).20 Importantly, five palmitoyl transferases were annotated, including DHHC5, DHHC6, 
DHHC7, DHHC17, and DHHC20. In addition, another nine PAT enzymes were 
identified that failed to pass the stringent thresholds, likely due to their low abundance 
(Table 3). This list does not include DHHC1, DHHC8, and DHHC23, which similarly 
failed to label with 2BPN3 when overexpressed in 293T cells (Figure 2-11). While this 
enzyme family is broadly inhibited by 2BP, it is 
by no means privileged or selective. Early 
reports demonstrated that 2BP inhibition of 
carnitine palmitoyl transferase activity blocked 
mitochondrial long-chain fatty acid oxidation in 
cells.3,21 Our results confirm that  
Figure 2-13 Select palmitoylated proteins are 
metabolically labeled with 2BPN3. Cells were 
transfected for 48 hours with epitope-tagged cDNAs for 
annotated palmitoylated proteins, and labeled for 1 hour 
with 2BPN3. Labeling was resistant to hydroxylamine 
treatment, showing it is not due to a thioester linkage. 
CPT1 is indeed labeled with 2BPN3 in cells, 
suggesting broad disruption of cellular lipid 
metabolism. Other identified targets include lipid-modifying enzymes, detoxifying 
enzymes, regulators of redox stress. The surprising breadth of targets demonstrates the 
broad reactivity of this promiscuous inhibitor in cells. 
 Importantly, a significant fraction of the metabolically labeled targets are 
themselves palmitoylated proteins, such as MTDH,HRAS, GNAI2, and FAM108B.15 
Further investigation of validated palmitoylated proteins showed robust 2BPN3 labeling 
of the unannotated serine hydrolase ABHD16A (ABHGA), EF-hand calcium-binding 
domain-containing protein 14 (EFCAB14), FAM108A, KIAA0152, and thioredoxin-
related transmembrane protein 1 (TXNDC1) (Figures 2-13 and 2-14). 
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Figure 2-14 2BP competes with palmitoylation sites on 
FAM108A. FAM108A‎and‎FAM108(∆1-19) were C-
terminally tagged with the FLAG epitope and transfected in 
293T cells. The palmitoylated protein KIAA0152 was also 
included. After 48 hours, cells were labeled‎with‎50‎μM‎
2BPN3 for 1 hour, conjugated to rhodamine-alkyne, and 
detected after separation by SDS-PAGE with or without 
incubation with 2.5% hydroxylamine. Red boxes denote 
recombinant protein bands. 
 
FAM108A is palmitoylated at 5 N-terminal 
cysteines and is readily labeled by 2BPN3 in 
cells. Deletion of the N-terminal 19 residues 
blocked 2BPN3 labeling, despite the presence of 
seven additional cysteines present in the remaining 291 amino acids (Figure 2-14). In 
addition, 2BP labeling of ABHD16A did not reduce fluorophosphonate reactivity (Figure 
2-15), suggesting 2BP alkylation occurs outside of the conserved α/β-hydrolase active 
site. Even though they label with 17-ODYA,22 neither H-Ras nor H-Ras-(G12 V) labeled 
effectively with 2BPN3 when overexpressed (Figure 2-16). Based on these findings, we 
propose that 2BPN3 labeling of annotated palmitoylated proteins may instead highlight 
sites of nonenzymatic palmitoylation, such as activated 
thiol residues that preferentially react with palmitoyl-CoA by 
thioester exchange. Thus, these labeled proteins may 
represent a pool of DHHC-independent palmitoylated 
proteins. Indeed, Gαi1 is reported to undergo autoacylation 
at sites of palmitoylation by direct, nonenzymatic, thioester 
exchange with palmitoyl-CoA.23 It is therefore not surprising 
to find the homologues GNAI2 and GNAI3 as targets of 
2BP in cells. 
 
Figure 2-15 ABHD16A activity is unaffected by 2BP labeling. ABHD16A transfected 293T cells were 
labeled with 50 FM 2BP for 1 hour, and then lysates were labeled with the serine hydrolase activity-based 
probe fluorophosphonate-rhodamine for 1 hour. There is no observed inhibition of ABHD16A by 2BP, 
suggesting non-catalytic residues, such as sites of palmitoylation, are labeled by 2BP in cells. 
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Figure 2-16 H-Ras is not effectively labeled with 2BPN3. 293T cells were 
transfected with FLAG-H-Ras, FLAG-H-Ras (G12V), or empty vector and 
labeled with 2BPN3 for 1 hour. Labeling is equivalent across all experiments. 
Longer incubation times do lead to enhanced H-Ras labeling (not shown). 
 
 Farnesylated Ras-family GTPases are carboxymethylated 
at their C-termini, which acts to reduce charge repulsion24 and 
enhance membrane anchoring. 2BP alkylation products yield a 
negatively 
charged free 
carboxylate, 
which may 
itself attenuate membrane 
association. Accordingly, our data 
supports at least two modes of 
palmitoylation inhibition by 2BP: 
either by covalent inactivation of 
DHHC PATs, or by directly 
competing for palmitoylation at 
select cysteine residues. The 
functional consequences of each 
mechanism are presumably very 
different, since some proteins are 
left unpalmitoylated, while others 
are irreversibly alkylated. 
Importantly, 2BP may block 
incorporation of [3H]- palmitate onto 
palmitoylated proteins, which 
superficially suggests a reduction in 
palmitoylation, but in reality may 
Table 2 Most abundant 2BPN3-labeled proteins identified by mass spectrometry. 293T cells 
were labeled with 2BPN3 and reacted with biotin-alkyne for enrichment, trypsin digestion, and mass 
spectrometry analysis. Proteins analyzed by spectral counting, a label-free quantification method for 
measuring relative abundance based on the number of fragmentation scans assigned to peptides 
from a specific protein. Standard errors are shown. 
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report 2BP-alkylation at the site of palmitoylation. Future experiments will examine the 
competition between 2BP and palmitoylation to shed light on the predicted role of 
nonenzymatic palmitoylation.   
Table 3 DHHC PAT enzymes identified by mass spectrometry 
profiling. Only DHHC5, 6, 7, 17 and 20 passed the filter thresholds, 
as described in the main text. 
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2.5 Discussion 
 In this study, the mechanism and  targets of the popular palmitoylation inhibitor, 
2-bromopalmitate (2BP), were characterized utilizing an analogue functionalized with a 
latent fluorescent reporter or an affinity handle. With this probe we profiled active PAT 
enzymes by mass spectrometry and analyzed  the activities of wild type, mutant 
enzymes and palmitoylated proteins with 2BP. A major goal of this chapter was to 
employ 2BP as a mechanistic probe to provide insight into how PAT enzymes may 
catalyze acyl transfer between Coenzyme A and protein substrates. Given that other 
DHHC2 active-site cysteines contributed to 2BPN3 Labeling (i.e. C163), it is likely that 
catalytic transfer is mediated by more than one cysteine. In connection to this point, a 
recent study demonstrated that the yeast PAT Erf2 employs its cofactor Erf4 in 
maintaining the stability of its catalytic acyl-enzyme intermediate. Interestingly, in the 
absence of Erf4, the PAT could still autoacylate, however, its transacylation activity was 
abrogated and instead it exhibited acylCoA thioesterase (ACOT) behavior.31 These 
results confirm that PATs use other residues besides the cysteine of the DHHC motif to  
maintain proper catalytic acyl transfer. 
 Although it was not directly addressed, we could have demonstrated 2-BP's 
broad amino acid reactivity by showing that in addition to cysteines, it was likely to react 
with lysine and histidine side-chains under the favorable circumstances. In principle,  to 
demonstrate 2BP's chemical selectivity towards cysteine-thiols, one would need to 
prove that prior treatment of a lysate with a thiol-directed alkylating agent such as N-
ethylmaleimide (NEM) or 2-Iodoacetamide (2IA), would abolish 2BPN3 labeling in a 
dose-dependent manner. However, we did not observe this type of competition in our 
studies (data not shown), suggesting that 2BP chemical reactivity parallels that of other 
α-halo carbonyls, and is expected to target other functional protein residues beyond 
reactive cysteines. Additionally, the lipophilic character of 2BP may direct its reactivity 
towards even smaller subsets of nucleophile-containing proteins while preventing its 
access to others. This is certainly true in the case of intrinsic membrane proteins in 
which the brominated acyl chains may partition into the lipid bilayer, thereby increasing 
their local effective concentrations and therefore reactivity with membrane-resident 
enzymes. 
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 Overall, we present click-enabled activity-based probes for profiling the targets of 
2BP inhibition. The probes preferentially label the active site of DHHC PATs, but 
similarly label hundreds of other proteins, including transporters, channels, enzymes, 
and chaperones. Nonetheless, 2BPN3 labeling reports the active state of DHHC PATs, 
and thus may be useful in inhibitor discovery or selectivity profiling in DHHC 
overexpressing cells. Importantly, 2BP has been used in nearly every paper in the last 
15 years studying protein palmitoylation. In light of this study, and a recent report 
describing‎ω-alkynyl 2BP analogues,19 2BP is clearly a nonselective probe with many 
targets beyond palmitoyl transferases. This finding has broad implications in the 
palmitoylation field, given the widespread use of 2BP in hundreds of published reports. 
Clearly, greater caution should be used when interpreting the phenotypic consequences 
of 2BP-inhibition in cell-based experiments.  
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Chapter 3:  
Structural and Biochemical Studies of LYPLA1/2 Active Site 
Selectivity toward Small Molecule Inhibitors ML348 and ML349 
3.1 Abstract 
 Human LYPLA1 and 2, more commonly referred to as APT1 and 2, are poorly 
defined members of the α/β family of metabolic serine hydrolases. Although LYPLAs 
have shown to process multiple substrates across unrelated classes of biomolecules, 
these enzymes are thought to function primarily as S-acyl-protein thioesterases in the 
context of regulating the palmitoylation and membrane association of key signaling and 
scaffolding proteins implicated in cancer and neurological disorders. Recently, a 
competitive ABPP screen identified two potent, in vivo active piperazinyl amide 
compounds, named ML348 and ML349, that selectively and reversibly inhibit LYPLA1 
and 2 hydrolase activity, respectively. Since direct structural information was 
unavailable, it was unclear how the inhibitors achieve target selectivity given the 
enzymes' high level of sequence homology. Here, we solve the co-crystal structures of 
human LYPLA1 and 2 bound to their selective inhibitors and use this information to 
define structural determinants that give rise to the observed selectivity. To confirm the 
significance of key residues, enzyme kinetic analyses were performed on point mutants 
in which the considered residue was exchanged for the analogous residue present in 
the homolog. Orthogonal inhibition measurements confirmed the requirement of I75 in 
LYPLA1 and Q83 and H152 in LYPLA2 for binding and discriminating the two ligands. 
We propose that these residues may contribute to active site conformational dynamics 
which could confer substrate specificity by gating access to physiological substrates. 
Taken together, these findings offer molecular insights into LYPLA divergent ligand 
recognition and suggest that it may have evolved from differences in their active-site 
loop dynamics. 
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 Individual contributions. Although I invested a large portion of my time in the this 
chapter's project, a number of individuals from the Martin lab have contributed 
significantly to the work and conclusions presented herein. Namely, Dr. Kristin J. Labby 
is credited with initiating this study by performing crystallization trials, characterizing the 
activities of a number of ML349 derivatives and helping to generate both diffractable 
crystals and LYPLA site-directed mutants. Dr. Jeannie L. Hernandez was instrumental 
in interpreting the crystal structures and highlighting their structural disparities. Dr. 
Jaimeen Majmudar synthesized and oversaw the synthesis of ML348, ML349 and its 
derivatives, most of which were generated by Andrea Chong. Sin Ye Hwang carried out 
Ki value measurements for all compounds and enzymes studied. Michael Sang Jun 
Won was involved in measuring koff values and in key discussions leading to a number 
of hypotheses. Christina and Laura Rodriguez helped to purify all the enzymes that 
were assayed. Rachel Pricer and I made all the PyMol structures of the cocrystal 
structures. Kira Armacost performed theoretical studies and simulations of compounds 
binding to LYPLAs. My principle investigator Dr. Brent R. Martin, conceived the project, 
provided funding for all the efforts described in this chapter, and oversaw the 
experimental design. My own part in this work was to develop and direct the kinetic 
measurements, help to design all experiments, offer insight into the binding modes of 
the inhibitors, provide a hypothesis-driven strategy for the project and write this chapter. 
The crystal structures were solved in collaboration with Dr. Jeanne Stuckey from 
University of Michigan's Center for Structural Biology. The use of the Advanced Photon 
Source was supported by the U. S. Department of Energy, Office of Science, Office of 
Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. Use of the LS-CAT 
Sector 21 was supported by the Michigan Economic Development Corporation and the 
Michigan Technology Tri-Corridor for the support of this research program (Grant 
085P1000817). Lastly, Dr. David Smith of LS-CAT helped with remote data collection. 
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in the PDB yet.  
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3.2 Introduction  
 The human serine hydrolases (SHs) form one of the largest enzyme families 
consisting of more than 240 members and therefore constitute ~1% of the proteome.1 
SHs include both serine proteases as well as metabolic hydrolases, the latter of which 
act primarily on metabolites and short peptides.2 The majority of metabolic SHs adopt 
an α/ß hydrolase (abhydrolase) fold3 featuring the classic Ser-His-Asp catalytic triad and 
are further organized into subfamilies comprised of esterases, lipases, peptidases and 
amidases2. Many metabolic hydrolases have been thoroughly studied over the years 
and details regarding their in vivo substrates and biochemical functions are well defined 
(e.g. FAAH4 and acetylcholinesterase5). However, nearly half of the members, 
especially hydrolases that act on larger classes of macromolecules, are still completely 
uncharacterized.6 
 Lysophospholipases 1 and 2, here throughout referred to as LYPLA1 and 2, are 
~25 kDa proteins that are paralogs belonging to a subclass of serine esterases within 
the abhydrolase superfamily.7 LYPLA proteins are conserved across eukaryotic 
species, with orthologues present from humans to unicellular microorganisms such as 
S. cerevisiae, although only vertebrates possess two distinct isoforms.8 In spite of the 
high sequence homolgy observed between LYPLA isoforms (~68% similarity in humans, 
Figure 3-1), it is probable that LYPLA1 and 2 have diverged sufficiently in higher 
organisms to perform non-redundant roles. 
 
Figure 3-1 Multiple sequence alignment highlights divergent residues between LYPLA1 and 2. 
. 
Regardless, the conserved orthology of LYPLAs implies these enzymes perform 
biological duties that are indispensible for the proper functioning of eukaryotic 
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organisms6, even though yeast knockout studies have not demonstrated an obvious 
physiological impairment9. Interestingly, phylogenetic analysis shows that LYPLAs are 
somewhat related to a clan of nonspecific carboxylesterases7 and a group of 
lysophospholipase-like proteins, which have preferred hydrolytic activities towards 
short-chain acyl-linked substrates10, contrasting with the reported biochemical activities 
of LYPLAs. 
 From a historical standpoint , it has been difficult to confidently assign  LYPLA1 
and 2 specific cellular roles due partly to the diverse range and nature of their substrate 
biomolecules (Figure 3-2). These enzymes were initially described as lysophospholipid 
esterases, hence their name, capable of hydrolyzing a variety of lysophosphatidyl 
choline, ethanolamine, serine and inositol molecules (LPC, LPE, LPS and LPI 
respectively) with moderate specificity constants (kcat/Km ~ 2.5 x 10
3 M-1 s-1 calculated 
from11–13). In addition, LYPLAs were also shown to cleave acetyl esters from platelet 
activating factor (PAF) like molecules but did not accept traditional 
diacylglycerophospholipids as substrates.12–14 Given these amphiphilic substrates are 
likely to partition into nonpolar phases such as micelles15,16, it was surprising to discover 
that LYPLAs lack the characteristic 'interfacial activation' kinetics observed for most 
lipases17–19, though a few other lipase members (e.g. cutinases) lack this activity as 
well20,21. Nevertheless, LYPLA1 and 2 activities shows dependence on the micellar 
surface density of their substrates13,14 which is consistent with all lipases that act on 
poorly soluble, aggregated hydrophobic substrates. 
100 
 
 
Figure 3-2 LYPLA1 and LYPLA2 breadth of physiological substrates embodies their widespread 
tolerance for hydrophobic acyl substrate. Initially described as lysophospholipid-specific esterases, 
LYPLAs exclude diacylglycerophospholipids as substrates. Later these enzymes were identified as 
protein and metabolic acyl thioesterases catalyzing acyl chain removal from both acyl CoAs, Ras and Gα 
subunits. More recently, they have been reported to hydrolyze inflammatory prostaglandin esters with 
similar Km values to S-acylated protein substrates. All specificity constants were calculated based on 
published average published kcat and Km values that are referenced in the main text. 
 Later on, LYPLAs were rediscovered as principle S-acyl-protein thioesterases 
(APTs) that cleave thioester linked fatty acids from a variety of signaling proteins, 
including Gα subunits22, Ras family members23 and eNOS.24 At that point, it was 
recognized that LYPLAs demonstrated higher kinetic efficiencies with palmitoylated 
proteins (kcat/Km ~ 5 x 10
4 M-1 s-1 for N-Ras23), and hence, LYPLA1 and 2 were given 
the names APT1 and 2, respectively, to reflect their dominant role as protein 
thioesterases in cells. Still, in the general sense, thioester hydrolysis is considered to be 
intrinsically more efficient but less specific than oxo-ester hydrolysis due to the labile 
nature of the scissile bond, and this may explain why greater kcat values are observed 
with thioester substrates.25 Affirming this point, LYPLA1 and 2 have since re-emerged 
as enzymes that process biomolecules unrelated to S-acylated proteins; LYPLA1 was 
reported to hydrolyze ester-linked octanoyl chains from both the short peptide hormone 
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ghrelin11,26 and neuraminidase prodrug laninamivir octanoate27, whereas LYPLA2 was 
shown to posses monoacylglycerol (MAG) esterase activity toward a variety of 
prostaglandin glycerol (PGE) and acylglycerol (AG) substrates in a regio- and 
stereospecific manner28. Overall, LYPLA1 and 2 catalyze a plethora of physiologically 
distinct reactions, however, their substrates share a common motif: possessing a 
hydrophobic acyl handle that is thought to aid in active site recognition (Figure 3-2). 
Indeed, knowledge of the three-dimensional architecture of these enzymes complexed 
to physiological substrates or analogs may inform on the scope of suitable substrates 
and, in turn, provide insight into their true functional roles. 
 While a few abhydrolase structures related to LYPLAs are known, to date, only 
human LYPLA1 crystal structure has been solved29. LYPLA1 exhibits a near-canonical 
abhydrolase fold closely resembling that of its distant homolog lysophospholipase-like 
1(LYPLAL1)7 and the poorly 
characterized carboxylesterase from P. 
fluorescence. (CPf)30. Together with 
LYPLA1, these are the only members of 
the lysophospholipase/related-
carboxylesterase subfamily (here 
collectively referred to as the LC family) 
for which three-dimensional structures 
are available. These particular proteins 
feature the core unit of the abhydrolase 
fold, namely the ß-pleated sheet 
structure‎flanked‎by‎α-helices and 
variable loops (Figure 3-3).12  
 
Figure 3-3 Previously solved human LYPLA1 
secondary and tertiary structures show 
significant deviation from classic 
abhydrolase fold. (a) Ribbon diagram 
highlighting the geometry of secondary structural 
element which are designated according to the 
structure of the canonical abhydrolase. Seven ß-
strands are numbered sequentially from 2 to 8. 
Four short ß irregular strands are denoted S1–S4. Five α helices are labeled from A to. Four short helical 
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segments are labeled from G1 to G4. The displayed numbering of the shown catalytic S114, D169, and 
H210 are actually 5 units less than that of the full-length sequence of LYPLA1. (b) Topology diagram of a 
canonical abhydrolase. (c) Topology of human LYPLA1. See text for further details. This Figure has been 
taken directly from the original publication of LYPLA1's crystal structure
29
 solely for illustrative purposes. 
Unlike typical abhydrolases however, these enzymes are considerably smaller, lack the 
first beta strand of the core sheet and exhibit non-traditional insertions composed of 
long winding loops and irregular ß-sheets7,29,30. Interestingly, in spite of LYPLA1's 
documented lipolytic activity, it lacks the structural topology of common lipases, most 
notably, the well defined lid-structure that is triggered to open and mobilize active site 
residues when docking to the lipid-water interface31,32. Instead, LYPLA1, along with 
other LC family members, are thought to use their atypical loops and sheets as a 
'flexible' hydrophobic channel for the purpose of substrate acquisition, thereby 
conferring the enzyme substrate specificity. This proposition is substantiated by the fact 
that among structurally-characterized LC family members, the length of the channel's 
cavity correlates with the observed substrate specificities of the enzyme; for instance, 
LYPLAL1 features an obstructed hydrophobic channel and demonstrates a strong 
preference towards short acyl chain substrates7, whereas LYPLA1 favors longer acyl 
lengths29 correlating with its more accommodating hydrophobic tunnel. 
 The quaternary structure of LC family members may represent another point of 
departure from prototypical abhydrolases, which are almost always monomeric in 
nature. While CPf has been shown biochemically and structurally to exist as a strict 
homodimer in solution10,33, crystal packing analysis suggests that LYPLAL1 is likely 
monomeric7. LYPLA1 is anticipated to form weak dimers which may hinder active site 
entry, and therefore, has been suggested to further augment and restrict the enzyme's 
substrate scope.29 However, this mode of dimerization has not been fully characterized 
in solution and is unclear whether it is also featured in the homologous LYPLA2 
enzyme. Indeed, a molecular structure for LYPLA2 is needed for a complete description 
of differences between LYPLAs, which may answer the question of why a pair of 
isoforms have evolved in higher eukaryotic species? 
 A recent study applied an activity-based probe strategy to screen for specific 
inhibitors of LYPLA1 and 2 in hopes of discovering isoform selective molecules that 
could be used to assay the exact cellular contributions of each LYPLA.34 In this 
103 
 
approach, the broadly-reactive SH suicide inhibitor, diethyl fluorophosphonate, was 
conjugated to a rhodamine fluorophore and used in a competition experiment to assay 
active site occupancy of small molecules35, yielding hit compounds that displayed either 
covalent or competitive inhibition behavior. Indeed, this methodology is geared towards 
discovery of compounds with prolonged drug-target residency times, an important facet 
that has shown to confer enhanced efficacy and selectivity in vivo.36–38 The high 
throughput screen of the NIH molecular libraries yielded a number of compounds that 
exhibited modest to strong active site occupancy (Figure 3-4A). Noteworthy among 
these hits were two potent reversible inhibitors, termed ML348 and ML349, that 
selectively inhibited either LYPLA1 or 2, respectively (Figure 3-4B)14. An orthogonal 
enzyme activity assay confirmed that each of the leads exhibited modest Ki values 
between 200-300nM, and had approximately 50 to 200-fold selectivity towards their 
corresponding target(Figure 3-4D and E). Above all, these reversible compounds are 
the first inhibitors to display isoform specificity between LYPLAs, making it possible to 
assay their biological contributions in a physiologically relevant manner. 
 Molecular structures of these lead inhibitors are noticeably different though both 
inhibitors incorporate an unsaturated 5-membered heterocycle (furan in ML348 and 
thiophene in ML349) substituted at carbon 2 by an amide-linked piperazine ring (Figure 
3-4B). This unexpected finding proved that in spite of the sequence and probable 
structural similarities of human LYPLAs, their active sites have diverged enough to give 
rise to the observed ligand selectivity. To better understand the structure activity 
relationship (SAR) of the molecules, the authors compiled a small library of derivatives, 
and described some of the pharmacophoric moieties present within each lead.39 It was 
found that for ML348, altering either the substitution or regiochemistry about the 2,5-
disubstituted anilide (Cl-CF3Anil) functionality diminished both its potency towards 
LYPLA1 and its target selectivity against LYPLA2. 
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Figure 3-4 Active site residency-time screen yields paralog selective, reversible LYPLA1/2 
inhibitors. (A) Fluopol-ABPP screening results for representative 16,000 compounds of the NIH small-
molecule library B. Chemical structures of top hits from the ABPP screen that selectively inhibit LYPLA1 
and 2 with negligible cross-reactivity. ML348 and ML349 inhibitory activities were examined further by 
employing a fluorogenic resorufin acetate substrate hydrolysis assay (as discussed in the main text) with 
10 nM purified human LYPLA1 and 2. C. Micaelis-Menten kinetic analysis of LYPLA1 and 2 with reported 
Km and Vmax values. D and E show ML348 and ML349 dose-dependent inhibition of hydrolase activities of 
LYPLA1 (D) and LYPLA2 (E). Ki values for ML348 and ML349 were calculated using the Cheng-Prusoff 
relation for competitive inhibitors. All values represent means ± SEM for four independent experiments. 
These images have been borrowed from the original publication of the HTS screen that found ML348 and 
ML349 (ref). Again, this figure is for illustrative purposes only. 
As for ML349, the relative para-configuration about the methoxyphenyl (pMeOPh) group 
was shown to be absolutely critical for inhibitory activity. Interestingly, substituting the 
sulfone of the thiochromene dioxide portion of the molecule for a bulky hydrophobic 
moiety yielded inhibitors with activities that mirrored the parent ML349 compound. 
Overall, the SAR study addressed some of the structural requirements that were 
necessary for inhibitor potency, however, knowledge of the exact ligand-specificity 
determinants in LYPLAs were still lacking. 
 Here we crystallized LYPLA1 and 2 in the presence of their selective compounds 
and provide a structural basis for inhibitor selection between LYPLA1 and 2. Employing 
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both steady-state and transient kinetic experiments we show that Ile75 residue in 
LYPLA1 and Pro86 and His152 residues in LYPLA2 are part of an essential gate-
keeping mechanism which selects for appropriate inhibitor scaffolds and may have 
implications for enzymatic specificities towards physiological substrates. Furthermore, 
we use the activities from a series of ML349 derivatives towards LYPLA1 and 2 to 
inform on the specific location of groups that may give rise to potency and selectivity of 
the ML349 molecule. Taken together, we propose that differences in the hydrophobic 
character and conformational dynamics about LYPLA active sites are primarily 
responsible for this ligand specificity.  
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3.3 Materials and Methods 
 Chemical and biological reagents. HindIII and BamHI restriction enzymes, T4 
DNA ligase, Superscript III reverse transcriptase, TRIzol reagent, pTrcHis2A vector, E. 
coli. BL21(DE3)pLysS and Top10 cells, dehydrated LB-Miller broth were all purchased 
from Thermo Fisher. Pfu Turbo polymerase was purchased from Stratagene. The 
sequencing, amplification and mutagenic primers were purchased from Eurofins 
Genomics. The immobilized cobalt affinity resin was purchased from Clontech. Dimethyl 
sulfoxide (DMSO), Resorufin O-acetate, Pluronic F-127, sodium acetate were 
purchased from Sigma. Phosphate-buffered saline (PBS) was purchased from Gibco. 
 Molecular cloning and site-directed mutagenesis. Jurkat cell RNA was extracted 
with TRIzol and corresponding cDNA was generated by RT-PCR. Custom-made PCR 
primers were then used to amplify human LYPLA1 and LYPLA2 genes from Jurkat cell 
cDNA. PCR products were inserted into a pTrcHis2A bacterial expression vector via 
ligation-dependent cloning techniques in which BamHI and EcoRI restriction sites were 
used for an in-frame fusion to a C-terminal hexahistidine (His6) affinity tag. During the 
cloning process, each gene was deliberately truncated to eliminate the first 5 residues 
to initiate translation at the second methionine residue. The genes were then sub-
cloned into a pMCSG7 bacterial expression vector40 (generously gifted by Dr. Jeanne 
Stuckey) via ligation-independent cloning techniques in which custom-made PCR 
primers were used for an in-frame fusion to an N-terminal His6 tag followed by a 
tabbaco etch virus (TEV) cleavage site. Site-directed mutagenesis was carried out on 
pMCSG7 vectors encoding the LYPLAs 1 and 2 following the Quik-Change PCR 
strategy (Stratagene) by using custom-made mutagenic primers and Pfu Turbo as the 
DNA polymerase. The sequence of the mutated genes were confirmed by an automated 
chain termination-based DNA sequencer (ABI Model 3730XL) at our institution's DNA 
sequencing core facility (University of Michigan). The recombinant wild type and mutant 
containing  plasmids were transformed into chemically competent E. coli. cells for either 
plasmid amplification (Top10) or protein purification (BL21(DE3)pLysS). 
 Protein expression and purification. All recombinant protein were purified as 
follows. After reaching an optical density of 0.5 at 600  nm, 1 L Lysogeny broth41 
cultures of transformed BL21(DE3)pLysS cells were induced for 4 h with 1 mM IPTG 
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and shaken in a bacterial incubator at 250 RPM at 37 oC. The following steps were 
carried out at 4 oC unless otherwise noted. Cells were sedimented by centrifugation at 
5,000 x g for 5 min and pellets were stored at -80Co until further processing. Frozen cell 
pellets were resuspended in 40 mL of lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl) 
supplemented with 10 % v/v glycerol and lysed to homogeneity using a an ultrasonic 
probe. Cell debris was pelleted by centrifugation at 12,000 x g for 30 min. Recombinant 
His6-tagged proteins were then purified using Talon immobilized cobalt affinity resin 
according to the manufacturer's protocol. Briefly, the supernatant was incubated with 
the cobalt resin, washed with 5 column volumes of lysis buffer supplemented with 1mM 
imidazole, and eluted over 4 steps with lysis buffer supplemented with 5, 10, 25 and 50 
mM imidazole. Fractions containing recombinant protein were identified by Coomassie 
stained SDS-PAGE gels, pooled and transferred to a dialysis tubing (10,000 MWCO). 
For kinetic experiments, recombinant proteins were dialyzed sequentially against 3 L of 
lysis buffer and their protein concentration was measured using the DC protein assay 
(Bio-Rad). Proteins were then diluted to 10 mg/mL in lysis buffer supplemented with 50 
% v/v glycerol, divided into 20 µL aliquots, flash-frozen in an ethanol-dry ice bath and 
stored at -80 oC until further processing. For crystallographic experiments, recombinant 
proteins were dialyzed sequentially against 2 L of 20 mM Tris pH 8.0 with 30 mM NaCl. 
The His6 tag was cleaved off by the addition of TEV protease during the first round of 
dialysis. The proteolyzed solution was incubated with the cobalt resin for 1 hr, collected 
and concentrated using an Amicon ultracentrifugal filter unit (Millipore) operated 
according to manufacturer's protocol. All recombinant proteins were purified to >90% 
purity as determined by SDS-PAGE analysis in typical yields of ~10-20mg protein / g of 
wet cell paste. 
 Protein Crystallization. Prior to crystallization, purified proteins were concentrated 
to 8 mg/mL and dithiothreitol (DTT) was added to a final concentration of 5 mM. 
LYPLA1 was incubated with 0.5 - 5 mM of ML348 and LYPLA2 was incubated with 0.5 - 
3 mM of ML349 for at least one hour at 4 °C before setting crystal trays. Trays were set 
at room temperature and incubated at 20 °C Crystals were produced by sitting drop 
vapor diffusion with drops containing 2 µL of protein-inhibitor solution and 2 µL of 
reservoir solution. For LYPLA1 with ML348, the best-diffracting crystals were formed 
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from reservoir solution containing 0.1 M sodium citrate, 22-24% PEG 3350, and 200 
mM MgCl2. For LYPLA2 with ML349, the best-diffracting crystals were formed from 
reservoir solution containing 0.1 mM sodium citrate pH 5.5, 20-24% PEG 3350. To 
obtain large diffractable crystals, drops were microseeded 24 hours after setup. After 1-
2 weeks, thin plate crystals formed. Cryopreservation solutions used to harvest each 
crystal contained reservoir solution reagents at the concentrations listed above with the 
addition of 25% ethylene glycol.  
 Data Collection and Structure Determination. Diffraction data for LYPLA1-ML348 
and LYPLA2-ML349 were collected on the Advanced Photon Source LS-CAT 
beamlines 21-ID-D and 21-ID-G, respectively. The data were processed with 
MOSFLM42 and scaled with SCALA43. LYPLA1-ML348 was solved to 1.55 Å resolution 
by molecular replacement using MOLREP44 with the A chain of apo LYPLA1 (PDB ID 
1FJ2) as the search model. The structure of LYPLA2-ML349 was solved to 1.64 Å 
resolution by molecular replacement via Balbes45, which also used the apo LYPLA1 
structure as the search model. Both structures went through iterative rounds of electron 
density fitting and structural refinement in Coot46and Buster47. Difference electron 
density maps contoured at 3 showed the presence of an inhibitor associated with each 
protein chain (Figure 3-5). 
Figure 3-5 Omit electron density maps for ML348 
(A) and ML349 (B). The A chain of LYPLA1 and 
LYPLA2 are displayed as grey cartoons with their 
respective ligands in sticks. ML348 is shown with 
carbon atoms in yellow, nitrogens in blue and oxygens 
in red. ML349 has its carbons colored green. The Fo-
Fc omit electron density maps are shown as black 
grids‎contoured‎at‎the‎3α‎level. 
Coordinates and restraint files for each ligand 
were created by Grade47 with the mogul+qm 
option. Two molecules of LYPLA1 were 
refined per asymmetric unit. Residues 8 – 230 
for both chains were visible in the electron 
density 2Fo-Fc maps. Four molecules of 
LYPLA2 were present in the asymmetric unit. 
109 
 
Residues 9 – 231 were visible in the electron density maps for chains A and B and 
residues 10 - 231 were present in chains C and D with the exception of residue 160 
missing from chain C. Data collection and refinement statistics for each structure are 
listed in Table 4. 
 Steady-state resorufin acetate hydrolytic assays. Resorufin acetate, ML348, 
ML349, and ML349 derivatives were all dissolved to 10 mM in anhydrous DMSO and 
stored as aliquots at -80oC. Assay buffer was prepared by adjusting PBS to pH 6.5 with 
sodium acetate (ca. 10mM) and supplementing it with 0.5 g/L Pluronic F-127. For 
steady-state substrate-dependence experiments, 5 µL of varying substrate 
concentration was dispensed into wells of a black-bottom, half-area, 96-well plate 
(Corning). Purified recombinant enzyme was diluted into assay buffer and allowed to 
equilibrate to room temperature for 20 minutes. The assay was initiated with 95 µL of 50 
nM enzyme using a multi-channel pipette, and then quickly mixed with the pipette 
several times. The absorbance from the wells were then measured at room temperature 
every 35 seconds for 20 minutes on a Tecan F500 plate reader using a 525/35 nm 
excitation filter, a 600/10 nm emission filter, and a 560 LP dichroic filter. Each enzyme 
was assayed in two separate runs, each consisting of 4 replicates per substrate 
concentration and performed simultaneously with another 4 replicates using the 
appropriate catalytic-dead enzymes S119A.LYPLA1 and S122A.LYPLA2. Initial reaction 
velocities were calculated by measuring the slope about the absorbance time course 
within the first 6-7 minutes. For each enzyme, the velocities from the two separate runs 
were combined and background hydrolytic rates were subtracted using the averaged 
rate from the appropriate catalytic-dead reactions. The baseline-subtracted data 
consisting of 8-replicates were imported into the Graphpad Prism 6 software and 
nonlinear regression analysis was used to measure the steady-state parameters Vmax 
and Km by fitting the curve to the standard Michaelis-Menten kinetic equation: 
      
            
      
    Equation 1  
Where Vi is the initial reaction velocity measured at a given substrate concentration, 
Vmax is the maximum rate achieved under saturating substrate concentration, Km is the 
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substrate concentration at which the reaction rate is half of Vmax, [E]t is the total enzyme 
concentration used and [s] represents the initial substrate concentration at time zero. 
 A similar experimental scheme was followed for the inhibitor-dose response 
measurements except for the initial setup used in preparing the 96-well plate. Namely, 
50 nM enzyme was pre-incubated in assay buffer containing varying inhibitor 
concentrations and a fixed 2 % v/v DMSO concentration for 30 minutes at room 
temperature. 95µL of solution were then dispensed into wells containing 5uL of a fixed 
resorufin acetate concentration to give 50µM substrate and 7 % v/v DMSO final reaction 
concentrations. Absorbance rate measurements were acquired as before and after 
subtraction of the catalytic dead activities, the initial velocities were divided by the 
velocities measured in the vehicle control treatments (denoted V0). The normalized 
data, consisting of 8 replicates per inhibitor concentration, was then imported into 
GraphPad Prism 6, transformed into Log10 units and nonlinear regression analysis was 
used to calculate a steady-state IC50 value by fitting the curves to a four parameter 
logistic equation of the form: 
  
                 
    
    
                      
  Equation 2 
Where [I] is the total inhibitor concentration used, Vi
res is the residual velocity measured 
at a given [I], lim[I]→∞Vi
res is the limit of residual velocity as [I] approaches infinity, Span is 
the range observed in the dose-response curve, Hill is the slope associated with the 
curve and IC50 is the inhibitor concentration at which residual velocity is half of the 
maximal velocity V0. The equilibrium inhibitory Ki constants for each compound towards 
either wild type or mutant enzyme were then derived using the Cheng-Prusoff 
equation48:  
   
    
  
   
  
      Equation 3 
 Transient fluorophosphonate rhodamine binding assays. Assay buffer was 
prepared by combining final concentrations of 50 mM Tris pH 8, 150mM NaCl and 0.5 
g/L Pluronic F-127. 125 nM of purified recombinant enzyme was pre-incubated in assay 
buffer containing either 12.5 µM of the indicated inhibitor or 2.5 % v/v DMSO for 30 
minutes at room temperature. 1µM of FP-PEG-TAMRA was then added to the mixture 
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to initiate the reaction. At the indicated time points, 20 µL of reaction mixture was 
removed, combined with 4 µL of 5 x Laemmli sample buffer and heat-inactivated at 
85oC, for 5 minutes. Mixtures were separated by SDS-PAGE using a 4% - 20% 
polyacrylamide precast Tris-Glycine gels (Invitrogen) and imaged using a Typhoon 9200 
fluorescence scanner. The fluorescence intensity of each band was integrated and 
quantified on the ImageJ software. For each run, the band intensity at every time point 
was divided by the band intensity of the final time point, thereby transforming the raw 
fluorescence intensities into fraction bound values. The normalized data were imported 
into the GraphPad Prism 6 software and nonlinear regression analysis was used to 
calculate the observed rate constant kobs by fitting the curve to a single-phase 
exponential association equation of the form: 
             
           Equation 4 
Where t is time, Fbound is the fraction of enzymes that are bound to the fluorophore at a 
given time and kobs is observed pseudo-first-order rate constant associated with the 
binding reaction in the presence of an inhibitor. Thus, the off rate constant (koff) for the 
decomposition of the competitive enzyme-inhibitor complex can be equated to kobs when 
it is the rate-limiting step in a two-step 'release-then-pull' kinetic experiment described in 
the results section.  
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3.4 Results 
 Protein crystallization. In light of the recent discovery of isoform-selective 
reversible inhibitors for LYPLA1 and 2, we wanted to understand how these highly 
homologous enzymes achieve exquisite specificity towards their corresponding 
inhibitors ML348 and ML349. For this purpose, we sought to obtain crystal structures for 
both uninhibited and inhibitor-bound LYPLA1 and 2 so that structural determinants and 
possible ligand-induced conformational changes may be examined on a molecular level. 
To this end, crystal trays of human recombinant proteins were prepared in which wild 
type LYPLAs were precipitated in their unliganded (apo) form or in the presence of 
saturating concentrations (>5 times the reported Ki values
34) of their corresponding 
inhibitors. LYPLA1 yielded diffraction-quality crystals for both the ML348-complexed and 
apo forms (data not shown), the latter of which a crystal structure has been previously 
solved by employing anomalous scattering from bromide ions introduced into the 
cryoprotectant solution29. Despite our efforts at screening numerous crystallization 
conditions, we were unable to grow well-ordered crystals for apo LYPLA2. It is possible 
that LYPLA2 contains intrinsically disordered regions imparting greater flexibility to its 
secondary structural elements and this can result in lattice irregularities during the 
crystallization process.49 We therefore conjectured that LYPLA2 will benefit from 
crystallization in the presence of its inhibitor ML349, as competitive inhibitors have 
shown to act as stabilizing ligands50 and may 'rigidify' the protein structure generating 
higher-quality crystals51. Indeed, adding the compound to the protein solution during the 
crystallization trials improved crystallogenensis and yielded cocrystals with good 
diffraction properties. 
 Quality of the models. The proteins studied in this work contain an N-terminal, 5-
residue deletion, resulting in amino acid sequences that begin at the sixth methionine. 
Nevertheless, the amino acid numbering reported herein refers to the original 
sequences of the human enzymes acquired from the Consensus Coding DNA 
Sequence Database (ID numbers CCDS6157.1 and CCDS241.1). The molecular 
models for both protein-inhibitor complexes were refined to high resolution, yielding 
atomic structures of 1.55Å for LYPLA1 and 1.64Å for LYPLA2. Table 4 summarizes the 
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acquisition parameters, refinement statistics and model quality associated with the 
solved structures. 
Table 4 Crystallography Data Collection and Refinement Statistics. 
Data Collection  APT1-CP83  APT2-CP115 
PDB Code N/A N/A 
SpaceGroup P2 21 21 C2 
Unit Cell   
a, b, c (Å)  
71.67, 73.69, 
81.82 
78.21, 79.79, 
138.61 =93.3° 
Wavelength (Å) 0.9792 0.9786 
Resolution (Å)1 1.55 (1.57-1.55) 1.64 (1.67-1.64) 
Rmerge  0.057 (0.42) 0.095 (0.488) 
<I/ 2 18.5 (4.2) 7.1 (2.0) 
Completeness (%)3 100 (100) 93.2 (84.5) 
Redundancy 8.1 (7.8) 3.7(2.9) 
 
Refinement  
  
Resolution (Å) 1.55 1.64 
Rwork 4 0.1784 0.2210 
Rfree5 0.1972 0.2523 
Monomers/ASU 2 4 
Protein atoms 6909 6615 
Heterogen atoms 470 546 
Water molecules 362 310 
Unique Reflections 63533 97049 
R.m.s.d.6 See main text See main text 
   Bonds 0.01 0.01 
   Angles 1.10 1.06 
MolProbity Score7 1.12 1.08 
Clash Score7 2.85 1.79 
Z-Score8 
(A,B,C,D) chain 
0.09, 0.29 0.01, 0.07, 
0.89, 0.53 
RSR8 
(A,B,C,D) chain 
0.128, 0.161 0.091, 0.088,  
0.080, 0.103 
RSCC8 
(A,B,C,D) chain 
0.819, 0.848 0.960, 0.959, 
0.962, 0.954 
1
Statistics for highest resolution bin of reflections in parentheses. 
2
Intensity signal-to-noise ratio. 
3
Completeness of the unique diffraction data. 
4
Rwork = h I IFoI – IFcI I / hIFoI, where Fo and Fc are the observed and calculated 
structure factor amplitudes for reflection h. 
5
Rfree is calculated against a 5% random sampling of the reflections that were removed 
before structural refinement. 
6
Root mean square deviation of bond lengths and bond angles. 
7
 REF MOLPROBITY 
8
REF EDS 
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The‎stereochemical‎quality‎of‎the‎molecules‎modeled‎in‎the‎ML348•LYPLA‎complexes‎
is quite high as assessed by MolProbity52, which showed that across backbone atoms, 
~100%‎of‎the‎residues‎had‎dihedral‎angles‎of‎the‎most‎favored‎φ/ψ‎conformations‎with‎
no outliers. On the other hand, not all bond geometries present in the atomic model of 
ML349•LYPLA2‎complexes‎were‎of‎the‎most‎favored‎Ramachandran‎angles,‎although 
all were of allowed dihedral angles. Indeed, particular regions of low electron density 
prevented the refinement algorithms from fitting the corresponding structure with totally 
accurate dihedral angles. The weak X-ray scattering observed only in certain high-
mobility regions of LYPLA2, but not in the corresponding region of LYPLA1, further 
supports the existence of intrinsically flexible domains within its polypeptide chain which 
may contribute to its unique affinity to ML349. Regardless, the electron density 
surrounding at least one of the LYPLA2 chains was well-defined throughout the 
structure and the relative conformation and location of the associated ligand atoms were 
well-resolved due to their inherent planar arrangement (Figure 3-5). 
 To facilitate comparisons with related abhydrolase structures, the subsequent 
description of secondary structural elements follows the nomenclature of the canonical 
abhydrolase fold developed by Ollis et al.3 For consistency, deviations from the 
prototypical fold and unique structural insertions are named in the same fashion as 
reported in the previous LYPLA1 crystal structure paper.29 Unless otherwise noted, 
discussions concerning either LYPLA complex refer to analyses exclusively performed 
on the A chains and their associated ligands as these had the highest overall quality 
statistics for both ligand and macromolecule. (Table 4). 
 Overall structures of LYPLA1 and LYPLA2 reveal highly similar abhydrolase 
folds. To begin to explore the elements that confer ligand selectivity to these enzyme, 
we chose to consider the structural commonalities and disparities present in these 
homologues. We envisioned that structurally-divergent components might help to locate 
ligand-specific residues. Broadly speaking, the cocrystal structure of LYPLA2 was found 
to be highly analogous to that of LYPLA1 (PDB ID: 1FJ2), as it adopts the same atypical 
α/ß hydrolase fold (Figure 3-6A and B). LYPLAs feature the same central, six-stranded, 
mostly parallel ß-sheet, corresponding to strands ß2-ß8, which are joined by variable 
lengths of loops, helices and strands. 
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Figure 3-6 Crystal structures of LYPLA1 and 2 bound to their corresponding inhibitors reveal 
distinc inhibitor binding modes. (A) and (B) are ribbon representations of LYPLA1 (A) and LYPLA2 (B) 
tertiary structure and relative positions of their respective inhibitors. (C) and (D) are close-ups of the 
active-site conformations in which proximity contacts between LYPLA catalytic side-chain and ML348 (C) 
and ML349 (D) are highlighted. (E) and (F) are surface representations of solvent exposure and 
accessibility of the bound ligands in APT1 (E) and APT2(F) complexes. The ligands are shown in sticks 
with green carbon atoms, red oxygen atoms, blue nitrogen atoms, orange phosphorus atoms, and a 
yellow sulfur atom. 
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As in all abhydrolyases, the core sheet structure is surrounded by a network of helices, 
five of which appear in all LC family members; αA and αF positioned on one side of the 
ß-sheet while αB, αC and αE located on its opposite face (refer to Figure 3-3 for a 
detailed topological map). It is worth noting that all structurally-documented LC 
members‎have‎replaced‎the‎forth‎α-helix of the classic fold (i.e. αD) with a short helical 
segment named G3. Akin to LYPLA1, LYPLA2 contains the same short, irregular 4-
stranded anti-parallel ß-sheet insertion, referred to as sß1-sß4, which is spliced 
between the ß4 strand and the αA helix. Together with the unique short helical 
segments G1 and G3, we refer to this portion of the protein as the short ß-G-ß-G motif. 
The exclusive occurrence of this structural motif among LC family members reinforces 
the notion that these enzymes belong to a structurally conserved, and perhaps 
functionally distinct subfamily of abhydrolases. 
 LYPLAs exhibit near-identical active site architecture. In addition to sharing the 
LC-family fold, LYPLAs incorporate the same trypsin-like catalytic triad, and in LYPLA2 
it is composed of Ser122, His210 and Asp176 housed within the short loops of its 
central ß-sheet structure (Figure 3-6C and D). The nucleophilic serine assumes a 
typical strained conformation located at the apex of the enzyme's 'catalytic elbow', and 
the catalytic histidine and aspartate side chains form the classic charge relay system. In 
addition, the location and orientation of the oxyanion hole with respect to the triad is 
identical in both LYPLAs, with backbone amides composed of the same Leu and Glu 
residues, which in LYPLA2 are located at positions 29 and 120, respectively. In 
essence, LYPLAs share comparable 'neighborhoods' (~90% amino acid conservation) 
within a 4A radius of their catalytic triads suggesting that ligand specificity arising from 
this region may require more than just unique inhibitor contacts, and may involve 
different conformational dynamics53. 
 LYPLAs feature putative substrate channels of differing plasticity. The other most 
likely region of LYPLAs to yield specificity would be the putative acyl binding channel 
defined primarily by the short ß-G-ß-G motif. Seeing that it encapsulates the majority of 
both ligands (Figure 3-6A, B, and surface representations in E and F) we surmised that 
this tunnel may harbor discriminatory residues to which critical interaction are made. We 
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propose that the majority of this channel is actually formed by the sß3 and sß4 anti-
parallel strands basing this claim on the shared space that is populated by the different 
ligands. The entrance proximal to the active site is formed by the G1 helical segment 
and the ß3-αA loop whereas the helical G3 segment exclusively makes up the distal 
end of the cavity (Figure 3-3). Oddly enough, LYPLA2's G3 segment, which in LYPLAL1 
has been shown to determine acyl length specificity, is connected to a flexible loop 
structure that is predicted to be highly mobile as evaluated from crystallographic 
temperature factors (data not shown). It is therefore very plausible that this high-mobility 
loop affects the dynamics about the G1 'cap', giving this hydrophobic channel plastic 
properties that are unique to LYPLA2. Overall, residues that map to this cavity are 
highly conserved between the enzymes although LYPLA point differences may still be 
sufficient to give rise to selectivity. 
 Considering only their backbone conformations, LYPLA1 and 2 appear to be 
virtually superimposable as shown by least-squares alignments of their main chain 
structures (Figure 3-7A); the exact Cα root mean squared differences (RMSD) reveal 
that LYPLAs share near-identical backbone conformations with the only key exception 
being that of the G3-proximal high-mobility loop. 
 
Figure 3-7 Least-squares structure overlay of LYPLA1/2 shows Low Cα-RMSD between cocrystal 
structures. A structural overlay of the multiple sequence alignment shows nearly identical tertiary folds 
with low (>2Å) RMSD over all backbone Cα atoms. Front (B) and side (C) projections show the 
compounds threading through structurally homologous hydrophobic tunnels in both enzymes. Both 
inhibitors seem to occupy the same topological surface resembling a shallow valley. 
In fact, the disordered region algorithm DisEMBL54 predicts this loop to exist in multiple 
conformations in LYPLA2 but not LYPLA1 amino acid sequence. With this description of 
their tertiary structures in mind, we decided to address comprehensive protein features 
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before we systematically look at differences between the enzymes' specific contacts 
with their inhibitors.  
 Global structural differences may contribute to active site ligand specificity: 
Since LYPLAs share much of the same architecture about their active sites and putative 
substrate channels, it is possible that all-encompassing factors may account for the 
observed ligand specificities. For example, the electrostatic potential distribution about 
an enzyme's molecular surface has been shown to contribute to the distinct substrate 
activities of esterases and lipases.31,55 To this regard, LYPLAs show true disparities in 
their surface charge characters, with LYPLA1 having an unexpectedly more polar 
character with scattered hydrophobic patches. Conversely, LYPLA2 shows a contiguous 
set of hydrophobic surfaces which may be useful for engaging the lipid phase where its 
endogenous substrate is likely to be found (Figure 3-8). 
 
Figure 3-8 Surface electrostatic comparison between LYPLA1 and 2 shows LYPLA2 has more 
contiguous hydrophobic interface suitable for lipolytic activity. The adaptive Poisson-Bolzmann 
solver (APBS) was used to compute the effective surface electrostatics for both LYPLA1 (A) and LYPLA 
(2) which clearly demonstrate that LYPLA2 has more hydrophobic character surrounding its active site. 
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Indeed, surface electrostatics alone suggest that LYPLA2 is a more suitable lipophilic 
attractant and may better lure hydrophobic compounds like ML348 and ML349 into its 
active site. These inhibitors are expected to have comparable hydrophobicities (2.92 
and 2.63 cLogP values for ML348 and ML349, respectively)  and are therefore 
predicted to be highly attracted to LYPLA2. However, the slightly more lipophilic ML348 
shows only faint activity towards LYPLA2 signifying that other electronic and steric 
elements must shield the active site from this inhibitor. Nevertheless, LYPLA1 and 2 
surface characters are vastly more hydrophobic than LYPLAL17, which exhibits 
pronounced surface charge which is reasonable given its preferential short chain 
hydrolytic activity. 
 It is also plausible that the unique surface polarity of each LYPLA may contribute 
to totally different oligomerization states56,57. Indeed, the crystal asymmetric units of the 
two LYPLA complexes are strikingly different in spite of being grown in virtually identical 
crystallization conditions; this implies that observed crystal packing is a consequence of 
either the presence of different ligands and or the protein's particular amino acid 
sequence. LYPLA1 contains two chains in its asymmetric unit, each, with its associated 
ML348 ligand, forms a dimer interface that is dissimilar to that observed in the 
previously reported unliganded structure (Figure 3-9). The apo LYPLA1 dimer interface 
is composed of cognate sß2-strand and ß8-loop interactions as well as a ß7-loop to an 
αA-helix inter-subunit interaction, whereas the non-covalent‎ML348•LYPLA1‎complex‎
displays a totally different dimeric interface forming novel inter-subunit interactions 
between all sß-strands and ß3, ß7 and ß8 loops (see Figure 3-3 for reference). Without 
additional in-solution characterization, it is challenging to conclude whether this 
alternative subunit arrangement results from trivial cocrystal packing or may actually 
reflect an ML348-induced dimerization of LYPLA1 in solution. On the other hand, the 
asymmetric‎unit‎of‎the‎ML349•LYPLA2‎cocrystal contains four chains, each of which is 
complexed to an ML349 ligand. The four macromolecules appear to form two distinct 
crystallographic dimers which are further stacked in an extended tetrameric 
conformation. Each dimeric interface is unlike any of those described in other LC family 
structures, solely consisting of symmetric interactions between the termini of each 
subunit: an anti-parallel sheet composed of inter-subunit ß2-strands and an anti-parallel 
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helical bundle composed of inter-subunit Fα helices. Although it is tempting to suggest 
that LYPLA ligand specificity could arise from exclusive subunit interactions, it is 
unknown how closely do the quaternary structures present in these crystals represent 
the oligomeric states in solution. Thus, to better understand the specificities of the 
ligands, we examined their contacts carefully as the following details.  
 
Figure 3-9 Comparison between apoLYPLA1 asymmetric unit to that of LYPLA1•ML348 complex 
shows significantly different mutual dispositions between their respective dimer interfaces. 
 Apo LYPLA1 conformational resemblance to ML348•LYPLA complex suggest a 
lock-and-key binding mechanism. Although both inhibitors are said to be specific for 
their targets, ML348 and ML349 do not exhibit the same degree of specificity; the 
former displays less than 35-fold selectivity towards LYPLA1 and the latter displays 
greater than 200-fold selectivity towards LYPLA2 as judged by the ratio of their 
inhibitory equilibrium constants (Ki). Thus, whereas ML349 is virtually an exclusive 
LYPLA2 ligand, ML348 is active towards both enzymes with LYPLA1 being the high 
affinity target. The promiscuous behavior of ML348 can be rationalized by the 
molecule's predicted degrees of freedom allowing it to better compensate for the 
differential electronic and steric requirements of LYPLAs. To this point, it can be seen 
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from the cocrystal structure that this complex features ML348 in an unexpected 
conformation;  there appears to be an intramolecular hydrogen bond that forces the 
molecule into a bent shape (Figure 3-7B). This configuration is made possible due to 
the presence of two sp2 hybridized atoms: the exocyclic methylene group and the 
tertiary amine of the piperazine ring (Figure 3-4B). These particular atoms enable the 
molecule to form a very stable hydrogen bond between the amide hydrogen and the 
lone pair of the tertiary amine of the piperazine ring, however it is unclear whether this 
configuration can be favored outside the active site. 
 To address this question, we superimposed the apo and the liganded LYPLA1 
structures and inspected for obvious changes that could explain the unpredictable 
conformation of ML348. Overall, there were no pronounced backbone conformational 
differences between the crystal structures as can be seen from the asymmetric unit 
alignments. This suggested that ML348 binds in a complementary fashion to the 
ground-state conformation of the enzyme. Remarkably, most amino acid side chains 
within 4Å radius of ML348 did not show much conformational changes between the 
structures with the exception of the active site proximal residues R149 and I75 and L78  
(Figure 3-10). 
 
Figure 3-10 Superposition of apo and ML348-occupied LYPLA1 reveal inhibitor engaging and 
disengaging proximal active site residues. 
Whereas both I75 and L78 side chains had shifted back to accommodate the anilide 
and piperazine respectively, R149 guanidino group seems engage the carbonyl of the 
2-furoyl amide. Certainly, R149 could be interacting with the carbonyl via hypothetical 
hydrogen bonds but this does not explain the kink observed in the inhibitor. Intriguingly, 
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3 highly stationary, active site-resident waters (as judged by their crystallographic 
placement factors) were found to coordinate the amide carbonyl of the disubstituted 
anilide through a network of hydrogen bonds (Figure 3-11). 
Figure 3-11 Two-dimensional representation 
of relevant LYPLA1-ML348 contacts 
observed in the cocrystal. The Molecular 
Operating Environment (MOE) protein ligand 
analysis software was used to automatically 
generate this ligand interaction diagram.
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These active site waters, which are 
present in both LYPLAs, may be 
contributing to the observed 
intramolecular hydrogen bonding of 
ML348 as they can draw electron 
density away from the amide's hydrogen 
making it partially positive and highly 
attracted to the piperazine's lone pair. 
Thus, LYPLA1 appears to stabilize the 
contortion about its ligand by employing 
conserved water molecules to donate 
hydrogen bonds to the carbonyl amides of the molecule. 
 Both LYPLAs exhibit a so-called 'open' active site with the catalytic triad and 
oxyanion hole exposed to the bulk solvent (Figure 3-6A and B). Therefore, a competitive 
inhibitor directed towards this class of active sites would be expected to prevent 
substrate binding by limiting its access to the conspicuous catalytic triad. Indeed, the 
sterically-demanding disubstituted analide group of ML348 appears to occlude both the 
catalytic triad and the entrance to the substrate channel (Figure 3-6A, Figure 3-7B and 
Figure 3-11). The hydrophobic CF3 group seems to contribute most to this effect seeing 
that it makes close contacts to a number of hydrophobic side chains including those of 
active site proximal L30 and L176 and of the hydrophobic channel entry residue I75. 
Aside from the two hydrogen bonds mentioned earlier, the majority of the ML348 
molecule appears to be held in the substrate channel (Figure 3-7B and C) via 
hydrophobic interactions with Trp, Phe and Leu residues which are conserved between 
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LYPLA homologues and therefore not likely to confer ligand specificity. Altogether, 
ML348 seems to bind LYPLA1 through a combination of hydrophobic attractions and 
specific hydrogen bonds through its carbonyls. ML348 in turn, binds LYPLA1 in a 'lock-
and-key' fashion as the ligand bends around the active site of the enzyme without 
inducing noticeable conformational changes about its secondary elements. 
 Distinct  ligand interactions mediate LYPLA2-ML349 interactions. Seeing that 
many, but not all of ML348 contacts to LYPLA1 were to residues that were also present 
in LYPLA2, it was still plausible that key substitutions in proximity to the compounds 
were important for ligand specificity. To explore this hypothesis, we turned our attention 
to‎the‎ML349•LYPLA2‎complex for clues to finding unshared residues that conferred 
specific ligand associations (Figure 3-12). 
Figure 3-12 Two-dimensional representation of relevant LYPLA2-ML349 contacts observed in the 
cocrystal. Again, The Molecular Operating Environment (MOE) protein ligand analysis software
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 was 
used to automatically generate this ligand 
interaction diagram. 
To this end, we noticed that ML349 
occluded active site entry like ML348, 
although it did so in a very different 
fashion; namely, the fused benzene of 
the thiochromene dioxide ring was 
engaging, via a sulfur-π‎interaction,‎the‎
thioether of M178 while the sulfone of 
ML349 was within hydrogen bonding 
distances to the catalytic S122 hydroxyl 
and H210 imidazole, and oxyanion 
residues Q123 and L33 (Figure 3-6B 
and Figure 3-12). This is in sharp 
contrast to the mode by which ML348 
blocks active site entry which appeared to be dependent on its CF3 group interacting 
with aliphatic side chains. ML349, however, uses its sulfone moiety to mimic the 
tetrahedral intermediate and or transition-state that is featured in ester hydrolysis, and 
this depiction is consistent with the fact that ML349 exhibits tighter binding to its target 
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compared to ML348 (Figure 3-6D). Although it may contribute to the potency of the 
compound, the tetrahedral analog feature of ML349 does not explain its exquisite 
selectivity for LYPLA2. Perhaps other portions distal from the catalytic residues of 
LYPLA2 may extend unique contact to ML349 to poise it in the optimal geometry for 
hydrogen bonding. 
  The hydrophobic channel was examined next to ascertain the existence of 
discriminatory residues which prefer the docking of ML349 but not of ML348. It is clear 
that for both compounds, more than half of the ligand is lodged into the putative acyl 
tunnel (Figure 3-6E and F, and Figure 3-7B and C). Therefore, we anticipated that at 
least one residue from this cavity could directly contribute to the formation of a selective 
complex. Remarkably, LYPLAs exhibit a high degree of conservation about the exterior 
of the channel defined by the sß3-sß4 sheet, but contain two different amino acids that 
flank the ends of this sheet, I75LYPLA1/L78LYPLA2 which is proximal to the active site and 
P86LYPLA1/Q83LYPLA2 which is distal (Figure 3-17). In addition, R149LYPLA1 which was 
coordinating the amide of ML348 is substituted for a H152LYPLA2 which together with the 
conserved Trp and Phe residues clamp down on the phenylmethoxy group of ML349. 
Thus, it appeared that 3-4 differential residues between LYPLAs were potential 
candidates that could give rise to the observed inhibitor selectivities of ML348 and 
ML349. These amino acids are:  
I75LYPLA1/L78LYPLA2, P86LYPLA1/Q83LYPLA2, R149LYPLA1/ H152LYPLA2 and 
L176LYPLA1/M178LYPLA2 which are all evident by inspection and comparison of LYPLAs 
ligand interaction maps (Figure 3-11and Figure 3-12). 
Steady-state and transient inhibition measurements of ML348 and ML349 with 
LYPLA mutants confirm residues that confer inhibitor selectivity. We sought to test our 
predictions by assaying the activities of the compounds toward point mutants wherein 
the candidate residue was swapped with the corresponding residue present in the 
homologous enzyme. We term this special type of substitution, a homologous inversion 
mutation, or inversion for short. In this manner, we generated 3 point inversion mutants 
for LYPLA1 and 4 for LYPLA2. We first measured both the mutant and wild type 
activities with the previously employed34 substrate analog resorufin O-acetate (Res-O-
Ac) to ensure they all had comparable activities (Figure 3-13A). 
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Figure 3-13 Steady-state kinetic analysis of APT1/2 with resorufin acetate. (A) The fluorogenic 
acetoxy derivative of the phenoxazinone resorufin was employed as a substrate analog for assaying the 
steady-state hydrolytic activities of wild type and mutant LYPLA1 and 2 variants. (B) and (C) depict the 
substrate dependent velocities of LYPLA1 and 2 variants, respectively. (D) and (E) depict the dose-
dependent inhibition curves for ML348 towards LYPLA1 and 2 variants, respectively.  (F) and (G) depict 
the dose-dependent inhibition curves for ML349 towards LYPLA1 and 2 variants, respectively. 
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Importantly, all mutants exhibited negligible differences in their Km towards Res-
O-Ac (Figure 3-13B and C). This was critical because the Km value is directly used in 
the calculations of inhibitor affinities48 and we wanted to be sure that any changes 
observed in the mutants' drug sensitivities were largely due to altered enzyme-drug 
interactions and due to altered enzyme-substrate interactions. No changes in Vmax, and 
hence kcat, were observed for LYPLA1, but interestingly, all LYPLA2 mutants exhibited 
improved kcat values (~10-fold) compared to wild type. This could indicate that LYPLA2 
mutants were more efficient at either turning over Res-O-Ac or at clearing their active 
site by hydrolyzing the remaining acetyl adduct. Regardless, neither kcat or Vmax 
constants are used for calculating a drug's equilibrium inhibitor constant Ki and therefore 
this variation was unlikely to interfere with our measurements. These steady-state 
activities demonstrated that ML348 and ML349 drug binding to all enzyme variants 
could be carried out to determine which residues were are in fact discriminating 
between these compounds (Table 5). 
Table 5 Summary of steady-state kinetic 
parameters measured for LYPLA mutants. 
All enzymes were assayed at 50 nM for both 
substrate dependence experiments and 
inhibitor dose-dependence measurements. 
The values reflect a mean of 8 independent 
replicate measurements with the error value 
represented by standard deviations. The 
estimated Ki measurementes are reported. 
Dose-dependent inhibition 
experiments were performed in which 
both inhibitors were assayed against all enzyme variants (Figure 3-13D-G). A few clear 
trends were already apparent from the steady-state IC50 measurements. First, among 
LYPLA1 point mutation, only the I75L substitution showed a true inversion of inhibitor 
selectivity as it lost considerable potency towards M348 (~10-fold) and gain exceptional 
binding properties to ML349 (Ki ~ 220 nM) (Figure 3-13D and F, respectively). This 
suggested that Ile75, which resides at the entrance to the acyl cavity, discriminates 
between ligands in LYPLA1 presumably based on bulk hydrophobic radius which was 
not clearly evident in the cocrystal structure. As per LYPLA2 variants, none of the 
inversion mutants were able gain LYPLA1-like sensitivity towards ML348 with P86Q 
having the closest Ki value which was still 10-fold higher than wild type LYPLA1 (Figure 
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3-13E). However, P86Q and H152R were the only LYPLA2 mutants to lose virtually all 
binding to ML349 with the P86Q substitution demonstrating a complete loss of ML349 
sensitivity (Figure 3-13G). These experimental outcomes (Table 5) were very surprising 
because the apparent specificity-conferring residue of LYPLA1(Ile75) had no inverting-
effect when substituted into LYPLA2. This implied that other differential residues must 
be in place to ensure ligand specificity for LYPLA2. 
 We then sought to use an orthogonal means to measure the sensitivities of the 
inhibitors towards all inversion mutants as we wished to validate these unforeseen 
findings. Drug target residency time measurements were thus performed to complement 
the thermodynamic data obtained for binding of the compounds to the mutants. To 
accomplish this goal, the active site-directed, covalent serine hydrolase probe 
fluorophosphonate rhodamine (FPRh)59,60 was employed in a classic, two-step kinetic 
experiment known as the 'release, then pull' reaction (Figure 3-14A). 
Figure 3-14 Residency time 
measurements with pre-formed 
inhibitor-enzyme complex can 
be used to corroborate steady-
state inhibition studies. (A) 
shows the order in which the 
reactions are performed. (B) Is a 
representative gel in which the 
time-course of FPRh labeling was 
followed and (C) is the 
densitometric analysis of the gel 
band fluorescence intensities. 
Residency time measurement of 
LYPLA2 with ML349 yields a ~5 
minute half-life (t1/2) complex 
decomposition. 
In this rendition of the 
residency time experiment37,61,62, the enzyme is pre-incubated with a saturating 
concentration (>5 times Ki)‎of‎inhibitor‎to‎form‎the‎predominant‎inhibitor•enzyme‎
complex species. The reaction with excess amount of FPRh is then initiated wherein the 
inhibitor•enzyme‎complex‎must‎fall‎apart‎before‎FPRh‎can‎engage‎the‎active‎site.‎That‎
being said, the speed at which this probe labels the active site is rate limited by the 
speed in which the inhibitor dissociates from the enzyme, and hence the dissociation 
rate constant (koff) of the inhibitor can be measured directly (Figure 3-14B and C) from 
the observed rate constant of this reaction (kobs). 
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 Using this method, we showed that indeed, the I75L.LYPLA1 mutant exhibits true 
inversion of selectivity displaying a smaller off rate with ML349 (t1/2 ~ 4 min), which is on 
par with that of the wild type LYPLA2 (t1/2 ~ 5 min), and a modestly larger koff constant 
compared to wild type LYPLA1 (Figure 3-15A). As with P86Q.LYPLA1 off rate kinetics, 
it exhibited a similar trend to that observed in steady-state experiments, showing rapid 
reactivity with FPRh when pre-incubated with either inhibitor (Figure 3-15B). Two 
possible scenarios may give rise to this result, one being complete loss of initial inhibitor 
binding characterize by infinitely slow on-rates, and the other being exceptionally fast 
off-rates‎which‎preclude‎the‎detection‎of‎an‎inhibitor•enzyme‎complex.‎Either‎way,‎we‎
were able to confirm via two unrelated 
kinetic measurements that I75LYPLA1 and 
Q86LYPLA2 were in fact responsible for 
the selectivity and potency of the drugs, 
respectively. 
Figure 3-15 koff measurements of ML348 and 
ML349 towards LYPLA inversion point 
mutants corroborate IC50 measurements 
further implicating L75 in LYPLA1 and P86Q 
in LYPLA2 in discriminating active site 
ligands. 
 Binding of ML349 derivatives 
define additional steric and electronic 
requirements for differential ligand 
specificity between LYPLA1 and 2. 
Seeing that a number of structural 
observations from the ML349-APT2 complex were not addressed by our current 
inversion mutant studies, we were interested in testing our structure-based hypotheses 
using a series of ML349 derivatives. The LYPLA2 cocrystal structure suggested that 
ML349 activity was partly due its sulfone functionality which appeared to serve as 
transition-state analog for the nucleophilic serine hydroxyl. To confirm this speculation, 
we synthesized two derivatives with varying degrees of oxidation about the sulfone 
moiety, termed ML349-sulfoxide and ML349-thioether. We theorized that if the oxygen 
atoms of the sulfone were indeed engaged in hydrogen bonding then their removal 
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would be detrimental to the activity of ML349 towards LYPLA2. Indeed, this sulfur series 
displayed the expected order of potency with the sulfone being having the highest 
affinity (0.15 µM) and the thioether having the weakest (>20 µM) (right panel of Figure 
3-16). These substitutions suggested that the sulfone was likely mimicking a tetrahedral 
intermediate in LYPLA2. 
 We also synthesized a series of molecules to investigate the SAR about the 
opposite end of the ML349 molecule, here referred to as the phenylmethoxy series. Our 
structural studies of LYPLA2 highlighted that the predominantly hydrophobic channel 
may be involved in both acquisition and specificity of acyl substrates. Since ML349 
appeared in an extended, linear-like disposition whereas ML348 was heavily contorted, 
we surmised that maybe these conformations reflect the different steric and geometric 
requirements of each hydrophobic channel. To explore this idea, we synthesized the 
phenylmethoxy series which contained four derivatives, two of which have a longer O-
alkyl or O-alkynyl substitution stemming from ring and the other two exhibit truncations 
in which either a methyl or a hydroxyl group is substituted for the methoxy substituent 
(Left panel of Figure 3-16). 
Figure 3-16 Summary of ML349 derivative structures and their estimated Ki values. Invariant 
scaffolds for each set of derivatives 
are placed at the top of their column 
and are boxed in black. Values 
listed correspond to the estimated 
Ki of the compounds towards 
LYPLA2. The propargyl substituted 
ML349 (left column, 2nd from top) 
exhibited 3-fold larger Ki value 
towards LYPLA1. 
Interestingly, increasing chain 
length about the phenyl ring 
correlated with increased 
potency, suggesting that 
maybe aliphatic chains were 
protruding out of the channel and or favorably interacting with LYPLA2's hydrophobic 
surfaces. Importantly, the hydroxy-substituted ML349 was the least potent of all 
phenylmethoxy derivatives signifying that a strong polar character was unfavorable in 
the putative acyl binding channel. Lastly, an ML349 derivative, the alkynyl compound, 
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was successfully synthesized which lost LYPLA selectivity at the expense of slightly 
reduced potency towards LYPLA2 (~1.5-fold). It could be that LYPLA1 is more 
restrictive about the geometry of the aliphatic chain to be inserted into its channel, 
however the electronics from the alkyne functionality might contribute to the observed 
binding of this derivative. 
 Phylogenetics-based structural analysis suggest a functional conservation for 
LYPLA2 but evolutionary adaptability for LYPLA1. Our structural studies suggest that 
these reversible inhibitors may share a number of commonalities with endogenous 
substrates such as occupying the same hydrophobic channel and interacting with key 
active site residues. Seeing that ligand specificity was conferred by select residues in 
each homolog, we wanted to determine whether the human discriminatory residues 
were conserved across LYPLA orthologues. Conservation of these residues would 
suggest two things, (1) that the active sites of the corresponding orthologues may be 
selectively targeted by these compounds, and (2) that these residues may represent 
conserved features 
between the active sites of 
LYPLAs and hence may 
shape the scope of 
acceptable substrates for 
each enzyme. 
Figure 3-17 Enzyme 
conservation corroborates 
active site discriminatory 
residues that confer inhibitor 
selectivity between LYPLA1 
and 2. The degree of 
evolutionary conservation was 
used to measure the significance 
of amino acid differences 
between the two enzyme 
isoforms in an effort to highlight 
residues that dictate inhibitor 
binding selectivity. Phylogeny alignments were generated using DIALIGN, anchored at the catalytic serine 
residue. The degree of sequence conservation shown in the scale bar corresponds to the weight scores 
used by DIALIGN to assess the degree of similarity among the sequences. In the ideal case, the analysis 
of the two isoforms would yield secondary structural elements that differ in a subset of residues, one or 
more of which was responsible for dictating ligand specificity. Beyond this notion, these multiple 
sequence alignments suggest different evolutionary adaptations between the two thioesterases: a 
divergent LYPLA1 and an evolutionary-conserved LYPLA2. Based on sequence conservation alone, 
LYPLA2 is predicted to be under higher selective pressures than LYPLY1, implying that the latter has 
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evolved to process an assortment of substrates across different organisms, whereas the former has a 
more defined scope of substrates. 
Therefore, we performed multiple sequence alignments (MSAs) across 14 vertebrate 
species for LYPLA1 and 11 species for LYPLA2. LYPLA co-crystal structures were then 
color-coded according to the degree of amino acid conservation observed in the MSA 
(Figure 3-17). It can be seen that the most conserved components between all LYPLA1 
orthologues and LYPLA2 orthologues are the sß3-sß4 anti-parallel sheet and the αB 
helix structures. Importantly, the discriminatory residues confirmed in the mutagenesis 
studies were all conserved within each family of orthologues, although the selectivity 
residues of LYPLA2 (i.e. P86 and H152) corresponded to residues within the most 
divergent portion of LYPLA1 orthologs, helix αC. This indicated that within each family 
of orthologs, the specificity conferring residues were functionally significant and may 
contribute to conserved and likely divergent substrate specificities. 
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3.5 Discussion 
 The major goals of this study were to define the critical interactions between the 
selective reversible inhibitors ML348 and ML349 and their cognate enzyme active sites, 
and to determine protein structural features giving rise the observed activities. LYPLA1 
and 2 share extensive sequence identity and bear seemingly superimposable main 
chain structures yet have very different competitive inhibitor specificities. Prior to solving 
these structures one would have surmised that selectivity would be born out of simple 
steric and electrostatic differences in their putative substrate binding sites. The co-
crystal structures of human LYPLAs revealed a very different story. Specifically, similar 
to LYPLA1, LYPLA2 possesses a canonical α/ß serine hydrolase fold featuring the 
same signature catalytic triad, oxyanion hole and putative substrate channel (Figure 3-
6).‎In‎spite‎of‎being‎crystallized‎in‎the‎presence‎of‎different‎compounds,‎LYPLA1•ML348‎
and‎LYPLA2•ML349‎exhibit‎pronounced‎structural similarities with each other and with 
the previously published apo LYPLA1 structure29. In contrast to other members of the 
LC-family such as the carboxylesterase from p. fluorescence and the distant homologue 
LYPLAL1, the short irregular ß-strands that are part of the exterior of the hydrophobic 
tunnel are even more peculiar in LYPLA1 and 2 in which they form a 'frustrated' ß-sheet 
structure and could indicate localized flexibility of LYPLAs. 
 These structural studies have also highlighted isoform-specific differences, 
namely regarding specificity determining regions. The first of these specificity regions is 
the so-called high-mobility loop structure which as stated previously, is juxtaposed to 
the G1 helical segment that caps the putative acyl docking channel (Figure 3-3). 
Interestingly, the amino acid sequence in this loop is highly conserved in LYPLA2 but 
not in LYPLA1, suggesting a significant role in LYPLA2's catalytic activity. Although 
distant from the hydrophobic channel, this region displays high-temperature factors and 
would be expected to affect the channel as it directly links to it via helices and flexible 
loops. This could also explain why LYPLA2 did not form well-ordered crystals in the 
absence of ML349. Furthermore, this may have physical implication on the mechanism 
of substrate acquisition and the nature of substrates processed by LYPLA2. One could 
imagine these loops to be highly mobile enabling their movement during the ejection of 
lipid substrates from their endogenous hydrophobic phases. 
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 We and others63 have suggested that LYPLA's G1 helical segment could function 
as clamp situated at the end of the hydrophobic channel. This would endow this region 
with 'plastic' properties which may be unique to LYPLA2 given its high-mobility loop. 
Regardless, as was shown for the LYPLAL1, the G1 segment may aid in determining 
the size and stereochemistry of physiological acyl substrates (left panel of Figure 3-16). 
The third potential specificity region would be the exterior portion of the hydrophobic 
channel defined by the flexible sß3-sß4 anti-parallel sheet which could theoretically 
restrict acyl substrates as it define the major, if not only, entry into this site. This 
proposition is based on the observation that the residues flanking this structure were 
among the only amino acids that differed within 4A away from the ligands which also 
corresponded to inversion mutants that displayed the most significant perturbations in 
ligand specificities. 
 In terms of ligand specificities, It is hard to believe that a minor Ile to Leu 
substitution can revert the selectivity of LYPLA1 (i.e. I75L mutation sensitizes LYPLA1 
to ML349 and desensitizes it to ML348), but this is indeed the case, and could possibly 
be rationalized by the ground-state structures of LYPLA1 and 2 (Figure 3-18); the ß-
methyl substituent of I75.LYPLA1 could be clashing with both thiophene sulfur and 
carbonyl‎oxygen‎atoms‎of‎ML349,‎whereas‎the‎γ-methyl substituent of L78.LYPLA2 
appears to come into contact with the aromatic trifluoromethyl group of ML348. 
Figure 3-18 Surface-
filling representations of 
possible ground-state 
interactions between 
ML348/ML349 and the 
very similar side chains 
of I75
LYPLA1
 and 
L78
LYPLA2
. 
However, these static 
observations should 
be tested at least on a theoretical level. Defining LYPLA2's selectivity determinant(s) is 
more of a challenge since a simple Ile-to-Leu substitution is definitely not sole 
determinant of LYPLA2 inhibitor selectivity given that L78I.LYPLA2 , the corresponding 
reversed mutant, doesn't exhibit inversion of inhibitor selectivity. On the other hand, 
P86Q, and to some extent H152R substitution in LYPLA2 certainly abolishes ML349 
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binding and could be an important prerequisite for ML348 binding as it renders the 
mutant almost twice as sensitive to ML348 relative to wild type (Table 5). It is possible 
that multiple amino acid substitutions (e.g. Leu and Pro) are required to establish an 
energetically-favorable interaction between LYPLA2 and ML348. 
 As implied earlier, ML348 is predicted to have more rotational degrees of 
freedom compared to ML349 since it contains a greater number of freely rotating bonds, 
and thus is expected to interact most favorably with a more rigid, stiff active-site. In 
LYPLA2, L78 and P86 flank the lower active-site capping loop (these residues 
correspond to I75 and Q83 in LYPLA1, see Figure 3-17), and could possibly affect the 
conformational dynamics of this loop and ultimately the accessibility of inhibitors and or 
substrates into the active-site. Perhaps substituting Pro and Leu together in LYPLA2 
produces a more rigid active-site, which effectively "pays" the entropic cost associated 
with binding and restricting the conformational flexibility of ML348, but again this needs 
to be tested from a physical standpoint. To summarize, we were able to account for 
LYPLA1 selectivity for ML348 and against ML349 by a single L75 residue; 
however, although it was clear that H152 and Q86 are necessary for ML349 binding, it 
remains ambiguous why LYPLA2 selects for ML349 and not ML348. Maybe future 
double, triple or even loop-segment inversion64 mutants may shed more light on this 
matter. 
 In conclusion, our data suggest that binding is primarily driven by the 
hydrophobic interaction, i.e. entropic exclusion of solvent from the lipid docking site. 
Therefore, we propose that ligand selectivity may be also influenced by intrinsic protein 
dynamics, such as the flexibility of the aforementioned disordered loops and side chains 
in vicinity of the active site. Future studies may benefit from probing the dynamics of 
about the flexible loops of LYPLAs either via NMR- or MS-based methods such 
hydrogen-deuterium exchange experiments65 or three-dimensional nuclear relaxation 
techniques66, respectively. Thus, the molecular basis for ligand selectivity may arise 
from differences in both the physical structure and conformational dynamics of LYPLA 
enzymes.  
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Chapter 4:  
APT2 Modulates the Activities of Oncogenes and Tumor-Suppressors 
of the MAPK Pathway During Epithelial-Mesenchymal Transition 
4.1 Abstract 
 Metastatic cancers exploit the MAPK signal transduction cascade to enable 
invasive outgrowth, making attractive drug targets of the molecular players within this 
pathway. Numerous scaffolds, including the tumor suppressor and cell polarity protein 
Scribble, appear to direct MAPK by assembling complexes that either increase or 
decrease‎activation‎of‎this‎pathway.‎Scrib’s‎ability‎to‎control‎MAPK‎depends‎on‎its‎
localization at the plasma membrane, but its localization becomes increasingly cytosolic 
in aggressive cancers. In the cytosolic milieu, however, Scrib now functions as a tumor-
promoting factor that paradoxically includes enhancement of MAPK activity. Here, we 
define‎a‎molecular‎mechanism‎responsible‎for‎regulating‎Scrib’s‎cellular‎localization‎and‎
tumor-suppressor potential. We demonstrate that Scribble S-palmitoylation is essential 
for membrane engagement in epithelial cells, and that its palmitoylation is disrupted in 
transformed epithelial cancer cell lines. These malignant lines show skewed activity of 
the palmitoylation enzymes involved in attaching and detaching palmitate modification in 
proteins, resulting in a decrease in steady-state palmitoylation and membrane-bound 
Scrib. Lastly, we show that small molecule inhibition of the depalmitoylating enzyme 
APT2, but not APT1, restores Scrib membrane localization and suppress MAPK activity 
in transformed cell lines. Thioesterases may therefore regulate the palmitoylation of cell 
polarity proteins, including scaffolding proteins like Scrib. This work highlights a new 
strategy to attenuate MAPK signaling in malignant cells by restoring the activity of an 
associated scaffold. 
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 Individual contributions. With a few exceptions, the majority of the work 
presented in this chapter was performed by me and Dr. Jeannie Hernandez. My 
principle investigator Dr. Brent R. Martin, conceived the project, provided funding for all 
the efforts described in this study, and oversaw the experimental design. Sirisha 
Pasupuleti helped to generate Scrib encoding epitope vectors for both transfection and 
transduction experiments. Margery Gang performed the localization assays of 
transiently expressed Scrib variants in MCF10a parent and Snail lines. Michael Sang 
Jun Won helped to perform the DHHC qRT-PCR measurements. Dr. Jaimeen 
Majmudar analyzed and processed all proteomic samples that I and Dr. Jeannie 
Hernandez had prepared. Dr. Jeannie Hernandez generated MDCK and MCF10a 
control and Snail stable cell lines, performed Scrib localization assays for all stably-
generated and human-derived cancer cell lines, conducted all acyl-biotin exchange 
experiments and 17ODYA enrichments, designed and carried out qRT-PCR 
experiments, and performed, acquired and analyzed the high-content image analysis 
data. As for my own part in this work, I generated MDCK and MDCK-Snail lines stably 
expressing GFP-tagged Scrib variants, performed localization assays of stably 
expressed Scrib variants in MDCK parent and Snail lines, conducted  the growth time 
course experiments, optimized the acyl biotin exchange protocol, performed the FP-
biotin enrichments, carried out all EGF stimulation experiments and subsequent probing 
of MAPK component activities, helped to design all experiments, offered insight into the 
bioinformatics analysis for all proteomic data, provide a hypothesis-driven strategy for 
the project and write this chapter.   
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4.2 Introduction 
 The Mitogen Activated Protein Kinase (MAPK) pathway is a conserved, three-
tiered phosphorylation cascade that leads to the activation of RAF, MEK, and ERK 
kinases in response to extracellular stimuli, resulting in transcription of genes involved in 
proliferation, differentiation, and apoptosis (Figure 1-24).1,2 Enhanced MAPK activity is a 
signature of many cancers, making valuable drug targets of the key components that 
make up this pathway.3,4 Various extracellular cues have been shown to stimulate 
MAPK, the most well-characterized route being executed through the Ras-coupled 
receptor tyrosine kinase (RTK), the epidermal growth factor receptor (EGFR).5–7 Upon 
receptor activation, the necessary membrane recruitment of core MAPK proteins is 
promoted by an interaction between inactive cytoplasmic Raf kinases and membrane-
anchored active Ras members, and culminates in a cell-wide phosphorylation cascade. 
8 Although once considered a linear pipeline, MAPK phosphorylation events are now 
thought to receive and elicit multiple positive and negative inputs and outputs via 
signaling channels outside this local network.9–13 A deeper understanding of MAPK 
regulation could therefore reveal useful drug targets for cancer - beyond the kinases 
associated with the core pathway.14 
 Scaffolding proteins like the archetypal Ste5 are well-established modulators of 
MAPK assembly and activation in yeast.15 In addition to serving as a tethering platform, 
Ste5 and its mammalian counterparts facilitate context-specific organization by spatially 
confining signaling components from extraneous cellular noise.16,17 MAPK scaffolding 
proteins can be thought of as signal-specific catalysts which provide additional fine-
tuning of signal intensity and duration.18–21 The leucine rich repeat (LRR) protein 
SHOC2 is one scaffold in mammalian cells that assembles a MAPK-specific 
phosphatase holoenzyme complex needed for activating Raf kinases in tumor cells.22,23 
Conversely, the LRR and PDZ (LAP) scaffold protein Scribble (Scrib) complexes to 
SHOC2 and antagonizes RAF1 activation by sequestering and preventing the catalytic 
protein‎phosphatase‎1α‎(PP1α)‎from‎dephosphorylating‎RAF1‎serine‎25924. A molecular 
understanding of how scaffold complexes are coordinated is an essential component of 
describing the MAPK pathway in cancer. 
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 Originally described in D. melanogaster, Scrib functions as a neoplastic tumor 
suppressor within the Scribble, Discs Large, Lethal Giant Larvae (Scrib/Dlg/Lgl) 
basolateral polarity complex.25 This highly conserved complex plays a determining role 
in planar cell polarity, suppresses tissue outgrowth, and promotes cell adhesion in 
epithelial cells.26 Importantly,‎Scrib’s‎ability‎to‎suppress‎oncogenic signaling pathways is 
highly correlated with its localization at the plasma membrane, which is frequently 
cytosolic in highly metastatic, de-differentiated tumors that have undergone epithelial-
mesenchymal transition (EMT).27,28 EMT is a morphogenic transformation of epithelial 
cells into mesenchymal-like, migratory cells capable of organogenesis in 
development.29,30 The process of EMT continues in adult tissues as a form of wound-
healing, but disruption of the pathways that control this process could confer normal 
cells with developmental-like invasive properties that define metastasis.31,32 Cytosolic 
Scrib appears to exchange its membrane-bound, tumor suppressor functions for pro-
oncogenic traits in EMT, potentially working in synergy with constitutively active Ras to 
boost MAPK activity and promote proliferation and metastasis.33,34 Notably, rescue of 
membrane-targeted, but not cytosolic, Scrib expression lead to a reversal of malignant 
EMT features in epithelial cell lines.28,35,36 Scrib’s‎localization‎at‎cell-junctions appears to 
be critical for its antitumor activities, particularly its ability to regulate MAPK.37–39 
 The‎precise‎molecular‎mechanisms‎that‎dictate‎Scrib’s‎localization‎are‎currently‎
unknown. Peripheral membrane proteins are typically targeted to the membrane phase 
through either protein interactions or post-translational modifications (PTMs) that enable 
direct interaction with the lipid bilayer.40–43 The idea of a protein interaction was explored 
in a recent report that found the cytoskeletal protein Spectrin contributing to Scrib 
membrane attachment via a conserved interaction motif.44 The collective absence of 
genetic mutations in the Scrib gene in malignant cancer biopsies suggests that 
membrane localization may be influenced by other targeting mechanisms, such as lipid 
modifications.45,46 The activities of numerous scaffolding and signaling proteins, such as 
PSD95 and HRas, are known to be modulated by some form of lipid modification47,48, 
most prominently through protein S-Palmitoylation. Palmitoylation is an enzymatically-
driven process by which specific proteins are reversibly equipped with long-chain fatty 
acids via a thioester linkage to their cysteine residue(s).49 This labile acyl moiety 
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enables signaling components to actively engage the cell membrane‎in‎a‎“switch-like”‎
manner, intrinsically limiting or accelerating their transduction potential.50,51 Indeed, 
palmitoylation is known to be a critical PTM that contributes to neurotransmission, 
immune response, and cell growth.52,53 
 In humans, two distinct enzyme families catalyze the attachment and removal of 
thioester-linked acyl moieties: the DHHC protein acyl transferase (PAT) family, which 
consists of 23 members sharing a catalytic Asp-His-His-Cys (DHHC) motif54–56, and the 
serine hydrolases acyl protein thioesterases (APTs) 1 and 2, which oppose PATs by 
catalyzing the cleavage of acyl chains off of proteins.57–59 Representatives from both 
enzyme families have been connected to central regulatory functions in neurological 
disorders and cancer.60–62 In particular, a recent genome-wide RNAi screen found the 
thioesterase APT2 among likely candidates that promote oncogenic growth in a mouse 
model of HRasG12V-driven hyperplasia.63 Further investigation with epithelial-derived 
fibroblasts transformed with HRasG12V reported the dual-APT1/2 inhibitor palmostatin 
B capable of suppressing MAPK signaling, leading to a partial reversion of the 
mesenchymal phenotype.64 Downregulation of MAPK was attributed to disruption in the 
palmitoylation dynamics of Ras proteins; however, the exact APT isoform and its 
corresponding in vivo substrate(s) were not explicitly confirmed. Taken together, APTs 
are likely involved in MAPK regulation, suggesting that metastasis could be offset by 
restoring normal palmitoylation dynamics. 
 Here we demonstrate that Scrib is a palmitoylated protein that requires this PTM 
to engage the plasma membrane in epithelial cells. Furthermore, we show that APT2 
controls the steady-state palmitoylation levels of Scrib but not Ras proteins, and both 
sets of proteins exhibit altered palmitoylation stoichiometries after EMT. We propose 
that‎Scrib’s‎cytosolic‎localization‎in‎metastatic cancers is partly due to changes in the 
expression of opposing palmitoylation enzymes, which heavily distorts palmitoylation 
equilibrium in the direction of thioester hydrolysis. We explore this hypothesis by 
inhibiting APT2 in induced EMT lines to restore Scrib palmitoylation, and therefore its 
ability to suppress aberrant MAPK signaling. 
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4.3 Materials and Methods 
 Cloning and generation of Scrib Variants. To prevent interference with putative 
N-terminal palmitoylation sites, we generate a C-terminal FLAG and GFP epitope 
tagged plasmids. To generate the GFP plasmid (here referred to as pcDNA-GFP), 
custom-made‎primers‎(Eurofins‎MWG‎Operon)‎flanked‎by‎5’-BamHI‎and‎3’-KpnI 
restriction sites were used in a polymerase chain reaction (PCR) with Phusion DNA 
polymerase (ThermoFisher) to amplify emerald GFP (emGFP) from a pcDNA6.2 vector 
(ThermoFisher) according to manufacturer's instructions. PCR products were test-
digested with Fast-Digest KpnI and BamHI enzymes (ThermoFisher), and then purified 
by agarose gel extraction. The mammalian expression plasmid pcDNA3 (ThermoFisher) 
was then double-digested with BamHI and KpnI, purified by gel extraction, and ligated 
to emGFP digest product using T4-DNA ligase (ThermoFisher). C-terminal incorporation 
of GFP was confirmed by automated DNA sequencing. 
 The cDNA encoding full-length human Scribble gene with a cytosolic mutation in 
the LRR domain (P305L) was obtained from AddGene (plasmid #24601). The proline 
was restored by site-directed mutagenesis with custom-made primers (Eurofins) and 
confirmed by DNA sequencing. PCRs with custom-made‎5’-HindIII and either 3’-BamHI 
or 3'-FLAG-BamHI primers were used to amplify full-length wild-type (WT) Scribble 
cDNA from the plasmid, as well as several truncated variants. The PCR products were 
digested with Fast-Digest HindIII and BamHI enzymes (ThermoFisher), and then 
purified by gel extraction. Amplified cDNAs were cloned as described before into either 
parent pcDNA3 or our custom-made pcDNA3-GFP vectors to produce both GFP and 
FLAG C-terminally tagged Scrib constructs. 
 To generate Scrib viral plasmids, the epitope-tagged Scrib variants were sub-
cloned into a modified pCLNCX viral plasmid (Novus Biologicals, here referred to as 
pCLHCX) in which the neomycin resistance gene was swapped for a hygromycin 
resistance gene65, enabling differential selection of mammalian cells for stable 
expression of two genes under hygromycin B and geneticin selections as described 
next. 
  Cell culture, transfection, and development of stable lines. Patient-derived stable 
cell lines were obtained from ATCC and cultured according to published 
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recommendations. Madin-Darby Canine Kidney (MDCK) and MCF10a were a generous 
gift from Dr. Ben Margolis (University of Michigan, Department of Internal Medicine). To 
generate virus encoding the transcriptional repressor Snail, 293T cells were utilized as a 
packaging medium and transfected with 2.5 µg total plasmid DNA comprised of equal 
parts of pVSVG (Clontech) and pGAG/Pol (Cell Biolabs), and pPGS-hSnail-NEO (also 
gifted by Dr. Ben Margolis), a neomycin-selectable plasmid encoding human FLAG-
tagged Snail under the control of a CMV promoter. The medium was changed 24 hours 
post-transfection, harvested 48h post-transfection and filtered through a 0.45 µm filter 
unit fitted to a Luer-lock syringe to remove traces of packaging cells and debris. The 
filtered medium was then supplemented with 8 µg/ml polybrene (Sigma) to increase 
infection of target lines with the virus. The medium was then added to sub-confluent 
MDCK and MCF10a. Cells were allowed to grow to confluency and then passaged in 
medium containing 0.6 mg/ml G418 (Gibco). Following the same protocol described for 
developing Snail lines, epithelial parental lines and their Snail derivatives were 
transduced with pCLHCX containing cDNAs encoding WT, P305L and truncated 
constructs of Scrib. To develop a stable over-expressing line, 48h post-infection, cells 
were passaged in medium containing 150 µg/ml Hygromycin B (Sigma). For transient 
expression studies, 293T or MCF10a cells were cultured in 6 cm-diameter dishes to 
25% confluence. Cells at ~40% confluency were transfected using FugeneHD 
(Promega) according to manufacturer's instructions. Briefly, in sterile 1.5mL conical 
tubes, 2 µg of pcDNA-FLAG and pcDNA-GFP vectors were complexed with 3% v/v 
FugeneHD transfection reagent in a total of 200 µL of Opti-MEM (Gibco) and solution 
was incubated for 15 minutes at room temperature. The mixture was then added to 
Cells which were experimented and harvested 48h post-transfection. 
 siRNA-mediated knockdowns.MCF10a and MDCK cells were seeded into 6 cm-
diameter dishes and grown in their respective complete growth media. Cells at ~50% 
confluency were transfected with predesigned siRNA pools (Dharmacon, ON-
TARGETplus P/N L-010007-00-0005, L-009256-00-0005 and D-001810-10-05) 
according to manufacturer's recommendations (GE Healthcare). Briefly, in sterile 1.5mL 
conical tubes,125nM of siRNA pool was complexed with 1.25% v/v transfection reagent 
(DharmaFECT Dharmacon T-2005) in a total of 800 µL of Opti-MEM (Gibco) and 
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solution was incubated for 5 minutes at room temperature. The mixture was then further 
diluted 5-fold into the appropriate complete growth medium to a final volume of 
4mL.Cells were washed with 1mL of DPBS (Gibco) and transfected with Dahrmafect-
complexed siRNAs (4mL total) and were cultured for 48 before experimentations. 
 EGF stimulation assays. Cells were seeded at 20-25% confluency into 6 cm-
diameter plates and cultured in their respective complete media modified with the 
corresponding dialyzed sera. After 24 hours, the medium was supplemented with final 
concentrations of either 5 µM inhibitor or 0.1% v/v vehicle (DMSO), and cells were 
allowed to grow overnight. The next day, the cells were washed with DPBS (Gibco) and 
cultured in basal medium lacking all supplements for 1-2 hours. Cells were treated with 
either vehicle (DPBS) or 20 ng/mL human recombinant EGF (Shenandoah-BT, P/N 
100-26-AF) for either 5 minutes or up to a 120 minute stimulation time course. Cells 
were washed with DPBS, harvested at designated time points, then immediately lysed 
in 20 g/L SDS and 62.5 mM Tris pH 7.4 lysis buffer to disrupt all enzymatic activity. 
Sample protein concentrations were quantified using the DC protein assay (Bio-Rad) 
and then processed for western blot analysis of target proteins. 
 Immunofluorescence. For live cell imaging, parent and Snail MDCK and MCF10a 
lines stably expressing Scrib variants were grown to sub-confluency and were imaged 
on a Nikon Eclipse TE2000-S inverted microscope customized with laser sources and 
filters appropriate for DAPI, GFP and mCherry fluorescence imaging. For fixed cell 
imaging, MDCK and MCF10a parent and stably-overexpressed Snail lines were plated 
onto glass coverslips, placed into 12-well plates and treated overnight with either DMSO 
vehicle or indicated final concentrations of inhibitors at 0.1% v/v final DMSO 
concentration. The following day, confluent cells were fixed with ice cold methanol for 
10 minutes, followed by a 1 minute wash with ice cold 100% acetone. Coverslips were 
washed once with PBS, then incubated with gentle agitation in SuperBlock 
(ThermoScientific, P/N 37515) for 15 minutes. Coverslips were then incubated for at 
least 24 hours at 4 oC in primary antibody solutions containing species-controlled 
combinations of the following antibodies in PBS supplemented with 0.3% v/v Triton X-
100 (PBST): goat-anti-Scribble (SCBT, P/N sc1149) diluted 1:200, mouse-anti-N-
cadherin (BD Bioscience, P/N 10920) diluted 1:250 and mouse-anti-E-cadherin (BD 
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Bioscience, P/N 610181) diluted 1:250. After primary antibody incubation, coverslips 
were washed 3 times for 5 minutes each in PBST. The coverslips were then incubated 
in species-matched, species-controlled AlexaFluor secondaries diluted in PBST for an 
additional hour at room temperature, protected from light. The coverslips were then 
washed, stained with DAPI, and washed an additional two times before mounting onto 
slides with Fluoromount (Sigma, P/N F4680). Images were obtained using the above 
Nikon epifluorescent microscope. 
 High-content fluorescence imaging microscopy. Cells were plated at identical 
conditions as described above onto either 384-well or 96-well PerkinElmer ViewPlates 
using sterile cassettes of a Thermo MultiDrop Dispenser. APT1 and APT2 inhibitors 
were titrated and diluted in complete medium with dialyzed serum before adding to sub-
confluent cells using either MultiDrop Dispenser or automated program on a Rainin 
Multichannel pipettor. Cells were fixed after inhibitor incubation with either cold 
methanol/acetone as described above, or with 4% PFA supplemented with 1% Triton X-
100 in PBS to permeabilize samples for staining. Immunofluorescence was performed 
as described above, with the exception of the mounting step. In the multi-well plates, 
PBS was added to half the volume of the well before imaging. Automated imaging was 
performed on the Molecular Devices ImageXpress Micro XLS High-Content Analysis 
System. 3-5 pre-defined regions per well were imaged and quantified using a custom 
MetaXpress analysis module that defined cell boundaries one of two ways: (1) First a 
cell-scoring watershed algorithm was used to identify cell boundaries by specifying 
individual cells based on the correspondence of their nuclear DAPI signal with a 
diffusive positive cell marker. For Snail cells, this diffusive marker was defined as that 
originating from the cytosolic Scrib signal recorded by the AlexaFluor 488 secondary. 
The cell boundary thickness was defined by standard graphical grow and shrink logical 
operations which set this value between 2-5µm to effectively account for Scrib cell 
perimeter colocalization. All positive Scrib signals were thresholded  based on vehicle-
treated wells such that any pixel value intensity that fell below the noise and above the 
saturation level were set to 0 while all remaining pixel values were given a value of 1. 
Thus, total Scrib signal and fractional cytosolic and membrane quantities were 
calculated per cell, averaged across cells per condition and errors were computed as 
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the standard deviations of the mean values. The membrane fraction values calculated 
for vehicle-treated cells were defined as the basal value for statistical comparisons to 
compound-treated or knock-down cells. (2) We also quantified Scrib signal at the 
membrane by measuring co-localization with a membrane-bound protein, although this 
initially presented some challenges because the expression and localization of so many 
proteins are heavily altered upon Snail induction. Using un-enriched SILAC proteomics 
to compare protein abundances between empty vector (EV) and Snail cell lines, we 
found the membrane-bound Na+/K++ ATPase‎pump‎α-1 subunit did not change in 
expression levels after EMT induction (data not shown). The monoclonal mouse 
antibody directed to this subunit (Millipore, P/N 05-369) was used at 1:500 in PBST for 
immunofluorescence in combination with goat-anti-Scrib and DAPI. Co-localization of 
Scrib with ATPase was obtained by measuring the overlap of their corresponding 
thresholded values which were generated as described earlier. Data obtained from 
these two separate analytical workflows were pooled and imported into GraphPad Prism 
6 for nonlinear regression analysis. Scrib membrane fraction was plotted as a function 
of Log10 drug concentration to generate a dose-response curve which was fit to the 
following 4-parameter logistic curve: 
              
       
                       
  Equation 5 
Where Fmembrane is defined as the fraction of Scrib's signal at the membrane, min is 
Fmembrane of MDCK-Snail line without drug treatment, max is the limit of Fmembrane as the 
drug concentration approaches infinity, Slope is the steepness associated with the 
dose-response curve and EC50 is the concentration of drug that provokes a response 
halfway between the baseline (min) and maximum response (max). 
 Western blot analyses. Frozen cell pellets collected from confluent plates were 
resuspended in PBS (Gibco), and then lysed by ultrasonic cavitation with a sonicator 
probe. The protein concentrations were determined by the DC protein assay (Bio-Rad), 
and for each sample processed, 15-25 µg of protein was separated by SDS-PAGE on 
home-made66 8% or 12% polyacrylamide gels for 1 hour at 180V. The proteins were 
then transferred to a methanol-activated PVDF membrane (Millipore) for 2 hours at 
75V67. After complete transfer, the membrane was blocked with 50 g/L of either non-fat 
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Milk of BSA (Fisher) in Tris-buffered saline supplemented with 0.5% v/v Tween20 
(TBST) for 1 hour at room temperature. The membranes were then incubated overnight 
on a rotisserie at 4 oC with the following primary antibody solutions prepared in TBST 
supplemented with 50 g/L of either milk or BSA according to manufacturer's 
recommendations: Mouse-anti-Scribble (Millipore, P/N MAB1820) diluted 1:500, mouse-
anti-E-cadherin (BD Bioscience, P/N 610181) diluted 1:5000, mouse-anti-αTubulin 
(Sigma, P/N T6074) diluted 1:2000, mouse-anti-FLAG M2 (Sigma, P/N F1804) diluted to 
1:5000, rabbit-anti-LYPLA2 (Pierce, P/N PA5-27653) diluted 1:500, rabbit-anti-
p259.Raf1 (Cell Signaling Tech., P/N 4694) diluted 1:500, rabbit-anti-p338.Raf1(Cell 
Signaling Tech., P/N 9427) diluted 1:500, mouse-anti-panRas (Millipore, P/N 50-171-
675) diluted 1:1000, mouse-anti-Mek1/2 (Cell Signaling Tech., P/N 4694) diluted 1:500 
and rabbit-anti-pMek1/2 (Cell Signaling Tech., P/N 9154) diluted 1:500. Membranes 
were washed thrice with TBST and blots were incubated with appropriate TBST 
solutions of goat and donkey AlexaFluor fluorescent secondary antibodies 
(ThermoFisher) diluted according to manufacturer's recommendations. The blots were 
washed thrice then scanned on a Typhoon Phosphoimager (GE Healthcare) using 
488nm, 532nm, 633nm excitation laser and appropriate emission filters. 
 Acyl-Biotin Exchange. Overexpressed or compound-treated cells were lysed and 
quantified at high proteome concentrations, then whole cell proteomes were diluted to 5 
mg/mL in 40 g/L final SDS in DPBS with a resulting pH around 6. Proteins were 
alkylated with 50 mM final N-ethyl maleimide for 2 hours at room temperature with 
rotation, then excess NEM was methanol-chloroform extracted and thoroughly washed 
with methanol before proceeding. Samples were re-suspended in DPBS and thioesters 
were cleaved by boiling samples at 95 oC for 5 minutes in the presence of either 
neutralized NH2OH (+, 500 mM final) or NaCl (-, 500 mM final). Both + and - samples 
were immediately extracted by methanol-chloroform, thoroughly washed with methanol, 
then resuspended in 20 g/L SDS in DPBS and reacted with 200 µM final biotin-PEG-
maleimide probe (Click Chemistry Tools) to capture newly-liberated thiols. Samples 
were incubated with the probe for 90 minutes at room temperature with end-over-end 
rotation before the final methanol-chloroform precipitation to remove excess probe, then 
resuspended in 10 g/L SDS w/v in DPBS and quantified. 40-60ug of proteome from 
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each sample was saved for loading onto one or two lanes of denaturing polyacrylamide 
gels. 0.5-1 mg/mL of proteomes were then combined with 20uL of streptavidin agarose 
(Millipore) in 200 µL final of 2.5 g/L SDS in DPBS and the suspensions were incubated 
for 90 minutes at room temperature with end-over-end rotation. The resin was washed 
with 200 µL of 2 g/L SDS in DPBS 4 times and then with 200 µL of DPBS twice. The 
resin was resuspended in 2 resin volumes of 1x Laemmli sample buffer and boiled for 
10 minutes at 95 oC to denature and elute proteins off the resin. The samples were 
spun down at 2000 rcf for 30 seconds, the supernatants were loaded on homemade 8% 
and 12% denaturing polyacrylamide gels for SDS-PAGE separation and western blot 
analysis. 
 qRT-PCR measurements. Total RNA was extracted from parental and Snail 
MCF10a cell lines using Trizol reagent (Invitrogen) according to manufacturer's 
recommendations. Equal amounts of only high-quality RNA template were reverse-
transcribed using iScriptTM Advanced cDNA Synthesis Kit (Bio-Rad), and equal 
volumes of cDNAs were loaded onto a customized 96-well qPCR plates containing 
Prime PCR Assay primers to genes of interest (Bio-Rad). SsoAdvanced Universal 
SYBR Green Supermix (Bio-Rad) was used for qPCR amplification. All samples were 
run as three biological replicates, each analyzed in triplicate. qPCR reactions were 
measured on a StepOne Plus instrument (Applied Biosystems) using SYBR Green 
detection. Baselines, thresholds, and Ct values were computed according to Applied 
Biosystems recommendations. All cycle threshold (Ct) values were normalized to that of 
the ß-actin housekeeping gene expression, which protein levels were found to be 
identical between parent and Snail lines. The relative expression level for each gene of 
interest was determined using the 2-ΔΔ-CT method
68, and all transcript fold-changes were 
calculated relative to the parent line. 
 17ODYA-enriched proteomic sample preparation. Stable isotopic labeling of 
amino acids in cell culture (SILAC) proteomics was used to measure palmitoylation 
changes upon induction of EMT with the oncogene Snail. Briefly, heavy and light 
isotopically-labeled MCF10a parent and Snail cells were generated by 10 sequential 
passages in SILAC DMEM-F12 complete growth media prepared from basal 
DMEM:F12 deficient in both L-lysine and L-arginine (Thermo, P/N 88215) supplemented 
153 
 
with 5% v/v dialyzed horse serum (Valley Biomedical, P/N NC9739549), 20 ng/mL 
recombinant human EGF (Shenandoah-BT, P/N 100-26AF), 0.5 mg/L cortisol (Sigma, 
P/N H0888), 0.1 mg/L CTX (Sigma, P/N C8052), 10 mg/L insulin (Gibco, P/N12585) and 
1X pen-strep (Gibco, P/N 15140). Isotopic heavy and light lysine and arginine amino 
acids were then added to a final concentration of 100 mg/mL to generate SILAC-light 
and SILAC-heavy media, respectively. Sub-confluent 15 cm-diameter plates for each 
cell line were treated overnight with compounds directed against APT1 and APT269. The 
following day, near-confluent cells were incubated with 20 µM final of the alkyne fatty 
acid 17-octadecynoic acid (17-ODYA, Cayman Chemical, N/P 90270) for 6 hours. Cells 
were then washed in DPBS, harvested and lysed by sonication in DPBS supplemented 
with 1 µM HDFP. Samples were fractionated by ultracentrifugation at 100,000 x g at 4 
0C, the supernatant was discarded and the insoluble fraction was resolubilized by 
sonication in DPBS. Protein concentrations were measure using the DC protein assay 
(Bio-Rad) and isotopic lysates were combined 1:1 molar ratio in both heavy and light 
directions, i.e. heavy(EV):light(Snail) and heavy(Snail):light(EV). Samples were diluted 
in PBS and then reacted at 5 mg/mL with the following Click reagents: 1mM final copper 
sulfate, 1mM tris(2-carboxyethyl)phosphine (TCEP, Sigma, N/P 93284), 17uM final 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, Sigma, N/P 678937) ligand, 
and 500 µM final biotin-azide70. Samples were incubated with agitation for 1 hour at 
room temperature, then proteins were methanol-chloroform extracted71 to remove 
unreacted Click reagents. Proteins were resuspended to 1 mg/mL in 2 g/L SDS in 
DPBS with 6 M urea (2SB). Disulfides were reduced with 10 mM final neutralized TCEP, 
then liberated thiols were capped by alkylation with 50 mM N-ethyl-maleimide (NEM). 
SILAC pairs were then diluted 10-fold in (2SB) and 10% final volume of pre-washed 
streptavidin resin was added to each tube, followed by 1 hour of end-over-end rotation 
at room temperature. The resin was then washed twice with 10 resin volumes of 2SB 
and four additional washes with 10 resin volumes of PBS to eliminate SDS. Cleared 
resin was resuspended in 2 M urea, 25 mM ammonium bicarbonate, 100mM CaCl2, 
and 1ug of sequencing-grade Trypsin (Promega) per 1mg total proteome starting 
material. The samples were moved to a shaker at 37C for 4 hours. The resin and two 
additional resin washes were pelleted and supernatants were lyophilized on a Savant 
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SpeedVac concentrator before being resuspended in LCMS buffer containing mass 
spectrometry-grade 5-20 fmol alcohol dehydrogenase (ADH, Waters, P/N 186002328) 
20 mM ammonium bicarbonate (Sigma), 3% v/v acetonitrile, 0.1 % v/v formic acid, pH 
10. 
 Serine hydrolase-enriched proteomic sample preparation. The serine hydrolase 
profiles of MCF10a parent and Snail lines were measured by using FP-PEG-Biotin 
activity-based probe to enrich enzymes across SILAC-generated cell lines as described 
previously70. SILAC lines were made as described earlier and cells were seeded into 15 
cm-diameter plates. Confluent cell dishes were washed with DPBS and harvested into 
1.5mL conical tubes. Cell pellets were lysed in DPBS by ultrasonication and protein 
concentrations were measured by the DC protein assay (Bio-Rad). Isotopic proteome 
pairs of EV and Snail lines were combined in 1:1 molar ratio to yield 1mL of 1 mg/mL 
proteome which was reacted with 5µM FP-PEG-biotin for 1 hour at room temperature 
with agitation. The proteome was then chloroform-methanol extracted thoroughly to 
remove excess free probe and the precipitate was resolubilized in 1mL 10g/L SDS in 
DPBS. Proteome was diluted further in DPBS to a final SDS concentration of 1 g/L 
before mixing with 100uL of streptavidin agarose for biotin enrichment. The subsequent 
washes, Trypsinization, and clean-up steps were all performed as described above for 
the 17ODYA-enriched proteomic sample prep.    
 Mass Spectrometry and Data Analysis. Tryptic digests were separated using a 
Waters‎NanoAcquity‎UPLC‎system‎equipped‎with‎a‎5‎μm‎Symmetry‎C18 (180‎μm‎×‎20‎
mm)‎trap‎column‎and‎a‎1.8‎μm‎high-strength silica (HSS-T3)‎analytical‎column‎(75‎μm‎×‎
150 mm) heated to 35 °C coupled to a picotip emitter (New Objective). Tryptic peptides 
were loaded onto the trap column over 3 min, followed by analytical separation over a 
90 min gradient (3% ACN to 40% ACN over 90 min). Peptides were analyzed using a 
Waters Synapt G2S HDMS time-of-flight mass spectrometer with ion mobility separation 
and data independent fragmentation algorithms. The quadruple mass analyzer was 
manually set for mass 500, 600, and 700. The sampling cone was adjusted to 32 eV, 
and the nano flow gas was set to flow at 0.2 bar. The purge gas was set to flow at 50 
L/h, and the source temperature was set at 70 °C. For all measurements, the mass 
spectrometer was operated in V-mode (resolution mode) with a resolving power of at 
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least‎20 000‎fwhm‎(full‎width‎at‎half-maximum) in positive-mode ESI. The time-of-flight 
analyzer‎of‎the‎mass‎spectrometer‎was‎calibrated‎with‎a‎100‎fmol/μL‎solution‎of‎[Glu1]-
fibrinopeptide B from m/z 50–1250 to within 0.5 ppm. The data were corrected in 
postacquisition analysis using the doubly charged monoisotopic ion of [Glu1]-
fibrinopeptide B (m/z = 785.8426) collected every 30 s from a separate calibrant fluidics 
source coupled to a tapertip emitter (New Objective). Accurate mass data were 
collected in data-independent acquisition (DIA) mode in combination with in-line ion 
mobility separation (IMS). For IMS, the wave height was set as 40 V and IMS wave 
velocity as 600 m/s. The spectral acquisition time in each mode was 0.5 s. In low-
energy MS mode, data were collected without applying collision energy in the trap or the 
transfer stage. A collision energy (CE) ramp from 15–45 eV during each 0.5 s 
integration was used as standard setting for the elevated energy MS scan in the transfer 
region for HDMSE mode. LC–MS spectra were collected in continuum mode and 
searched using the ProteinLynx Global SERVER version 3.0.2 (Waters) against the 
reviewed human reference proteome (UniProtKB downloaded on 2014–08–01). 
Precursor- and fragment-ion mass tolerances were automatically determined by PLGS 
3.0.2 based on the following search criteria: (i) trypsin as digestion enzyme, (ii) a 
maximum of one missed cleavage, (iii) lysine (+8) or arginine (+10) defined as fixed 
modifier reagent group, (iv) carbamidomethyl cysteine as a fixed modification and 
methionine oxidation as the variable modification, (v) a minimum of two identified 
fragment ions per peptide and a minimum of five fragments per protein, and (vi) at least 
two identified peptides/protein. The false discovery rate (FDR) for peptide and protein 
identification was set at 1% using a reversed database. By using in-house Python 
scripts, all data from technical and biological replicates were merged by removing any 
precursors greater than ± 10 ppm in mass difference from the calculated theoretical 
mass. SILAC ratios were computed based on MS1 intensities of the SILAC precursor 
pairs. All reported ratios in the manuscript are consolidated ratios from runs in each 
direction and from merging technical replicates. 
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4.4 Results 
 Scrib membrane localization correlates with hyper-activated MAPK pathway in 
metastatic cancer lines. Scrib’s‎cytoplasmic‎localization‎is‎prevalent‎in‎progressive,‎
malignant carcinomas, particularly those already initiating a full-fledged EMT program. 
As‎such,‎we‎sought‎to‎develop‎and‎investigate‎cell‎lines‎that‎model‎Scrib’s‎cellular‎
localization before and after induction of EMT. We first profiled a number of patient-
derived, stable cell lines to assess their level of malignancy and their degree of Scrib 
mislocalization. We expected an inverse correlation between metastatic potential and 
the expression of E-cadherin (E-cad), a cell adhesion protein indicative of differentiated 
epithelia.72 Aggressive cancers typically show complete loss of E-cad, although its loss 
is not universally correlated across all cancer EMT lines.73 The more differentiated, 
benign cell lines like SW1990 and MCF10a showed strong co-localization of E-cad and 
Scrib at the plasma membrane. More aggressive lines like MDA-MB-231 and OVCAR3 
expressed virtually no E-cad, and Scrib expression appeared predominantly cytosolic. 
Interestingly, the mutant KRas-driven metastatic Panc1 line74 is positive for E-cad, but 
exhibits Scrib localization that is diffuse within the cytosol. Thus, Panc1 line 
demonstrates that Scrib membrane targeting is independent of E-cad expression 
(Figure 4-1A) and hence other perturbations during EMT are likely to account for its 
localization. 
 Madin-Darby Canine Kidney (MDCK) and MCF10a human breast epithelial cell 
lines were chosen for further examination of EMT-induced changes due to their defined 
epithelial morphology and the ability to resolve, by immunofluorescence, whether Scrib 
is localized at the membrane or cytosol. Corresponding EMT cell models were 
generated through stable overexpression of the oncogenic transcription factor Snail.75 
Snail expression positively correlates with activation of epigenetic circuits involved in 
EMT76, namely the transcriptional repression of E-cad, and causes cells to adopt a 
mesenchymal-like morphology with signatures of late-stage malignant tumors77. After 
selection in G418, the resulting empty vector (EV) control and Snail lines were analyzed 
for E-cad and Scrib expression and cellular localization. MDCK and MCF10a EV lines 
expressed high levels of E-cad, which co-localized with Scrib at the cell peripheries. 
MDCK-Snail and MCF10a-Snail lines exhibited pronounced spindle-like morphology 
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and showed a complete loss of E-cad expression, confirming initiation of the EMT 
program. Importantly, Snail cells displayed a redistribution of Scrib from the membrane 
to the cytosol, while overall expression levels decreased only slightly (Figure 4-1B and 
C). 
 Mislocalization of Scrib in metastatic cancers is frequently accompanied by 
hyperactivation of growth pathways, namely the MAPK cascade27. We therefore aimed 
to compare specific nodes of activation and de-activation before and after EMT to 
confirm that these cell models could recapitulate the scenario observed in malignancy. 
The signal intensity and duration of several MAPK components were assessed in Snail 
and EV-derived lines by a serum starvation period followed by brief stimulation with 
EGF to trigger the MAPK cascade. In all EV lines examined, EGF treatment resulted in 
little to no detectable levels of pMEK1/2 (S217/S221) and pS338-RAF1. In contrast, the 
Snail lines were much more responsive to EGF, exhibiting about 3- and 5-fold 
enhancement in active RAF1, and MEK1/2 levels after stimulation (Figure 4-1D). These 
observations may be attributed to changes in gene expression induced by EMT, leading 
to upregulation of activators (e.g. SHOC2) or downregulation of repressors of MAPK. 
Both EMT lines interestingly displayed overall reductions in total Ras expression as 
detected with pan-Ras antibody, in spite of enhanced EGF-response of its downstream 
effectors. This result supports the idea of a Snail transcriptional program that silences 
the expression of MAPK-antagonizers, rendering the cascade increasingly excitable.  
 Scrib has been shown to suppress MAPK by directly interacting with ERK via two 
highly conserved kinase interaction motif (KIM) docking sites.78,79 This association is 
necessary for ERK-mediated phosphorylation of two distinct serine residues of Scrib, 
one of which is located within Scrib's second PDZ domain (PDZ-2)80. We found a 
commercial monoclonal antibody raised against Scrib PDZ-2 to be highly sensitive to 
chemical modifications within this target antigenic epitope, and therefore could serve as 
a reporter of any dynamic changes specific to this domain, such as its phosphorylation 
state. To establish whether a link may exist between MAPK hyperactivation and mis-
regulation of Scrib in EMT, we use this antibody to monitor EGF-induced 
posttranslational changes in Scrib's PDZ-2 in the  
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Figure 4-1 Cell models of EMT show a common theme where Scrib cytoplasmic localization 
coincides with elevated MAPK activation. 
a. Immunofluorescnece analysis of patient-derived stable cell lines show correlation between 
increasing metastatic markers and Scrib localization. 
b. Snail-induced EMT program in model epithelial cells results in predominant cytoplasmic 
relocalization of the polarity tumor suppressor Scrib. 
c. EMT changes induce a marked decrease in overall Ras isoforms but not Scrib levels. Ras protein 
expression level was probed by a pan H-, N- and K-Ras4B monoclonal antibody.   
d. Snail EMT program results in increased MAPK output signified by elevated MEK1/2, CRAF 
activities in MDCK-pPGS/Snail. 
e. MCF10a-pPGS/Snail EGF stimulation time course also displays enhanced MAPK signaling 
accompanied by concomitant post-translational modification of Scrib's second PDZ domain. 
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background of a MEK1/2 stimulation time course. As expected, EGF treatment of 
serum-starved MCF10a-EV cells did not elicit detectable levels of phosphorylated 
MEK1/2; however, a stable signal was observed for Scrib PDZ-2, indicating that this 
domain was not modified in response to EGF in these cells. On the other hand, EGF-
stimulated MCF10a-Snail cells exhibited MEK1/2 activity throughout the time course, 
with phosphorylation detectable between 5 to 30 minutes post treatment. Interestingly, 
the Snail line also demonstrated corresponding time-dependent changes in the Scrib 
phosphorylation, which disappeared completely at the peak of MEK1/2 activation and 
returned as MEK1/2 activation plateaued to basal levels (Figure 4-1E). Importantly, the 
interplay observed between PDZ-2 and MEK1/2 occurs only after Snail-induced 
malignancy, suggesting that the cellular response to EGF changes significantly upon in 
EMT, when Scrib is in the cytosol. Mis-localization of Scrib to the cytosol creates a 
dominant-negative‎effect,‎where‎this‎protein’s‎ability‎to‎repress‎MAPK‎is‎lost‎in‎
malignant cells. This is reasonable, since the MAPK cascade affects the activation of 
Snail family transcription factors81, and EMT is thought to exploit this signaling pathway 
to abolish growth suppression. 
 Scrib is palmitoylated and requires this PTM for membrane localization and 
tumor suppressor function. Scrib is a member of the leucine rich repeat (LRR) and 
PSD95/DLG1/ZO1 (PDZ)  family of proteins, also known as LAP proteins, which 
includes three additional members, Lano, Densin and Erbin (Figure 4-2A).82,83 This 
multi-functional family of scaffolds is characterized by sixteen N-terminal LRRs and four 
C-terminal PDZ domains, which account for over a dozen combinatorial protein-protein 
interactions involved in a plethora of physiological activities.84,85 Multiple sequence 
alignments of the N-terminal region upstream of the first LRR display significant 
sequence homology, highlighting conserved residues that may be functionally important 
for LAP proteins (Figure 4-2A). Erbin and Densin both require palmitoylation of their N-
terminal cysteine residues for proper membrane targeting and function.86,87 N-terminal 
S-palmitoylation of the close relative Scrib, however, has not been biochemically 
verified, although the Scrib protein has appeared in a number of palmitoylation 
proteomic data sets.70,88 To test whether Scrib N-terminus was essential for its 
membrane association, we generated plasmids encoding wild type Scrib (WT) along 
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with the known cytosolic LRR point-mutant (P305L)89, and a truncated variant missing 
the first 22 residues (Δ22) containing the three N-terminal cysteine residues C4, C10 
and C22, the first two of which being the hypothetical palmitoylation sites based on 
sequence homology with Erbin and Densin (Figure 4-2A). GFP-tagged Scrib variants 
were transfected into both MDCK and MCF10a EV cells, and in vivo localization of 
variants were assessed by fluorescence microscopy. WT appeared predominantly at 
cell membranes and faintly within the cytosol, while the P305L and Δ22 mutants were 
located entirely within the cytosol (Figure 4-2B), suggesting the N-terminus of Scrib is 
required for membrane-localization. 
 
Figure 4-2 Scrib is palmitoylated, which is required for proper membrane localization and tumor 
suppressor function in epithelial cell models. 
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a. Multiple sequence alignment and modular domain organization of LAP family members highlight 
additional conserve regions upstream of LRR domain suggesting that N-terminal cysteines of 
Scrib are palmitoylated in vivo. 
b. GFP-tagged Scrib variants demonstrate that both N-terminus and intact LRR are required for 
proper membrane localization in MDCK and MCF10a. 
c. GFP-tagged Scrib variants show that both N-terminus and intact LRR are required for 
palmitoylation. ABE shows loss of palmitoylation in Δ22.Scrib-GFP compared to wild-type. 
d. Transiently expressed cytoplasmic Scrib variants lead to increased cell proliferation in MCF10a 
cells corroborated by various studies of cytosolic Scrib mutants. Cell proliferation was measured 
via the WST-1 assay (ref) which correlates the light absorbance of the WST1 probe to the 
approximate density of cells present in the dish, hence the A440nm-A750nm measurement. 
 
 To test whether Scrib was palmitoylated and determine if the first 22 residues 
contained the sites of this‎PTM,‎we‎transfected‎WT‎and‎Δ22‎GFP‎variants‎into‎HEK-
293T cells and assessed their palmitoylation levels using a modified acyl-biotin 
exchange protocol71. After cell lysis, free thiols were alkylated with N-ethylmaleimide 
(NEM), followed by hydrolysis of thioester-linked fatty acids with hydroxylamine 
(NH2OH). Newly liberated thiols can then be captured with an NEM-functionalized biotin 
probe and enriched on streptavidin agarose. In the absence of NH2OH, the 
thioesterified proteins are left intact and therefore not enriched in the process. This 
control condition was used to account for non-specific biotin labeling and streptavidin 
binding during enrichment. Both (+) and (-) NH2OH samples were reacted with the 
maleimide-biotin affinity probe, and all newly-generated free thiols in the NH2OH 
treatment were captured by streptavidin agarose. The attached proteins were eluted off 
in strongly denaturing SDS loading buffer and loaded on SDS-PAGE for analysis by 
western blot. Only WT and not Δ22 Scrib was seen in the elution with NH2OH, 
suggesting the N-terminus of Scrib is required for palmitoylation (Figure 4-2C). 
 Many reports cite that mislocalized Scrib can enhance tumorigenesis by 
activating growth signals of the Akt/mTOR/S6K and MAPK pathways.39,90–92 We 
assessed whether introduction of our cytosolic Scrib mutants in a benign cell line like 
MCF10a was sufficient to replicate the growth phenotypes of malignant cancers. 
MCF10a cells were transiently transfected with GFP constructs expressing WT, P305L, 
or‎Δ22‎Scrib‎variants.‎The‎cytosolic‎Scrib‎variants‎significantly‎accelerated‎MCF10a‎
proliferation as measured by WST1 metabolic assay, while growth of cells expressing 
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the WT protein did not change compared to empty vector transfection control (Figure 4-
2D).  
 Snail-induced EMT alters palmitoylation machinery in favor of thioester 
hydrolysis. A large number of signaling proteins undergo post-translational modification 
by reversible palmitoylation, which fundamentally contributes to their cellular activity.93–
96 
 
Figure 4-3 Snail-induced EMT causes a transcriptional imbalance in the expression of the 
palmitoylation machinery. 
a. qPCR demonstrates that DHHC expression decreased across the board in MCF10a 
b. qPCR suggests that APT1 and 2 transcripts are elevated in MCF10a-Snail 
c. Potentially elevated serine hydrolases upon Snail induction are confirmed by ABPP SILAC in 
MCF10a proteomics. 
d. 17ODYA-enriched proteomics reveals a decrease in steady-state palmitoylation of Scrib 
in MCF10a-Snail. 
e. Model by which Scrib palmitoylation may have decreased in malignant cancer cells 
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These dynamic palmitoylation events demand an exquisitely tuned cycle of de-
palmitoylation/re-palmitoylation, allowing the protein to localize appropriately during the 
course of signal transmission.59 Indeed, disrupted palmitoylation dynamics in Ras 
isoforms have been shown to alter MAPK signal transduction.97,98 We therefore 
conjectured that EMT programs may distort palmitoylation equilibrium by biasing the 
expression profile of the palmitoylation machinery and in turn drive Scrib off the 
membrane. To test this hypothesis in the Snail-induced model, we determined the 
relative expression levels of enzymes that make up this so-called machinery. We first 
performed a quantitative real-time PCR measurement of all human PATs (ZDHHC1-9 
and 11-24) and APTs 1 and 2 in MCF10a cells before and after induction of EMT. We 
found that in MCF10a-Snail, nearly all DHHC mRNAs were reduced in expression, most 
drastically DHHC23, which exhibited a near 8-fold reduction when compared to 
MCF10a-EV (Figure 4-3A). Conversely, MCF10a-Snail cells showed elevated 
expression of APT1 (1.2 fold increase) and APT2 (2 fold increase), contrasting with the 
overall trend observed with DHHC PATs (Figure 4-3B). 
 To determine whether APTs were also upregulated on the protein (activity) level, 
we applied an activity-based proteomics approach combined with stable isotopic 
labeling of amino acids in cells (SILAC)70,99 to profile and compare the expression levels 
of serine hydrolases between EV and Snail derived MCF10a lines. Changes in protein 
levels of APT1 and 2 were in remarkable agreement with corresponding changes 
mRNA levels, with both measurements showing a 1.2 and 2-fold increase in MCF10a-
Snail APT1 and 2 levels, respectively (Figure 4-3C). Our data demonstrate that while 
PATs may be downregulated in EMT, APTs are certainly upregulated, confirming an 
oncogenic role for these thioesterases100 similar to other serine hydrolases from the 
superfamily to which these enzymes belong101,102. These results also suggest that 
Scrib’s‎cytosolic‎redistribution‎and‎loss‎of‎tumor‎suppressor‎function‎in‎metastatic‎
cancers could be due to changes in the overall protein expression of opposing 
enzymatic palmitoylation machineries (Figure 4-3E). 
 Acyl-protein Thioesterase 2 inhibition restores palmitoylation of Scrib and 
attenuates MAPK in Snail-induced EMT models. Earlier work in malignant T cell 
hybridomas showed that inhibiting thioesterase activity with the non-selective lipase 
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inhibitor hexadecylfluorophosphonate (HDFP) caused a marked stabilization in the 
palmitoylation levels of numerous key signaling proteins including Ras isoforms and 
Scrib.70 Since the EMT program likely distorts palmitoylation equilibrium in favor of 
hydrolysis, we theorized that inhibitors of acyl protein thioesterases may be used to 
restore the balance by increasing the steady-state fraction of palmitoylated proteins. To 
test this hypothesis, we chose to use previously reported isoform-selective APT1 and 2 
inhibitors69 which would aid in parsing out the contributions from each enzyme to 
thioester hydrolysis of particular palmitoylated substrates. EV and Snail-derived 
MCF10a cultures were treated overnight with either vehicle (DMSO) or the APT2 
inhibitor ML349 and the steady-state palmitoylation levels of both Ras isoforms and 
Scrib were assayed by ABE. The vehicle-treated samples showed that Scrib was 
indeed less palmitoylated after Snail-induction (Figure 4-4A), corroborating our 
proteomics findings that were obtained orthogonally by the 17ODYA SILAC proteomics 
approach (Figure 4-3D). On the other hand, even though Ras isoforms protein levels 
decreased in the Snail line, the fraction of palmitoylated Ras remained proportional to 
the levels observed in the EV line (Figure 4-3D and Figure 4-4A). This suggested that a 
higher steady-state fraction of Ras molecules were more palmitoylated post EMT. 
Importantly, small molecule inhibition of APT2 in both EV and Snail lines led to a 2- and 
4-fold increase in palmitoylated Scrib, whereas Ras palmitoylation levels did not change 
significantly (Figure 4-4B). Thus, Scrib, and not Ras, steady-state palmitoylation fraction 
declines in our Snail model, and selective inhibition of APT2 activity can boost 
palmitoylated Scrib levels even after EMT. 
 Our ABE data supported the notion that EMT induces a hyper-active MAPK via 
dysregulated Scrib palmitoylation, therefore, we were eager to perform phenotypic 
assays to confirm that disrupted palmitoylation was indeed responsible for Scrib's 
mislocalization and function. EV and Snail induced MDCK lines were treated overnight 
with either vehicle, the APT1-selective inhibitor ML348 or ML349, fixed onto coverslips 
and immunostained to ascertain Scrib membrane localization. As demonstrated by the 
fluorescence microscopy images, small molecule inhibition of APT2, but not APT1, led 
to a noticeable increase in Scrib membrane signal in MDCK-Snail cells (Figure 4-4C). 
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Thus, it appears that APT2 is a physiologically-relevant depalmitoylase of Scrib that is 
transcriptionally upregulated in EMT to force Scrib off the membrane. 
 The qualitative nature of our microscopy results prompted us to employ a more 
quantitative approach to accurately confirm that Scrib was in fact membrane targeted in 
a ML349 dose-dependent manner. To this end, we developed a high-content analysis-
based microscopy protocol that combines powerful measurement statistics with a more 
detailed criterion for measuring membrane-localized Scrib (Figure 4-4D). Namely, cell 
monolayers fixed onto 384-well plates are first immunostained with Scrib, a stable 
plasma membrane marker (Na+/K+ ATPase) and the nuclear dye DAPI. Unbiased high 
resolution, near-confocal images are then captured by an automated microscope. Our 
custom-designed analytical modules then process these fluorescent images, by 
counting the cells and defining their boundaries using the appropriate fluorescent 
signals. The Scrib fraction at the membrane is then defined as the membrane marker- 
 
Figure 4-4 Small molecule targeting of APT2 enhances Scrib but not Ras palmitoylation leading to 
MAPK attenuation in snail-induced EMT models. 
a. APT2 inhibitor enhances Scrib palmitoylation as assayed by ABE in MCF10a EV and Snail lines. 
b. Densitometric quantitation of ABE results demonstrate APT2-inhibitor rescue of Scrib but not Ras 
palmitoylation in MCF10a-Snail. 
c. APT2 inhibitor treatment enhances Scrib membrane-localization as judged by pronounced 
immunofluorescence signals at the cell peripheries compared to vehicle treatment. 
d. High-content screen-based membrane localization workflow in MDCK cells. 
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e. EC50 quantitation of ML349 dose-dependent induction of Scrib membrane re-localization. Error 
bars represent standard deviations across all cell measurements. Asterisks indicate statistically 
significant (p<0.05) membrane relocalization responses between the two compound treatment 
groups as revealed by the analysis of variance statistical test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
f. siRNA mediated APT2 knockdown validated by immunoblotting in EV and Snail-derived MDCK 
cell lines. 
g. APT2 knockdown in MDCK-Snail rescues Scrib palmitoylation. 
h. APT2 inhibitor ablates RAF1 and MEK1/2 activation in MDCK-Snail. 
i. APT2 inhibitor ablates RAF1 and MEK1/2 activation in MCF10a-Snail 
j. APT2 knockdown attenuates MEK1/2 activation time course in MCF10a. 
k. Quantitiation of (j) clearly showing shortened MEK1/2 activity duration with APT2 KD. 
l. Validated APT2 knockdown in MCF10a-Snail attenuates RAF1 abrogates MEK1/2 activities. 
 
colocalized Scrib signal divided by the total Scrib signal per cell. Our typical workflow for 
each inhibitor concentration employed consisted of 3 well-replicates, each capturing 5 
views per well with every image containing a thousand cell measurements on average. 
In turn, this systematic approach permits the accurate and precise measurement of 
Scrib membrane re-targeting by small-molecule inhibition of APTs in our EMT-model. 
 We then subjected EV and Snail-derived MDCK lines to our high-content 
analysis by culturing monolayers in 384-well plates in the presence of increasing 
inhibitor concentrations and measuring the percent membrane-localized Scrib by our 
custom-built workflow. Our analysis demonstrated that Scrib in MDCK-Snail cells was 
only about 70% membrane localized compared to MDCK-EV and that dose-dependent 
inhibition of APT2 and not APT1, restored membrane-Scrib levels back to that observed 
in EV lines (Figure 4-4E). The induced membrane-relocalization response EC50 for 
ML349 was measured around 2µM concentration of compound which was 10-fold 
L 
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higher than its reported Ki towards APT2
69. Given this drug's highly hydrophobic 
character, it is not unlikely for serum proteins to bind this compound and reduce its 
effective, free cellular concentrations. Nevertheless, to further validate and rule out non-
specific drug interaction that could be associated with ML349 treatment, we chose to 
measure Scrib membrane re-targeting in the presence of siRNA-mediated APT2 
knockdown as well. The knockdown data confirmed the involvement of APT2 in Scrib 
membrane dysregulation (Figure 4-4F and G), highlighting a novel role for this enzyme 
in metastatic transformation. 
 The metastatic transcriptional program induced by snail appears to boost APT2 
activity, which consequently depalmitoylates and releases Scrib from the membrane. 
Given the anti-tumor propensities of membrane-localized Scrib, we speculated whether 
its membrane re-targeting via APT2 inhibition would inhibit the highly-excitable MAPK 
pathway seen in our Snail models. We therefore treated Snail-induced MDCK and 
MCF10a cells with either vehicle, ML348, ML349 or the two published dual APT1/2 
triazole urea-based inhibitors that potently and irreversibly inhibit their targets and 
measured MAPK output in response to EGF stimulation as described previously. In both 
Snail lines, APT2 inhibition by the isoform-selective inhibitor ML349 resulted in a 
pronounced reductions in levels of both active RAF1 and MEK1/2, the downstream 
effectors of Ras. In contrast, the structurally-related ML349-null compound derivative 
showed no or negligible activity with either kinases in both Snail cell lines, suggesting 
that reductions in activated RAF1 and MEK1/2 were not due to off-target drug activities 
(Figure 4-4H and I). Interestingly, in MCF10a-Snail, the APT1-selective ML348 brought 
about similar attenuation in MEK activation in compare to ML349 treatment, suggesting 
a comparable contribution of APT1 to heightened MAPK activity in the MCF10a-Snail 
model. In more support to this mechanism, pretreatment of MDCK-Snail cells with the 
dual covalent APT1/2 inhibitors AA401 and AA642 both led to virtually complete 
inactivation of RAF1 as signified by the intense phosphorylated serine 259 inhibitory 
signal. Lastly, siRNA-mediated knockdown in MCF10a-Snail cells confirmed the role of 
APT2 in sustaining MAPK signal duration as reduced APT2 levels resulted in shorter 
signaling time frames for MEK1/2 and near complete attenuation in RAF1 activation 
(Figure 4-4J and K and L). Therefore, as corroborated by previous reports, small 
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molecule inhibitors of both APT1 and 2 lead to deactivation of certain MAPK proteins 
likely in both Ras-dependent and independent manners.  
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4.5 Discussion 
 MAPK transduction is frequently enhanced and exploited in the growth and 
invasion of metastatic cancer cells; however, the exact mechanism(s) that modulate its 
hypersensitivity in the absence of stimulus are still just partially understood. Within this 
context, scaffolding proteins may provide both a stimulatory and inhibitory platform upon 
which MAPK regulation can be achieved. The 175kDa tumor suppressor Scrib is the 
prime example of a contextually-defined, dual-acting regulator. Its localization at the 
plasma membrane enables it to control ERK1 expression through a direct interaction at 
two-conserved kinase interaction motifs, where ERK could conceivably dock in to Scrib 
and remain sequestered there through phosphorylation of Scrib at its second PDZ 
domain.78 Scrib’s‎position‎at‎the‎cortical‎(leading)‎edge‎during‎epithelial‎cell‎migration‎in‎
MCF10a cells suggests that it localizes there to restore epithelial cell identity once a 
wound has fully closed; in its absence migrating cells fail to re-polarize.103,104 C-terminal 
phosphorylation of Scrib was required for it to complex with Rho-kinase and Shroom2, 
an interaction that promoted contractility and therefore mobility at the cortical edge of 
keratinocytes.105 We show in our EMT model that stimulation with EGF potentially 
causes a de-phosphorylation of cytosolic Scrib at its second PDZ domain, coinciding 
with an increase in phospho-MEK1/2 activity. While one set of phosphorylations by Rho-
kinase enables Scrib to establish cell polarity in wound healing, another set of 
phosphorylations enables it to regulate MAPK - but these PTMs only work if Scrib is 
membrane-bound. Scrib is doing more than maintaining cell junctions; it appears to 
exquisitely orchestrate and fine-tune signaling cascades 
 Though still present and expressed in its genetically wild-type form in malignant 
cells, Scrib mis-localizes to the cytosol, suggesting either a now-missing protein-protein 
interaction or a disrupted PTM that ordinarily brings this large scaffold to the membrane. 
Given‎Scrib’s‎homology‎with‎known‎palmitoylated‎LAP‎proteins‎Erbin‎and‎Densin‎and‎
our recent identification of it by MS as being rapidly de-palmitoylated in a T-cell 
hybridoma line, we explored the latter hypothesis that Scrib could undergo 
palmitoylation in epithelial cells to keep it engaged at the membrane. We showed by 
acyl-biotin exchange on over-expressed Scrib variants, including a the cytosolic P305L 
mutant within the LRR domain, that Scrib does in fact undergo this modification. The 
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P305L mutant was significantly less palmitoylated than WT (Figure 5-3), while the N-
terminal mutant showed no detectable palmitoylation through this method. Decreased 
palmitoylation of the Scrib and Erbin LRR mutants could be the result of a disrupted 
enzyme-substrate interaction; replacing the rigid proline residue with the larger 
hydrophobic side chain of leucine could create a significant change in protein structure 
and potential interactions, though this proline residue is not conserved in Lano or 
Densin. Other alterations in membrane-recruitment events, such as disrupted 
organization of ankyrin and spectrin proteins in EMT, may also play a role, though many 
of the observed changes are also intimately linked with palmitoylation.44  We show the 
cysteines within Scrib’s‎first‎twenty-two amino acids are required for its proper 
localization, as well, further suggesting a post-translational modification. Using mass 
spectrometry coupled with detection of the metabolically-incorporated fatty acid probe 
17ODYA, we found that Scrib palmitoylation decreases by over 50% in Snail-driven 
EMT cell lines.  
 We explored a potential mechanism that could explain the loss of this 
modification on Scrib by examining the palmitoylation machinery in our EMT cell 
models. We discovered that upon EMT, the enzymatic palmitoylation machinery that 
catalyzes the cycling of this PTM is skewed two-fold in the direction of thioester 
hydrolysis. Our unpublished results also showed upregulation of other serine hydrolases 
like RBBP9 and seprase, which were elevated 16- and 30- fold respectively in the Snail 
lines and have been previously identified in similar cancer models.102,106 We were 
surprised to find Snail-induced EMT down-regulated mRNA expression of nearly every 
protein acyltransferase we were able to detect by qPCR, including the PDZ binding 
motif-containing DHHC5 and DHHC14, the latter of which was recently identified as an 
oncogenic factor promoting metastasis of non small-cell lung cancer (NSCLC)60 
 We narrowed the focus of our investigation on the putative de-palmitoylating acyl 
protein thioesterases 1 and 2 (APT1 and APT2). Using both a pharmacological 
approach with various chemotypes and a genetic approach to reduce protein 
expression with siRNA, we found that blocking APT2 activity but not APT1 activity 
enhanced‎Scrib‎palmitoylation‎and‎membrane‎localization‎in‎Snail‎cells.‎APT2’s‎
elevated activity in many EMT models could account for the significant fraction of 
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cytosolic Scrib that has been observed by us and others38,90. The use of a high-content 
screen to test for compounds that modulate Scrib localization could lead to identifying 
other means of Scrib regulation through proteomic profiling of compound targets and 
Scrib interacting partners. The Z-factors, which have been estimated around 0.45 could 
be improved with a more reliable membrane marker other than Na+/K++ ATPase, which 
was found to be heterogeneously expressed in Snail cell membranes.  
        Membrane association of Scrib is important in suppressing MAPK signaling and 
preventing activation of other oncogenic pathways. Together, our ABE and MAPK 
activation data suggest that as a scaffold that was previously shown to interact with 
MAPK players, Scrib is a leading candidate to linking its palmitoylation status with 
MAPK regulation. We observed that APT2, and not APT1 regulates MAPK activity 
possibly via Scrib localization in malignant cells, which supports earlier reports that 
APT1 may be working on Ras instead. The contribution of the Ras family of GTPases, 
all well-known substrates of palmitoylation, will need to be further addressed in the 
context of our EMT model in order to fully assign the unique contributions of 
palmitoylated small second-messengers vs. large scaffolds in MAPK signaling. Our 
results do demonstrate, however, that both APTs may coordinate pro-oncogenic effects 
on multiple regulatory components of the MAPK pathway, likely through disrupting the 
localization of membrane-tethered proteins. At the same time KRas4B is one isoform 
that is not palmitoylated, raising the possibility that APTs ought to extend their activities 
onto other non-core pathway regulators. Additionally, Scrib recruits and suppresses a 
RAF1 activating complex composed of the oncogenic LRR scaffold SHOC2, MRAS, 
RAF1‎and‎PP1α.24 The idea that two scaffolds with competing interests in MAPK 
activation would form a complex poses an interesting question. EMT-induced disruption 
in Scrib palmitoylation might partially explain how these two scaffolds lose their 
coordinated regulation of MAPK, with SHOC2 winning out. Indeed, the problem of 
elevated cellular growth through MAPK is further-complicated by other pathways 
changing in EMT and intersecting with Scrib, in particular the PI3-K/Akt and Hippo 
pathways.35,90,107 
 In summary, we demonstrate that Scrib palmitoylation is key to its normal 
localization and therefore function in epithelial cells before and after undergoing EMT. 
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The palmitoylation enzymes that play a direct role in modulating this important post-
translational modification showed promising drug targets in APT1 and APT2, which in 
EMT displayed heightened expression and activity. Inhibition and knockdown of APT2 
re-established‎palmitoylation‎of‎Scrib,‎but‎not‎Ras,‎while‎Scrib’s‎localization‎returned‎to‎
near wild-type proportions. This phenomenon correlated with reduced Raf1 and MEK1/2 
activation, suggesting that palmitoylation-dependent changes in MAPK were mediated 
through Scrib, rather than increased membrane-bound Ras59. The contribution of 
scaffolding proteins to regulating MAPK activity is a rich area of investigation, and the 
mechanisms that dictate their proper function, localization and palmitoylation in cell 
polarity complexes and signal transduction is an untapped area of biomedical 
exploration.  
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Chapter 5:  
Conclusions, Perspectives and Future Directions 
5.1 Overall conclusions 
 Proteins are often regulated through the addition of chemical modifications to 
modulate their localization, activity, and interactions.1–3 Protein S-palmitoylation 
describes the reversible attachment of long-chain fatty acids to cysteine residues in 
proteins to promote membrane association.4–6 Altered palmitoylation contributes to the 
pathogenesis of cancer, neurological disorders and many other human diseases.7–10 In 
fact, protein palmitoylation is involved in the regulation of essentially all cellular 
processes, yet the enzymes that catalyze lipid attachment (Protein Acyl Transferases, 
PATs) and removal (Acyl Protein Thioesterases, APTs) are poorly characterized. This 
work addresses this gap by focusing on the molecular mechanisms and biological roles 
of PATs and APTs in the regulation of palmitoylation. The research presented herein 
was divided into three chapters, each exploring a different aspect of protein S-
palmitoylation. 
 The inhibitor 2-bromopalmitate (2BP) has been adopted over the past thirty years 
as a pan PAT inhibitor, widely used in hundreds of papers to interfere with 
palmitoylation. While not directly demonstrated, this inhibitor presumably modifies the 
active site of PAT enzymes, and potentially of a various unrelated enzymes involved in 
other biological pathways. In chapter two, novel 2BP derivatives were used to describe 
2BP proteome reactivity, explore its mechanism of palmitoylation blockade and evaluate 
its general utility as a probe for assaying PAT enzyme activities in cells. To accomplish 
these goals, a functionalized 2BP analogue was synthesized that allowed for selective 
capture and mass spectrometric identification of inhibited proteins. Surprisingly, PAT 
enzymes were not the primary targets of 2BP. Furthermore, many of the targets 
identified were themselves palmitoylated proteins, suggesting that in addition to PAT 
inactivation, 2BP may inhibit protein palmitoylation by directly blocking palmitoylation 
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sites on target proteins. These findings highlighted the non-specific nature of 2BP, and 
suggested re-evaluation of the hundreds of publications that utilized 2BP for studying 
palmitoylation. 
 Two candidate protein depalmitoylases, APT1 and 2, have so-far been described 
in the literature, however their primary physiological roles are still incompletely defined. 
APT1 and 2 are serine hydrolases that show broad and possibly overlapping substrate 
specificities across diverse sets of biomolecules, further complicating the assignment of 
their primary cellular role(s). Indeed, isoform-selective pharmacological tools would aid 
in parsing out the specific contributions of these enzymes and defining their true 
biochemical functions. In chapter three, the molecular basis for the binding of two 
distinct, selective, reversible APT inhibitors was investigated from both a structural and 
chemical standpoint. To this end, the co-crystal structures for both APT1 and 2 with 
their corresponding selective inhibitors were solved and kinetic enzyme activity assays 
were used to confirm the structural determinants that give rise to the observed 
selectivity.‎The‎crystal‎structures‎reveal‎that‎APT1‎and‎2‎share‎identical‎α/ß-hydrolase 
folds with nearly complete conservation of active-site residues. Interestingly, inhibitors 
occupied cognate active-site locations, yet retained relatively specific interactions with 
key residues in APT1 and 2. Taken together, the existence of discriminatory residues 
were invoked to gate access to the active-sites of APT1 and 2. 
 We previously identified the cell polarity regulator Scribble (Scrib) as a 
palmitoylated protein rapidly processed by APT enzymes. Epithelial cells normally 
exhibit a polarized structure that is lost when tumors undergo metastatic transformation. 
Scrib normally localizes to the basolateral membrane where it protects the cells against 
this transformation by scaffolding proteins that define polarity gradients, regulate cellular 
proliferation, and maintain cellular adhesion. Importantly, Scrib is often mislocalized in 
most malignant cancers, displaced from the plasma membrane, allowing cells to 
proliferate unchecked. Based on these observations, in chapter four, we explored the 
hypothesis that APT enzymes may remove Scrib palmitoylation, releasing it from the 
plasma membrane to promote malignancy. To this end, APT1 and 2 activities were 
inhibited with both pharmacological and genetic tools and Scrib palmitoylation and 
localization was measured in malignant cells. Indeed, incubating malignant cells with 
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these drugs largely rescues Scrib plasma membrane localization. Furthermore, APT2 
inhibition also attenuated the mitogen activated protein kinase (MAPK) cascade, a 
growth signaling pathway that is known to be hyper-activated in metastatic cancers. 
Overall, we identified a new function for palmitoylation in suppressing cancer by 
regulating Scrib, a critical gatekeeper of cell polarity. 
 In summary, this thesis investigated novel biological activities of protein 
palmitoylation. Using a variety of biochemical methods and chemical biology 
techniques, I report preliminary data constituting an original contribution to the fields of 
chemistry, biochemistry, and cell biology. These findings provide new insights into the 
mechanistic role of PAT enzymes in mediating palmitoylation, describe the small-
molecule selectivities of APT enzymes and characterize their biological role in 
regulating cell polarity and signaling complexes in cancer. 
 Most importantly, this thesis, throughout its chapters, continued to address the 
'window of opportunity' concept of chemical biology, which is more often than not 
overlooked in studies of protein S-palmitoylation. Indeed, no chemical compound, or 
probe for this matter, is truly selective for its cellular target(s); instead, there is a useful 
range of concentrations and other assay conditions that allow for relatively specific 
probing of the desired on-target(s). This work along with many other valuable studies 
serve as cautionary tales for research communities, emphasizing that virtually all 
chemical biology techniques are prone to off-target effects. Therefore, these types of 
experiments should be performed within their known limits of specificity along with 
validated positive and negative controls to yield accurate and biologically relevant 
results.  
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5.2 Perspective and future directions for chapter 2 
In the 2-bromopalmitate (2BP) study presented in the second chapter, we 
provided a proteomic and mechanistic view of this inhibitor's cellular targets by 
employing click-enabled derivatives (Figure 2-1A). Corroborating several earlier 
findings11–13, we confirmed the promiscuity of this PAT inhibitor and demonstrated that 
despite its selective reaction with active DHHCs (Figure 2-7 and Figure 2-11), it largely 
targeted other classes of proteins of various function, the majority of which were 
membrane associated proteins (Table 2). Therefore, we concluded that 2BP lacked the 
pharmacological specificity necessary for correctly assigning the physiological roles and 
annotating the molecular substrates of PATs. Given the scarcity of PAT inhibitors 
however, it is understandable why many still resort to using 2BP for probing the 
palmitoylation effect in vivo. In this event, we highly recommend that investigators use 
multiple methods of inhibiting palmitoylation to clearly demonstrate its significance to the 
particular study. In addition to the pharmacological agents discussed in the first chapter, 
molecular biology approaches could also be applied to prevent acylation from taking 
place; these techniques include mutation of the exact palmitoylation site and genetic 
knockdowns of suspected PATs.  
Despite the finding of 2BP's non-selective behavior, characterization of its 
reactivity did lead to several interesting findings that may support its use for the 
discovery of non-enzymatic palmitoylation events, also known as autoacylation14–16. 
Unexpectedly, a large number of 2BP targets were also validated palmitoylated proteins 
(Table 2 and Figure 2-13) which led us to theorize that 2BP reactivity can report on non-
enzymatically, self plamitoylating proteins, here referred to as autopalmitoylated 
proteins. A number of proteins, including the GPCR rhodopsin17, heterotrimeric Gα 
subuits14 and tubulin dimers18, have been reported to undergo palmitoylation reactions 
in vitro when subjected to acyl-CoA donors. Perhaps, the intrinsic ability of these 
membrane proteins to self-install acyl chains is due to their harboring a heightened 
cysteine thiol nucleophile. This electronic argument is further supported by our 
experiments (Figure 2-7D) which show increased protein labeling observed for the more 
electrophilic 2BP coenzyme A variant in compare to the free fatty acid form. Since 
existence of this non-enzymatic process has yet to be confirmed in vivo, one would 
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need to demonstrate that a putative autopalmitoylated protein can undergo 
palmitoylation in the absence of any PATs, or their activities. Such an experiment could 
be performed in heterologous organism that lacks PAT enzymes but bears long chain 
acyl-CoA donors available to react with the exogenous protein.  
Another aspect of chapter two that can be explored further is the mechanism by 
which 2BP blocks protein palmitoylation by direct competition for the palmitoylation site. 
We showed that FAM108B, a validated N-terminally palmitoylated protein, could no 
longer label with our 2BP probe when its N-terminus was deleted (Figure 2-14). This 
raised the possibility that 2BP modification site is likely coinciding with the native 
palmitoylated cysteine residue. However, it is unclear whether deleting the N-terminus 
of FAM10B prevents other cysteines, outside of the N-terminal portion, from reacting 
with 2BP resulting in the observed loss of labeling. One strategy to identify native 
palmitoylation sites that are directly competed by 2BP, is by performing a competitive-
metabolic labeling experiment in which the 2BP probe is pre-incubated with cells and 
then a palmitoylation reporter (e.g. 17-ODYA, the ω-alkynylated stearic fatty acid 
analog, Figure 1-3) is used sequentially to measure the levels of both 2BP and 
palmitate incorporation into 
specific targets (Figure 5-1). 
Figure 5-1 2BPN3/17ODYA 
competition experiment to 
resolve 2BP alkylated proteins 
from proteins that are truly 
depalmitoylated in the presence 
of this inhibitor. 
In this manner, 
proteins that exhibit an 
inverse correlation between 
2BP and 17ODYA incorporations are possibly 2BP-alkylated at the site(s) of their fatty 
acid attachment. An important caveat is that for some targets, 17ODYA-blockade may 
be achieved via both PAT inhibition and direct site alkylation, and therefore, in these 
cases, it is difficult to determine which mode is the primarily contributing to inhibition of 
acyl attachment.  
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5.3 Perspective and future directions for chapter 3 
In chapter three, we explored the activities of the two homologous thioesterase 
enzymes, APT1 and 219, towards the isoform selective inhibitors, ML348 and ML34920 
respectively, in an effort to understand APT differential active-site ligand preferences. 
The co-crystal structures for each enzyme-inhibitor pair solved revealed the existence of 
residues that may confer active-site selectivity through both steric and electronic effects 
(Figure 3-11and Figure 3-12). These discriminatory amino acids, when mutated to their 
corresponding homologous residues, exhibited selective inhibitor affinities (Ki) and 
residency times (koff) which mirrored those of wild type enzymes (Table 5 and Figure 3-
15, respectively). Interestingly, the discriminating residue of APT1 had no effect when 
substituted into APT2 and vice versa (Table 5). These finding suggest that more than 
one amino acid contributes to inhibitor selectivity, and that inhibitor preference is 
possibly due to differences in the conformational dynamics about APT1 and 2 active-
sites21–24. 
The most intriguing aspect of these reversible inhibitors was the different 
geometries in which they were docked into their respective active sites (Figure 3-6 and 
Figure 3-7). The more flexible ML348 was somewhat kinked when complexed to APT1 
suggesting that the active site may have certain steric and or electronic requirements 
which scan for ligands that posses non-linear chemical structures. This could 
presumably be tested by designing and measuring the potency of ML348 analogs that 
have severely restricted rotational movement. In addition to ML348's unique 
conformation, the CF3 substituent of the anilide structure appeared to block APT1 
catalytic residues via strong hydrophobic interactions with residues lining the active site 
entry (Figure 3-6, Figure 3-7 and Figure 3-11). This finding was corroborated by the 
original SAR studies about ML34820 which showed that substituting the trifluoromethyl 
group in any way, reduced the potency of the compound relative to the lead. Another 
important observation was made about guanidino group of R149 which appeared to be 
engaging, via a hydrogen bond, the carbonyl of the 2-furoyl amide group (Figure 3-10). 
Fortunately, a direct means of testing this hydrogen bond hypothesis is tractable as it 
would be to assay the affinity of ML348 towards an Arg mutant, such as an Ile, which 
lacks the ganidino group but still retains similar steric bulk. Alternatively, this 
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hypothetical hydrogen bond can be assessed by substituting the amide in question for 
the isosteric thioamide group (i.e. -(C=S)-NR2), which should alter the potency if the 
aforementioned carbonyl was in fact H-bonding. 
On the other hand, the ML349-APT2 interaction had defined planar contacts and 
yielded more direct structural information regarding the mechanism of ML349 binding 
(Figure 3-6 and Figure 3-7). While the sulfone moiety of ML349 was clearly engaging 
the nucleophilic hydroxyl of APT2 and resembling a transition-state analog, ML349 
derivatives having the sulfone group swapped for aliphatic and sterically-demanding 
groups paralleled the activities of ML349 as reported in previous SAR studies20. This 
suggests that the sulfone may be serving both the role of a bulky group as well as a 
tetrahedral analog. This proposition is supported by the finding that the smaller sulfoxide 
derivative, representing a racemic mixture of diastereomers, lost marked potency 
compared to the lead compound (Figure 3-16). Thus, it should be evident that we 
cannot not directly assess the contribution of the serine hydroxyl-ML349 sulfone 
hydrogen bonds because isosterically modifying ML349 about its sulfone would be 
synthetically intractable. In addition, the thioether derivative could not be used to assess 
the H-bond contribution either because this variant lacks the steric bulk that was 
demonstrated to inhibit the enzyme as well. Therefore, the remaining approach to use 
for probing the transition state binding of the sulfone, would be to measure the binding 
of ML349 towards Ser122Ala mutant lacking the hydroxyl group altogether. Our Res-O-
Ac substrate analog activity assay would not be applicable since this binding 
measurement relies on the enzyme possessing catalytic activity. Thus, one would need 
to perform binding experiments in an activity-independent manner, such a measurement 
could be acquired via thermodynamic binding experiments such as the well-known 
isothermal titration calorimetric method.25 
The APT inhibitor studies also provided clues as to how these two thioesterase 
may have diverged in recognizing molecules at their active sites. Given that APT active 
sites must be different enough to discriminate between these reversible inhibitors, it is 
possible that the same residues that confer specificity towards small molecules may be 
involved in selection towards physiological substrates (Figure 3-17). One experiment 
that can establish this connection would be to measure the catalytic activities of these 
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mutants towards a variety of acyl substrates (i.e. S-palmitoylcysteine) and determine 
whether the residues in question confer substrate specificity as well. A faster way to 
achieve the same goal would be to perform product inhibition-like experiments in which 
enzyme activities are still assayed with Res-O-Ac except now in the presence of 
increasing concentrations of various fatty acids. These lipids represent the putative 
endogenous products of APTs and could therefore resemble acylated substrate binding 
the enzyme. In addition to point mutants, we also noted that flexibility of APT2's high 
mobility loop structure could exert some effects on the putative substrate channel of the 
enzyme, although we did not address its contribution towards ligand selectivity. Thus, 
one could  generate APT1 and 2 loop-exchanged24 mutants and assay their resulting 
inhibitor sensitivities to validate this claim. As a whole, thoroughly defining the scope of 
substrates efficiently hydrolyzed by APTs is expected to aid in future drug design 
attempts, which could then employ a substrate-guided approach in their medicinal 
chemistry efforts. 
A comparison between the three-dimensional electrostatic maps of APT1 and 2 
suggests that while both enzymes share hydrophobic residues inside their hydrophobic 
channels, it is APT2 which possess greater hydrophobic character bordering its active 
site (Figure 3-8). This fact, along with the high orthologous conservation of APT2 
residues (Figure 3-17) suggest that it has evolved to engage and process specific sets 
of biomolecules that are hydrophobic in nature. To date, specific membrane affinity 
studies have focused on the role that fatty acylated residues play in APT membrane 
localization.26–28 ; membrane affinity contributions from APT surface residues have not 
been addressed yet. Therefore, to measure the dependence of membrane association 
on surface character, surface point mutants can be designed which introduce residues 
that overwhelm the existing hydrophobic character of APT2. Membrane localization 
studies of GFP-tagged wild type and mutant constructs can then be assessed by 
microscopy techniques such as FRAP measurements29–33 that were discussed in the 
first chapter. 
Lastly, in light of the observed specificities of ML348 and ML349, we suggest 
these inhibitors could be utilized as probes to assay the exact contributions of each 
enzyme to depalmitoylation dynamics in vivo. For example, APTs have been implicated 
190 
 
in the deacylation and thus regulation of Ras isoforms34–37, which are notorious cancer 
targets that have shown to promote uncontrolled growth and proliferation among other 
roles38–42. The current thinking is that Ras GTPases maintain imperative dynamic cycles 
of palmitoylation/depalmitoylation34,43 which if altered, affect their signal transduction 
potential36. Therefore, the search for the bona fide Ras depalmitoylase(s) has been a 
recent focus in Ras biology studies. Specifically, APT1 has been suggested to 
deacylate HRas, whereas APT2 has shown to deacylate semi-synthetic NRas more 
efficiently than APT1. While these experiments are informative, they do not report on 
the physiological activities of APTs which would require further genetic knockout 
experiments to confirm APT in vitro activities. Instead of invoking these elaborate 
methods, we suggest to implement APT selective compounds to achieve these same 
goals. To this end, we used these inhibitors and some of their less potent derivatives in 
growth factor stimulation experiments and assessed the contributions of APTs to the 
activity of Ras isoforms. As can be seen in the active-Ras pulldown results44,45 (Figure 
5-2), treatment with ML349 led to a near-complete deactivation of Ras proteins, which 
were detected simultaneously with a pan-Ras antibody. This was in contrast to ML348 
which only modestly reduced active Ras levels. Given that even selective-inhibitors may 
have unexpected yet relevant off-targets, we would need to confirm that the observed 
Ras deactivation was a result of inhibition of APT2 and not of a potential ML349 off-
target. To conclude, APT-directed probes can be used as quick, inexpensive, 
preliminary tools for assessing their physiological contributions. 
 
Figure 5-2 Active panRas pulldown from EGF-stimulated MCF7 breast cancer cells is dependent 
on APT2 but not on APT1 activity. MCF7 cells were pre-treated overnight with 5 µM of each inhibitor, 
serum starved briefly, and stimulated with EGF for 5 minutes. Inactive ML349 is the thioether-derivative 
presented in   
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5.4 Perspective and future directions for chapter 4 
The Scrib palmitoylation and membrane localization studies that were conducted 
in chapter four demonstrated that dynamic palmitoylation played a central role in 
regulating the localization and activities of tumor-suppressor and oncogenes in cancer 
(Figure 4-2 and Figure 4-4). We specifically showed that the tumorigenic EMT program 
leads to the up-regulation of APT2 (Figure 4-3), which we revealed to be a bona fide 
Scrib depalmitoylase in epithelial cells (Figure 4-4). We suggested that APT2 activity 
would account for a significant fraction of cytosolic Scrib given the recent literature 
reports on LAP family membrane recruitment requirements. Namely, palmitoylation 
appears to be a unifying theme of LAP protein scaffolds as demonstrated by the close-
relative LAP protein homologues Densin and Erbin, the latter of which has been shown 
to require palmitoylation for membrane targeting46. 
In this regard, we showed that deleting Scrib's first 22 N-terminal residues was 
enough to preclude its palmitoylation and membrane localization. We interpreted these 
findings to mean that Scrib's N-terminal cysteine residues were the sites of 
palmitoylation and that they were necessary for the protein's membrane association. As 
this is one way of perceiving these palmitoylation and membrane association results, 
there could be many other potential explanations such as deletion of N-terminus 
allosterically affects a distal palmitoylation site or protein interaction which is necessary 
for membrane recruitment. Thus, one would need to generate single and double point-
mutants of the alleged N-cysteines (i. e. C4 and C10) and assay their palmitoylation 
levels and membrane localization. Nevertheless, these exact experiments were already 
performed on Scrib's close relative LAP member, Erbin, which showed that indeed the 
cysteine were the site of acyl attachment and that they led to loss of membrane Erbin. 
Interestingly, the cytosolic Scrib P305L mutant, which corresponds to a P315L 
mutation in Erbin46, showed a decrease in palmitoylation levels as well (Figure 5-3), but 
the origin of this reduction was not addressed. One likely explanation for why Pro-to-Leu 
mutation in Scrib, and likely other LAP members, exhibits decreased palmitoylation 
levels is that the substituted Leu residue alters the conformation of this domain affecting 
the engagement of the palmitoylation site to its corresponding palmitoylase (i.e. DHHC 
PAT). This disengagement could occur via two plausible mechanisms. In the first 
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scenario, the mutant Scrib is physically unable to reach the membrane in which the 
DHHC resides. In the alternative scenario, the mutant Scrib does reach the proper 
membrane but can no longer interact with the enzyme in a catalytically competent 
conformation. The latter would be more difficult to ascertain since the full-length Scrib 
structure is unknown and the proline mutation is distant in sequence to the 
palmitoylation site and therefore could exert its effects through a number of 
mechanisms. 
 
Figure 5-3 ABE of 293T cells overexpressing wild type or P305L Scrib mutant demonstrate a near-complete 
loss in Scrib P305L palmitoylation. 
It is more likely that P305L mutant is just unable to engage the proper membrane 
and hence, does not get palmitoylated. As stated in chapter one, many proteins require 
a transitory membrane engagement before they can get stably palmitoylated by 
membrane-resident DHHCs5,47. Therefore it would not be surprising if the Scrib P305L 
mutant is lacking this transient interaction. Indeed, proteins can be weakly attracted to 
the membrane via either protein-protein interactions48,49 or just by the sheer number of  
hydrophobic and basic residues present on their surface50–52. Thus, to clearly 
demonstrate that Pro305 mediates transient membrane association that is independent 
of prior N-terminal palmitoylation events, the membrane localization of a palmitoylation-
deficient mutant should be compared with that of another palmitoylation-deficient mutant 
that also features the P305L substitution. This experiment would eliminate any 
contribution that may be conferred by the palmitoylation sites. It is possible that both 
constructs will exhibit the same localization properties given our data that suggests 
palmitoylation-deficient mutants do not bind membranes. In addition, mass-
spectrometric analyses of wild type and P305L protein enrichments may reveal protein 
interactions that are lost in the mutant and thus could be contributing to transient 
membrane recruitment.  
α-Scrib 
α-Tubulin 
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Another unexplored highlight of the Scrib chapter involved the high-content 
imaging analysis which demonstrated that inhibiting APT2 in MDCK-Snail cells seemed 
to retarget Scrib to membrane in a dose-dependent manner (Figure 4-4). Interesting 
enough, we did not observe reversion of MDCK-Snail's mesenchymal morphology upon 
drug treatment suggesting that we were not restoring the epithelial phenotype. This was 
a concern because Scrib membrane localization was shown to correlate with the 
epithelial identity of the cells53,54, with the more polarized cells showing most signal at 
the cell membrane. It is possible, although highly unlikely, that morphological changes 
were induced in drug-treated MDCK-Snail cells and this could have affected the cells' 
physical shape which in turn would augment the our high-content calculations of Scrib 
membrane fractions. One way this could result in apparent membrane signal increase is 
if the membrane marker has now shifted into the cytosolic milieu of the cells. Thus, to 
limit membrane signal artifacts, we suggest to employ a supplementary membrane 
marker to aid in defining the membrane. Additionally, one may choose report more 
morphological features about the cells to be used in membrane fraction calculations; 
these include circularity and ellipticity measurements which can be used to filter 
abnormal-looking cells from the analysis. 
A central finding in the Scrib chapter was that APT2 positively regulated the 
MAPK pathway during cancer transformation. We were able to demonstrate that 
inhibiting this APT2 in the oncogenic lines led to an attenuation of this signaling pathway 
(Figure 4-4). The main issue that was presented to us was determining through which 
protein(s) does APT2 exert effects that would lead to increased activation or relieved 
suppression of the MAPK cascade (Figure 5-4). Seeing that APT2 has been primarily 
characterized as a protein acyl thioesterase enzyme19, our first guess was that MAPK-
associated palmitoylated proteins were the direct targets of APT2. While numerous 
palmitoylated proteins have shown to indirectly affect this pathway in one way or 
another, to our knowledge, palmitoylatable Ras isoforms (i.e. H, N and K4b) are primary 
MAPK effectors which are thought to be physiological substrates of APTs. Thus we 
hypothesized that APT2 may exert its regulation on the MAPK though either appropriate 
Ras isoforms or Scrib which define to be another likely substrate of this enzyme. 
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Figure 5-4 Determining the exact molecular node by which APT2 exerts its affects on MAPK. APT2 
could active an oncogene or deactivate a tumor suppressor to bring about similar highly excitable MAPK 
pathway found in transformed fibroblastic cancer cells which show a loss of the epithelial marker ECAD. 
To this end, we showed that APT2 does not affect the steady-state palmitoylation 
levels of Ras isoforms but does affect those of Scrib, with APT2 inhibition leading to a 
marked increase in steady-state Scrib palmitoylation. This result alone is not enough to 
suggest that APT2 could not exert effects through Ras; this is because we did not 
address APT2's contribution to Ras palmitoylation turnover dynamics, which has been 
shown to be essential to Ras transduction potential43. Another way to get at the 
question "is APT2 regulating Ras activity?" would be to assay the levels of active, GTP-
bond Ras and determine if APT2 inhibition perturbs the activity of these GTPases. 
Regardless of the aforementioned experiment, Bastians and coworkers37 have 
convincingly shown that inhibiting APTs may be detrimental to Ras activity as the 
acylated Ras proteins are allowed to equilibrate throughout all endo-membranes diluting 
their effective concentration at the plasma membrane43. 
 Although it makes a lot of sense for the Scrib repressor to be the MAPK-node by 
which APT2 exerts its effects, it is still worth assaying Scrib's direct contribution to the 
attenuation of this signaling pathway. One would therefore need to knockdown or 
knockout Scrib in the Snail line, and determine whether inhibition of APT2 still leads to 
MAPK suppression. If Scrib was truly the palmitoylated MAPK effector responsible for 
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attenuation, then removal of Scrib from the equation would render a highly excitable 
cascade that cannot be suppressed by APT2 drug treatment. 
Although we focused on APT contribution to Scrib palmitoylation, a decrease in 
steady-state palmitoylation may also result from a reduction in the levels or activity of its 
corresponding PAT enzyme(s). We showed by qRT-PCR experiments that inducing 
oncogenic transformation in MCF10a epithelial cells reduced the mRNA transcript levels 
across all DHHC PAT enzymes (Figure 4-3), suggesting that DHHC protein levels were 
reduced as well, however we did not validate this claim comprehensively in our study. 
Since our qRT-PCR data represented the fold-change between transcripts from the 
parent and oncogenic lines, we could not determine the definite mRNA levels of DHHCs 
between the tested lines, and to do so would required customized PCR standards for 
each DHHC. Therefore, it is inappropriate to compare and draw conclusion from the 
fold-change values between different DHHC transcripts, since low-level transcripts may 
still exhibit large fold changes if they are absent in one of the lines tested. Regardless, 
to draw meaningful conclusions, protein detection techniques, such as western blots, 
should be utilized to determine the levels of DHHCs between parent and oncogenic cell 
lines as mRNA transcript levels do not always correlate with protein levels although they 
did so perfectly for APTs (Figure 4-3). 
In addition to describing changes in DHHCs, the qRT-PCR screen was also an 
effort to identify Scrib's palmitoyltransferase(s). Since Scrib featured reduced 
palmitoylation levels, we hypothesized that its DHHC PAT could be reduced in the 
oncogene line. However, changes in enzyme levels do not always reflect their catalytic 
outputs. Thus, to achieve this goal in a more direct manner, an elegant approach is 
offered which may accelerate the finding of Scrib's palmitoyltransferase. This method 
relies on the hypothesis that Scrib uses its PDZ interaction domains to engage its PAT 
and allow for concomitant palmitoylation; this is not a radical or novel proposition as 
several PATs have been shown to catalyze the palmitolyation of their substrate in a 
PDZ interaction-dependent manner.55 Interestingly, there are 5 DHHC members (3, 5, 8, 
14, 23) that contain the so-called PDZ interaction motif, a short C-terminal 4-peptide 
sequence which binds a cognate PDZ domain (Figure 1-7). Thus, if Scrib palmitoylation 
was dependent on PDZ interactions, one would expect that deleting or impairing the 
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alleged PDZ domain would hinder the palmitoylation of Scrib. If this were found to be 
the case, then it would be good grounds for employing the critical PDZ domain(s) as a 
bait to pulldown the associated DHHC PAT and assay its contribution directly. 
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Appendix A 
2BPN3 Enriched 293T Proteomic Data Set 
 In the second chapter we presented label-free mass spectrometry-based 
proteomic data comparing the amounts of 2BPN3-enriched proteins relative to control 
enrichments in the presence of 2BP. In the tables below, we have included the entire 
data set for proteins enriched in both 2BPN3 and 2BP treated 293T cells. Relative 
abundance was measured by spectral counting, as previously described86. 
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Table 6 Full-length 2BPN3 Enriched 293T Proteomic Data Set. 
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Appendix B 
17ODYA Enriched MCF10a Proteomic Data Set 
 In Chapter four, we presented SILAC mass spectrometry-based proteomic data 
comparing 17ODYA-enriched proteins between MCF10a-EV and MCF10a-Snail cells. 
In the tables below, we have included the entire data set for the proteins enriched 
across these stable MCF10a lines. Mean SILAC ratios in each direction (i.e. REV/Snail and 
RSnail/EV) were computed based on the MS1 ion intensities of the precursor SILAC pairs. 
Proteins were first sorted by a directional consistency parameter referred to as R•R-1 
and then by a fold-change parameter referred‎to‎as‎∆. The value for R•R-1 is defined as 
the product of the mean ratios computed in each direction (i.e. REV/Snail x RSnail/EV) which, 
in the ideal case, would be inverses on one another. Thus, the closer this value is to 
unity the more consistent are the mean ratios between inverse experiments. The fold-
change parameter ∆ is defined as the sum of REV/Snail and 1/RSnail/EV divided by the sum 
of 1/REV/Snail and RSnail/EV. This value represents the overall fold-change observed for EV 
over Snail. Lower‎values‎(0<∆<1)‎‎indicate proteins that were enriched more in the EV 
line compared to Snail, while‎larger‎values‎(∆>1)‎are‎associated‎with‎proteins‎enriched‎
more in the Snail line compared to EV. Fold change values were not computed for 
proteins which only have a ratio in one direction. For more details regarding data 
analysis, see the methods section of chapter four.  
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Table 7 Full-length 17ODYA Enriched MCF10a Proteomic Data Set 
 
L(Snail) : H(EV) L(EV) : H(Snail) 
  
UniProt 
Accession 
UniProt Entry 
Name 
UniProt Protein Name Mean SD 
SILAC 
Pairs 
Mean SD 
SILAC 
Pairs 
R•R
-1 ∆ 
Q9UMD9 COHA1_HUMAN Collagen alpha-1(XVII) chain 
   
28.57 6.71 10 0 
 
Q86X29 LSR_HUMAN Lipolysis-stimulated lipoprotein receptor 
   
12.22 1.302 4 0 
 
P09758 TACD2_HUMAN 
Tumor-associated calcium signal transducer 
2 
   
14.55 0 2 0 
 
P12429 ANXA3_HUMAN Annexin A3 
   
7.582 5.643 7 0 
 
P22223 CADH3_HUMAN Cadherin-3 
   
7.78 0 2 0 
 
Q9Y446 PKP3_HUMAN Plakophilin-3 
   
9.053 1.037 6 0 
 
Q9Y624 JAM1_HUMAN Junctional adhesion molecule A 
   
9.692 0 2 0 
 
P22735 TGM1_HUMAN 
Protein-glutamine gamma-
glutamyltransferase K 
   
9.946 3.39 12 0 
 
Q8WY22 BRI3B_HUMAN BRI3-binding protein 
   
3.23 1.713 4 0 
 
Q9UBC5 MYO1A_HUMAN Unconventional myosin-Ia 
   
4.15 2.579 6 0 
 
Q8TDN6 BRX1_HUMAN Ribosome biogenesis protein BRX1 homolog 
   
4.094 0 2 0 
 
O60437 PEPL_HUMAN Periplakin 
   
4.424 0.628 4 0 
 
Q8IYB8 SUV3_HUMAN 
ATP-dependent RNA helicase SUPV3L1, 
mitochondrial 
   
3.299 0 2 0 
 
Q9H0S4 DDX47_HUMAN 
Probable ATP-dependent RNA helicase 
DDX47 
   
4.82 0 2 0 
 
Q3SY69 AL1L2_HUMAN 
Mitochondrial 10-formyltetrahydrofolate 
dehydrogenase 
   
2.466 0 2 0 
 
P09622 DLDH_HUMAN Dihydrolipoyl dehydrogenase, mitochondrial 
   
2.421 0.348 12 0 
 
P18754 RCC1_HUMAN Regulator of chromosome condensation 
   
2.424 0.387 12 0 
 
Q96HS1 PGAM5_HUMAN 
Serine/threonine-protein phosphatase 
PGAM5, mitochondrial 
   
2.731 0.363 4 0 
 
O75380 NDUS6_HUMAN 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6, mitochondrial 
   
2.741 0.443 6 0 
 
Q02338 BDH_HUMAN 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial 
   
3.039 0.008 4 0 
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Q07021 C1QBP_HUMAN 
Complement component 1 Q subcomponent-
binding protein, mitochondrial 
   
3.095 0.276 10 0 
 
Q14684 RRP1B_HUMAN 
Ribosomal RNA processing protein 1 
homolog B 
   
2.508 0.19 6 0 
 
Q16531 DDB1_HUMAN DNA damage-binding protein 1 
   
3.226 0 2 0 
 
P08574 CY1_HUMAN Cytochrome c1, heme protein, mitochondrial 0.25 0.01 6 
   
0 
 
Q13428 TCOF_HUMAN Treacle protein 
   
4.032 0 2 0 
 
O00767 ACOD_HUMAN Acyl-CoA desaturase 
   
4.076 0.912 12 0 
 
P17480 UBF1_HUMAN Nucleolar transcription factor 1 
   
1.905 0.438 5 0 
 
O95140 MFN2_HUMAN Mitofusin-2 
   
1.905 0 2 0 
 
P10319 1B58_HUMAN 
HLA class I histocompatibility antigen, B-58 
alpha chain 
   
2.518 0.628 4 0 
 
P18465 1B57_HUMAN 
HLA class I histocompatibility antigen, B-57 
alpha chain 
   
2.518 0.628 4 0 
 
P30492 1B54_HUMAN 
HLA class I histocompatibility antigen, B-54 
alpha chain 
   
2.518 0.628 4 0 
 
P07339 CATD_HUMAN Cathepsin D 
   
3.806 0 2 0 
 
Q9NQ55 SSF1_HUMAN Suppressor of SWI4 1 homolog 
   
3.816 1.179 4 0 
 
P49411 EFTU_HUMAN Elongation factor Tu, mitochondrial 
   
3.982 0.589 14 0 
 
Q9ULB1 NRX1A_HUMAN Neurexin-1 
   
4.194 0 2 0 
 
- L_HRSVB - 0.286 0 2 
   
0 
 
P36957 ODO2_HUMAN 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 
   
1.7 0.161 12 0 
 
P08559 ODPA_HUMAN 
Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, mitochondrial 
   
1.988 0.152 7 0 
 
Q9Y5W8 SNX13_HUMAN Sorting nexin-13 
   
2.6 0 2 0 
 
Q96SI9 STRBP_HUMAN Spermatid perinuclear RNA-binding protein 
   
2.602 2.837 8 0 
 
O43615 TIM44_HUMAN 
Mitochondrial import inner membrane 
translocase subunit TIM44 
   
2.229 0.155 8 0 
 
Q9H7B2 RPF2_HUMAN Ribosome production factor 2 homolog 
   
2.17 0 2 0 
 
Q9BVP2 GNL3_HUMAN Guanine nucleotide-binding protein-like 3 
   
2.313 0.225 17 0 
 
Q9Y3T9 NOC2L_HUMAN Nucleolar complex protein 2 homolog 
   
2.328 0.271 8 0 
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Q8IYB3 SRRM1_HUMAN Serine/arginine repetitive matrix protein 1 0.31 0.08 8 
   
0 
 
Q8TCS8 PNPT1_HUMAN 
Polyribonucleotide nucleotidyltransferase 1, 
mitochondrial 
   
3.323 0.504 6 0 
 
O95810 SDPR_HUMAN Serum deprivation-response protein 0.312 0 2 
   
0 
 
Q16134 ETFD_HUMAN 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial 
0.312 0.02 6 
   
0 
 
Q9Y4K1 AIM1_HUMAN Absent in melanoma 1 protein 
   
1.236 0.092 10 0 
 
- R1AB_CVHN5 - 0.316 0 2 
   
0 
 
- R1A_CVHN1 - 0.316 0 2 
   
0 
 
- R1AB_CVHN1 - 0.316 0 2 
   
0 
 
- R1A_CVHN5 - 0.316 0 2 
   
0 
 
O15269 SPTC1_HUMAN Serine palmitoyltransferase 1 
   
1.086 0.117 4 0 
 
Q9NZN4 EHD2_HUMAN EH domain-containing protein 2 
   
1.087 0.118 12 0 
 
Q15643 TRIPB_HUMAN Thyroid receptor-interacting protein 11 0.318 0.31 4 
   
0 
 
Q14571 ITPR2_HUMAN Inositol 1,4,5-trisphosphate receptor type 2 0.321 0.09 4 
   
0 
 
O14684 PTGES_HUMAN Prostaglandin E synthase 
   
3.657 0.172 4 0 
 
P09211 GSTP1_HUMAN Glutathione S-transferase P 
   
2.689 0.702 16 0 
 
Q9NU22 MDN1_HUMAN Midasin 0.337 0 2 
   
0 
 
O95602 RPA1_HUMAN 
DNA-directed RNA polymerase I subunit 
RPA1 
0.337 0 2 
   
0 
 
P30498 1B78_HUMAN 
HLA class I histocompatibility antigen, B-78 
alpha chain 
   
2.179 0 2 0 
 
P18464 1B51_HUMAN 
HLA class I histocompatibility antigen, B-51 
alpha chain 
   
2.179 0 2 0 
 
P30490 1B52_HUMAN 
HLA class I histocompatibility antigen, B-52 
alpha chain 
   
2.179 0 2 0 
 
O95716 RAB3D_HUMAN Ras-related protein Rab-3D 
   
2.204 0.258 8 0 
 
Q5VTL8 PR38B_HUMAN Pre-mRNA-splicing factor 38B 
   
2.275 0.18 4 0 
 
Q15413 RYR3_HUMAN Ryanodine receptor 3 
   
2.647 0 2 0 
 
O00483 NDUA4_HUMAN Cytochrome c oxidase subunit NDUFA4 
   
1.993 0.092 8 0 
 
Q15424 SAFB1_HUMAN Scaffold attachment factor B1 
   
1.886 0.18 22 0 
 
Q9NP92 RT30_HUMAN 28S ribosomal protein S30, mitochondrial 0.365 0 2 
   
0 
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P82921 RT21_HUMAN 28S ribosomal protein S21, mitochondrial 
   
2.441 0.528 8 0 
 
Q9NRC6 SPTN5_HUMAN Spectrin beta chain, non-erythrocytic 5 0.366 0 2 
   
0 
 
Q9Y6C9 MTCH2_HUMAN Mitochondrial carrier homolog 2 
   
1.895 0.071 4 0 
 
Q9H6R4 NOL6_HUMAN Nucleolar protein 6 
   
2.68 0.149 4 0 
 
Q3ZCQ8 TIM50_HUMAN 
Mitochondrial import inner membrane 
translocase subunit TIM50 
0.366 0 2 
   
0 
 
Q92614 MY18A_HUMAN Unconventional myosin-XVIIIa 0.372 0 2 
   
0 
 
Q8N1A0 KT222_HUMAN Keratin-like protein KRT222 
   
6.625 0 2 0 
 
P35900 K1C20_HUMAN Keratin, type I cytoskeletal 20 
   
6.625 0 2 0 
 
Q9BRX8 F213A_HUMAN Redox-regulatory protein FAM213A 
   
6.748 0 2 0 
 
Q9UBX3 DIC_HUMAN Mitochondrial dicarboxylate carrier 0.383 0 2 
   
0 
 
Q6ZR08 DYH12_HUMAN Dynein heavy chain 12, axonemal 0.384 0 2 
   
0 
 
O14578 CTRO_HUMAN Citron Rho-interacting kinase 0.386 0 2 
   
0 
 
- DHSB_HUMAN - 
   
2.114 0.314 16 0 
 
Q14151 SAFB2_HUMAN Scaffold attachment factor B2 
   
1.734 0.092 8 0 
 
P14678 RSMB_HUMAN 
Small nuclear ribonucleoprotein-associated 
proteins B and B' 
   
1.965 0.414 3 0 
 
P49756 RBM25_HUMAN RNA-binding protein 25 
   
1.966 0 2 0 
 
Q9UFH2 DYH17_HUMAN Dynein heavy chain 17, axonemal 
   
1.968 0 2 0 
 
P30510 1C14_HUMAN 
HLA class I histocompatibility antigen, Cw-14 
alpha chain 
   
1.974 0 2 0 
 
Q29865 1C18_HUMAN 
HLA class I histocompatibility antigen, Cw-18 
alpha chain 
   
1.974 0 2 0 
 
P30504 1C04_HUMAN 
HLA class I histocompatibility antigen, Cw-4 
alpha chain 
   
1.974 0 2 0 
 
P17693 HLAG_HUMAN 
HLA class I histocompatibility antigen, alpha 
chain G 
   
1.974 0 2 0 
 
P78559 MAP1A_HUMAN Microtubule-associated protein 1A 0.398 0 2 
   
0 
 
Q6P1L8 RM14_HUMAN 39S ribosomal protein L14, mitochondrial 
   
1.949 0 2 0 
 
Q13185 CBX3_HUMAN Chromobox protein homolog 3 
   
1.106 0 2 0 
 
P83916 CBX1_HUMAN Chromobox protein homolog 1 
   
1.106 0 2 0 
 
P12268 IMDH2_HUMAN Inosine-5'-monophosphate dehydrogenase 2 
   
1.107 0.162 14 0 
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Q9H5Q4 TFB2M_HUMAN 
Dimethyladenosine transferase 2, 
mitochondrial 
   
1.642 0 2 0 
 
Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein 
   
1.643 0 2 0 
 
P19404 NDUV2_HUMAN 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
   
2.065 0.146 3 0 
 
Q16718 NDUA5_HUMAN 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 5 
   
1.853 0 2 0 
 
Q9P015 RM15_HUMAN 39S ribosomal protein L15, mitochondrial 
   
1.853 0 2 0 
 
Q5SY16 NOL9_HUMAN Polynucleotide 5'-hydroxyl-kinase NOL9 
   
1.84 0.219 12 0 
 
Q8NDA2 HMCN2_HUMAN Hemicentin-2 0.697 0.32 4 
   
0 
 
Q15006 EMC2_HUMAN ER membrane protein complex subunit 2 
   
1.401 0.18 10 0 
 
P55769 NH2L1_HUMAN NHP2-like protein 1 
   
2.241 0.155 6 0 
 
- DEN_HHV11 - 
   
2.141 0 2 0 
 
Q4G0P3 HYDIN_HUMAN Hydrocephalus-inducing protein homolog 0.424 0 2 
   
0 
 
P13646 K1C13_HUMAN Keratin, type I cytoskeletal 13 
   
3.737 1.784 8 0 
 
Q9Y230 RUVB2_HUMAN RuvB-like 2 
   
1.368 0.23 12 0 
 
Q7Z3Z0 K1C25_HUMAN Keratin, type I cytoskeletal 25 0.445 0.03 4 
   
0 
 
Q7Z3Y9 K1C26_HUMAN Keratin, type I cytoskeletal 26 0.445 0.03 4 
   
0 
 
Q7Z3Y8 K1C27_HUMAN Keratin, type I cytoskeletal 27 0.445 0.03 4 
   
0 
 
P11277 SPTB1_HUMAN Spectrin beta chain, erythrocytic 
   
1.634 0 2 0 
 
P52907 CAZA1_HUMAN F-actin-capping protein subunit alpha-1 
   
1.539 0.168 8 0 
 
P62314 SMD1_HUMAN Small nuclear ribonucleoprotein Sm D1 0.451 0.02 6 
   
0 
 
P25445 TNR6_HUMAN 
Tumor necrosis factor receptor superfamily 
member 6 
   
1.457 0.14 12 0 
 
Q29RF7 PDS5A_HUMAN 
Sister chromatid cohesion protein PDS5 
homolog A 
   
1.459 0.093 6 0 
 
Q9BSD7 NTPCR_HUMAN Cancer-related nucleoside-triphosphatase 
   
1.423 0.345 4 0 
 
Q9NVI7 ATD3A_HUMAN 
ATPase family AAA domain-containing 
protein 3A 
   
1.744 0.573 12 0 
 
Q9UQE7 SMC3_HUMAN 
Structural maintenance of chromosomes 
protein 3 
   
1.66 0.402 12 0 
 
Q8IY95 TM192_HUMAN Transmembrane protein 192 
   
1.759 0.067 6 0 
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Q92797 SYMPK_HUMAN Symplekin 
   
2.077 0.26 6 0 
 
Q8NI27 THOC2_HUMAN THO complex subunit 2 
   
1.775 0.097 5 0 
 
Q9Y512 SAM50_HUMAN 
Sorting and assembly machinery component 
50 homolog 
   
1.785 0.093 4 0 
 
Q9Y4W6 AFG32_HUMAN AFG3-like protein 2 
   
1.787 0 2 0 
 
Q53H12 AGK_HUMAN Acylglycerol kinase, mitochondrial 0.462 0 2 
   
0 
 
Q8NBS9 TXND5_HUMAN Thioredoxin domain-containing protein 5 
   
1.219 0 2 0 
 
Q9H583 HEAT1_HUMAN HEAT repeat-containing protein 1 0.466 0.42 28 
   
0 
 
Q8NBM4 UBAC2_HUMAN 
Ubiquitin-associated domain-containing 
protein 2 
   
1.136 0 2 0 
 
Q9NSE4 SYIM_HUMAN Isoleucine--tRNA ligase, mitochondrial 
   
1.862 0.662 27 0 
 
P53804 TTC3_HUMAN E3 ubiquitin-protein ligase TTC3 
   
0.611 0 2 0 
 
Q9Y383 LC7L2_HUMAN Putative RNA-binding protein Luc7-like 2 
   
1.506 0.138 10 0 
 
Q9BZE1 RM37_HUMAN 39S ribosomal protein L37, mitochondrial 
   
1.488 1.027 4 0 
 
Q7Z3Y7 K1C28_HUMAN Keratin, type I cytoskeletal 28 0.477 0.19 10 
   
0 
 
Q8N684 CPSF7_HUMAN 
Cleavage and polyadenylation specificity 
factor subunit 7 
0.478 0.02 6 
   
0 
 
Q5JTV8 TOIP1_HUMAN Torsin-1A-interacting protein 1 
   
2.566 1.072 4 0 
 
Q9BQ67 GRWD1_HUMAN 
Glutamate-rich WD repeat-containing protein 
1 
   
1.683 0 2 0 
 
O94906 PRP6_HUMAN Pre-mRNA-processing factor 6 
   
1.684 0.325 14 0 
 
Q8NAT2 TDRD5_HUMAN Tudor domain-containing protein 5 0.48 0 2 
   
0 
 
Q96RL7 VP13A_HUMAN 
Vacuolar protein sorting-associated protein 
13A 
0.48 0 2 
   
0 
 
Q9P225 DYH2_HUMAN Dynein heavy chain 2, axonemal 0.481 0 2 
   
0 
 
Q8WXX0 DYH7_HUMAN Dynein heavy chain 7, axonemal 0.483 0 2 
   
0 
 
- R1AB_CVHOC - 
   
1.266 0.518 6 0 
 
- R1A_CVHOC - 
   
1.266 0.518 6 0 
 
P30040 ERP29_HUMAN Endoplasmic reticulum resident protein 29 
   
1.425 0 2 0 
 
Q16850 CP51A_HUMAN Lanosterol 14-alpha demethylase 
   
1.418 0 2 0 
 
P42765 THIM_HUMAN 3-ketoacyl-CoA thiolase, mitochondrial 
   
1.636 0.329 10 0 
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Q9NW13 RBM28_HUMAN RNA-binding protein 28 0.501 0.15 12 
   
0 
 
Q9Y6M5 ZNT1_HUMAN Zinc transporter 1 
   
1.315 0 2 0 
 
Q9UHX1 PUF60_HUMAN Poly(U)-binding-splicing factor PUF60 
   
1.578 0.52 6 0 
 
Q9Y2L1 RRP44_HUMAN Exosome complex exonuclease RRP44 
   
1.359 0 2 0 
 
P04156 PRIO_HUMAN Major prion protein 
   
1.361 0.014 8 0 
 
O60508 PRP17_HUMAN Pre-mRNA-processing factor 17 
   
1.361 0 2 0 
 
Q9Y320 TMX2_HUMAN Thioredoxin-related transmembrane protein 2 
   
1.361 0 2 0 
 
O94901 SUN1_HUMAN SUN domain-containing protein 1 0.506 0 4 
   
0 
 
Q8IUE6 H2A2B_HUMAN Histone H2A type 2-B 0.511 0.13 4 
   
0 
 
Q14674 ESPL1_HUMAN Separin 0.513 
 
1 
   
0 
 
Q16787 LAMA3_HUMAN Laminin subunit alpha-3 0.521 0 2 
   
0 
 
O95071 UBR5_HUMAN E3 ubiquitin-protein ligase UBR5 0.527 0 2 
   
0 
 
O14936 CSKP_HUMAN Peripheral plasma membrane protein CASK 0.528 0 2 
   
0 
 
O95292 VAPB_HUMAN 
Vesicle-associated membrane protein-
associated protein B/C 
   
1.767 0.115 4 0 
 
Q01081 U2AF1_HUMAN Splicing factor U2AF 35 kDa subunit 
   
1.678 0.025 4 0 
 
P21817 RYR1_HUMAN Ryanodine receptor 1 0.537 0.45 4 
   
0 
 
O75251 NDUS7_HUMAN 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 7, mitochondrial 
   
1.957 0.091 6 0 
 
Q6NZI2 PTRF_HUMAN Polymerase I and transcript release factor 
   
1.265 0.269 4 0 
 
Q587I9 SFT2C_HUMAN Vesicle transport protein SFT2C 
   
1.464 0.051 3 0 
 
Q9NQA5 TRPV5_HUMAN 
Transient receptor potential cation channel 
subfamily V member 5 
   
1.292 0 2 0 
 
Q9BX66 SRBS1_HUMAN Sorbin and SH3 domain-containing protein 1 
   
1.293 0 2 0 
 
Q9Y394 DHRS7_HUMAN 
Dehydrogenase/reductase SDR family 
member 7 
   
1.339 0.257 4 0 
 
Q9BXP5 SRRT_HUMAN Serrate RNA effector molecule homolog 
   
1.341 0 2 0 
 
P38159 RBMX_HUMAN RNA-binding motif protein, X chromosome 
   
1.342 0 2 0 
 
Q96E39 RMXL1_HUMAN RNA binding motif protein, X-linked-like-1 
   
1.342 0 2 0 
 
Q96QV6 H2A1A_HUMAN Histone H2A type 1-A 0.55 0.09 10 
   
0 
 
P16104 H2AX_HUMAN Histone H2AX 0.55 0.09 10 
   
0 
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Q12873 CHD3_HUMAN 
Chromodomain-helicase-DNA-binding protein 
3 
   
1.24 0 2 0 
 
Q8TDI0 CHD5_HUMAN 
Chromodomain-helicase-DNA-binding protein 
5 
   
1.24 0 2 0 
 
Q99798 ACON_HUMAN Aconitate hydratase, mitochondrial 
   
2.574 0 2 0 
 
O60763 USO1_HUMAN General vesicular transport factor p115 
   
1.146 0.069 4 0 
 
Q6DRA6 H2B2D_HUMAN Putative histone H2B type 2-D 
   
1.322 0 2 0 
 
O75915 PRAF3_HUMAN PRA1 family protein 3 
   
1.297 0.116 6 0 
 
Q8WUM0 NU133_HUMAN Nuclear pore complex protein Nup133 
   
1.298 0 2 0 
 
Q9C0F0 ASXL3_HUMAN Putative Polycomb group protein ASXL3 0.578 0.03 4 
   
0 
 
Q8WXF1 PSPC1_HUMAN Paraspeckle component 1 
   
1.531 0.415 6 0 
 
Q6ZRV2 FA83H_HUMAN Protein FAM83H 
   
1.481 0.294 4 0 
 
P54753 EPHB3_HUMAN Ephrin type-B receptor 3 
   
1.28 0 2 0 
 
Q13283 G3BP1_HUMAN 
Ras GTPase-activating protein-binding 
protein 1 
0.59 0.1 18 
   
0 
 
Q15751 HERC1_HUMAN Probable E3 ubiquitin-protein ligase HERC1 0.594 0.5 4 
   
0 
 
P28288 ABCD3_HUMAN ATP-binding cassette sub-family D member 3 0.601 0.13 22 
   
0 
 
Q9UKA9 PTBP2_HUMAN Polypyrimidine tract-binding protein 2 
   
1.316 0 2 0 
 
Q149N8 SHPRH_HUMAN E3 ubiquitin-protein ligase SHPRH 
   
2.019 0 2 0 
 
P0C0S5 H2AZ_HUMAN Histone H2A.Z 0.608 0.02 6 
   
0 
 
Q71UI9 H2AV_HUMAN Histone H2A.V 0.608 0.02 6 
   
0 
 
P54886 P5CS_HUMAN Delta-1-pyrroline-5-carboxylate synthase 
   
1.417 0.443 12 0 
 
P11532 DMD_HUMAN Dystrophin 
   
1.077 0.544 4 0 
 
Q8WUD1 RAB2B_HUMAN Ras-related protein Rab-2B 
   
1.077 0.346 8 0 
 
P11498 PYC_HUMAN Pyruvate carboxylase, mitochondrial 
   
1.228 1.739 22 0 
 
- K1967_HUMAN - 
   
1.23 0.104 12 0 
 
Q5JRX3 PREP_HUMAN Presequence protease, mitochondrial 
   
1.232 0 2 0 
 
Q9P2P6 STAR9_HUMAN StAR-related lipid transfer protein 9 0.628 0 2 
   
0 
 
Q9Y305 ACOT9_HUMAN 
Acyl-coenzyme A thioesterase 9, 
mitochondrial 
   
1.33 0.241 12 0 
 
Q9H2J7 S6A15_HUMAN 
Sodium-dependent neutral amino acid 
0.632 0 2 
   
0 
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transporter B(0)AT2 
Q6NUK1 SCMC1_HUMAN 
Calcium-binding mitochondrial carrier protein 
SCaMC-1 
0.635 0.13 4 
   
0 
 
P02549 SPTA1_HUMAN Spectrin alpha chain, erythrocytic 1 0.64 0 2 
   
0 
 
P37108 SRP14_HUMAN Signal recognition particle 14 kDa protein 
   
0.939 0.026 8 0 
 
Q9NXF1 TEX10_HUMAN Testis-expressed sequence 10 protein 0.658 0.16 6 
   
0 
 
Q12923 PTN13_HUMAN 
Tyrosine-protein phosphatase non-receptor 
type 13 
0.666 0 2 
   
0 
 
P20674 COX5A_HUMAN 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
0.668 0.52 6 
   
0 
 
Q4VXU2 PAP1L_HUMAN Polyadenylate-binding protein 1-like 
   
0.888 0.227 4 0 
 
Q9Y4L1 HYOU1_HUMAN Hypoxia up-regulated protein 1 0.672 0.09 16 
   
0 
 
Q96A33 CCD47_HUMAN Coiled-coil domain-containing protein 47 0.673 0.4 20 
   
0 
 
Q8TDW7 FAT3_HUMAN Protocadherin Fat 3 0.675 0 2 
   
0 
 
Q9H2M9 RBGPR_HUMAN 
Rab3 GTPase-activating protein non-catalytic 
subunit 
0.681 0 2 
   
0 
 
Q9Y2H5 PKHA6_HUMAN 
Pleckstrin homology domain-containing family 
A member 6 
   
1.018 0.111 4 0 
 
Q8WVM8 SCFD1_HUMAN Sec1 family domain-containing protein 1 
   
1.024 0.165 12 0 
 
O95714 HERC2_HUMAN E3 ubiquitin-protein ligase HERC2 0.693 
 
1 
   
0 
 
Q86UQ4 ABCAD_HUMAN 
ATP-binding cassette sub-family A member 
13 
0.694 0 2 
   
0 
 
Q460N5 PAR14_HUMAN Poly [ADP-ribose] polymerase 14 0.695 0.3 6 
   
0 
 
Q12830 BPTF_HUMAN Nucleosome-remodeling factor subunit BPTF 0.701 0 2 
   
0 
 
P51587 BRCA2_HUMAN Breast cancer type 2 susceptibility protein 0.704 0 2 
   
0 
 
- ENV_FOAMV - 0.717 0.01 3 
   
0 
 
P08F94 PKHD1_HUMAN Fibrocystin 0.718 0.54 4 
   
0 
 
P30876 RPB2_HUMAN 
DNA-directed RNA polymerase II subunit 
RPB2 
   
1.234 0.003 4 0 
 
P50395 GDIB_HUMAN Rab GDP dissociation inhibitor beta 0.734 0.3 4 
   
0 
 
Q92736 RYR2_HUMAN Ryanodine receptor 2 0.737 0 2 
   
0 
 
Q92526 TCPW_HUMAN T-complex protein 1 subunit zeta-2 
   
0.944 0 2 0 
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Q9BZZ5 API5_HUMAN Apoptosis inhibitor 5 0.738 0.08 4 
   
0 
 
Q9P003 CNIH4_HUMAN Protein cornichon homolog 4 0.739 0.13 6 
   
0 
 
Q9Y221 NIP7_HUMAN 
60S ribosome subunit biogenesis protein 
NIP7 homolog 
0.743 0 2 
   
0 
 
Q13905 RPGF1_HUMAN Rap guanine nucleotide exchange factor 1 0.75 0.54 4 
   
0 
 
- R1A_CVHSA - 
   
1.032 0 2 0 
 
O15027 SC16A_HUMAN Protein transport protein Sec16A 0.809 0.18 8 
   
0 
 
P05026 AT1B1_HUMAN 
Sodium/potassium-transporting ATPase 
subunit beta-1 
   
1.148 0.082 8 0 
 
P33527 MRP1_HUMAN Multidrug resistance-associated protein 1 0.786 0.03 6 
   
0 
 
O75165 DJC13_HUMAN DnaJ homolog subfamily C member 13 0.787 0.18 14 
   
0 
 
Q14517 FAT1_HUMAN Protocadherin Fat 1 0.789 0.77 8 
   
0 
 
Q58FF7 H90B3_HUMAN Putative heat shock protein HSP 90-beta-3 
   
0.974 0.042 5 0 
 
P13667 PDIA4_HUMAN Protein disulfide-isomerase A4 
   
1.604 0.946 12 0 
 
Q8N4Y2 EFC4A_HUMAN 
EF-hand calcium-binding domain-containing 
protein 4A 
   
1.217 0 2 0 
 
P55884 EIF3B_HUMAN 
Eukaryotic translation initiation factor 3 
subunit B 
   
0.753 0.021 10 0 
 
A6NNZ2 TBB8L_HUMAN Tubulin beta-8 chain-like protein LOC260334 
   
0.754 0.048 4 0 
 
Q9H254 SPTN4_HUMAN Spectrin beta chain, non-erythrocytic 4 0.817 0.79 4 
   
0 
 
Q13501 SQSTM_HUMAN Sequestosome-1 
   
1.14 0.219 10 0 
 
Q8NF37 PCAT1_HUMAN Lysophosphatidylcholine acyltransferase 1 0.822 0 2 
   
0 
 
O95425 SVIL_HUMAN Supervillin 
   
1.306 0 2 0 
 
Q12802 AKP13_HUMAN A-kinase anchor protein 13 0.824 0 2 
   
0 
 
P34932 HSP74_HUMAN Heat shock 70 kDa protein 4 0.826 0 2 
   
0 
 
Q01518 CAP1_HUMAN Adenylyl cyclase-associated protein 1 
   
0.849 0.238 8 0 
 
Q86WV6 STING_HUMAN Stimulator of interferon genes protein 0.834 0.03 8 
   
0 
 
Q8IXB1 DJC10_HUMAN DnaJ homolog subfamily C member 10 0.838 0.06 4 
   
0 
 
Q9HC07 TM165_HUMAN Transmembrane protein 165 
   
0.764 0.591 4 0 
 
Q9Y6E2 BZW2_HUMAN 
Basic leucine zipper and W2 domain-
containing protein 2 
   
0.788 0 2 0 
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P14868 SYDC_HUMAN Aspartate--tRNA ligase, cytoplasmic 
   
0.788 0.051 4 0 
 
O60568 PLOD3_HUMAN 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3 
   
1.257 0 2 0 
 
P54707 AT12A_HUMAN 
Potassium-transporting ATPase alpha chain 
2 
   
1.258 0 2 0 
 
P0CG08 GPHRB_HUMAN Golgi pH regulator B 
   
0.96 0.2 4 0 
 
A6NKF9 GPHRC_HUMAN Putative Golgi pH regulator C 
   
0.96 0.2 4 0 
 
B7ZAQ6 GPHRA_HUMAN Golgi pH regulator A 
   
0.96 0.2 4 0 
 
O75592 MYCB2_HUMAN E3 ubiquitin-protein ligase MYCBP2 
   
0.962 0 2 0 
 
P30508 1C12_HUMAN 
HLA class I histocompatibility antigen, Cw-12 
alpha chain 
   
0.99 0.608 8 0 
 
Q29960 1C16_HUMAN 
HLA class I histocompatibility antigen, Cw-16 
alpha chain 
   
0.99 0.608 8 0 
 
P30505 1C08_HUMAN 
HLA class I histocompatibility antigen, Cw-8 
alpha chain 
   
0.99 0.608 8 0 
 
Q29963 1C06_HUMAN 
HLA class I histocompatibility antigen, Cw-6 
alpha chain 
   
0.99 0.608 8 0 
 
Q07000 1C15_HUMAN 
HLA class I histocompatibility antigen, Cw-15 
alpha chain 
   
0.99 0.608 8 0 
 
P30501 1C02_HUMAN 
HLA class I histocompatibility antigen, Cw-2 
alpha chain 
   
0.99 0.608 8 0 
 
Q9TNN7 1C05_HUMAN 
HLA class I histocompatibility antigen, Cw-5 
alpha chain 
   
0.99 0.608 8 0 
 
Q8IZA0 K319L_HUMAN 
Dyslexia-associated protein KIAA0319-like 
protein 
   
0.99 0.262 4 0 
 
P30455 1A36_HUMAN 
HLA class I histocompatibility antigen, A-36 
alpha chain 
   
0.99 0.608 8 0 
 
P16188 1A30_HUMAN 
HLA class I histocompatibility antigen, A-30 
alpha chain 
   
0.99 0.608 8 0 
 
P05534 1A24_HUMAN 
HLA class I histocompatibility antigen, A-24 
alpha chain 
   
0.99 0.608 8 0 
 
P30447 1A23_HUMAN 
HLA class I histocompatibility antigen, A-23 
alpha chain 
   
0.99 0.608 8 0 
 
P13746 1A11_HUMAN 
HLA class I histocompatibility antigen, A-11 
alpha chain 
   
0.99 0.608 8 0 
 
P04439 1A03_HUMAN 
HLA class I histocompatibility antigen, A-3 
alpha chain 
   
0.99 0.608 8 0 
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P30443 1A01_HUMAN 
HLA class I histocompatibility antigen, A-1 
alpha chain 
   
0.99 0.608 8 0 
 
P01893 HLAH_HUMAN 
Putative HLA class I histocompatibility 
antigen, alpha chain H 
   
0.99 0.608 8 0 
 
O95674 CDS2_HUMAN Phosphatidate cytidylyltransferase 2 
   
0.991 0 2 0 
 
P20042 IF2B_HUMAN 
Eukaryotic translation initiation factor 2 
subunit 2 
   
1.083 0.187 6 0 
 
Q9UBF2 COPG2_HUMAN Coatomer subunit gamma-2 0.852 0.39 4 
   
0 
 
O94973 AP2A2_HUMAN AP-2 complex subunit alpha-2 0.887 0.13 26 
   
0 
 
P07195 LDHB_HUMAN L-lactate dehydrogenase B chain 
   
0.815 0.044 8 0 
 
P51809 VAMP7_HUMAN Vesicle-associated membrane protein 7 0.884 0.08 20 
   
0 
 
P04114 APOB_HUMAN Apolipoprotein B-100 0.866 0.48 10 
   
0 
 
P46776 RL27A_HUMAN 60S ribosomal protein L27a 
   
0.904 0.069 12 0 
 
P42167 LAP2B_HUMAN 
Lamina-associated polypeptide 2, isoforms 
beta/gamma 
   
0.905 0.141 20 0 
 
Q58FG1 HS904_HUMAN Putative heat shock protein HSP 90-alpha A4 0.878 0 2 
   
0 
 
Q9BZF1 OSBL8_HUMAN Oxysterol-binding protein-related protein 8 0.882 0.3 8 
   
0 
 
P39019 RS19_HUMAN 40S ribosomal protein S19 
   
0.856 0.175 6 0 
 
- CHCH3_HUMAN - 
   
1.35 0.062 4 0 
 
P46783 RS10_HUMAN 40S ribosomal protein S10 0.893 0.01 4 
   
0 
 
P10620 MGST1_HUMAN Microsomal glutathione S-transferase 1 0.895 0.02 6 
   
0 
 
Q9NZJ4 SACS_HUMAN Sacsin 0.895 0 2 
   
0 
 
Q01844 EWS_HUMAN RNA-binding protein EWS 
   
1.039 0.535 6 0 
 
Q9Y5S2 MRCKB_HUMAN Serine/threonine-protein kinase MRCK beta 0.898 0 2 
   
0 
 
P57088 TMM33_HUMAN Transmembrane protein 33 0.9 0 2 
   
0 
 
Q969V3 NCLN_HUMAN Nicalin 
   
0.798 0.001 4 0 
 
Q9UBV2 SE1L1_HUMAN Protein sel-1 homolog 1 0.925 0.54 8 
   
0 
 
Q5T890 ER6L2_HUMAN DNA excision repair protein ERCC-6-like 2 0.926 0 2 
   
0 
 
Q99698 LYST_HUMAN Lysosomal-trafficking regulator 
   
0.87 0 2 0 
 
A4UGR9 XIRP2_HUMAN Xin actin-binding repeat-containing protein 2 0.929 0.25 5 
   
0 
 
Q68DK2 ZFY26_HUMAN 
Zinc finger FYVE domain-containing protein 
0.936 0 2 
   
0 
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26 
Q6ZMW3 EMAL6_HUMAN 
Echinoderm microtubule-associated protein-
like 6 
   
1.016 0 2 0 
 
Q5SZK8 FREM2_HUMAN FRAS1-related extracellular matrix protein 2 0.947 0 2 
   
0 
 
Q8WXG9 GPR98_HUMAN G-protein coupled receptor 98 
   
0.828 0 2 0 
 
Q9H490 PIGU_HUMAN 
Phosphatidylinositol glycan anchor 
biosynthesis class U protein 
0.955 0.01 4 
   
0 
 
Q5JNZ5 RS26L_HUMAN Putative 40S ribosomal protein S26-like 1 0.958 0.04 4 
   
0 
 
Q12907 LMAN2_HUMAN Vesicular integral-membrane protein VIP36 0.962 0 2 
   
0 
 
Q08722 CD47_HUMAN Leukocyte surface antigen CD47 
   
0.901 0.043 4 0 
 
Q6NUM9 RETST_HUMAN All-trans-retinol 13,14-reductase 0.967 0.15 4 
   
0 
 
O95864 FADS2_HUMAN Fatty acid desaturase 2 
   
1.097 0.156 8 0 
 
Q9Y6M1 IF2B2_HUMAN 
Insulin-like growth factor 2 mRNA-binding 
protein 2 
   
0.774 0.222 8 0 
 
P16401 H15_HUMAN Histone H1.5 
   
1.309 0.155 10 0 
 
Q15041 AR6P1_HUMAN 
ADP-ribosylation factor-like protein 6-
interacting protein 1 
0.972 0 2 
   
0 
 
P27695 APEX1_HUMAN DNA-(apurinic or apyrimidinic site) lyase 
   
0.928 0.273 6 0 
 
Q8TCU4 ALMS1_HUMAN Alstrom syndrome protein 1 
   
0.661 0 2 0 
 
P31150 GDIA_HUMAN Rab GDP dissociation inhibitor alpha 1.004 0.02 4 
   
0 
 
P53992 SC24C_HUMAN Protein transport protein Sec24C 
   
0.518 0 2 0 
 
- L_SABVB - 1.03 0 2 
   
0 
 
Q9Y673 ALG5_HUMAN Dolichyl-phosphate beta-glucosyltransferase 
   
1.454 0 2 0 
 
P22307 NLTP_HUMAN Non-specific lipid-transfer protein 
   
1.455 0 2 0 
 
Q9UBM7 DHCR7_HUMAN 7-dehydrocholesterol reductase 
   
1.455 0 2 0 
 
P63000 RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 
   
0.921 0.376 4 0 
 
Q5ZPR3 CD276_HUMAN CD276 antigen 
   
0.622 0 2 0 
 
Q9Y6V0 PCLO_HUMAN Protein piccolo 
   
0.624 0 2 0 
 
Q9H0X9 OSBL5_HUMAN Oxysterol-binding protein-related protein 5 1.054 0.46 9 
   
0 
 
Q9Y4P3 TBL2_HUMAN Transducin beta-like protein 2 
   
0.725 0.005 4 0 
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P11717 MPRI_HUMAN 
Cation-independent mannose-6-phosphate 
receptor 
1.042 0.47 8 
   
0 
 
Q9H4B7 TBB1_HUMAN Tubulin beta-1 chain 
   
0.791 0.038 2 0 
 
- YI016_HUMAN - 
   
0.791 0.038 2 0 
 
P11217 PYGM_HUMAN Glycogen phosphorylase, muscle form 1.052 0 2 
   
0 
 
P56539 CAV3_HUMAN Caveolin-3 
   
0.53 0 2 0 
 
Q04826 1B40_HUMAN 
HLA class I histocompatibility antigen, B-40 
alpha chain 
   
2.405 0.517 6 0 
 
P30483 1B45_HUMAN 
HLA class I histocompatibility antigen, B-45 
alpha chain 
   
2.405 0.517 6 0 
 
P30480 1B42_HUMAN 
HLA class I histocompatibility antigen, B-42 
alpha chain 
   
2.405 0.517 6 0 
 
P30485 1B47_HUMAN 
HLA class I histocompatibility antigen, B-47 
alpha chain 
   
2.405 0.517 6 0 
 
P30487 1B49_HUMAN 
HLA class I histocompatibility antigen, B-49 
alpha chain 
   
2.405 0.517 6 0 
 
P30481 1B44_HUMAN 
HLA class I histocompatibility antigen, B-44 
alpha chain 
   
2.405 0.517 6 0 
 
P30475 1B39_HUMAN 
HLA class I histocompatibility antigen, B-39 
alpha chain 
   
2.405 0.517 6 0 
 
Q95365 1B38_HUMAN 
HLA class I histocompatibility antigen, B-38 
alpha chain 
   
2.405 0.517 6 0 
 
Q29836 1B67_HUMAN 
HLA class I histocompatibility antigen, B-67 
alpha chain 
   
2.405 0.517 6 0 
 
P18463 1B37_HUMAN 
HLA class I histocompatibility antigen, B-37 
alpha chain 
   
2.405 0.517 6 0 
 
Q29718 1B82_HUMAN 
HLA class I histocompatibility antigen, B-82 
alpha chain 
   
2.405 0.517 6 0 
 
P03989 1B27_HUMAN 
HLA class I histocompatibility antigen, B-27 
alpha chain 
   
2.405 0.517 6 0 
 
P30466 1B18_HUMAN 
HLA class I histocompatibility antigen, B-18 
alpha chain 
   
2.405 0.517 6 0 
 
P01891 1A68_HUMAN 
HLA class I histocompatibility antigen, A-68 
alpha chain 
1.054 0.49 6 
   
0 
 
P30457 1A66_HUMAN 
HLA class I histocompatibility antigen, A-66 
alpha chain 
1.054 0.49 6 
   
0 
 
P30453 1A34_HUMAN 
HLA class I histocompatibility antigen, A-34 
alpha chain 
1.054 0.49 6 
   
0 
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P30450 1A26_HUMAN 
HLA class I histocompatibility antigen, A-26 
alpha chain 
1.054 0.49 6 
   
0 
 
P18462 1A25_HUMAN 
HLA class I histocompatibility antigen, A-25 
alpha chain 
1.054 0.49 6 
   
0 
 
P30479 1B41_HUMAN 
HLA class I histocompatibility antigen, B-41 
alpha chain 
   
2.405 0.517 6 0 
 
P30488 1B50_HUMAN 
HLA class I histocompatibility antigen, B-50 
alpha chain 
   
2.405 0.517 6 0 
 
P01889 1B07_HUMAN 
HLA class I histocompatibility antigen, B-7 
alpha chain 
   
2.405 0.517 6 0 
 
P30460 1B08_HUMAN 
HLA class I histocompatibility antigen, B-8 
alpha chain 
   
2.405 0.517 6 0 
 
P30461 1B13_HUMAN 
HLA class I histocompatibility antigen, B-13 
alpha chain 
   
2.405 0.517 6 0 
 
P30462 1B14_HUMAN 
HLA class I histocompatibility antigen, B-14 
alpha chain 
   
2.405 0.517 6 0 
 
Q9BVG9 PTSS2_HUMAN Phosphatidylserine synthase 2 
   
0.797 
 
1 0 
 
O00487 PSDE_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 14 
   
0.664 0.024 6 0 
 
Q9UG63 ABCF2_HUMAN ATP-binding cassette sub-family F member 2 
   
0.668 0.297 4 0 
 
P27348 1433T_HUMAN 14-3-3 protein theta 
   
0.95 
 
1 0 
 
P59190 RAB15_HUMAN Ras-related protein Rab-15 
   
0.986 0.028 6 0 
 
Q92930 RAB8B_HUMAN Ras-related protein Rab-8B 
   
0.986 0.028 6 0 
 
P61006 RAB8A_HUMAN Ras-related protein Rab-8A 
   
0.986 0.028 6 0 
 
Q709C8 VP13C_HUMAN 
Vacuolar protein sorting-associated protein 
13C 
1.082 1.49 3 
   
0 
 
Q6P2E9 EDC4_HUMAN Enhancer of mRNA-decapping protein 4 
   
0.778 0 2 0 
 
P18206 VINC_HUMAN Vinculin 1.094 0 2 
   
0 
 
Q3V6T2 GRDN_HUMAN Girdin 1.102 0 2 
   
0 
 
- R1AB_CVHNL - 1.103 0 2 
   
0 
 
- R1A_CVHNL - 1.103 0 2 
   
0 
 
Q96P70 IPO9_HUMAN Importin-9 1.105 0 2 
   
0 
 
O14672 ADA10_HUMAN 
Disintegrin and metalloproteinase domain-
containing protein 10 
   
1.165 0.422 6 0 
 
P10321 1C07_HUMAN 
HLA class I histocompatibility antigen, Cw-7 
   
0.658 0 2 0 
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alpha chain 
P31947 1433S_HUMAN 14-3-3 protein sigma 
   
1 0.071 2 0 
 
Q8N3C0 ASCC3_HUMAN 
Activating signal cointegrator 1 complex 
subunit 3 
1.121 0.06 4 
   
0 
 
Q13200 PSMD2_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 2 
1.128 0.21 8 
   
0 
 
Q7Z401 MYCPP_HUMAN C-myc promoter-binding protein 1.141 1.08 4 
   
0 
 
- K6PP_HUMAN - 
   
0.64 0 2 0 
 
A1L0T0 ILVBL_HUMAN Acetolactate synthase-like protein 1.165 0.07 16 
   
0 
 
P22090 RS4Y1_HUMAN 40S ribosomal protein S4, Y isoform 1 
   
0.643 0.208 4 0 
 
Q8TD47 RS4Y2_HUMAN 40S ribosomal protein S4, Y isoform 2 
   
0.643 0.208 4 0 
 
Q6UB99 ANR11_HUMAN Ankyrin repeat domain-containing protein 11 
   
1.173 0 2 0 
 
Q96AE4 FUBP1_HUMAN Far upstream element-binding protein 1 
   
1.178 0.043 6 0 
 
Q9UIG0 BAZ1B_HUMAN Tyrosine-protein kinase BAZ1B 
   
1.179 
 
1 0 
 
O00232 PSD12_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 12 
1.176 0 2 
   
0 
 
Q9UH99 SUN2_HUMAN SUN domain-containing protein 2 1.179 0.24 8 
   
0 
 
Q9BT22 ALG1_HUMAN 
Chitobiosyldiphosphodolichol beta-
mannosyltransferase 
1.182 0.4 4 
   
0 
 
Q9UHB9 SRP68_HUMAN Signal recognition particle subunit SRP68 
   
1.081 0.426 4 0 
 
P35241 RADI_HUMAN Radixin 1.193 0 2 
   
0 
 
P61619 S61A1_HUMAN 
Protein transport protein Sec61 subunit alpha 
isoform 1 
1.201 0 2 
   
0 
 
Q96RQ1 ERGI2_HUMAN 
Endoplasmic reticulum-Golgi intermediate 
compartment protein 2 
   
0.826 0.056 4 0 
 
Q9H5V8 CDCP1_HUMAN CUB domain-containing protein 1 
   
6.047 0.109 4 0 
 
Q9C075 K1C23_HUMAN Keratin, type I cytoskeletal 23 
   
6.09 0 2 0 
 
Q6DN03 H2B2C_HUMAN Putative histone H2B type 2-C 
   
1.322 0 2 0 
 
P42285 SK2L2_HUMAN Superkiller viralicidic activity 2-like 2 
   
1.813 0.011 4 0 
 
Q5THJ4 VP13D_HUMAN 
Vacuolar protein sorting-associated protein 
13D 
1.276 0 2 
   
0 
 
Q15392 DHC24_HUMAN Delta(24)-sterol reductase 
   
0.685 
 
1 0 
 
Q9NYC9 DYH9_HUMAN Dynein heavy chain 9, axonemal 
   
0.714 0.803 4 0 
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P35610 SOAT1_HUMAN Sterol O-acyltransferase 1 1.331 0.03 4 
   
0 
 
Q5W111 SPRY7_HUMAN SPRY domain-containing protein 7 1.662 0.51 8 
   
0 
 
Q9P035 HACD3_HUMAN 
Very-long-chain (3R)-3-hydroxyacyl-CoA 
dehydratase 3 
1.341 0.07 12 
   
0 
 
Q9Y2Q3 GSTK1_HUMAN Glutathione S-transferase kappa 1 
   
1.071 0.506 10 0 
 
P25398 RS12_HUMAN 40S ribosomal protein S12 
   
0.625 0.095 6 0 
 
P23528 COF1_HUMAN Cofilin-1 
   
0.625 0.061 4 0 
 
Q9Y3F4 STRAP_HUMAN 
Serine-threonine kinase receptor-associated 
protein 
   
0.627 0 2 0 
 
Q15046 SYK_HUMAN Lysine--tRNA ligase 
   
0.629 0.049 12 0 
 
O76094 SRP72_HUMAN Signal recognition particle subunit SRP72 
   
0.913 0.482 8 0 
 
P15151 PVR_HUMAN Poliovirus receptor 
   
0.653 0 2 0 
 
Q08J23 NSUN2_HUMAN tRNA (cytosine(34)-C(5))-methyltransferase 
   
0.653 0.053 4 0 
 
O75489 NDUS3_HUMAN 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 3, mitochondrial 
   
0.605 0.005 4 0 
 
Q99536 VAT1_HUMAN 
Synaptic vesicle membrane protein VAT-1 
homolog 
   
0.707 0.155 12 0 
 
P50281 MMP14_HUMAN Matrix metalloproteinase-14 
   
0.616 0 2 0 
 
P20929 NEBU_HUMAN Nebulin 1.374 1.02 12 
   
0 
 
Q96TA1 NIBL1_HUMAN Niban-like protein 1 1.388 0.4 14 
   
0 
 
P56192 SYMC_HUMAN Methionine--tRNA ligase, cytoplasmic 1.398 0.35 12 
   
0 
 
O15371 EIF3D_HUMAN 
Eukaryotic translation initiation factor 3 
subunit D 
   
0.671 0.168 12 0 
 
Q15012 LAP4A_HUMAN 
Lysosomal-associated transmembrane 
protein 4A 
   
0.571 0 2 0 
 
Q5VT25 MRCKA_HUMAN Serine/threonine-protein kinase MRCK alpha 
   
0.709 0 2 0 
 
O00429 DNM1L_HUMAN Dynamin-1-like protein 1.845 1.46 10 
   
0 
 
Q9BRR6 ADPGK_HUMAN ADP-dependent glucokinase 1.494 0.27 4 
   
0 
 
Q99943 PLCA_HUMAN 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase alpha 
1.525 0 2 
   
0 
 
Q9Y281 COF2_HUMAN Cofilin-2 
   
0.678 0 2 0 
 
Q13724 MOGS_HUMAN Mannosyl-oligosaccharide glucosidase 1.556 0.08 4 
   
0 
 
Q9UNK0 STX8_HUMAN Syntaxin-8 1.558 0.09 4 
   
0 
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O96005 CLPT1_HUMAN Cleft lip and palate transmembrane protein 1 
   
0.696 0.196 6 0 
 
P09543 CN37_HUMAN 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
   
1.251 0.324 18 0 
 
Q9UHG3 PCYOX_HUMAN Prenylcysteine oxidase 1 1.632 1.38 20 
   
0 
 
Q7Z2W4 ZCCHV_HUMAN Zinc finger CCCH-type antiviral protein 1 
   
1.335 0.211 10 0 
 
- APOOL_HUMAN - 
   
2.862 0 2 0 
 
Q2TB90 HKDC1_HUMAN Putative hexokinase HKDC1 
   
2.866 0.03 4 0 
 
P62888 RL30_HUMAN 60S ribosomal protein L30 
   
0.847 0.057 8 0 
 
P00558 PGK1_HUMAN Phosphoglycerate kinase 1 
   
0.848 0.247 6 0 
 
Q96N66 MBOA7_HUMAN Lysophospholipid acyltransferase 7 
   
0.881 0.113 10 0 
 
P29144 TPP2_HUMAN Tripeptidyl-peptidase 2 
   
0.914 0.174 6 0 
 
Q8NCM8 DYHC2_HUMAN Cytoplasmic dynein 2 heavy chain 1 1.695 0 2 
   
0 
 
Q9UBI6 GBG12_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-12 
   
0.881 
 
1 0 
 
O15438 MRP3_HUMAN 
Canalicular multispecific organic anion 
transporter 2 
1.76 0.21 6 
   
0 
 
O00299 CLIC1_HUMAN Chloride intracellular channel protein 1 
   
0.225 0.207 4 0 
 
Q13421 MSLN_HUMAN Mesothelin 
   
0.254 0 2 0 
 
O00220 TR10A_HUMAN 
Tumor necrosis factor receptor superfamily 
member 10A 
1.799 0.77 14 
   
0 
 
P30613 KPYR_HUMAN Pyruvate kinase PKLR 
   
0.583 0.04 6 0 
 
Q96RT1 LAP2_HUMAN Protein LAP2 1.838 0.2 4 
   
0 
 
Q9NRQ2 PLS4_HUMAN Phospholipid scramblase 4 
   
0.45 0 2 0 
 
P60174 TPIS_HUMAN Triosephosphate isomerase 
   
0.457 0.209 6 0 
 
Q8TF72 SHRM3_HUMAN Protein Shroom3 1.888 0 2 
   
0 
 
Q04917 1433F_HUMAN 14-3-3 protein eta 
   
0.95 
 
1 0 
 
Q7Z3J3 RGPD4_HUMAN 
RanBP2-like and GRIP domain-containing 
protein 4 
   
1.194 0 2 0 
 
A6NKT7 RGPD3_HUMAN 
RanBP2-like and GRIP domain-containing 
protein 3 
   
1.194 0 2 0 
 
- R1AB_CVH22 - 2.115 0.21 4 
   
0 
 
O75396 SC22B_HUMAN Vesicle-trafficking protein SEC22b 2.206 0.09 4 
   
0 
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Q02809 PLOD1_HUMAN 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 
   
0.377 0.001 6 0 
 
Q8TED1 GPX8_HUMAN Probable glutathione peroxidase 8 
   
0.291 0.001 3 0 
 
- POLG_HPE2W - 2.308 0 2 
   
0 
 
Q9Y4A5 TRRAP_HUMAN 
Transformation/transcription domain-
associated protein 
2.395 2.47 4 
   
0 
 
Q9NZI8 IF2B1_HUMAN 
Insulin-like growth factor 2 mRNA-binding 
protein 1 
   
0.582 0 2 0 
 
O00425 IF2B3_HUMAN 
Insulin-like growth factor 2 mRNA-binding 
protein 3 
   
0.582 0.022 4 0 
 
P55209 NP1L1_HUMAN Nucleosome assembly protein 1-like 1 2.52 0.41 4 
   
0 
 
Q86UW6 N4BP2_HUMAN NEDD4-binding protein 2 
   
0.595 0 2 0 
 
O94874 UFL1_HUMAN E3 UFM1-protein ligase 1 
   
0.595 0 2 0 
 
Q92626 PXDN_HUMAN Peroxidasin homolog 
   
0.596 0.039 4 0 
 
Q8TC12 RDH11_HUMAN Retinol dehydrogenase 11 
   
0.7 0.209 10 0 
 
Q8NEV8 EXPH5_HUMAN Exophilin-5 2.674 0 2 
   
0 
 
Q6NUQ4 TM214_HUMAN Transmembrane protein 214 2.833 0 2 
   
0 
 
Q9NV31 IMP3_HUMAN 
U3 small nucleolar ribonucleoprotein protein 
IMP3 
   
0.363 0 2 0 
 
Q10472 GALT1_HUMAN 
Polypeptide N-
acetylgalactosaminyltransferase 1 
3.348 1.19 16 
   
0 
 
P15529 MCP_HUMAN Membrane cofactor protein 
   
0.459 0 2 0 
 
Q5T4S7 UBR4_HUMAN E3 ubiquitin-protein ligase UBR4 3.607 1.94 10 
   
0 
 
Q9NRR3 C42S2_HUMAN CDC42 small effector protein 2 3.652 0.79 4 
   
0 
 
Q14118 DAG1_HUMAN Dystroglycan 4.043 0 2 
   
0 
 
Q86WI1 PKHL1_HUMAN Fibrocystin-L 4.069 4.08 4 
   
0 
 
O00469 PLOD2_HUMAN 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 
   
0.098 0.011 22 0 
 
Q03252 LMNB2_HUMAN Lamin-B2 
   
0.133 0 2 0 
 
Q9NYQ8 FAT2_HUMAN Protocadherin Fat 2 4.239 0.83 6 
   
0 
 
O60831 PRAF2_HUMAN PRA1 family protein 2 4.325 0.08 4 
   
0 
 
Q8TD57 DYH3_HUMAN Dynein heavy chain 3, axonemal 5.992 11.1 10 
   
0 
 
P04264 K2C1_HUMAN Keratin, type II cytoskeletal 1 9.458 0 2 
   
0 
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- MLL1_HUMAN - 30.97 0 2 
   
0 
 
O15230 LAMA5_HUMAN Laminin subunit alpha-5 41.75 0 2 
   
0 
 
Q6R327 RICTR_HUMAN Rapamycin-insensitive companion of mTOR 66.61 0 2 
   
0 
 
O60664 PLIN3_HUMAN Perilipin-3 0.639 0.37 8 0.446 0.116 14 0.28 1.433 
O75531 BAF_HUMAN Barrier-to-autointegration factor 0.473 0.09 10 0.611 0.059 4 0.29 0.774 
- MLL3_HUMAN - 0.695 0 2 0.492 0 2 0.34 1.413 
Q14978 NOLC1_HUMAN Nucleolar and coiled-body phosphoprotein 1 0.325 0.04 12 1.088 0.106 10 0.35 0.299 
O95613 PCNT_HUMAN Pericentrin 0.373 0 2 0.964 0 2 0.36 0.387 
P13639 EF2_HUMAN Elongation factor 2 0.596 0.08 34 0.648 0.055 38 0.39 0.92 
Q5SRD1 TI23B_HUMAN 
Putative mitochondrial import inner 
membrane translocase subunit Tim23B 
0.315 0 2 1.236 0 2 0.39 0.255 
O14925 TIM23_HUMAN 
Mitochondrial import inner membrane 
translocase subunit Tim23 
0.315 0 2 1.236 0 2 0.39 0.255 
O15121 DEGS1_HUMAN Sphingolipid delta(4)-desaturase DES1 2.078 0 2 0.202 0 2 0.42 10.29 
Q14533 KRT81_HUMAN Keratin, type II cuticular Hb1 0.248 0 6 1.695 0.745 6 0.42 0.146 
O43790 KRT86_HUMAN Keratin, type II cuticular Hb6 0.248 0 6 1.695 0.745 6 0.42 0.146 
P78385 KRT83_HUMAN Keratin, type II cuticular Hb3 0.248 0 6 1.695 0.745 6 0.42 0.146 
P35222 CTNB1_HUMAN Catenin beta-1 0.192 0.03 8 2.19 0.384 19 0.42 0.088 
P02751 FINC_HUMAN Fibronectin 5.895 2.66 4 0.072 0.035 6 0.42 81.88 
Q99714 HCD2_HUMAN 3-hydroxyacyl-CoA dehydrogenase type-2 0.173 0.03 6 2.497 0.34 10 0.43 0.069 
Q7Z794 K2C1B_HUMAN Keratin, type II cytoskeletal 1b 0.086 0 4 5.115 1.216 8 0.44 0.017 
Q3SY84 K2C71_HUMAN Keratin, type II cytoskeletal 71 0.086 0 4 5.115 1.216 8 0.44 0.017 
Q7RTS7 K2C74_HUMAN Keratin, type II cytoskeletal 74 0.086 0 4 5.158 1.076 10 0.44 0.017 
O75071 EFC14_HUMAN 
EF-hand calcium-binding domain-containing 
protein 14 
0.895 0.02 4 0.496 0 2 0.44 1.804 
P57721 PCBP3_HUMAN Poly(rC)-binding protein 3 0.636 0 2 0.698 0.208 8 0.44 0.911 
Q99456 K1C12_HUMAN Keratin, type I cytoskeletal 12 0.128 0.01 4 3.473 0 2 0.44 0.037 
P41091 IF2G_HUMAN 
Eukaryotic translation initiation factor 2 
subunit 3 
0.738 0.13 22 0.603 0.25 12 0.45 1.224 
Q15365 PCBP1_HUMAN Poly(rC)-binding protein 1 0.636 0 2 0.714 0.243 6 0.45 0.891 
P53999 TCP4_HUMAN 
Activated RNA polymerase II transcriptional 
0.6 0.02 4 0.758 0.084 16 0.45 0.792 
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coactivator p15 
P35527 K1C9_HUMAN Keratin, type I cytoskeletal 9 0.131 0.01 6 3.473 0 2 0.45 0.038 
P02533 K1C14_HUMAN Keratin, type I cytoskeletal 14 0.141 0.11 58 3.251 0.948 82 0.46 0.043 
Q2VIR3 IF2GL_HUMAN 
Putative eukaryotic translation initiation factor 
2 subunit 3-like protein 
0.765 0.14 16 0.603 0.31 12 0.46 1.269 
Q9H8H3 MET7A_HUMAN Methyltransferase-like protein 7A 0.195 0.05 10 2.427 0.131 10 0.47 0.08 
P07942 LAMB1_HUMAN Laminin subunit beta-1 0.541 0.03 14 0.879 0.081 14 0.48 0.615 
Q14764 MVP_HUMAN Major vault protein 1.775 0.88 38 0.269 0.012 10 0.48 6.599 
P10412 H14_HUMAN Histone H1.4 0.283 0.03 16 1.696 0.174 12 0.48 0.167 
P16402 H13_HUMAN Histone H1.3 0.283 0.03 16 1.696 0.174 12 0.48 0.167 
P16403 H12_HUMAN Histone H1.2 0.283 0.03 16 1.696 0.174 12 0.48 0.167 
P21397 AOFA_HUMAN Amine oxidase [flavin-containing] A 1.382 0.05 6 0.356 0.106 13 0.49 3.882 
O75477 ERLN1_HUMAN Erlin-1 0.726 0.07 6 0.684 0.099 16 0.5 1.061 
P26038 MOES_HUMAN Moesin 1.193 0 2 0.418 0.102 6 0.5 2.854 
Q01628 IFM3_HUMAN Interferon-induced transmembrane protein 3 0.984 0.39 8 0.51 0.09 20 0.5 1.929 
P08133 ANXA6_HUMAN Annexin A6 11.43 8.5 6 0.044 0 2 0.5 259.7 
Q31612 1B73_HUMAN 
HLA class I histocompatibility antigen, B-73 
alpha chain 
0.774 0 2 0.658 0 2 0.51 1.176 
P62258 1433E_HUMAN 14-3-3 protein epsilon 0.558 0.12 13 0.913 0.063 8 0.51 0.611 
P48047 ATPO_HUMAN ATP synthase subunit O, mitochondrial 0.268 0.11 6 1.907 0.297 9 0.51 0.141 
Q15366 PCBP2_HUMAN Poly(rC)-binding protein 2 0.643 0.02 8 0.795 0.194 14 0.51 0.809 
P07737 PROF1_HUMAN Profilin-1 0.731 0.09 10 0.7 0.043 22 0.51 1.044 
P35637 FUS_HUMAN RNA-binding protein FUS 0.773 0.25 34 0.668 0.158 36 0.52 1.157 
P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A 0.442 0.1 32 1.169 0.253 28 0.52 0.378 
P22492 H1T_HUMAN Histone H1t 0.297 0 2 1.74 0.012 4 0.52 0.171 
Q02539 H11_HUMAN Histone H1.1 0.297 0 2 1.74 0.012 4 0.52 0.171 
Q7Z406 MYH14_HUMAN Myosin-14 0.47 0.01 8 1.1 0.521 16 0.52 0.427 
Q99623 PHB2_HUMAN Prohibitin-2 0.287 0.14 8 1.805 0.266 20 0.52 0.159 
P08729 K2C7_HUMAN Keratin, type II cytoskeletal 7 0.157 0.08 47 3.308 1.313 78 0.52 0.047 
O43776 SYNC_HUMAN Asparagine--tRNA ligase, cytoplasmic 0.764 0.09 6 0.693 0.106 4 0.53 1.102 
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Q9H0D6 XRN2_HUMAN 5'-3' exoribonuclease 2 0.36 0.15 18 1.482 0.35 6 0.53 0.243 
P31949 S10AB_HUMAN Protein S100-A11 0.682 0 6 0.783 0.158 17 0.53 0.871 
Q92621 NU205_HUMAN Nuclear pore complex protein Nup205 0.364 0.07 18 1.47 0.43 16 0.54 0.248 
Q9Y4G6 TLN2_HUMAN Talin-2 1.026 0 2 0.522 0 2 0.54 1.966 
O95299 NDUAA_HUMAN 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
0.28 0.1 6 1.923 0 2 0.54 0.146 
Q16795 NDUA9_HUMAN 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial 
0.399 0 4 1.35 0 2 0.54 0.296 
P04083 ANXA1_HUMAN Annexin A1 0.583 0.14 72 0.924 0.28 66 0.54 0.631 
P78386 KRT85_HUMAN Keratin, type II cuticular Hb5 0.248 0 6 2.175 0.036 4 0.54 0.114 
Q8WUM4 PDC6I_HUMAN Programmed cell death 6-interacting protein 0.946 0.04 6 0.577 0.101 4 0.55 1.64 
Q92804 RBP56_HUMAN TATA-binding protein-associated factor 2N 0.582 0.14 18 0.938 0.27 20 0.55 0.62 
O75746 CMC1_HUMAN 
Calcium-binding mitochondrial carrier protein 
Aralar1 
0.205 0 2 2.667 0.34 10 0.55 0.077 
O94905 ERLN2_HUMAN Erlin-2 0.787 0.09 16 0.699 0.095 20 0.55 1.126 
O75131 CPNE3_HUMAN Copine-3 0.651 0.07 10 0.847 0.109 20 0.55 0.769 
- R1AB_CVHSA - 0.539 0.5 4 1.032 0 2 0.56 0.522 
Q58FF8 H90B2_HUMAN Putative heat shock protein HSP 90-beta 2 0.791 0.03 8 0.706 0.055 12 0.56 1.12 
Q14568 HS902_HUMAN Heat shock protein HSP 90-alpha A2 0.791 0.03 8 0.706 0.055 12 0.56 1.12 
P63104 1433Z_HUMAN 14-3-3 protein zeta/delta 0.634 0.1 21 0.885 0.13 16 0.56 0.716 
P30153 2AAA_HUMAN 
Serine/threonine-protein phosphatase 2A 65 
kDa regulatory subunit A alpha isoform 
0.462 0 2 1.221 0.664 6 0.56 0.378 
P60660 MYL6_HUMAN Myosin light polypeptide 6 0.635 0.05 8 0.89 0.015 4 0.57 0.713 
P04406 G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 0.609 0.07 53 0.934 0.059 36 0.57 0.652 
Q9BUJ2 HNRL1_HUMAN 
Heterogeneous nuclear ribonucleoprotein U-
like protein 1 
0.451 0.08 4 1.262 0.146 8 0.57 0.357 
P13647 K2C5_HUMAN Keratin, type II cytoskeletal 5 0.114 0.06 80 5.003 2.053 123 0.57 0.023 
O95782 AP2A1_HUMAN AP-2 complex subunit alpha-1 1.053 0.19 24 0.546 0.086 8 0.57 1.929 
P52789 HXK2_HUMAN Hexokinase-2 0.272 0.08 8 2.117 0.321 10 0.58 0.128 
Q09666 AHNK_HUMAN 
Neuroblast differentiation-associated protein 
AHNAK 
0.934 1.81 650 0.618 0.186 594 0.58 1.511 
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P23786 CPT2_HUMAN 
Carnitine O-palmitoyltransferase 2, 
mitochondrial 
0.211 0.03 10 2.748 0.473 6 0.58 0.077 
Q96PK6 RBM14_HUMAN RNA-binding protein 14 0.332 0 2 1.754 0.234 12 0.58 0.189 
Q04695 K1C17_HUMAN Keratin, type I cytoskeletal 17 0.081 0.06 42 7.19 2.829 62 0.58 0.011 
P35579 MYH9_HUMAN Myosin-9 0.419 0.11 158 1.41 0.335 158 0.59 0.297 
O94826 TOM70_HUMAN Mitochondrial import receptor subunit TOM70 0.376 0.06 45 1.575 0.213 31 0.59 0.239 
Q53EL6 PDCD4_HUMAN Programmed cell death protein 4 0.472 0.02 4 1.255 0.243 7 0.59 0.376 
P05783 K1C18_HUMAN Keratin, type I cytoskeletal 18 0.142 0.05 11 4.179 1.653 12 0.59 0.034 
Q9NYF8 BCLF1_HUMAN Bcl-2-associated transcription factor 1 0.297 0.07 24 2.002 0.353 20 0.59 0.148 
P08758 ANXA5_HUMAN Annexin A5 2.874 0.88 32 0.207 0.039 29 0.59 13.88 
P11216 PYGB_HUMAN Glycogen phosphorylase, brain form 1.09 0.15 28 0.548 0.07 20 0.6 1.989 
Q03701 CEBPZ_HUMAN CCAAT/enhancer-binding protein zeta 0.3 0.04 24 1.992 0.089 6 0.6 0.151 
P14649 MYL6B_HUMAN Myosin light chain 6B 0.672 0.05 4 0.89 0.015 4 0.6 0.755 
P31946 1433B_HUMAN 14-3-3 protein beta/alpha 0.732 0.23 5 0.822 0.137 10 0.6 0.891 
Q14498 RBM39_HUMAN RNA-binding protein 39 0.477 0.04 30 1.264 0.408 22 0.6 0.377 
Q12905 ILF2_HUMAN Interleukin enhancer-binding factor 2 0.499 0.13 54 1.211 0.187 48 0.6 0.412 
P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha 0.92 0.25 34 0.657 0.158 30 0.6 1.4 
P35221 CTNA1_HUMAN Catenin alpha-1 0.188 0.04 78 3.221 0.499 58 0.61 0.058 
Q8NC51 PAIRB_HUMAN 
Plasminogen activator inhibitor 1 RNA-
binding protein 
0.841 0.05 8 0.721 0.157 6 0.61 1.166 
P09874 PARP1_HUMAN Poly [ADP-ribose] polymerase 1 0.443 0.16 50 1.376 0.159 44 0.61 0.322 
P19012 K1C15_HUMAN Keratin, type I cytoskeletal 15 0.166 0.22 24 3.684 1.578 10 0.61 0.045 
P62318 SMD3_HUMAN Small nuclear ribonucleoprotein Sm D3 0.391 0 4 1.574 0.097 6 0.62 0.248 
P46940 IQGA1_HUMAN Ras GTPase-activating-like protein IQGAP1 0.815 0.16 110 0.756 0.122 118 0.62 1.078 
P49448 DHE4_HUMAN Glutamate dehydrogenase 2, mitochondrial 0.486 0.07 12 1.268 0.127 32 0.62 0.383 
P06733 ENOA_HUMAN Alpha-enolase 0.974 0.18 46 0.635 0.128 52 0.62 1.534 
Q9Y2W1 TR150_HUMAN 
Thyroid hormone receptor-associated protein 
3 
0.345 0.04 15 1.802 0.172 12 0.62 0.191 
P62851 RS25_HUMAN 40S ribosomal protein S25 0.812 0.13 8 0.766 0.061 8 0.62 1.06 
P19338 NUCL_HUMAN Nucleolin 0.6 0.08 128 1.047 0.145 124 0.63 0.573 
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Q9BW60 ELOV1_HUMAN 
Elongation of very long chain fatty acids 
protein 1 
0.787 0 2 0.8 0.025 6 0.63 0.984 
P30048 PRDX3_HUMAN 
Thioredoxin-dependent peroxide reductase, 
mitochondrial 
0.202 0 2 3.131 0.007 4 0.63 0.065 
Q9NSB2 KRT84_HUMAN Keratin, type II cuticular Hb4 0.153 0.09 14 4.135 1.742 12 0.63 0.037 
P13010 XRCC5_HUMAN X-ray repair cross-complementing protein 5 0.514 0.06 110 1.237 0.221 51 0.64 0.416 
P16520 GBB3_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-3 
0.82 0 2 0.776 0.024 6 0.64 1.057 
P20700 LMNB1_HUMAN Lamin-B1 0.445 0.09 38 1.434 0.359 56 0.64 0.31 
Q13423 NNTM_HUMAN NAD(P) transhydrogenase, mitochondrial 0.391 0.07 52 1.633 0.465 51 0.64 0.239 
P62879 GBB2_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
0.77 0.24 14 0.833 0.086 11 0.64 0.924 
O60264 SMCA5_HUMAN 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A 
member 5 
0.405 0 2 1.597 0.386 28 0.65 0.254 
Q13247 SRSF6_HUMAN Serine/arginine-rich splicing factor 6 0.507 0.1 22 1.276 0.204 20 0.65 0.397 
P18031 PTN1_HUMAN 
Tyrosine-protein phosphatase non-receptor 
type 1 
0.608 0.15 6 1.065 0.143 14 0.65 0.571 
P09104 ENOG_HUMAN Gamma-enolase 1.038 0.02 6 0.624 0.011 6 0.65 1.663 
Q9BUF5 TBB6_HUMAN Tubulin beta-6 chain 0.922 0.15 12 0.703 0.047 14 0.65 1.312 
Q9C0G6 DYH6_HUMAN Dynein heavy chain 6, axonemal 1.299 0 2 0.501 0 2 0.65 2.593 
P55084 ECHB_HUMAN 
Trifunctional enzyme subunit beta, 
mitochondrial 
0.427 0.07 36 1.525 0.212 52 0.65 0.28 
Q01082 SPTB2_HUMAN Spectrin beta chain, non-erythrocytic 1 0.629 0.18 150 1.036 0.32 195 0.65 0.607 
Q9H307 PININ_HUMAN Pinin 0.245 0.03 10 2.66 0.498 10 0.65 0.092 
P13929 ENOB_HUMAN Beta-enolase 1.048 0.02 6 0.624 0.011 6 0.65 1.679 
P49748 ACADV_HUMAN 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
0.485 0.12 24 1.349 0.134 38 0.65 0.36 
P21333 FLNA_HUMAN Filamin-A 1.292 0.33 183 0.507 0.147 162 0.66 2.548 
P50990 TCPQ_HUMAN T-complex protein 1 subunit theta 0.757 0.19 36 0.866 0.097 47 0.66 0.874 
P62995 TRA2B_HUMAN Transformer-2 protein homolog beta 0.415 0.06 15 1.589 0.236 18 0.66 0.261 
O00159 MYO1C_HUMAN Unconventional myosin-Ic 0.87 0.1 56 0.759 0.114 44 0.66 1.146 
P52272 HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M 0.503 0.1 58 1.315 0.297 60 0.66 0.383 
Q00610 CLH1_HUMAN Clathrin heavy chain 1 0.998 0.25 146 0.663 0.148 126 0.66 1.505 
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Q15287 RNPS1_HUMAN 
RNA-binding protein with serine-rich domain 
1 
0.356 0.01 12 1.86 0.045 6 0.66 0.191 
Q16698 DECR_HUMAN 2,4-dienoyl-CoA reductase, mitochondrial 0.615 0.1 34 1.077 0.058 30 0.66 0.571 
Q99613 EIF3C_HUMAN 
Eukaryotic translation initiation factor 3 
subunit C 
1.013 0.16 38 0.655 0.099 14 0.66 1.547 
P24539 AT5F1_HUMAN 
ATP synthase F(0) complex subunit B1, 
mitochondrial 
0.376 0.03 26 1.766 0.128 16 0.66 0.213 
P42166 LAP2A_HUMAN 
Lamina-associated polypeptide 2, isoform 
alpha 
0.696 0.31 6 0.959 0.298 20 0.67 0.726 
Q96EY7 PTCD3_HUMAN 
Pentatricopeptide repeat domain-containing 
protein 3, mitochondrial 
0.31 0.08 10 2.155 0.452 18 0.67 0.144 
P63010 AP2B1_HUMAN AP-2 complex subunit beta 1.004 0.17 30 0.666 0.026 12 0.67 1.508 
P08779 K1C16_HUMAN Keratin, type I cytoskeletal 16 0.215 0.14 24 3.111 1.054 28 0.67 0.069 
Q99729 ROAA_HUMAN Heterogeneous nuclear ribonucleoprotein A/B 0.406 0.1 18 1.648 0.103 16 0.67 0.246 
O75947 ATP5H_HUMAN ATP synthase subunit d, mitochondrial 0.349 0.1 20 1.918 0.351 16 0.67 0.182 
Q9UJZ1 STML2_HUMAN Stomatin-like protein 2, mitochondrial 0.308 0.03 34 2.174 0.487 30 0.67 0.142 
P53675 CLH2_HUMAN Clathrin heavy chain 2 1.02 0.14 34 0.657 0.15 32 0.67 1.553 
P13164 IFM1_HUMAN Interferon-induced transmembrane protein 1 1.194 0.01 6 0.562 0.046 14 0.67 2.125 
Q01629 IFM2_HUMAN Interferon-induced transmembrane protein 2 1.194 0.01 6 0.562 0.046 14 0.67 2.125 
P61981 1433G_HUMAN 14-3-3 protein gamma 0.564 0.03 3 1.191 0.287 8 0.67 0.474 
P00338 LDHA_HUMAN L-lactate dehydrogenase A chain 0.845 0.21 22 0.795 0.072 27 0.67 1.063 
Q01814 AT2B2_HUMAN 
Plasma membrane calcium-transporting 
ATPase 2 
0.945 0.1 12 0.711 0.054 14 0.67 1.329 
Q9Y6N5 SQRD_HUMAN 
Sulfide:quinone oxidoreductase, 
mitochondrial 
0.072 0.02 16 9.335 1.625 28 0.67 0.008 
Q9Y3U8 RL36_HUMAN 60S ribosomal protein L36 0.968 0.15 6 0.695 0.06 6 0.67 1.393 
P62857 RS28_HUMAN 40S ribosomal protein S28 0.865 0.02 6 0.779 0.102 10 0.67 1.11 
P60842 IF4A1_HUMAN Eukaryotic initiation factor 4A-I 0.718 0.21 34 0.939 0.247 24 0.67 0.765 
Q9NY65 TBA8_HUMAN Tubulin alpha-8 chain 1.049 0.25 22 0.645 0.098 29 0.68 1.626 
Q14574 DSC3_HUMAN Desmocollin-3 0.044 0 2 15.39 17.09 4 0.68 0.003 
P62873 GBB1_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
0.788 0.23 16 0.86 0.104 15 0.68 0.916 
O15042 SR140_HUMAN 
U2 snRNP-associated SURP motif-containing 
0.452 0.05 4 1.504 0.463 26 0.68 0.301 
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protein 
Q9H9B4 SFXN1_HUMAN Sideroflexin-1 0.355 0.13 28 1.915 0.374 28 0.68 0.185 
Q8WXA9 SREK1_HUMAN 
Splicing regulatory glutamine/lysine-rich 
protein 1 
0.45 0.04 6 1.511 0 2 0.68 0.298 
P62269 RS18_HUMAN 40S ribosomal protein S18 0.792 0.21 4 0.859 0.038 6 0.68 0.922 
Q15149 PLEC_HUMAN Plectin 0.703 0.2 852 0.97 0.229 859 0.68 0.725 
P26232 CTNA2_HUMAN Catenin alpha-2 0.187 0 2 3.656 1.302 6 0.68 0.051 
Q9Y490 TLN1_HUMAN Talin-1 1.621 0.97 95 0.422 0.144 48 0.68 3.841 
P51991 ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3 0.394 0.11 40 1.737 0.452 40 0.68 0.227 
Q14980 NUMA1_HUMAN Nuclear mitotic apparatus protein 1 0.441 0.13 18 1.552 0.346 12 0.68 0.284 
P51648 AL3A2_HUMAN Fatty aldehyde dehydrogenase 0.307 0.08 24 2.23 0.291 28 0.68 0.138 
Q13733 AT1A4_HUMAN 
Sodium/potassium-transporting ATPase 
subunit alpha-4 
0.485 0.09 22 1.414 0.198 23 0.69 0.343 
P49792 RBP2_HUMAN E3 SUMO-protein ligase RanBP2 0.359 0.06 8 1.913 0.477 16 0.69 0.188 
P50993 AT1A2_HUMAN 
Sodium/potassium-transporting ATPase 
subunit alpha-2 
0.505 0.07 46 1.364 0.223 51 0.69 0.37 
Q14103 HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 0.497 0.08 26 1.388 0.426 14 0.69 0.358 
O14979 HNRDL_HUMAN 
Heterogeneous nuclear ribonucleoprotein D-
like 
0.499 0.06 28 1.384 0.522 20 0.69 0.361 
- R1AB_CVHN2 - 0.316 0 2 2.19 0 2 0.69 0.144 
Q13148 TADBP_HUMAN TAR DNA-binding protein 43 0.524 0.08 16 1.321 0.285 14 0.69 0.397 
Q02543 RL18A_HUMAN 60S ribosomal protein L18a 0.914 0.11 14 0.758 0.046 12 0.69 1.206 
Q9UQ80 PA2G4_HUMAN Proliferation-associated protein 2G4 0.652 0.11 20 1.064 0.164 22 0.69 0.613 
Q13740 CD166_HUMAN CD166 antigen 2.307 1.46 10 0.301 0.039 8 0.69 7.664 
Q13084 RM28_HUMAN 39S ribosomal protein L28, mitochondrial 0.366 0 4 1.898 0 2 0.69 0.193 
Q8IY81 SPB1_HUMAN pre-rRNA processing protein FTSJ3 0.377 0.1 32 1.844 0.262 36 0.7 0.204 
P13637 AT1A3_HUMAN 
Sodium/potassium-transporting ATPase 
subunit alpha-3 
0.502 0.07 53 1.385 0.206 63 0.7 0.362 
P00367 DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial 0.545 0.29 34 1.276 0.167 66 0.7 0.427 
Q96IX5 USMG5_HUMAN 
Up-regulated during skeletal muscle growth 
protein 5 
0.309 0 2 2.251 0.31 4 0.7 0.137 
P42677 RS27_HUMAN 40S ribosomal protein S27 0.854 0.07 6 0.815 0.075 10 0.7 1.048 
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P0CW22 RS17L_HUMAN 40S ribosomal protein S17-like 0.955 0.31 30 0.729 0.043 18 0.7 1.31 
P08708 RS17_HUMAN 40S ribosomal protein S17 0.955 0.31 30 0.729 0.043 18 0.7 1.31 
Q08945 SSRP1_HUMAN FACT complex subunit SSRP1 0.737 0.2 32 0.945 0.152 30 0.7 0.78 
Q14974 IMB1_HUMAN Importin subunit beta-1 0.552 0.08 20 1.262 0.121 23 0.7 0.437 
P22087 FBRL_HUMAN rRNA 2'-O-methyltransferase fibrillarin 0.317 0.03 12 2.198 0.278 18 0.7 0.144 
Q9NTI5 PDS5B_HUMAN 
Sister chromatid cohesion protein PDS5 
homolog B 
0.562 0.15 10 1.241 0.317 10 0.7 0.453 
P78527 PRKDC_HUMAN 
DNA-dependent protein kinase catalytic 
subunit 
0.452 0.1 194 1.547 0.325 203 0.7 0.292 
O15523 DDX3Y_HUMAN ATP-dependent RNA helicase DDX3Y 0.681 0.17 24 1.029 0.135 19 0.7 0.662 
P05198 IF2A_HUMAN 
Eukaryotic translation initiation factor 2 
subunit 1 
0.744 0.22 24 0.942 0.057 16 0.7 0.79 
P32969 RL9_HUMAN 60S ribosomal protein L9 0.959 0.1 34 0.734 0.092 26 0.7 1.307 
Q16695 H31T_HUMAN Histone H3.1t 0.496 0.06 12 1.42 0.078 13 0.7 0.349 
P68431 H31_HUMAN Histone H3.1 0.496 0.06 12 1.42 0.078 13 0.7 0.349 
Q71DI3 H32_HUMAN Histone H3.2 0.496 0.06 12 1.42 0.078 13 0.7 0.349 
P84243 H33_HUMAN Histone H3.3 0.496 0.06 12 1.42 0.078 13 0.7 0.349 
P12956 XRCC6_HUMAN X-ray repair cross-complementing protein 6 0.549 0.1 68 1.285 0.185 70 0.71 0.427 
P48668 K2C6C_HUMAN Keratin, type II cytoskeletal 6C 0.114 0.07 62 6.193 2.678 92 0.71 0.018 
Q14254 FLOT2_HUMAN Flotillin-2 1.637 0.27 47 0.432 0.075 32 0.71 3.789 
P28331 NDUS1_HUMAN 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial 
0.367 0.05 48 1.928 0.273 65 0.71 0.19 
P48643 TCPE_HUMAN T-complex protein 1 subunit epsilon 0.833 0.1 58 0.85 0.124 44 0.71 0.98 
Q13509 TBB3_HUMAN Tubulin beta-3 chain 0.974 0.14 34 0.727 0.128 42 0.71 1.34 
- HSP71_HUMAN - 0.522 0.19 30 1.357 0.291 24 0.71 0.385 
Q9HAV0 GBB4_HUMAN 
Guanine nucleotide-binding protein subunit 
beta-4 
0.913 0.13 8 0.777 0.022 7 0.71 1.175 
P22695 QCR2_HUMAN 
Cytochrome b-c1 complex subunit 2, 
mitochondrial 
0.355 0.05 52 1.999 0.469 32 0.71 0.178 
P49368 TCPG_HUMAN T-complex protein 1 subunit gamma 0.789 0.1 46 0.9 0.072 52 0.71 0.877 
Q9UGP8 SEC63_HUMAN Translocation protein SEC63 homolog 0.643 0.18 18 1.105 0.185 8 0.71 0.582 
P31943 HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H 0.477 0.13 52 1.49 0.2 48 0.71 0.32 
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P05787 K2C8_HUMAN Keratin, type II cytoskeletal 8 0.153 0.09 14 4.653 2.402 16 0.71 0.033 
Q8WTT2 NOC3L_HUMAN Nucleolar complex protein 3 homolog 0.324 0.06 16 2.199 0.304 12 0.71 0.147 
Q9BVA1 TBB2B_HUMAN Tubulin beta-2B chain 1.035 0.09 44 0.689 0.12 52 0.71 1.502 
Q13885 TBB2A_HUMAN Tubulin beta-2A chain 1.035 0.09 44 0.689 0.12 52 0.71 1.502 
P04259 K2C6B_HUMAN Keratin, type II cytoskeletal 6B 0.115 0.08 56 6.204 2.768 85 0.71 0.019 
P46781 RS9_HUMAN 40S ribosomal protein S9 0.879 0.33 21 0.812 0.044 6 0.71 1.083 
Q9UJS0 CMC2_HUMAN 
Calcium-binding mitochondrial carrier protein 
Aralar2 
0.245 0.02 22 2.914 0.136 16 0.71 0.084 
P61313 RL15_HUMAN 60S ribosomal protein L15 0.921 0.27 28 0.776 0.158 24 0.71 1.187 
Q96A08 H2B1A_HUMAN Histone H2B type 1-A 0.508 0.1 14 1.41 0.15 13 0.72 0.36 
Q99460 PSMD1_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 1 
1.073 0.29 14 0.668 0.118 14 0.72 1.606 
- DHSA_HUMAN - 0.308 0.16 28 2.329 0.904 19 0.72 0.132 
P61247 RS3A_HUMAN 40S ribosomal protein S3a 0.929 0.11 36 0.773 0.09 28 0.72 1.202 
Q6PEY2 TBA3E_HUMAN Tubulin alpha-3E chain 1.107 0.22 24 0.649 0.05 33 0.72 1.706 
P62750 RL23A_HUMAN 60S ribosomal protein L23a 1.026 0 2 0.701 0.137 9 0.72 1.464 
O75367 H2AY_HUMAN Core histone macro-H2A.1 0.29 0.11 18 2.481 0.469 22 0.72 0.117 
P34931 HS71L_HUMAN Heat shock 70 kDa protein 1-like 0.555 0.19 24 1.297 0.26 30 0.72 0.428 
O75533 SF3B1_HUMAN Splicing factor 3B subunit 1 0.518 0.14 59 1.394 0.31 46 0.72 0.372 
P23246 SFPQ_HUMAN Splicing factor, proline- and glutamine-rich 0.51 0.06 48 1.416 0.172 46 0.72 0.36 
O60841 IF2P_HUMAN Eukaryotic translation initiation factor 5B 0.904 0.17 14 0.799 0.211 24 0.72 1.131 
P60903 S10AA_HUMAN Protein S100-A10 0.88 0.2 26 0.825 0.047 20 0.73 1.067 
P12236 ADT3_HUMAN ADP/ATP translocase 3 0.445 0.11 42 1.636 0.376 34 0.73 0.272 
P43243 MATR3_HUMAN Matrin-3 0.509 0.11 54 1.432 0.155 52 0.73 0.355 
P62266 RS23_HUMAN 40S ribosomal protein S23 0.925 0.12 12 0.788 0.097 15 0.73 1.174 
P02538 K2C6A_HUMAN Keratin, type II cytoskeletal 6A 0.118 0.07 60 6.189 2.764 87 0.73 0.019 
P62854 RS26_HUMAN 40S ribosomal protein S26 1.021 0.07 10 0.716 0.021 6 0.73 1.426 
P0C7P4 UCRIL_HUMAN 
Putative cytochrome b-c1 complex subunit 
Rieske-like protein 1 
0.303 0.06 10 2.413 0.522 14 0.73 0.126 
Q00839 HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U 0.519 0.11 80 1.409 0.149 80 0.73 0.368 
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P62249 RS16_HUMAN 40S ribosomal protein S16 0.814 0.12 13 0.899 0.042 6 0.73 0.905 
P17987 TCPA_HUMAN T-complex protein 1 subunit alpha 0.817 0.1 42 0.896 0.101 52 0.73 0.912 
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein 0.659 0.11 98 1.111 0.094 84 0.73 0.593 
Q13523 PRP4B_HUMAN 
Serine/threonine-protein kinase PRP4 
homolog 
0.314 0.01 4 2.334 0 2 0.73 0.135 
Q71U36 TBA1A_HUMAN Tubulin alpha-1A chain 1.114 0.13 40 0.659 0.089 47 0.73 1.69 
P68363 TBA1B_HUMAN Tubulin alpha-1B chain 1.114 0.12 42 0.659 0.089 47 0.73 1.69 
P23396 RS3_HUMAN 40S ribosomal protein S3 0.964 0.08 53 0.763 0.08 61 0.74 1.263 
P49821 NDUV1_HUMAN 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
0.378 0.1 10 1.946 0.14 12 0.74 0.194 
P62081 RS7_HUMAN 40S ribosomal protein S7 0.941 0.14 16 0.782 0.043 12 0.74 1.203 
Q9BQE3 TBA1C_HUMAN Tubulin alpha-1C chain 1.114 0.12 42 0.661 0.092 43 0.74 1.685 
P07437 TBB5_HUMAN Tubulin beta chain 1.069 0.1 60 0.689 0.139 72 0.74 1.552 
P42704 LPPRC_HUMAN 
Leucine-rich PPR motif-containing protein, 
mitochondrial 
0.369 0.08 99 2 0.309 103 0.74 0.185 
P47985 UCRI_HUMAN 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial 
0.303 0.06 10 2.436 0.49 16 0.74 0.124 
O96008 TOM40_HUMAN 
Mitochondrial import receptor subunit TOM40 
homolog 
0.328 0.06 12 2.252 0.224 20 0.74 0.146 
O00571 DDX3X_HUMAN ATP-dependent RNA helicase DDX3X 0.752 0.13 52 0.985 0.154 39 0.74 0.763 
- IMMT_HUMAN - 0.442 0.15 50 1.676 0.245 50 0.74 0.264 
Q13243 SRSF5_HUMAN Serine/arginine-rich splicing factor 5 0.694 0.19 6 1.068 0.126 12 0.74 0.65 
P83731 RL24_HUMAN 60S ribosomal protein L24 0.954 0.02 14 0.777 0.115 16 0.74 1.228 
A6NIZ1 RP1BL_HUMAN Ras-related protein Rap-1b-like protein 0.58 0.09 8 1.279 0.101 4 0.74 0.453 
P04350 TBB4A_HUMAN Tubulin beta-4A chain 0.974 0.1 32 0.762 0.146 32 0.74 1.278 
P54652 HSP72_HUMAN Heat shock-related 70 kDa protein 2 0.662 0.11 42 1.124 0.056 34 0.74 0.589 
Q15165 PON2_HUMAN Serum paraoxonase/arylesterase 2 2.305 0.14 12 0.323 0.002 4 0.74 7.136 
P62847 RS24_HUMAN 40S ribosomal protein S24 0.951 0 2 0.783 0.017 6 0.74 1.215 
Q14839 CHD4_HUMAN 
Chromodomain-helicase-DNA-binding protein 
4 
0.48 0.09 14 1.552 0.279 30 0.74 0.309 
P07355 ANXA2_HUMAN Annexin A2 1.163 0.13 144 0.641 0.092 133 0.75 1.814 
P63241 IF5A1_HUMAN Eukaryotic translation initiation factor 5A-1 0.7 0.09 4 1.065 0.142 8 0.75 0.657 
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Q12846 STX4_HUMAN Syntaxin-4 1.059 0.19 8 0.704 0.101 20 0.75 1.504 
- R13AX_HUMAN - 0.901 0.08 6 0.828 0.077 6 0.75 1.088 
Q6S8J3 POTEE_HUMAN POTE ankyrin domain family member E 0.576 0.1 32 1.298 0.07 18 0.75 0.444 
P68371 TBB4B_HUMAN Tubulin beta-4B chain 1.01 0.11 50 0.741 0.151 60 0.75 1.363 
P35659 DEK_HUMAN Protein DEK 0.407 0.12 15 1.839 0.107 14 0.75 0.221 
O75844 FACE1_HUMAN CAAX prenyl protease 1 homolog 0.683 0.11 22 1.096 0.136 18 0.75 0.623 
Q01130 SRSF2_HUMAN Serine/arginine-rich splicing factor 2 0.456 0.01 6 1.642 0.026 6 0.75 0.278 
P52790 HXK3_HUMAN Hexokinase-3 0.317 0.01 6 2.363 0.063 6 0.75 0.134 
P0CG38 POTEI_HUMAN POTE ankyrin domain family member I 0.574 0.07 20 1.306 0.016 6 0.75 0.44 
P0CG39 POTEJ_HUMAN POTE ankyrin domain family member J 0.574 0.07 20 1.306 0.016 6 0.75 0.44 
P63244 GBLP_HUMAN 
Guanine nucleotide-binding protein subunit 
beta-2-like 1 
0.945 0.08 26 0.794 0.107 34 0.75 1.19 
P46777 RL5_HUMAN 60S ribosomal protein L5 0.96 0.07 38 0.782 0.076 40 0.75 1.228 
O95831 AIFM1_HUMAN Apoptosis-inducing factor 1, mitochondrial 0.398 0.1 38 1.891 0.423 36 0.75 0.21 
P62917 RL8_HUMAN 60S ribosomal protein L8 0.935 0.21 15 0.805 0.066 12 0.75 1.161 
P14866 HNRPL_HUMAN Heterogeneous nuclear ribonucleoprotein L 0.474 0.09 72 1.588 0.284 74 0.75 0.298 
P62906 RL10A_HUMAN 60S ribosomal protein L10a 0.924 0.1 34 0.815 0.2 26 0.75 1.134 
P68032 ACTC_HUMAN Actin, alpha cardiac muscle 1 0.568 0.09 74 1.327 0.086 72 0.75 0.428 
P68133 ACTS_HUMAN Actin, alpha skeletal muscle 0.568 0.09 74 1.327 0.086 72 0.75 0.428 
Q02878 RL6_HUMAN 60S ribosomal protein L6 1.011 0.11 58 0.746 0.07 43 0.75 1.355 
P56537 IF6_HUMAN Eukaryotic translation initiation factor 6 0.449 0.04 10 1.68 0.059 6 0.75 0.267 
P08238 HS90B_HUMAN Heat shock protein HSP 90-beta 0.969 0.22 54 0.779 0.152 56 0.75 1.244 
Q9BZE4 NOG1_HUMAN Nucleolar GTP-binding protein 1 0.379 0.01 12 1.992 0.225 18 0.75 0.19 
Q05639 EF1A2_HUMAN Elongation factor 1-alpha 2 1.04 0.24 23 0.726 0.036 30 0.76 1.433 
A6NMY6 AXA2L_HUMAN Putative annexin A2-like protein 1.173 0.14 114 0.644 0.087 103 0.76 1.821 
P10809 CH60_HUMAN 60 kDa heat shock protein, mitochondrial 0.299 0.04 77 2.528 0.471 69 0.76 0.118 
- HNRCL_HUMAN - 0.396 0.07 10 1.909 0.472 12 0.76 0.207 
P46782 RS5_HUMAN 40S ribosomal protein S5 0.883 0.04 12 0.857 0.256 14 0.76 1.03 
P18085 ARF4_HUMAN ADP-ribosylation factor 4 1.74 0 2 0.435 0.025 4 0.76 4 
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O43707 ACTN4_HUMAN Alpha-actinin-4 1.139 0.21 167 0.665 0.089 178 0.76 1.713 
Q14204 DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 1.134 0.26 147 0.668 0.125 106 0.76 1.698 
P51572 BAP31_HUMAN B-cell receptor-associated protein 31 0.59 0.09 10 1.284 0.463 12 0.76 0.46 
P18621 RL17_HUMAN 60S ribosomal protein L17 0.98 0.06 48 0.774 0.079 36 0.76 1.266 
P50991 TCPD_HUMAN T-complex protein 1 subunit delta 0.877 0.09 50 0.865 0.112 43 0.76 1.014 
Q09161 NCBP1_HUMAN Nuclear cap-binding protein subunit 1 0.505 0.08 8 1.509 0.068 8 0.76 0.335 
Q15233 NONO_HUMAN 
Non-POU domain-containing octamer-binding 
protein 
0.584 0.13 42 1.305 0.514 32 0.76 0.448 
Q13748 TBA3C_HUMAN Tubulin alpha-3C/D chain 1.149 0.21 36 0.664 0.086 41 0.76 1.73 
Q99877 H2B1N_HUMAN Histone H2B type 1-N 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
Q99880 H2B1L_HUMAN Histone H2B type 1-L 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
O60814 H2B1K_HUMAN Histone H2B type 1-K 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
Q93079 H2B1H_HUMAN Histone H2B type 1-H 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
Q99879 H2B1M_HUMAN Histone H2B type 1-M 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
Q5QNW6 H2B2F_HUMAN Histone H2B type 2-F 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
P57053 H2BFS_HUMAN Histone H2B type F-S 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
P62807 H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
P58876 H2B1D_HUMAN Histone H2B type 1-D 0.518 0.1 26 1.473 0.153 41 0.76 0.352 
P35908 K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 0.159 0.07 18 4.805 1.939 20 0.76 0.033 
P63267 ACTH_HUMAN Actin, gamma-enteric smooth muscle 0.576 0.1 68 1.327 0.09 72 0.76 0.434 
P62736 ACTA_HUMAN Actin, aortic smooth muscle 0.576 0.09 68 1.327 0.086 72 0.76 0.434 
Q02880 TOP2B_HUMAN DNA topoisomerase 2-beta 0.62 0.06 4 1.233 0.294 12 0.76 0.503 
Q6NXT2 H3C_HUMAN Histone H3.3C 0.551 0.04 2 1.388 
 
1 0.76 0.397 
Q14240 IF4A2_HUMAN Eukaryotic initiation factor 4A-II 0.812 0.12 16 0.942 0.203 20 0.76 0.862 
Q14137 BOP1_HUMAN Ribosome biogenesis protein BOP1 0.359 0.07 12 2.132 0.276 26 0.77 0.168 
Q08170 SRSF4_HUMAN Serine/arginine-rich splicing factor 4 0.48 0.09 18 1.596 0.407 20 0.77 0.301 
O60506 HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q 0.57 0.1 74 1.344 0.236 93 0.77 0.424 
Q92945 FUBP2_HUMAN Far upstream element-binding protein 2 0.636 0.19 27 1.206 0.179 27 0.77 0.527 
P62805 H4_HUMAN Histone H4 0.493 0.08 20 1.556 0.174 22 0.77 0.317 
P63261 ACTG_HUMAN Actin, cytoplasmic 2 0.571 0.09 124 1.344 0.102 116 0.77 0.425 
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P60709 ACTB_HUMAN Actin, cytoplasmic 1 0.571 0.09 124 1.344 0.102 116 0.77 0.425 
P08727 K1C19_HUMAN Keratin, type I cytoskeletal 19 0.152 0.05 14 5.049 1.82 4 0.77 0.03 
P12814 ACTN1_HUMAN Alpha-actinin-1 1.321 0.25 177 0.581 0.108 134 0.77 2.274 
P43304 GPDM_HUMAN 
Glycerol-3-phosphate dehydrogenase, 
mitochondrial 
0.434 0.05 38 1.769 0.603 16 0.77 0.245 
Q95604 1C17_HUMAN 
HLA class I histocompatibility antigen, Cw-17 
alpha chain 
1.167 0.34 6 0.658 0 2 0.77 1.774 
Q5SSJ5 HP1B3_HUMAN Heterochromatin protein 1-binding protein 3 0.671 0.24 18 1.146 0.231 8 0.77 0.586 
Q9BYX7 ACTBM_HUMAN Putative beta-actin-like protein 3 0.606 0.1 20 1.269 0.06 12 0.77 0.478 
Q14683 SMC1A_HUMAN 
Structural maintenance of chromosomes 
protein 1A 
0.418 0.23 5 1.84 0.045 6 0.77 0.227 
Q14692 BMS1_HUMAN Ribosome biogenesis protein BMS1 homolog 0.336 0.03 4 2.291 0.349 12 0.77 0.147 
A5A3E0 POTEF_HUMAN POTE ankyrin domain family member F 0.607 0.09 26 1.269 0.06 12 0.77 0.478 
P22314 UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 0.913 0.14 6 0.847 0 2 0.77 1.078 
Q8N257 H2B3B_HUMAN Histone H2B type 3-B 0.519 0.1 24 1.492 0.141 36 0.77 0.348 
P61106 RAB14_HUMAN Ras-related protein Rab-14 0.823 0.01 4 0.941 0.14 12 0.77 0.875 
P01892 1A02_HUMAN 
HLA class I histocompatibility antigen, A-2 
alpha chain 
1.177 0.41 10 0.658 0 2 0.77 1.789 
P07954 FUMH_HUMAN Fumarate hydratase, mitochondrial 0.343 0.09 18 2.259 0.236 10 0.77 0.152 
Q15029 U5S1_HUMAN 
116 kDa U5 small nuclear ribonucleoprotein 
component 
0.446 0.1 56 1.741 0.288 55 0.78 0.256 
O75923 DYSF_HUMAN Dysferlin 1.592 0.02 6 0.488 0.009 8 0.78 3.262 
O60832 DKC1_HUMAN H/ACA ribonucleoprotein complex subunit 4 0.351 0.06 26 2.214 0.42 10 0.78 0.159 
P17066 HSP76_HUMAN Heat shock 70 kDa protein 6 0.656 0.16 20 1.185 0.018 12 0.78 0.554 
P23527 H2B1O_HUMAN Histone H2B type 1-O 0.518 0.1 26 1.501 0.139 39 0.78 0.345 
P06899 H2B1J_HUMAN Histone H2B type 1-J 0.518 0.1 26 1.501 0.139 39 0.78 0.345 
Q16778 H2B2E_HUMAN Histone H2B type 2-E 0.518 0.1 26 1.501 0.139 39 0.78 0.345 
P33778 H2B1B_HUMAN Histone H2B type 1-B 0.518 0.1 26 1.501 0.139 39 0.78 0.345 
Q14739 LBR_HUMAN Lamin-B receptor 0.755 0.16 12 1.032 0.182 14 0.78 0.732 
O95202 LETM1_HUMAN 
LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
0.366 0.04 36 2.129 0.275 40 0.78 0.172 
P01111 RASN_HUMAN GTPase NRas 0.8 0.16 6 0.975 0.225 7 0.78 0.821 
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P54819 KAD2_HUMAN Adenylate kinase 2, mitochondrial 0.401 0.09 8 1.946 0.085 10 0.78 0.206 
Q5VTE0 EF1A3_HUMAN Putative elongation factor 1-alpha-like 3 1.107 0.22 73 0.706 0.063 62 0.78 1.568 
P68104 EF1A1_HUMAN Elongation factor 1-alpha 1 1.107 0.22 73 0.706 0.063 62 0.78 1.568 
P08754 GNAI3_HUMAN 
Guanine nucleotide-binding protein G(k) 
subunit alpha 
0.794 0.28 36 0.985 0.226 36 0.78 0.806 
Q9UNX4 WDR3_HUMAN WD repeat-containing protein 3 0.347 0.01 4 2.259 0.356 4 0.78 0.154 
Q9BQ39 DDX50_HUMAN ATP-dependent RNA helicase DDX50 0.325 0.01 6 2.412 0.305 7 0.78 0.135 
P68366 TBA4A_HUMAN Tubulin alpha-4A chain 1.094 0.16 22 0.717 0.319 35 0.78 1.526 
P40939 ECHA_HUMAN 
Trifunctional enzyme subunit alpha, 
mitochondrial 
0.397 0.1 122 1.976 0.335 143 0.78 0.201 
P31930 QCR1_HUMAN 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
0.316 0.06 45 2.483 0.908 55 0.78 0.127 
O43390 HNRPR_HUMAN Heterogeneous nuclear ribonucleoprotein R 0.501 0.13 68 1.568 0.342 87 0.79 0.32 
P39023 RL3_HUMAN 60S ribosomal protein L3 1.001 0.22 94 0.785 0.101 78 0.79 1.275 
Q99832 TCPH_HUMAN T-complex protein 1 subunit eta 0.815 0.12 22 0.966 0.17 44 0.79 0.844 
P46778 RL21_HUMAN 60S ribosomal protein L21 1.064 0.11 18 0.74 0.059 20 0.79 1.438 
P40429 RL13A_HUMAN 60S ribosomal protein L13a 0.953 0.08 14 0.828 0.077 6 0.79 1.151 
P34897 GLYM_HUMAN 
Serine hydroxymethyltransferase, 
mitochondrial 
0.285 0.07 21 2.772 0.078 10 0.79 0.103 
P35609 ACTN2_HUMAN Alpha-actinin-2 1.221 0.14 41 0.648 0.062 41 0.79 1.884 
P46939 UTRO_HUMAN Utrophin 1.117 0.32 26 0.71 0.348 6 0.79 1.573 
O15162 PLS1_HUMAN Phospholipid scramblase 1 4.118 0.1 4 0.193 0.01 6 0.79 21.34 
P12035 K2C3_HUMAN Keratin, type II cytoskeletal 3 0.153 0.09 14 5.196 2.039 20 0.79 0.029 
Q96EP5 DAZP1_HUMAN DAZ-associated protein 1 0.504 0 2 1.578 0.154 8 0.8 0.319 
P09471 GNAO_HUMAN 
Guanine nucleotide-binding protein G(o) 
subunit alpha 
1.082 0.1 8 0.736 0.09 12 0.8 1.47 
Q562R1 ACTBL_HUMAN Beta-actin-like protein 2 0.605 0.1 18 1.318 0.099 32 0.8 0.459 
Q14152 EIF3A_HUMAN 
Eukaryotic translation initiation factor 3 
subunit A 
1.103 0.25 54 0.723 0.14 52 0.8 1.526 
P55265 DSRAD_HUMAN 
Double-stranded RNA-specific adenosine 
deaminase 
0.483 0.09 50 1.653 0.263 44 0.8 0.292 
O95758 PTBP3_HUMAN Polypyrimidine tract-binding protein 3 0.532 0.03 6 1.501 0.388 6 0.8 0.354 
P15880 RS2_HUMAN 40S ribosomal protein S2 1.113 0.58 26 0.718 0.183 11 0.8 1.55 
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Q8N1N4 K2C78_HUMAN Keratin, type II cytoskeletal 78 0.248 0 6 3.227 1.629 6 0.8 0.077 
Q9BVK6 TMED9_HUMAN 
Transmembrane emp24 domain-containing 
protein 9 
0.953 0.08 8 0.84 0.012 6 0.8 1.135 
Q27J81 INF2_HUMAN Inverted formin-2 0.431 0.11 24 1.859 0.336 6 0.8 0.232 
P19367 HXK1_HUMAN Hexokinase-1 0.347 0.06 66 2.31 0.364 74 0.8 0.15 
P60866 RS20_HUMAN 40S ribosomal protein S20 0.995 0.13 6 0.807 0.088 12 0.8 1.233 
P50454 SERPH_HUMAN Serpin H1 0.925 0.06 22 0.869 0.069 16 0.8 1.064 
Q9P2E9 RRBP1_HUMAN Ribosome-binding protein 1 2.31 0.3 40 0.348 0.175 16 0.8 6.638 
P12235 ADT1_HUMAN ADP/ATP translocase 1 0.454 0.09 32 1.772 0.245 28 0.8 0.256 
P41252 SYIC_HUMAN Isoleucine--tRNA ligase, cytoplasmic 0.927 0.25 12 0.87 0.342 25 0.81 1.066 
Q14789 GOGB1_HUMAN Golgin subfamily B member 1 1.158 0.5 8 0.697 0 2 0.81 1.661 
Q92901 RL3L_HUMAN 60S ribosomal protein L3-like 0.937 0.04 4 0.862 0.049 4 0.81 1.087 
P55795 HNRH2_HUMAN Heterogeneous nuclear ribonucleoprotein H2 0.551 0.07 18 1.466 0.202 38 0.81 0.376 
Q05519 SRS11_HUMAN Serine/arginine-rich splicing factor 11 0.511 0.27 6 1.582 0.066 6 0.81 0.323 
Q15269 PWP2_HUMAN Periodic tryptophan protein 2 homolog 0.313 0.05 10 2.583 0.139 10 0.81 0.121 
P62834 RAP1A_HUMAN Ras-related protein Rap-1A 0.58 0.09 8 1.394 0.117 14 0.81 0.416 
Q9ULV4 COR1C_HUMAN Coronin-1C 0.669 0.06 18 1.209 0.139 20 0.81 0.553 
Q8WXH0 SYNE2_HUMAN Nesprin-2 0.457 0.21 59 1.771 0.366 46 0.81 0.258 
P40227 TCPZ_HUMAN T-complex protein 1 subunit zeta 0.875 0.13 48 0.925 0.228 42 0.81 0.946 
P36776 LONM_HUMAN Lon protease homolog, mitochondrial 0.387 0 2 2.094 0 2 0.81 0.185 
O15427 MOT4_HUMAN Monocarboxylate transporter 4 0.897 0.13 16 0.904 0.077 16 0.81 0.992 
P26641 EF1G_HUMAN Elongation factor 1-gamma 1.366 0.18 12 0.594 0 2 0.81 2.3 
Q15717 ELAV1_HUMAN ELAV-like protein 1 0.583 0.03 11 1.393 0.35 18 0.81 0.419 
P60953 CDC42_HUMAN Cell division control protein 42 homolog 0.553 0.03 8 1.47 0.315 4 0.81 0.376 
Q9Y2X3 NOP58_HUMAN Nucleolar protein 58 0.383 0.12 42 2.123 0.684 40 0.81 0.18 
P78371 TCPB_HUMAN T-complex protein 1 subunit beta 0.897 0.3 74 0.907 0.098 62 0.81 0.989 
P22626 ROA2_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
0.465 0.12 65 1.751 0.39 73 0.81 0.266 
Q96CS3 FAF2_HUMAN FAS-associated factor 2 0.767 0.05 12 1.063 0.099 18 0.82 0.722 
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P10515 ODP2_HUMAN 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial 
0.259 0.02 8 3.148 0.286 20 0.82 0.082 
P61978 HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K 0.557 0.1 48 1.464 0.267 31 0.82 0.38 
P40926 MDHM_HUMAN Malate dehydrogenase, mitochondrial 0.34 0.1 8 2.403 0.475 28 0.82 0.141 
Q969X5 ERGI1_HUMAN 
Endoplasmic reticulum-Golgi intermediate 
compartment protein 1 
1.711 0.44 26 0.478 0.042 26 0.82 3.579 
P06576 ATPB_HUMAN ATP synthase subunit beta, mitochondrial 0.387 0.15 100 2.117 0.36 98 0.82 0.183 
P05386 RLA1_HUMAN 60S acidic ribosomal protein P1 0.793 0.37 14 1.034 0.322 14 0.82 0.767 
P02545 LMNA_HUMAN Prelamin-A/C 0.739 0.12 48 1.111 0.25 69 0.82 0.665 
Q6P2Q9 PRP8_HUMAN Pre-mRNA-processing-splicing factor 8 0.448 0.13 104 1.837 0.655 65 0.82 0.244 
P05023 AT1A1_HUMAN 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
0.552 0.1 110 1.491 0.194 119 0.82 0.37 
O95678 K2C75_HUMAN Keratin, type II cytoskeletal 75 0.151 0.08 24 5.456 3.471 26 0.82 0.028 
P52597 HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F 0.466 0.09 34 1.768 0.282 40 0.82 0.264 
Q08211 DHX9_HUMAN ATP-dependent RNA helicase A 0.543 0.12 116 1.518 0.231 108 0.82 0.358 
O43143 DHX15_HUMAN 
Pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15 
0.428 0.09 26 1.926 0.218 31 0.82 0.222 
P49207 RL34_HUMAN 60S ribosomal protein L34 1.016 0.12 18 0.812 0.061 12 0.82 1.251 
P48741 HSP77_HUMAN Putative heat shock 70 kDa protein 7 0.698 0.16 12 1.182 0.015 6 0.83 0.591 
P26373 RL13_HUMAN 60S ribosomal protein L13 0.961 0.17 8 0.859 0.071 4 0.83 1.119 
Q9BWM7 SFXN3_HUMAN Sideroflexin-3 0.461 0.02 8 1.792 0.238 10 0.83 0.257 
P07910 HNRPC_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 
0.433 0.07 26 1.909 0.472 36 0.83 0.227 
P08240 SRPR_HUMAN 
Signal recognition particle receptor subunit 
alpha 
1.365 0.28 14 0.606 0.047 8 0.83 2.252 
Q16720 AT2B3_HUMAN 
Plasma membrane calcium-transporting 
ATPase 3 
1.442 0.75 14 0.574 0.199 20 0.83 2.512 
Q07666 KHDR1_HUMAN 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
0.491 0.08 24 1.686 0.556 36 0.83 0.291 
P61224 RAP1B_HUMAN Ras-related protein Rap-1b 0.58 0.09 8 1.428 0.117 14 0.83 0.406 
Q9NP72 RAB18_HUMAN Ras-related protein Rab-18 1.048 0.29 9 0.791 0.115 8 0.83 1.325 
Q99959 PKP2_HUMAN Plakophilin-2 0.035 0.02 14 23.71 4.104 20 0.83 0.001 
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P35232 PHB_HUMAN Prohibitin 0.449 0.12 35 1.852 0.191 25 0.83 0.242 
P15311 EZRI_HUMAN Ezrin 1.092 0.12 4 0.762 0.261 4 0.83 1.433 
P26640 SYVC_HUMAN Valine--tRNA ligase 1.123 0.41 22 0.741 0.14 14 0.83 1.516 
P50416 CPT1A_HUMAN 
Carnitine O-palmitoyltransferase 1, liver 
isoform 
0.76 0.05 16 1.096 0.231 20 0.83 0.693 
P16144 ITB4_HUMAN Integrin beta-4 0.163 0.06 126 5.111 1.454 142 0.83 0.032 
P23634 AT2B4_HUMAN 
Plasma membrane calcium-transporting 
ATPase 4 
1.101 0.6 32 0.757 0.487 37 0.83 1.454 
P84103 SRSF3_HUMAN Serine/arginine-rich splicing factor 3 0.576 0.06 28 1.447 0.046 21 0.83 0.398 
P19013 K2C4_HUMAN Keratin, type II cytoskeletal 4 0.162 0.08 8 5.15 1.075 10 0.83 0.031 
P15924 DESP_HUMAN Desmoplakin 0.038 0.02 58 21.98 7.269 84 0.84 0.002 
P38919 IF4A3_HUMAN Eukaryotic initiation factor 4A-III 0.406 0.11 18 2.057 0.986 20 0.84 0.197 
P53985 MOT1_HUMAN Monocarboxylate transporter 1 0.629 0.25 14 1.332 0.166 18 0.84 0.472 
Q14318 FKBP8_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP8 0.804 0.12 12 1.043 0.038 6 0.84 0.771 
P29401 TKT_HUMAN Transketolase 1.043 0.11 18 0.804 0.068 8 0.84 1.297 
O95470 SGPL1_HUMAN Sphingosine-1-phosphate lyase 1 0.406 0 2 2.067 0.1 4 0.84 0.196 
Q6FI13 H2A2A_HUMAN Histone H2A type 2-A 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
Q93077 H2A1C_HUMAN Histone H2A type 1-C 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
P04908 H2A1B_HUMAN Histone H2A type 1-B/E 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
P20671 H2A1D_HUMAN Histone H2A type 1-D 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
Q96KK5 H2A1H_HUMAN Histone H2A type 1-H 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
Q7L7L0 H2A3_HUMAN Histone H2A type 3 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
P0C0S8 H2A1_HUMAN Histone H2A type 1 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
Q99878 H2A1J_HUMAN Histone H2A type 1-J 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
Q16777 H2A2C_HUMAN Histone H2A type 2-C 0.555 0.06 12 1.516 0.053 6 0.84 0.366 
P62424 RL7A_HUMAN 60S ribosomal protein L7a 1.02 0.13 48 0.826 0.063 32 0.84 1.235 
P46977 STT3A_HUMAN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
1.082 0.5 20 0.779 0.354 7 0.84 1.389 
A8MTJ3 GNAT3_HUMAN 
Guanine nucleotide-binding protein G(t) 
subunit alpha-3 
1.041 0 4 0.81 0.074 10 0.84 1.285 
P19087 GNAT2_HUMAN 
Guanine nucleotide-binding protein G(t) 
subunit alpha-2 
1.041 0 4 0.81 0.074 10 0.84 1.285 
245 
 
P11488 GNAT1_HUMAN 
Guanine nucleotide-binding protein G(t) 
subunit alpha-1 
1.041 0 4 0.81 0.074 10 0.84 1.285 
P27635 RL10_HUMAN 60S ribosomal protein L10 1.058 0.05 22 0.798 0.075 18 0.84 1.326 
Q9UMS4 PRP19_HUMAN Pre-mRNA-processing factor 19 0.553 0.13 28 1.529 0.558 30 0.85 0.362 
P09651 ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 0.587 0.18 40 1.441 0.051 32 0.85 0.407 
Q01546 K22O_HUMAN Keratin, type II cytoskeletal 2 oral 0.172 0.08 18 4.918 2.067 18 0.85 0.035 
P62913 RL11_HUMAN 60S ribosomal protein L11 1.043 0.08 18 0.812 0.073 18 0.85 1.284 
P09382 LEG1_HUMAN Galectin-1 1.372 0.12 36 0.618 0.056 26 0.85 2.22 
Q9Y678 COPG1_HUMAN Coatomer subunit gamma-1 1.322 0.25 24 0.642 0.135 12 0.85 2.059 
P62244 RS15A_HUMAN 40S ribosomal protein S15a 1.028 0.07 12 0.827 0.01 4 0.85 1.243 
Q8NHW5 RLA0L_HUMAN 60S acidic ribosomal protein P0-like 1.193 0.11 34 0.713 0.058 28 0.85 1.673 
Q9GZL7 WDR12_HUMAN Ribosome biogenesis protein WDR12 0.362 0.07 12 2.351 0.72 9 0.85 0.154 
P23284 PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B 0.88 0.07 14 0.969 0.21 16 0.85 0.908 
Q08043 ACTN3_HUMAN Alpha-actinin-3 1.172 0.15 23 0.728 0.201 26 0.85 1.61 
P46779 RL28_HUMAN 60S ribosomal protein L28 1.167 0.11 20 0.732 0.089 16 0.85 1.594 
P38405 GNAL_HUMAN 
Guanine nucleotide-binding protein G(olf) 
subunit alpha 
1.038 0 2 0.823 0.003 6 0.85 1.261 
O75369 FLNB_HUMAN Filamin-B 0.339 0.19 142 2.52 0.689 156 0.85 0.135 
Q8N1F7 NUP93_HUMAN Nuclear pore complex protein Nup93 0.424 0.16 12 2.016 0.666 18 0.85 0.21 
P05387 RLA2_HUMAN 60S acidic ribosomal protein P2 1.14 0.65 16 0.75 0.381 14 0.86 1.52 
P24752 THIL_HUMAN Acetyl-CoA acetyltransferase, mitochondrial 0.258 0.08 10 3.316 0.535 12 0.86 0.078 
Q9Y3I0 RTCB_HUMAN tRNA-splicing ligase RtcB homolog 1.057 0.11 12 0.812 0.209 20 0.86 1.302 
P04844 RPN2_HUMAN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
1.159 0.16 47 0.741 0.116 36 0.86 1.564 
P18124 RL7_HUMAN 60S ribosomal protein L7 1.026 0.16 21 0.838 0.136 31 0.86 1.224 
Q8IWA0 WDR75_HUMAN WD repeat-containing protein 75 0.364 0.08 16 2.363 0.022 5 0.86 0.154 
O75694 NU155_HUMAN Nuclear pore complex protein Nup155 0.495 0.07 26 1.739 0.337 23 0.86 0.285 
O76021 RL1D1_HUMAN Ribosomal L1 domain-containing protein 1 0.302 0.06 28 2.853 0.342 38 0.86 0.106 
Q03135 CAV1_HUMAN Caveolin-1 1.664 0.24 36 0.518 0.073 34 0.86 3.212 
P05388 RLA0_HUMAN 60S acidic ribosomal protein P0 1.228 0.22 52 0.704 0.055 40 0.86 1.744 
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O60716 CTND1_HUMAN Catenin delta-1 0.331 0.09 52 2.612 0.741 52 0.86 0.127 
P15144 AMPN_HUMAN Aminopeptidase N 3.163 0.66 154 0.274 0.052 159 0.87 11.54 
Q9Y5B9 SP16H_HUMAN FACT complex subunit SPT16 0.807 0.13 30 1.074 0.131 44 0.87 0.751 
P62277 RS13_HUMAN 40S ribosomal protein S13 0.963 0.04 6 0.902 0.062 10 0.87 1.068 
Q9Y5M8 SRPRB_HUMAN 
Signal recognition particle receptor subunit 
beta 
0.67 0.17 14 1.299 0.122 18 0.87 0.516 
Q3ZCM7 TBB8_HUMAN Tubulin beta-8 chain 1.062 0.02 6 0.824 0.067 10 0.88 1.289 
P49755 TMEDA_HUMAN 
Transmembrane emp24 domain-containing 
protein 10 
0.826 0.1 28 1.063 0.218 30 0.88 0.777 
P36578 RL4_HUMAN 60S ribosomal protein L4 1.033 0.41 58 0.85 0.057 32 0.88 1.215 
Q15436 SC23A_HUMAN Protein transport protein Sec23A 2.296 0.43 28 0.383 0.088 6 0.88 5.995 
P45880 VDAC2_HUMAN 
Voltage-dependent anion-selective channel 
protein 2 
0.545 0.09 41 1.615 0.254 37 0.88 0.337 
P54709 AT1B3_HUMAN 
Sodium/potassium-transporting ATPase 
subunit beta-3 
0.377 0.05 14 2.338 0.401 24 0.88 0.161 
P16435 NCPR_HUMAN NADPH--cytochrome P450 reductase 0.756 0.12 38 1.167 0.163 8 0.88 0.648 
P05141 ADT2_HUMAN ADP/ATP translocase 2 0.409 0.09 41 2.164 0.351 34 0.89 0.189 
P21796 VDAC1_HUMAN 
Voltage-dependent anion-selective channel 
protein 1 
0.472 0.07 56 1.876 0.988 66 0.89 0.252 
P26599 PTBP1_HUMAN Polypyrimidine tract-binding protein 1 0.771 1.23 64 1.149 0.473 48 0.89 0.671 
P39656 OST48_HUMAN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
1.208 0.13 26 0.734 0.067 20 0.89 1.646 
Q92542 NICA_HUMAN Nicastrin 0.718 0.03 14 1.235 0.145 9 0.89 0.581 
Q9HDC9 APMAP_HUMAN 
Adipocyte plasma membrane-associated 
protein 
0.557 0.04 8 1.593 0.111 18 0.89 0.35 
P14618 KPYM_HUMAN Pyruvate kinase PKM 1.528 1.59 36 0.581 0.061 40 0.89 2.63 
Q9P2J5 SYLC_HUMAN Leucine--tRNA ligase, cytoplasmic 1.291 0.16 44 0.688 0.194 28 0.89 1.876 
Q96I24 FUBP3_HUMAN Far upstream element-binding protein 3 0.605 0.22 12 1.469 0.173 14 0.89 0.412 
P53007 TXTP_HUMAN 
Tricarboxylate transport protein, 
mitochondrial 
0.69 0.05 6 1.292 0.108 12 0.89 0.534 
P27105 STOM_HUMAN 
Erythrocyte band 7 integral membrane 
protein 
0.603 0.09 72 1.481 0.64 53 0.89 0.407 
Q99575 POP1_HUMAN Ribonucleases P/MRP protein subunit POP1 0.421 0 2 2.124 0.236 4 0.89 0.198 
Q16629 SRSF7_HUMAN Serine/arginine-rich splicing factor 7 0.533 0.1 14 1.678 0.223 14 0.89 0.318 
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O75955 FLOT1_HUMAN Flotillin-1 2.626 0.61 46 0.341 0.078 51 0.9 7.701 
P33121 ACSL1_HUMAN Long-chain-fatty-acid--CoA ligase 1 0.583 0.1 60 1.539 0.212 65 0.9 0.379 
P12532 KCRU_HUMAN Creatine kinase U-type, mitochondrial 0.041 0.01 12 21.89 3.507 22 0.9 0.002 
Q9UKV3 ACINU_HUMAN 
Apoptotic chromatin condensation inducer in 
the nucleus 
0.366 0 2 2.454 0.29 14 0.9 0.149 
Q15738 NSDHL_HUMAN 
Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating 
0.809 0.18 12 1.112 0.029 6 0.9 0.728 
P62701 RS4X_HUMAN 40S ribosomal protein S4, X isoform 1.034 0.44 37 0.871 0.159 32 0.9 1.187 
Q03113 GNA12_HUMAN 
Guanine nucleotide-binding protein subunit 
alpha-12 
1.218 0.36 6 0.741 0.04 4 0.9 1.644 
P11387 TOP1_HUMAN DNA topoisomerase 1 0.533 0.18 44 1.699 0.554 38 0.91 0.314 
Q13838 DX39B_HUMAN Spliceosome RNA helicase DDX39B 0.898 0.06 16 1.01 0.249 22 0.91 0.889 
P17844 DDX5_HUMAN 
Probable ATP-dependent RNA helicase 
DDX5 
0.604 0.12 46 1.503 0.263 51 0.91 0.402 
Q12788 TBL3_HUMAN Transducin beta-like protein 3 0.337 0.01 4 2.697 0.433 18 0.91 0.125 
P25705 ATPA_HUMAN ATP synthase subunit alpha, mitochondrial 0.434 0.12 94 2.096 0.642 88 0.91 0.207 
P56134 ATPK_HUMAN ATP synthase subunit f, mitochondrial 0.424 0.01 6 2.146 0 2 0.91 0.198 
Q9NYU2 UGGG1_HUMAN 
UDP-glucose:glycoprotein 
glucosyltransferase 1 
0.768 0.16 70 1.187 0.15 86 0.91 0.647 
Q01780 EXOSX_HUMAN Exosome component 10 0.531 0.17 6 1.72 0.226 12 0.91 0.309 
P61026 RAB10_HUMAN Ras-related protein Rab-10 0.786 0.08 7 1.164 0.207 11 0.91 0.675 
Q07020 RL18_HUMAN 60S ribosomal protein L18 0.982 0.06 12 0.932 0.11 18 0.92 1.054 
P07196 NFL_HUMAN Neurofilament light polypeptide 1.776 0.7 6 0.516 0.039 6 0.92 3.442 
P01116 RASK_HUMAN GTPase KRas 0.834 0.19 4 1.101 0.083 5 0.92 0.757 
P08195 4F2_HUMAN 4F2 cell-surface antigen heavy chain 0.192 0.2 90 4.787 1.161 84 0.92 0.04 
Q9BTM1 H2AJ_HUMAN Histone H2A.J 0.608 0.06 12 1.516 0.053 6 0.92 0.401 
P36542 ATPG_HUMAN ATP synthase subunit gamma, mitochondrial 0.485 0.29 18 1.904 0.159 8 0.92 0.255 
Q9BSJ8 ESYT1_HUMAN Extended synaptotagmin-1 0.602 0.14 60 1.535 0.275 51 0.92 0.392 
Q71UM5 RS27L_HUMAN 40S ribosomal protein S27-like 1.144 0.26 8 0.808 0.07 12 0.92 1.416 
Q00765 REEP5_HUMAN Receptor expression-enhancing protein 5 1.036 0.06 6 0.893 0.046 6 0.93 1.16 
P84095 RHOG_HUMAN Rho-related GTP-binding protein RhoG 0.799 0.08 8 1.159 0.314 10 0.93 0.689 
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P35606 COPB2_HUMAN Coatomer subunit beta' 1.297 0.18 25 0.714 0.17 12 0.93 1.817 
Q16630 CPSF6_HUMAN 
Cleavage and polyadenylation specificity 
factor subunit 6 
0.816 0.58 12 1.136 0.019 8 0.93 0.718 
P06748 NPM_HUMAN Nucleophosmin 0.556 0.49 71 1.669 0.225 70 0.93 0.333 
P00403 COX2_HUMAN Cytochrome c oxidase subunit 2 0.351 0.06 20 2.65 0.4 19 0.93 0.132 
Q9NR30 DDX21_HUMAN Nucleolar RNA helicase 2 0.31 0.04 52 3.008 0.598 65 0.93 0.103 
O15260 SURF4_HUMAN Surfeit locus protein 4 1.842 0.64 20 0.508 0.043 8 0.94 3.626 
P61019 RAB2A_HUMAN Ras-related protein Rab-2A 0.922 0.06 14 1.015 0.216 22 0.94 0.908 
P01112 RASH_HUMAN GTPase HRas 0.82 0.15 6 1.142 0.076 7 0.94 0.718 
Q9BQG0 MBB1A_HUMAN Myb-binding protein 1A 0.366 0.08 62 2.56 0.455 45 0.94 0.143 
P62753 RS6_HUMAN 40S ribosomal protein S6 0.978 0.22 28 0.959 0.201 20 0.94 1.02 
P51149 RAB7A_HUMAN Ras-related protein Rab-7a 0.824 0.2 26 1.139 0.202 35 0.94 0.723 
P20020 AT2B1_HUMAN 
Plasma membrane calcium-transporting 
ATPase 1 
1.407 0.54 48 0.672 0.444 48 0.95 2.094 
P62280 RS11_HUMAN 40S ribosomal protein S11 1.278 1.25 22 0.742 0.084 24 0.95 1.722 
Q9H0C2 ADT4_HUMAN ADP/ATP translocase 4 0.472 0.05 10 2.01 0.088 7 0.95 0.235 
Q02218 ODO1_HUMAN 2-oxoglutarate dehydrogenase, mitochondrial 0.417 0.28 36 2.283 0.691 22 0.95 0.183 
P30050 RL12_HUMAN 60S ribosomal protein L12 1.186 0.31 18 0.803 0.126 16 0.95 1.477 
P30101 PDIA3_HUMAN Protein disulfide-isomerase A3 0.801 0.09 54 1.189 0.204 50 0.95 0.674 
Q92616 GCN1L_HUMAN Translational activator GCN1 1.033 0.18 15 0.922 0.361 9 0.95 1.12 
P31942 HNRH3_HUMAN Heterogeneous nuclear ribonucleoprotein H3 0.498 0.06 12 1.913 0.304 22 0.95 0.26 
Q9NZB2 F120A_HUMAN 
Constitutive coactivator of PPAR-gamma-like 
protein 1 
1.461 0.69 22 0.653 0.081 18 0.95 2.237 
P05556 ITB1_HUMAN Integrin beta-1 0.953 0.22 44 1.002 0.143 44 0.95 0.951 
Q8WYP5 ELYS_HUMAN Protein ELYS 0.65 0.11 6 1.471 0.172 4 0.96 0.442 
Q9Y277 VDAC3_HUMAN 
Voltage-dependent anion-selective channel 
protein 3 
0.48 0.24 20 1.992 0.517 34 0.96 0.241 
P35268 RL22_HUMAN 60S ribosomal protein L22 0.94 
 
1 1.018 0 2 0.96 0.923 
Q14728 MFS10_HUMAN 
Major facilitator superfamily domain-
containing protein 10 
0.461 0 2 2.076 0.165 5 0.96 0.222 
O75643 U520_HUMAN 
U5 small nuclear ribonucleoprotein 200 kDa 
helicase 
0.516 0.39 50 1.857 0.39 50 0.96 0.278 
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Q7L014 DDX46_HUMAN 
Probable ATP-dependent RNA helicase 
DDX46 
0.496 0.41 6 1.933 0.246 18 0.96 0.257 
P04899 GNAI2_HUMAN 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
1.601 0.42 50 0.599 0.143 42 0.96 2.673 
P07237 PDIA1_HUMAN Protein disulfide-isomerase 1.387 0.46 66 0.692 0.124 76 0.96 2.004 
P18583 SON_HUMAN Protein SON 0.424 0.18 12 2.268 0.302 14 0.96 0.187 
Q7KZF4 SND1_HUMAN 
Staphylococcal nuclease domain-containing 
protein 1 
1.343 0.82 107 0.722 0.085 106 0.97 1.86 
P84098 RL19_HUMAN 60S ribosomal protein L19 0.998 0.04 12 0.972 0.297 8 0.97 1.027 
A0FGR8 ESYT2_HUMAN Extended synaptotagmin-2 0.858 0.23 14 1.131 0.032 6 0.97 0.759 
O14980 XPO1_HUMAN Exportin-1 0.858 0.58 18 1.131 0.448 8 0.97 0.759 
Q9BTT6 LRRC1_HUMAN Leucine-rich repeat-containing protein 1 0.49 0.05 8 1.982 0.196 7 0.97 0.247 
Q00325 MPCP_HUMAN Phosphate carrier protein, mitochondrial 0.676 0.1 34 1.439 0.191 33 0.97 0.47 
O15020 SPTN2_HUMAN Spectrin beta chain, non-erythrocytic 2 0.446 0.73 8 2.198 0 2 0.98 0.203 
P55072 TERA_HUMAN Transitional endoplasmic reticulum ATPase 1.718 0.39 76 0.571 0.09 38 0.98 3.009 
Q9UNL2 SSRG_HUMAN 
Translocon-associated protein subunit 
gamma 
1.271 0.03 4 0.772 0.034 6 0.98 1.646 
Q92841 DDX17_HUMAN 
Probable ATP-dependent RNA helicase 
DDX17 
0.874 0.25 32 1.124 0.411 44 0.98 0.778 
O00567 NOP56_HUMAN Nucleolar protein 56 0.47 0.23 34 2.091 0.217 37 0.98 0.225 
P62829 RL23_HUMAN 60S ribosomal protein L23 0.903 0.23 30 1.089 0.282 18 0.98 0.829 
O75494 SRS10_HUMAN Serine/arginine-rich splicing factor 10 0.59 0.16 8 1.668 0.103 16 0.98 0.354 
Q9NRY6 PLS3_HUMAN Phospholipid scramblase 3 2.461 0.15 6 0.4 0.019 6 0.98 6.153 
P51659 DHB4_HUMAN Peroxisomal multifunctional enzyme type 2 0.895 0.18 52 1.102 0.206 49 0.99 0.812 
P51148 RAB5C_HUMAN Ras-related protein Rab-5C 0.582 0.12 6 1.696 0.296 16 0.99 0.343 
P08621 RU17_HUMAN U1 small nuclear ribonucleoprotein 70 kDa 0.631 0.02 8 1.566 0.173 4 0.99 0.403 
Q9BTV4 TMM43_HUMAN Transmembrane protein 43 1.299 0.47 29 0.761 0.069 22 0.99 1.707 
Q01650 LAT1_HUMAN 
Large neutral amino acids transporter small 
subunit 1 
0.159 0 6 6.225 0.402 6 0.99 0.026 
Q8TCJ2 STT3B_HUMAN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 
1.418 0.06 6 0.7 0.046 8 0.99 2.026 
P20645 MPRD_HUMAN 
Cation-dependent mannose-6-phosphate 
receptor 
1.405 0.21 12 0.709 0.002 4 1 1.982 
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P50914 RL14_HUMAN 60S ribosomal protein L14 1.064 0.04 11 0.941 0.109 18 1 1.131 
P04843 RPN1_HUMAN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
1.214 0.21 81 0.826 0.154 69 1 1.47 
Q07955 SRSF1_HUMAN Serine/arginine-rich splicing factor 1 0.554 0.1 36 1.816 0.509 29 1.01 0.305 
Q63HN8 RN213_HUMAN E3 ubiquitin-protein ligase RNF213 1.196 0.5 8 0.843 0.481 4 1.01 1.419 
Q9BY44 EIF2A_HUMAN Eukaryotic translation initiation factor 2A 0.936 0 2 1.082 0.187 12 1.01 0.865 
Q96AG4 LRC59_HUMAN Leucine-rich repeat-containing protein 59 0.983 0.06 16 1.031 0.051 25 1.01 0.953 
P27708 PYR1_HUMAN CAD protein 1.038 0.34 15 0.978 0.064 7 1.02 1.061 
Q7L2E3 DHX30_HUMAN 
Putative ATP-dependent RNA helicase 
DHX30 
0.635 0.08 11 1.601 0.116 11 1.02 0.397 
P51153 RAB13_HUMAN Ras-related protein Rab-13 1.381 0.61 4 0.738 0.225 14 1.02 1.871 
P61353 RL27_HUMAN 60S ribosomal protein L27 1.073 0.32 10 0.95 0.156 9 1.02 1.129 
Q00341 VIGLN_HUMAN Vigilin 2.427 1.92 48 0.421 0.078 22 1.02 5.765 
P60228 EIF3E_HUMAN 
Eukaryotic translation initiation factor 3 
subunit E 
1.083 0.32 22 0.944 0.296 22 1.02 1.147 
P08670 VIME_HUMAN Vimentin 2.008 0.52 131 0.51 0.338 117 1.02 3.937 
O75976 CBPD_HUMAN Carboxypeptidase D 0.979 0.76 66 1.05 0.483 41 1.03 0.932 
Q9Y265 RUVB1_HUMAN RuvB-like 1 0.627 0.14 20 1.641 0.319 16 1.03 0.382 
P11177 ODPB_HUMAN 
Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
0.435 0.18 8 2.367 0.613 24 1.03 0.184 
O00763 ACACB_HUMAN Acetyl-CoA carboxylase 2 1.016 0.31 4 1.014 0.051 2 1.03 1.002 
P23229 ITA6_HUMAN Integrin alpha-6 0.097 0.06 9 10.7 10.61 9 1.04 0.009 
Q12931 TRAP1_HUMAN Heat shock protein 75 kDa, mitochondrial 0.311 0.33 10 3.339 1.49 18 1.04 0.093 
O00161 SNP23_HUMAN Synaptosomal-associated protein 23 1.428 0.33 52 0.728 0.131 49 1.04 1.962 
Q5JTH9 RRP12_HUMAN RRP12-like protein 0.455 0.16 13 2.29 0.444 22 1.04 0.199 
Q15155 NOMO1_HUMAN Nodal modulator 1 0.985 0.22 26 1.058 0.208 28 1.04 0.931 
O15127 SCAM2_HUMAN 
Secretory carrier-associated membrane 
protein 2 
1.189 0.23 8 0.877 0.021 6 1.04 1.356 
O15126 SCAM1_HUMAN 
Secretory carrier-associated membrane 
protein 1 
0.922 0.08 22 1.135 0.108 18 1.05 0.812 
O94919 ENDD1_HUMAN Endonuclease domain-containing 1 protein 2.584 0.42 6 0.405 0 2 1.05 6.38 
Q9UQ35 SRRM2_HUMAN Serine/arginine repetitive matrix protein 2 0.425 0.23 36 2.475 0.774 28 1.05 0.172 
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Q9H0A0 NAT10_HUMAN N-acetyltransferase 10 0.372 0.08 48 2.829 3.644 43 1.05 0.131 
Q6DD88 ATLA3_HUMAN Atlastin-3 1.411 0.22 28 0.746 0.329 26 1.05 1.891 
Q1KMD3 HNRL2_HUMAN 
Heterogeneous nuclear ribonucleoprotein U-
like protein 2 
0.633 0.07 10 1.664 0.223 20 1.05 0.38 
Q96GQ7 DDX27_HUMAN 
Probable ATP-dependent RNA helicase 
DDX27 
0.538 0.34 8 1.962 0.185 10 1.06 0.274 
Q92499 DDX1_HUMAN ATP-dependent RNA helicase DDX1 1.549 0.73 32 0.682 0.115 14 1.06 2.271 
Q04637 IF4G1_HUMAN 
Eukaryotic translation initiation factor 4 
gamma 1 
1.762 0.35 14 0.6 0.298 20 1.06 2.937 
Q9BUQ8 DDX23_HUMAN 
Probable ATP-dependent RNA helicase 
DDX23 
0.671 0.43 4 1.576 0.499 7 1.06 0.426 
Q93050 VPP1_HUMAN 
V-type proton ATPase 116 kDa subunit a 
isoform 1 
0.625 0.17 21 1.693 0.382 18 1.06 0.369 
Q15758 AAAT_HUMAN Neutral amino acid transporter B(0) 0.967 0.11 20 1.098 0.278 26 1.06 0.881 
Q9Y3L5 RAP2C_HUMAN Ras-related protein Rap-2c 1.08 0.45 18 0.987 0.234 36 1.07 1.094 
P11940 PABP1_HUMAN Polyadenylate-binding protein 1 1.344 0.33 12 0.794 0.151 14 1.07 1.693 
P20648 ATP4A_HUMAN 
Potassium-transporting ATPase alpha chain 
1 
0.846 0.83 12 1.262 0.027 8 1.07 0.67 
P69849 NOMO3_HUMAN Nodal modulator 3 1.016 0.19 24 1.061 0.216 26 1.08 0.958 
Q5JPE7 NOMO2_HUMAN Nodal modulator 2 1.016 0.19 24 1.061 0.216 26 1.08 0.958 
P00387 NB5R3_HUMAN NADH-cytochrome b5 reductase 3 1.481 0.13 20 0.728 0.118 22 1.08 2.034 
P07814 SYEP_HUMAN Bifunctional glutamate/proline--tRNA ligase 1.334 0.79 76 0.81 0.161 90 1.08 1.647 
Q5XKE5 K2C79_HUMAN Keratin, type II cytoskeletal 79 0.265 0.31 22 4.087 1.917 26 1.08 0.065 
O00148 DX39A_HUMAN ATP-dependent RNA helicase DDX39A 1.078 0.25 12 1.008 0.394 14 1.09 1.069 
P63096 GNAI1_HUMAN 
Guanine nucleotide-binding protein G(i) 
subunit alpha-1 
0.808 0.34 26 1.346 0.864 22 1.09 0.6 
Q13310 PABP4_HUMAN Polyadenylate-binding protein 4 1.351 0.14 8 0.806 0.139 4 1.09 1.676 
P60033 CD81_HUMAN CD81 antigen 1.834 0.04 6 0.594 0.053 8 1.09 3.088 
O60488 ACSL4_HUMAN Long-chain-fatty-acid--CoA ligase 4 0.72 0.4 34 1.514 0.638 27 1.09 0.476 
Q14697 GANAB_HUMAN Neutral alpha-glucosidase AB 0.66 0.11 32 1.653 0.338 35 1.09 0.399 
Q969E2 SCAM4_HUMAN 
Secretory carrier-associated membrane 
protein 4 
1.57 0 2 0.697 0.001 4 1.09 2.253 
P14923 PLAK_HUMAN Junction plakoglobin 0.11 0.03 12 10.04 3.095 22 1.1 0.011 
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O14828 SCAM3_HUMAN 
Secretory carrier-associated membrane 
protein 3 
1.365 0.19 44 0.81 0.344 42 1.11 1.685 
Q14160 SCRIB_HUMAN Protein scribble homolog 0.544 0.15 26 2.033 0.582 13 1.11 0.268 
P54136 SYRC_HUMAN Arginine--tRNA ligase, cytoplasmic 1.475 0.45 20 0.752 0.276 16 1.11 1.961 
P63092 GNAS2_HUMAN 
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short 
1.435 0.46 4 0.773 0.091 8 1.11 1.856 
Q5JWF2 GNAS1_HUMAN 
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms XLas 
1.435 0.46 4 0.773 0.091 8 1.11 1.856 
P02786 TFR1_HUMAN Transferrin receptor protein 1 3.059 0.77 124 0.363 0.074 101 1.11 8.427 
Q92928 RAB1C_HUMAN Putative Ras-related protein Rab-1C 1.002 0.68 20 1.111 0.103 20 1.11 0.902 
P46087 NOP2_HUMAN 
Probable 28S rRNA (cytosine(4447)-C(5))-
methyltransferase 
0.416 0.07 28 2.681 0.477 24 1.12 0.155 
P07099 HYEP_HUMAN Epoxide hydrolase 1 1.275 0.75 28 0.876 0.173 33 1.12 1.455 
Q9H0U4 RAB1B_HUMAN Ras-related protein Rab-1B 1.117 0.64 26 1.001 0.274 24 1.12 1.116 
P61204 ARF3_HUMAN ADP-ribosylation factor 3 1.392 0.31 10 0.804 0.32 6 1.12 1.731 
P84077 ARF1_HUMAN ADP-ribosylation factor 1 1.392 0.31 10 0.804 0.32 6 1.12 1.731 
Q10471 GALT2_HUMAN 
Polypeptide N-
acetylgalactosaminyltransferase 2 
2.609 0.46 24 0.429 0.038 24 1.12 6.082 
Q9ULC5 ACSL5_HUMAN Long-chain-fatty-acid--CoA ligase 5 0.712 0.11 6 1.574 0.146 8 1.12 0.452 
Q9P0L0 VAPA_HUMAN 
Vesicle-associated membrane protein-
associated protein A 
0.815 0.4 10 1.385 0.1 10 1.13 0.588 
Q9H3P7 GCP60_HUMAN Golgi resident protein GCP60 1.054 0.08 12 1.082 0.04 4 1.14 0.974 
P62820 RAB1A_HUMAN Ras-related protein Rab-1A 1.052 0.36 26 1.085 0.272 28 1.14 0.97 
P17661 DESM_HUMAN Desmin 2.252 0.19 16 0.507 0.034 13 1.14 4.442 
Q9P2B2 FPRP_HUMAN Prostaglandin F2 receptor negative regulator 0.519 0.2 49 2.202 0.549 49 1.14 0.236 
P07197 NFM_HUMAN Neurofilament medium polypeptide 2.227 0.1 4 0.516 0.039 6 1.15 4.316 
P14625 ENPL_HUMAN Endoplasmin 0.73 0.25 20 1.579 0.397 30 1.15 0.462 
P51571 SSRD_HUMAN Translocon-associated protein subunit delta 1.634 1.05 14 0.706 0.193 10 1.15 2.314 
Q12906 ILF3_HUMAN Interleukin enhancer-binding factor 3 0.886 1.22 77 1.306 0.97 86 1.16 0.678 
Q53GQ0 DHB12_HUMAN Very-long-chain 3-oxoacyl-CoA reductase 1.18 0.07 16 0.981 0.015 10 1.16 1.203 
Q13308 PTK7_HUMAN Inactive tyrosine-protein kinase 7 2.316 0.72 35 0.503 0.143 31 1.16 4.604 
Q32P51 RA1L2_HUMAN 
Heterogeneous nuclear ribonucleoprotein A1-
like 2 
0.814 0.69 24 1.434 0.039 18 1.17 0.568 
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P61225 RAP2B_HUMAN Ras-related protein Rap-2b 1.08 0.37 26 1.086 0.227 28 1.17 0.994 
Q86Y82 STX12_HUMAN Syntaxin-12 1.679 0.14 40 0.701 0.034 30 1.18 2.395 
Q6IAA8 LTOR1_HUMAN Ragulator complex protein LAMTOR1 0.993 0.1 36 1.19 0.051 27 1.18 0.834 
P11021 GRP78_HUMAN 78 kDa glucose-regulated protein 1.082 0.18 72 1.093 0.403 72 1.18 0.99 
Q16666 IF16_HUMAN Gamma-interferon-inducible protein 16 0.279 0.19 17 4.239 2.833 28 1.18 0.066 
P48449 ERG7_HUMAN Lanosterol synthase 0.876 0.08 26 1.354 0.252 34 1.19 0.647 
P49327 FAS_HUMAN Fatty acid synthase 0.931 0.16 96 1.278 0.188 76 1.19 0.728 
P13987 CD59_HUMAN CD59 glycoprotein 2.539 0.87 12 0.469 0.027 14 1.19 5.414 
O43795 MYO1B_HUMAN Unconventional myosin-Ib 0.182 0.13 34 6.544 1.187 34 1.19 0.028 
Q8WVX9 FACR1_HUMAN Fatty acyl-CoA reductase 1 0.426 0.18 12 2.805 0.324 10 1.19 0.152 
Q9BXY0 MAK16_HUMAN Protein MAK16 homolog 0.326 0.04 20 3.672 0.146 4 1.2 0.089 
Q9UKD2 MRT4_HUMAN mRNA turnover protein 4 homolog 0.439 0.01 8 2.75 0.015 4 1.21 0.16 
Q8TDD1 DDX54_HUMAN ATP-dependent RNA helicase DDX54 0.446 0.15 6 2.711 0.039 4 1.21 0.165 
P54760 EPHB4_HUMAN Ephrin type-B receptor 4 0.91 0.15 4 1.333 0.062 4 1.21 0.683 
P61513 RL37A_HUMAN 60S ribosomal protein L37a 1.206 0.01 6 1.015 0.011 4 1.22 1.188 
Q9NVP1 DDX18_HUMAN ATP-dependent RNA helicase DDX18 0.456 0.27 4 2.685 0.562 23 1.22 0.17 
Q9H3Z4 DNJC5_HUMAN DnaJ homolog subfamily C member 5 0.755 0.03 6 1.623 0.18 14 1.23 0.465 
O00116 ADAS_HUMAN 
Alkyldihydroxyacetonephosphate synthase, 
peroxisomal 
0.78 0.53 24 1.575 0.409 24 1.23 0.495 
Q14344 GNA13_HUMAN 
Guanine nucleotide-binding protein subunit 
alpha-13 
1.433 0.26 33 0.858 0.136 28 1.23 1.67 
Q14573 ITPR3_HUMAN Inositol 1,4,5-trisphosphate receptor type 3 0.479 0.17 16 2.573 0.411 20 1.23 0.186 
P62263 RS14_HUMAN 40S ribosomal protein S14 0.915 0.1 12 1.354 0.631 14 1.24 0.676 
Q12797 ASPH_HUMAN Aspartyl/asparaginyl beta-hydroxylase 1.476 0.27 52 0.844 0.575 42 1.25 1.749 
Q13085 ACACA_HUMAN Acetyl-CoA carboxylase 1 0.616 0.17 12 2.028 0.946 8 1.25 0.304 
P37268 FDFT_HUMAN Squalene synthase 1.041 0.1 17 1.201 0.191 26 1.25 0.867 
O75691 UTP20_HUMAN 
Small subunit processome component 20 
homolog 
0.427 0.19 14 2.941 0.66 8 1.26 0.145 
Q8TCT9 HM13_HUMAN Minor histocompatibility antigen H13 1.673 0.09 12 0.752 0.064 14 1.26 2.225 
Q96FQ6 S10AG_HUMAN Protein S100-A16 0.12 0.04 16 10.49 0.826 14 1.26 0.011 
Q86UP2 KTN1_HUMAN Kinectin 0.941 1.6 38 1.352 0.188 32 1.27 0.696 
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Q969X1 LFG3_HUMAN Protein lifeguard 3 1.07 0 2 1.19 0 2 1.27 0.899 
O00559 RCAS1_HUMAN 
Receptor-binding cancer antigen expressed 
on SiSo cells 
0.972 0.08 4 1.311 0.09 12 1.27 0.741 
O60313 OPA1_HUMAN Dynamin-like 120 kDa protein, mitochondrial 0.495 0.5 28 2.583 0.466 14 1.28 0.192 
P62241 RS8_HUMAN 40S ribosomal protein S8 1.32 0.72 28 0.973 0.507 32 1.28 1.357 
O95573 ACSL3_HUMAN Long-chain-fatty-acid--CoA ligase 3 1.615 0.42 74 0.796 0.133 50 1.29 2.029 
O15400 STX7_HUMAN Syntaxin-7 0.871 0.15 30 1.477 0.154 20 1.29 0.59 
Q9BTU6 P4K2A_HUMAN Phosphatidylinositol 4-kinase type 2-alpha 1.283 0.28 46 1.005 0.217 32 1.29 1.277 
P10316 1A69_HUMAN 
HLA class I histocompatibility antigen, A-69 
alpha chain 
1.11 0.41 12 1.167 0.784 6 1.3 0.951 
O75400 PR40A_HUMAN Pre-mRNA-processing factor 40 homolog A 0.415 0.07 10 3.123 2.814 16 1.3 0.133 
Q99848 EBP2_HUMAN Probable rRNA-processing protein EBP2 0.481 0.57 7 2.7 0 2 1.3 0.178 
P62987 RL40_HUMAN Ubiquitin-60S ribosomal protein L40 1.55 0.65 17 0.841 0.155 11 1.3 1.843 
P62979 RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a 1.55 0.65 17 0.841 0.155 11 1.3 1.843 
Q9H3N1 TMX1_HUMAN Thioredoxin-related transmembrane protein 1 1.031 0.07 14 1.269 0.14 22 1.31 0.812 
Q14126 DSG2_HUMAN Desmoglein-2 0.303 0.18 94 4.324 1.698 78 1.31 0.07 
P09525 ANXA4_HUMAN Annexin A4 2.059 3.53 19 0.639 0.053 16 1.32 3.222 
P32926 DSG3_HUMAN Desmoglein-3 0.04 0.02 4 32.95 0 2 1.32 0.001 
Q9Y262 EIF3L_HUMAN 
Eukaryotic translation initiation factor 3 
subunit L 
1.092 1 30 1.224 1.558 26 1.34 0.892 
Q7Z5G4 GOGA7_HUMAN Golgin subfamily A member 7 1.251 0 2 1.071 0.08 4 1.34 1.168 
Q14690 RRP5_HUMAN Protein RRP5 homolog 0.532 0.5 36 2.524 0.253 24 1.34 0.211 
P50148 GNAQ_HUMAN 
Guanine nucleotide-binding protein G(q) 
subunit alpha 
1.868 0.29 28 0.722 0.067 18 1.35 2.587 
Q9NTJ5 SAC1_HUMAN Phosphatidylinositide phosphatase SAC1 0.811 0.23 13 1.682 0.607 14 1.36 0.482 
Q6UW68 TM205_HUMAN Transmembrane protein 205 1.175 0.4 8 1.181 0.053 12 1.39 0.995 
Q8WXF0 SRS12_HUMAN Serine/arginine-rich splicing factor 12 0.854 0 2 1.648 0.096 10 1.41 0.518 
P63027 VAMP2_HUMAN Vesicle-associated membrane protein 2 2.152 0.3 12 0.654 0.045 12 1.41 3.291 
P29992 GNA11_HUMAN 
Guanine nucleotide-binding protein subunit 
alpha-11 
2.513 0.6 36 0.564 0.104 15 1.42 4.456 
O00560 SDCB1_HUMAN Syntenin-1 1.407 0.9 18 1.009 0.41 10 1.42 1.394 
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P30519 HMOX2_HUMAN Heme oxygenase 2 0.757 0.16 32 1.904 0.396 22 1.44 0.398 
Q96JJ7 TMX3_HUMAN Protein disulfide-isomerase TMX3 1.341 0.23 28 1.075 0.118 20 1.44 1.247 
O00461 GOLI4_HUMAN Golgi integral membrane protein 4 1.561 0.29 14 0.927 0.198 16 1.45 1.684 
Q68D91 MBLC2_HUMAN 
Metallo-beta-lactamase domain-containing 
protein 2 
0.671 0 2 2.204 0.564 8 1.48 0.304 
O15270 SPTC2_HUMAN Serine palmitoyltransferase 2 0.723 0 2 2.052 0 2 1.48 0.352 
O15381 NVL_HUMAN Nuclear valosin-containing protein-like 0.646 0 2 2.305 0 2 1.49 0.28 
P27797 CALR_HUMAN Calreticulin 1.032 0.23 20 1.456 0.367 24 1.5 0.709 
P16070 CD44_HUMAN CD44 antigen 1.234 0.4 44 1.218 0.157 33 1.5 1.013 
P10301 RRAS_HUMAN Ras-related protein R-Ras 3.892 1.28 14 0.388 0.15 14 1.51 10.03 
Q6PIU2 NCEH1_HUMAN Neutral cholesterol ester hydrolase 1 2.275 0.23 14 0.664 0.051 6 1.51 3.426 
Q14165 MLEC_HUMAN Malectin 2.34 0.31 38 0.648 0.116 38 1.52 3.611 
Q15393 SF3B3_HUMAN Splicing factor 3B subunit 3 0.622 0.18 36 2.439 2.427 51 1.52 0.255 
P15291 B4GT1_HUMAN Beta-1,4-galactosyltransferase 1 3.027 0.67 14 0.502 0.137 12 1.52 6.03 
Q07065 CKAP4_HUMAN Cytoskeleton-associated protein 4 3.242 0.4 123 0.469 0.062 122 1.52 6.913 
A3KMH1 VWA8_HUMAN 
von Willebrand factor A domain-containing 
protein 8 
0.448 0 2 3.404 0.322 4 1.52 0.132 
P84085 ARF5_HUMAN ADP-ribosylation factor 5 1.74 0 2 0.881 0 2 1.53 1.975 
P53618 COPB_HUMAN Coatomer subunit beta 1.604 0 2 0.965 0.731 18 1.55 1.662 
Q15836 VAMP3_HUMAN Vesicle-associated membrane protein 3 2.07 0.27 19 0.748 0.153 18 1.55 2.767 
P10114 RAP2A_HUMAN Ras-related protein Rap-2a 1.69 0.44 18 0.919 0.161 26 1.55 1.839 
P08962 CD63_HUMAN CD63 antigen 3.377 0.92 9 0.46 0.021 4 1.55 7.341 
P35613 BASI_HUMAN Basigin 0.457 0.11 14 3.437 3.274 16 1.57 0.133 
Q6YHK3 CD109_HUMAN CD109 antigen 0.61 0.15 38 2.576 1.927 40 1.57 0.237 
Q5CZC0 FSIP2_HUMAN Fibrous sheath-interacting protein 2 1.47 1.6 6 1.071 0.307 6 1.57 1.373 
Q15084 PDIA6_HUMAN Protein disulfide-isomerase A6 0.948 0.56 30 1.675 1.053 26 1.59 0.566 
Q92896 GSLG1_HUMAN Golgi apparatus protein 1 2.062 0.63 11 0.773 0.124 8 1.59 2.668 
P49257 LMAN1_HUMAN Protein ERGIC-53 1.466 0.75 8 1.096 0.834 6 1.61 1.338 
Q03001 DYST_HUMAN Dystonin 0.451 0.51 16 3.57 1.322 8 1.61 0.126 
O95837 GNA14_HUMAN 
Guanine nucleotide-binding protein subunit 
alpha-14 
2.565 0.47 18 0.634 0.018 6 1.63 4.046 
256 
 
P27824 CALX_HUMAN Calnexin 1.692 0.56 143 0.97 0.135 120 1.64 1.744 
P11388 TOP2A_HUMAN DNA topoisomerase 2-alpha 1.647 0 2 0.998 0.155 6 1.64 1.65 
Q14008 CKAP5_HUMAN Cytoskeleton-associated protein 5 1.248 0.5 20 1.322 0.131 4 1.65 0.944 
Q8WZ42 TITIN_HUMAN Titin 0.916 0.42 6 1.823 0.404 6 1.67 0.502 
P26006 ITA3_HUMAN Integrin alpha-3 2.3 0.56 17 0.729 0.271 19 1.68 3.155 
Q16352 AINX_HUMAN Alpha-internexin 2.227 0.1 4 0.768 0.467 8 1.71 2.9 
Q8IVF2 AHNK2_HUMAN Protein AHNAK2 0.754 0.33 8 2.284 0 2 1.72 0.33 
Q8N766 EMC1_HUMAN ER membrane protein complex subunit 1 1.07 0.68 19 1.614 0.557 14 1.73 0.663 
P43121 MUC18_HUMAN Cell surface glycoprotein MUC18 67.1 11.5 6 0.026 0 2 1.74 2581 
P16615 AT2A2_HUMAN 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
1.205 3.21 80 1.461 0.246 75 1.76 0.825 
Q14315 FLNC_HUMAN Filamin-C 1.146 1 14 1.563 0.956 16 1.79 0.733 
P35749 MYH11_HUMAN Myosin-11 1.353 2.23 16 1.328 0.158 28 1.8 1.019 
P47914 RL29_HUMAN 60S ribosomal protein L29 2.245 2.21 8 0.818 0.069 12 1.84 2.744 
O43169 CYB5B_HUMAN Cytochrome b5 type B 1.557 0.08 10 1.185 0.028 6 1.85 1.314 
P53396 ACLY_HUMAN ATP-citrate synthase 2.002 0.45 12 0.956 0.315 11 1.91 2.094 
Q14108 SCRB2_HUMAN Lysosome membrane protein 2 1.704 0.19 32 1.131 1.13 28 1.93 1.507 
O75306 NDUS2_HUMAN 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 2, mitochondrial 
0.862 0.94 10 2.249 0.106 6 1.94 0.383 
Q9Y3E5 PTH2_HUMAN Peptidyl-tRNA hydrolase 2, mitochondrial 1.403 0.97 16 1.397 0.18 10 1.96 1.004 
Q9H078 CLPB_HUMAN Caseinolytic peptidase B protein homolog 0.832 0.46 8 2.399 0.784 8 2 0.347 
Q86UE4 LYRIC_HUMAN Protein LYRIC 1.603 0.55 26 1.253 0.286 32 2.01 1.279 
Q9NQC3 RTN4_HUMAN Reticulon-4 1.775 0.39 36 1.156 1.363 38 2.05 1.535 
O14786 NRP1_HUMAN Neuropilin-1 22.18 2.16 6 0.094 0 2 2.08 235.9 
Q96QD8 S38A2_HUMAN 
Sodium-coupled neutral amino acid 
transporter 2 
5.181 0.74 16 0.414 0.094 16 2.14 12.51 
P08865 RSSA_HUMAN 40S ribosomal protein SA 2.516 4.27 16 0.858 0.086 12 2.16 2.932 
Q13151 ROA0_HUMAN Heterogeneous nuclear ribonucleoprotein A0 1.225 1.15 5 1.794 0.303 30 2.2 0.683 
P55290 CAD13_HUMAN Cadherin-13 1.478 0.72 20 1.544 0.398 9 2.28 0.957 
P53621 COPA_HUMAN Coatomer subunit alpha 1.271 0.26 38 1.814 4.565 42 2.31 0.701 
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Q13813 SPTN1_HUMAN Spectrin alpha chain, non-erythrocytic 1 1.912 9.74 92 1.209 0.291 114 2.31 1.581 
P14136 GFAP_HUMAN Glial fibrillary acidic protein 1.073 1.53 8 2.175 0.036 4 2.33 0.493 
Q8WTV0 SCRB1_HUMAN Scavenger receptor class B member 1 3.04 1.4 28 0.827 0.132 12 2.51 3.676 
P30493 1B55_HUMAN 
HLA class I histocompatibility antigen, B-55 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P30491 1B53_HUMAN 
HLA class I histocompatibility antigen, B-53 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
Q29940 1B59_HUMAN 
HLA class I histocompatibility antigen, B-59 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P30685 1B35_HUMAN 
HLA class I histocompatibility antigen, B-35 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P30464 1B15_HUMAN 
HLA class I histocompatibility antigen, B-15 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P30495 1B56_HUMAN 
HLA class I histocompatibility antigen, B-56 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P30484 1B46_HUMAN 
HLA class I histocompatibility antigen, B-46 
alpha chain 
1.054 0.49 6 2.405 0.517 6 2.53 0.438 
P35580 MYH10_HUMAN Myosin-10 1.961 7.49 50 1.301 0.223 48 2.55 1.507 
O15031 PLXB2_HUMAN Plexin-B2 1.743 0.81 16 1.464 0.766 4 2.55 1.191 
P62070 RRAS2_HUMAN Ras-related protein R-Ras2 3.258 0.98 18 0.786 0.153 18 2.56 4.145 
P58107 EPIPL_HUMAN Epiplakin 0.374 0.28 44 6.882 9.524 42 2.57 0.054 
Q14534 ERG1_HUMAN Squalene monooxygenase 3.552 1.14 26 0.735 0.082 20 2.61 4.833 
P26368 U2AF2_HUMAN Splicing factor U2AF 65 kDa subunit 1.819 4.38 24 1.469 0.093 14 2.67 1.238 
Q70UQ0 IKIP_HUMAN 
Inhibitor of nuclear factor kappa-B kinase-
interacting protein 
2.622 0.61 12 1.196 1.106 10 3.14 2.192 
P00533 EGFR_HUMAN Epidermal growth factor receptor 0.586 0.09 14 5.386 1.771 8 3.16 0.109 
P38646 GRP75_HUMAN Stress-70 protein, mitochondrial 1.187 5 58 2.772 0.416 91 3.29 0.428 
O14983 AT2A1_HUMAN 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 1 
2.297 5.46 24 1.46 0.147 29 3.35 1.573 
Q9HCY8 S10AE_HUMAN Protein S100-A14 0.073 0.06 6 48.96 11.86 8 3.57 0.001 
P21589 5NTD_HUMAN 5'-nucleotidase 11.03 15 62 0.336 0.403 38 3.7 32.82 
P12036 NFH_HUMAN Neurofilament heavy polypeptide 2.227 0.1 4 1.72 2.228 8 3.83 1.295 
Q8NI36 WDR36_HUMAN WD repeat-containing protein 36 1.181 0.93 4 4.328 1.334 6 5.11 0.273 
Q86Y46 K2C73_HUMAN Keratin, type II cytoskeletal 73 1.123 1.61 6 5.158 1.216 10 5.79 0.218 
258 
 
Q9NZM1 MYOF_HUMAN Myoferlin 1.832 0.65 157 3.388 10.74 123 6.21 0.541 
P15941 MUC1_HUMAN Mucin-1 16.4 27.1 8 0.42 0.055 8 6.89 39.05 
Q14CN4 K2C72_HUMAN Keratin, type II cytoskeletal 72 1.417 2.06 6 4.964 1.7 20 7.03 0.285 
Q9UPN3 MACF1_HUMAN 
Microtubule-actin cross-linking factor 1, 
isoforms 1/2/3/5 
3.927 9.27 20 1.85 0.531 8 7.26 2.123 
P17301 ITA2_HUMAN Integrin alpha-2 1.228 1.4 16 6.14 1.088 8 7.54 0.2 
Q13751 LAMB3_HUMAN Laminin subunit beta-3 0.839 1.62 10 11.24 2.635 8 9.43 0.075 
Q93084 AT2A3_HUMAN 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 3 
7.151 9.98 6 1.579 0.094 9 11.3 4.529 
P13645 K1C10_HUMAN Keratin, type I cytoskeletal 10 4.328 4.17 46 4.953 3.108 10 21.4 0.874 
  
